Identification of MLL-A9 related target genes and microRNAs involved in leukemogenesis by Fleischmann, Katrin Kristina
  
 
 
 
Identification of MLL-AF9 related  
target genes and microRNAs 
involved in leukemogenesis 
 
 
 
Dissertation zur Erlangung des Doktorgrades der 
Naturwissenschaften (Dr. rer. nat.) 
an der Fakultät für Biologie der  
Ludwig-Maximilians-Universität München 
 
Durchgeführt am Forschungszentrum des Dr. von Haunerschen Kinderspitals der 
Ludwig-Maximilians-Universität München 
 
 
 
 
vorgelegt von 
Katrin Kristina Fleischmann 
München, 3. Mai 2012 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Erstgutachterin: Frau Prof. Dr. Elisabeth Weiss 
 
Zweitgutachter: Herr Prof. Dr. Michael Schleicher 
 
Sondergutachter: Herr Prof. Dr. Adelbert Roscher 
 
 
Tag der Abgabe:    03.05.2012 
Tag der mündlichen Prüfung: 17.09.2012  
  
 
 
 
What is a scientist after all?  
 
 
It is a curious man looking through a keyhole,  
 
the keyhole of nature, trying to know what's going on. 
  
 
Jacques Yves Cousteau 
  
Preamble and Acknowledgments 
How to explain the change from evolutionary ecology to tumor biology?  
After my diploma thesis in evolutionary ecology and a major in ecology, I was facing some 
skepticism while being interviewed for PhD positions in the biomedical field.  
What was my motivation to study biology? Why do I continue to feel this strong enthusiasm for 
this field? For me, it was always the grand question “How does life work?” that drove me and 
which may interconnect almost every aspect within natural sciences. Only when we strive to get 
answers to this grand question we may reach an understanding as to what happens in disease.    
I am profoundly grateful to my dear colleagues Dr. Julia von Frowein, Dr. Thomas Magg and 
Dr. Uta Fuchs who supported me to become one of their colleagues at the research center of the 
Dr. von Haunerschen Kinderspital. Since then, innumerable great and inspiring discussions allied 
us. With them and many other splendid colleagues at our research center (among them Kristin 
Hähnel, Carola Laudano, Rita Meilbeck and many others who may forgive that I can not name 
all), I shared a vivid exchange of information and cordial coffee breaks. They all made every-
day-life at our research center always joyful and worthwhile.  
I profoundly thank Prof. Dr. Adelbert Roscher for his experimental advice and supervision, 
many stimulating discussions, for directing my thesis over these years and for his help when it 
was most crucial. 
Further great thanks go to: Prof. Dr. Elisabeth Weiss for her friendly support and for representing 
this thesis at the Faculty of Biology of the Ludwig-Maximilians Universität München. PD Dr. 
Irene Schmid whose friendly support has always been of great value for my research at the Dr. 
von Haunerschen Kinderspital and for providing insights into the clinical oncology. PD Dr. 
Philipp Pagel for bioinformatical collaboration, stimulating discussions and open ears in a truly 
remarkable cooperation. Prof. Dr. Arndt Borkhardt for the initiation of this work and for 
supporting me while he was still at our institute.  
And last but not least to: My dearest Markus, with whom I could share endless happy moments 
in nature and every-day-life while traveling, climbing and going on ski-randonnée, for taking 
care of a healthy work-life-balance. My loving parents Sigrid and Prof. Dr. Rudolf Schröck for 
supporting me in my interests and in every way anyone could wish. My brother and fellow 
scientist Dr. Florian Schröck for his friendship and interest in my work and for seeing it from a 
different angle. My family and friends for their friendship and support. 
 
This work has been supported by the Graduiertenkolleg 1202 „Oligonucleotides in Cell Biology 
and Therapy“ from the Deutsche Forschungsgemeinschaft.  
Index 
 
I 
1 Index 
1 Index ..................................................................................................................................... I 
2 List of figures...................................................................................................................... V 
3 List of tables .................................................................................................................... VII 
4 Summary ............................................................................................................................. 1 
5 Zusammenfassung .............................................................................................................. 3 
6 Introduction ........................................................................................................................ 5 
6.1 Genetic aberrations in leukemia ...................................................................................... 5 
6.2 The genes MLL, AF9, MLL-AF9 and their functions ...................................................... 5 
6.3 The role of MLL-AF9 fusion gene in leukemia ............................................................. 10 
6.4 MicroRNAs and their role in hematologic malignancies .............................................. 11 
6.5 Aim of this study ........................................................................................................... 14 
7 Material and Methods ...................................................................................................... 15 
7.1 Cell and molecular biological methods ......................................................................... 15 
7.1.1  Cell culture ............................................................................................................ 15 
7.1.2  SiRNAs and miRNA mimics ................................................................................ 15 
7.1.3  Transfections of siRNAs, miRNA-mimics and shRNA plasmids ........................ 16 
7.1.4  Confocal fluorescence microscopy ....................................................................... 17 
7.1.5  Cell diameter and proliferation ............................................................................. 18 
7.1.6  Flow cytometric measurements ............................................................................. 19 
7.1.6.1 Transfection efficiency ................................................................................... 19 
7.1.6.2 Monitoring of stable transfected cells ............................................................. 19 
7.1.6.3 Cell cycle analysis ........................................................................................... 19 
7.1.6.4 Apoptosis detection ......................................................................................... 20 
7.1.7  RNA extraction and determination of RNA concentration, purity and integrity .. 21 
7.1.8  Reverse transcriptase quantitative real-time PCR ................................................. 21 
7.1.9  Gene expression profiling ..................................................................................... 22 
7.1.10 MicroRNA profiling and confirmatory techniques ............................................... 23 
7.1.10.1 Quantitative microRNA detection via TaqMan miRNA Low Density  
  Array and single assay qRT-PCR .................................................................. 23 
7.1.10.2 Semiquantitative microRNA detection via microarrays ................................ 23 
 
 
Index 
 
II 
7.2 Biochemical methods .................................................................................................... 24 
7.2.1  Western blot .......................................................................................................... 24 
7.2.2 TaqMan Protein Assay ........................................................................................... 25 
7.3 Biostatistical methods ................................................................................................... 27 
7.3.1 Gene expression profiling data analysis ................................................................. 27 
7.3.2 Quantitative LDA miRNA profiling data analysis ................................................ 29 
7.3.3 Semiquantitative microarray miRNA profiling data analysis ................................ 30 
7.3.4 Correlation analysis of array and qRT-PCR data ................................................... 31 
7.3.5 Functional disease ontology analysis ..................................................................... 31 
7.3.6 Functional gene ontology analysis ......................................................................... 31 
7.3.7 MiRNA target prediction ....................................................................................... 32 
7.4 Prioritization of likely candidate genes ......................................................................... 32 
8 Results ................................................................................................................................ 35 
8.1 Experimental design and siRNA selection .................................................................... 35 
8.1.1 Transfection method and efficiency ....................................................................... 35 
8.1.2 Design and selection of efficient siRNAs against MLL-AF9 in THP1 cells .......... 37 
8.2 MLL-AF9 knockdown ................................................................................................... 39 
8.2.1 Experimental conditions ........................................................................................ 39 
8.2.2 Validation of MLL-AF9 knockdown ...................................................................... 39 
8.3 Cellular phenotype and functional endpoints of MLL-AF9 knockdown ....................... 43 
8.4 MLL-AF9 knockdown dependent effects on gene expression ...................................... 47 
8.4.1 Quality control of gene expression profiling results .............................................. 48 
8.4.2 Differentially expressed genes in MLL-AF9 knockdown ...................................... 49 
8.4.3 Mediation MLL-AF9 leukemogenic effects: involved processes and  
subset selection of deregulated genes for prioritization of likely candidates ........ 50 
8.4.3.1 Genes with strong differential expression ...................................................... 50 
8.4.3.2 Functional disease ontology and gene association to leukemia ...................... 53 
8.4.3.3 Functional gene ontology analysis .................................................................. 57 
8.4.3.4 Comparison of in vitro gene expression data with published in vivo  
findings ........................................................................................................... 64 
8.4.4 Candidate genes with likely relevance in mediation of MLL-AF9  
leukemogenic effects .............................................................................................. 66 
8.5 MicroRNAs in MLL-AF9 knockdown .......................................................................... 72 
8.5.1 MLL-AF9 knockdown dependent effects on miRNA expression .......................... 72 
8.5.2 Comparison of differential miRNA expression after MLL-AF9 knockdown  
to data from patient studies .................................................................................... 76 
8.5.3 Association of differentially expressed miRNAs to monocytic differentiation ..... 78 
8.5.4 Potential direct targets of upregulated miR-511 .................................................... 80 
 
 
Index 
 
III 
9 Discussion .......................................................................................................................... 83 
9.1 Experimental Design ..................................................................................................... 83 
9.2 Confirmation of MLL-AF9 knockdown ........................................................................ 84 
9.3 Cellular phenotype and functional endpoints of MLL-AF9 knockdown ....................... 85 
9.4 Differential gene expression profile after MLL-AF9 knockdown ................................. 87 
9.4.1 Biological processes potentially involved in mediation of MLL-AF9  
leukemogenic effects .............................................................................................. 88 
9.4.1.1 Proliferation, cell growth and cell death ......................................................... 90 
9.4.1.2 Differentiation ................................................................................................. 90 
9.4.1.3 Early development .......................................................................................... 92 
9.4.1.4 Calcium associated gene functions and protein folding .................................. 92 
9.4.1.5 Estrogen signaling ........................................................................................... 93 
9.4.1.6 Evasion of immunosurveillance ...................................................................... 94 
9.4.2 Candidate genes for mediation of MLL-AF9 leukemogenic effects ...................... 95 
9.4.3 Genes considered as likely therapeutic targets ..................................................... 104 
9.5 MLL-AF9 associated changes in miRNA expression ................................................. 105 
9.5.1 Deregulated miRNAs ........................................................................................... 106 
9.5.2 MiR-511 in monocytic differentiation and potential target genes ....................... 109 
10 Conclusions ...................................................................................................................... 111 
11 References ........................................................................................................................ 113 
12 Abbreviations .................................................................................................................. 135 
13 Supplementary data ....................................................................................................... 137 
14 Erklärung ........................................................................................................................ 187 
 
Index 
 
V 
2 List of figures 
Figure 1:   The MLL complex and its molecular functions ............................................................ 8 
Figure 2:   Model of MLL complexes and their functions. ............................................................. 9 
Figure 3:   MicroRNA biogenesis and mode of action. ................................................................ 12 
Figure 4:   Example of Cellscreen image evaluation. ................................................................... 18 
Figure 5:   Cell cycle Analysis of THP1 cells by flow cytometry ................................................ 20 
Figure 6:   TaqMan
®
 Protein Assay generated to detect MLL-AF9 protein. ................................ 26 
Figure 7:   Gene expression microarray analysis: Percentage of significant identical replicate  
                  probe sets as a function of p-value threshold. ............................................................. 28 
Figure 8:   Transfection efficiency of THP1 cells with Dreamfect. .............................................. 36 
Figure 9:   Images of THP1 cells transfected with fluorescently labeled siRNA ......................... 37 
Figure 10: Overview of the binding positions of all designed and tested siRNAs against  
                 MLL-AF9. ..................................................................................................................... 38 
Figure 11: Confirmation of MLL-AF9 knockdown in THP1 cells over the experimental  
                  time course .................................................................................................................. 40 
Figure 12: MLL and AF9 wildtype transcript levels in presence or absence of MLL-AF9  
                  knockdown in THP1 cells ........................................................................................... 41 
Figure 13: Detection of MLL-AF9 by Western blot. .................................................................... 42 
Figure 14: Proliferation of THP1 cells in presence or absence of MLL-AF9 knockdown. ........... 43 
Figure 15: Apoptosis of THP1 cells in presence or absence of MLL-AF9 knockdown ................ 44 
Figure 16: Cell cycle distribution of THP1 cells in presence or absence of MLL-AF9  
                  knockdown .................................................................................................................. 45 
Figure 17: Cell size of THP1 cells in presence or absence of MLL-AF9 knockdown .................. 46 
Figure 18: Cell size of THP1 cells in presence or absence of MLL-AF9 knockdown over the  
                  experimental time course. ........................................................................................... 47 
Figure 19: Correlation between gene expression microarray and qRT-PCR results after  
                  MLL-AF9 knockdown in THP1 cells .......................................................................... 49 
Figure 20: Strongest differentially regulated transcripts from microarray data of MLL-AF9  
                  knockdown in THP1 cells. .......................................................................................... 51 
Figure 21: Functional Disease Ontology (FunDO): The top 5 diseases associated with our  
                  set of differentially expressed genes after MLL-AF9 knockdown in THP1 cells ....... 54 
Figure 22: MLL-AF9 knockdown and “leukemia” associated genes ............................................ 55 
Figure 23: MLL-AF9 knockdown associated enriched functional gene annotations. ................... 58 
Index 
 
VI 
Figure 24: Differentially expressed genes after MLL-AF9 knockdown in THP1 cells with   
                  concordance to patient studies of acute leukemia ....................................................... 66 
Figure 25: Strategy to prioritize candidate genes for mediation of MLL-AF9 leukemogenic  
                  effects .......................................................................................................................... 67 
Figure 26: Distribution of rating categories over the assessed 92 genes ...................................... 70 
Figure 27: Differentially expressed genes potentially involved in mediation of MLL-AF9  
                  leukemogenic effects. .................................................................................................. 71 
Figure 28: Differentially expressed miRNAs after MLL-AF9 knockdown in THP1 cells. .......... 74 
Figure 29: Correlation between miRNA data from LDA and single assay qRT-PCR after  
                  MLL-AF9 knockdown in THP1 cells. ......................................................................... 75 
Figure 30: Morphological changes of differentiated THP1 cells. ................................................. 79 
Figure 31: Expression of miR-511 in differentiated THP1 cells .................................................. 80 
Figure 32: Overview of the selection process of predicted targets of miR-511 with potential  
                  3’-UTR binding sites for experimental validation. ..................................................... 81 
Figure 33: Effect of transient upregulation of miR-511 in THP1 cells on potential direct  
                  target genes. ................................................................................................................ 82 
 
Index 
 
VII 
3 List of tables 
Table 1:   Comparison of MLL and AF9 genes and transcripts to the average of human  
                genes and transcripts. ...................................................................................................... 7 
Table 2:   THP1-breakpoint specific siRNA sequences against MLL-AF9. .................................. 16 
Table 3:   Overview of THP1-breakpoint specific shRNA sequences. ......................................... 17 
Table 4:   Western blot reagents and supplier. .............................................................................. 25 
Table 5:   Strategy to rate the potential role of selected, differentially expressed genes after  
                MLL-AF9 knockdown concerning mediation of MLL-AF9 leukemogenic effects. ..... 33 
Table 6:   Percentage of transfected and viable THP1 cells 24 h after transfection. ..................... 36 
Table 7:   Results of tested siRNAs against MLL-AF9 in THP1 cells. ......................................... 38 
Table 8:   Rating of selected differentially expressed genes after MLL-AF9 knockdown in  
                THP1 cells concerning mediation of leukemogenic effects. ......................................... 68 
Table 9:   Confirmation of differential miRNA expression via single assay qRT-PCR. .............. 76 
Table 10: Overview of concordant differential miRNA expression between in vitro  
                MLL-AF9 knockdown and in vivo patient studies. ........................................................ 78 
Table 11: Overview of MLL-AF9 knockdown associated enriched functional gene  
                annotations .................................................................................................................... 89 
Table 12: Overview of differentially expressed genes potentially involved in mediation  
                of MLL-AF9 leukemogenic effects. .............................................................................. 97 
 
 
Summary 
 
1 
4 Summary 
The translocation t(9;11)(p22;q23), leading to the leukemogenic hybrid gene and fusion protein 
MLL-AF9, is one of the most frequent translocations in infant acute myeloid leukemia (AML) 
and particularly associated with monoblastic AML (FAB classification M5). MLL and AF9 
wildtype proteins play essential roles in embryogenesis and hematopoiesis and lead to 
transcriptional initiation (MLL) and elongation (AF9) of their target gene transcripts. The fusion 
protein MLL-AF9 is believed to combine these properties, leading to increased activation of 
target genes.  
AML in childhood is a malignant type of leukemia with currently insufficient therapeutic 
options, as survival rates are still low with a 5-year overall survival of 57%. Therefore, this study 
set out to identify genes and miRNAs downstream of MLL-AF9 which could serve as potential 
targets in new therapeutic strategies. 
The function of MLL-AF9 was investigated by efficient and specific knockdown via siRNAs in 
the AML M5 cell line THP1 which harbors this t(9;11) translocation. MLL-AF9 is known to 
change the expression of target genes via epigenetic mechanisms. To ensure that a reversal of 
these effects can be detected, the experimental setting included a prolonged knockdown over 
eight days. Besides biological assays, comprehensive gene and miRNA expression profiles 
following MLL-AF9 knockdown were generated.  
Endogenous MLL-AF9 protein showed low solubility and appeared to be prone to aggregate 
making its quantitation by Western blot difficult. HOXA9 expression, however, could be utilized 
as a surrogate marker for MLL-AF9 protein reduction since its levels are increased via direct 
interaction between MLL-AF9 and the HOXA9 promoter. 
A highly significant reduction of 0.3 µm in cell diameter was detected after MLL-AF9 
knockdown which we hypothesize to be due to AF9 protein co-aggregation with MLL-AF9 
because deletion of the AF9 homolog leads to an abnormally large phenotype in yeast. 
Additionally, our gene expression data suggested that the observed cell size reduction could be 
due to changes in intracellular ion concentrations and / or reduced ribosomal biogenesis. 
Gene expression profiling revealed transcripts of 1269 genes to be differentially expressed. 
Together with functional gene ontology analyses, these results argued for a more differentiated 
state of MLL-AF9 depleted THP1 cells. Our data suggest effects of MLL-AF9 on differentiation 
and apoptosis as well as on calcium signaling, estrogen signaling, immunosurveillance and the 
heat-shock / unfolded protein response. Among the deregulated transcripts, a set of 40 likely 
candidates for mediation of the leukemogenic effects of MLL-AF9 was prioritized via a rating 
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strategy. Of these, 8 appear to be prone to therapeutic exploitation as they fall into protein 
classes well known as „druggable“. 
MicroRNA expression screening yielded 23 differentially expressed miRNAs after MLL-AF9 
knockdown. A subset of these was selected for further validation via single-assay qRT-PCR and 
confirmed differential expression for 7 out of 11 tested microRNAs. Among these, miR-511, as 
the strongest differentially expressed miRNA, was additionally shown to be significantly 
upregulated in phorbol 12-myristate 13-acetate (PMA) differentiated THP1 cells. This 
observation is consistent with the hypothesis that miR-511 plays a role in the differentiation 
process of monoblasts. Expression strength was inversely correlated between miR-511 and 445 
in silico predicted miR-511 targets within MLL-AF9 knockdown samples. A subset of these was 
selected for experimental validation. Here, a trend towards reduced expression of eight predicted 
targets was detected after miR-511 mimic treatments in THP1 cells.  
 
Our study revealed processes as well as novel candidate genes and miRNAs for mediation of 
MLL-AF9 leukemogenic effects, thus expanding previous knowledge of MLL-aberrant leukemia. 
Subsequent investigations of these candidates may aim to further evaluate their potential for new 
therapeutic strategies. 
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5 Zusammenfassung 
Die Translokation t(9;11)(p22;q23), die zu dem leukämogenen Hybridgen und Fusionsprotein 
MLL-AF9 führt, ist eine der häufigsten Translokationen der frühkindlichen akuten myeloischen 
Leukämie (AML) und ist besonders mit dem monoblastischen Subtyp (FAB Klassifikation M5) 
assoziiert. Die MLL und AF9 Wildtyp-Proteine üben essentielle Funktionen in der 
Embryogenese und Hämatopoese aus und führen zur Initiation (MLL) und Elongation (AF9) der 
Transkription ihrer Zielgene. Das Fusionsprotein MLL-AF9 soll diese Eigenschaften 
kombinieren und so zu einer erhöhten Aktivität von Zielgenen führen.  
AML im Kindesalter ist ein maligner Leukämietyp mit bislang unzureichenden 
Therapieoptionen, da die 5 Jahres Überlebensraten bei 57% liegen. Somit war das übergeordnete 
Ziel dieser Studie Gene und miRNAs zu identifizieren, die MLL-AF9 nachgeschaltet sind und 
die potentiell mit neuen therapeutischen Strategien beeinflusst werden können. 
Die Wirkung von MLL-AF9 wurde mittels einer effizienten und spezifischen Stilllegung durch 
siRNAs in der Zellline THP1, die diese t(9;11) Translokation trägt, untersucht. Es ist bekannt, 
dass MLL-AF9 über epigenetische Mechanismen zu Veränderungen in der Expression seiner 
Zielgene führt. Um sicherzustellen, dass die Umkehr dieser Auswirkungen nachgewiesen werden 
kann, wurde ein experimentelles Protokoll gewählt, das eine über acht Tage anhaltende 
Supprimierung von MLL-AF9 einschloss. Neben Untersuchungen der biologischen 
Auswirkungen wurden umfassende Gen- und miRNA-Expressionsprofile nach Stilllegung von 
MLL-AF9 generiert. 
Endogenes MLL-AF9 Protein war schwer löslich und schien zur Aggregatbildung zu neigen, 
was die verlässliche Quantifizierungen mittels Western Blot verhinderte. Jedoch konnte die 
Expressionsstärke von HOXA9 als Ersatz-Marker für die Reduktion des MLL-AF9 Proteins 
verwendet werden, da die Transkription von HOXA9 über eine direkte Interaktion zwischen 
MLL-AF9 Protein und dem HOXA9 Promotor erhöht wird.  
Eine hochsignifikante Reduktion des Zelldurchmessers um 0,3 µm wurde nach Stilllegung von 
MLL-AF9 beobachtet. Wir haben die Hypothese, dass dies durch eine Co-Aggregation des AF9 
Proteins mit MLL-AF9 bedingt sein könnte, da die Deletion des AF9 homologs in Hefe zu einer 
abnorm erhöhten Zellgröße führt. Des Weiteren legten unsere Genexpressionsdaten nahe, dass 
die reduzierte Zellgröße durch Veränderungen der intrazellulären Ionenkonzentrationen und / 
oder durch reduzierte Ribosomen-Biogenese bedingt sein könnte. 
Genexpressionsanalysen zeigten die differentielle Expression von 1269 Genen. Zusammen mit 
funktionellen Gen-Ontologieanalysen sprachen die Ergebnisse für einen differenzierteren 
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Zustand der Zellen nach Verminderung von MLL-AF9. Unsere Daten weisen auf Effekte von 
MLL-AF9 auf die Differenzierung, die Apoptose und die Immunüberwachung hin, sowie auf die 
Beteiligung von Kalzium- und Östrogen-Signalwegen sowie der Hitzeschock- und Protein-
Missfaltungs-Antwort (heat-shock / unfolded protein response) bei der MLL-AF9 vermittelten 
Leukämogenese. Unter den differentiell regulierten Transkripten konnten mittels einer 
Bewertungs-Strategie 40 vielversprechende Kandidaten für die Vermittlung des leukämogenen 
Effekts von MLL-AF9 priorisiert werden. Darunter wurden acht identifiziert, die für die 
therapeutische Nutzung prädestiniert erscheinen, da die kodierten Proteine in Proteinklassen 
fallen welche häufige Angriffspunkte für Medikamente darstellen.   
Das erstellte miRNA Expressionsprofil zeigte 23 differenziell exprimierte miRNAs nach MLL-
AF9 Stilllegung. Eine Untergruppe dieser miRNAs wurde für die Validierung mittels qRT-PCR 
ausgewählt. Dabei bestätigte sich die differenzielle Expression bei sieben der elf getesteten 
miRNAs. Unter diesen zeigte sich miR-511, die am stärksten differentiell exprimierte miRNA, 
als zusätzlich signifikant hochreguliert nach der Differenzierung von THP1 Zellen mittels 
phorbol 12-myristate 13-acetate (PMA). Diese Beobachtung ist stimmig mit der Hypothese, dass 
miR-511 eine Rolle innerhalb des Differenzierungsprozesses von Monoblasten spielen könnte. 
Nach MLL-AF9 Stilllegung wurde eine inverse Korrelation der Expression zwischen miR-511 
und 445 seiner in silico vorhergesagten Zieltranskripte beobachtet. Ein Teil davon wurde zur 
experimentellen Validierung ausgewählt. Nach einer Erhöhung der zellulären miR-511 
Konzentration mittels sogenannter „mimics“ in THP1 Zellen zeigte sich bei acht vorhergesagten 
Zielgenen ein Trend zu reduzierter Expression. 
 
Unsere Studie identifizierte Prozesse sowie neue Kandidaten-Gene und -miRNAs für die 
Vermittlung der leukämogenen Effekte von MLL-AF9 und erweitert damit das bisherige Wissen 
um MLL-aberrante Leukämien. Zukünftige Forschung an diesen Kandidaten sollte zur weiteren 
Evaluierung ihres Potentials hinsichtlich neuer therapeutischer Strategien führen. 
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6 Introduction 
6.1 Genetic aberrations in leukemia 
Acute leukemias are malignancies of the hematopoietic system. They are caused by the 
accumulation of genetic aberrations in progenitor cells which lead to a block in cell 
differentiation and to an increase in cell proliferation (Stavropoulou, et al. 2010). In childhood, 
acute leukemias are the most prevalent forms of cancer, with acute lymphoblastic leukemia 
(ALL) being the most common form, followed by the more aggressive acute myeloid leukemia 
(AML), while chronic myeloid leukemia (CML) and chronic lymphoblastic leukemias (CLL) are 
rare (Kufe, et al. 2003; Bender-Götze, et al. 2003; Deschler, et al. 2006).  
For AML, accounting for 15-20% of leukemias in childhood (Deschler, et al. 2006), new 
targeted therapies are urgently needed due to the aggressiveness of the disease and relative low 
survival rates (5-year overall survival of 57%, (Creutzig, et al. 2005)). 
The majority of children with AML, i.e. 50-80%, harbor leukemic cells with clonal chromosomal 
aberrations (Raimondi, et al. 1999; Deschler, et al. 2006). Among these are numerous 
translocations resulting in hybrid genes and fusion proteins (Deschler, et al. 2006). Chromosomal 
aberrations involving the mixed-lineage leukemia gene (MLL) at 11q23 are the most common 
form, being present in 20% of childhood AML cases (Hollink, et al. 2009) and in 51% of very 
young AML patients (below 2 years of age) (Balgobind, et al. 2011). 
Originally, these MLL aberrations were detected in a subset of acute leukemias with especially 
dismal prognosis and in leukemic blasts expressing surface markers of both the myeloid and 
lymphoid lineage. Thus the associated gene was named mixed-lineage leukemia (MLL) (Mirro, et 
al. 1986). MLL has been found to be translocated to over 50 different partner genes, whose 
associated leukemias nevertheless represent an entity (Meyer, et al. 2006; Slany 2009). The most 
common form of MLL gene rearrangement in AML is the translocation t(9;11)(p22;q23), 
resulting in the fusion protein MLL-AF9 (Jansen, et al. 2005).  
6.2 The genes MLL, AF9, MLL-AF9 and their functions  
Unraveling the molecular mechanism by which MLL fusion proteins lead to deregulated gene 
expression might assist the development of new, targeted therapies for this type of leukemia. The 
following short overview on the two participating genes and functions of their proteins shall 
summarize the pre-existing knowledge and illustrate the potential molecular function of the 
fusion protein. 
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Gene deletion and disruption experiments yielded information on the biological role of the 
corresponding proteins, e.g. in the mouse model.  
Mll gene disruption experiments in the mouse are embryonically lethal for homozygous Mll -/- 
animals. Mll is widely and dynamically expressed in the mouse embryo, indicating its 
importance in embryogenesis. (Yu, et al. 1995) Its expression is required to maintain the 
expression of Hox genes in early embryogenesis (Gan, et al. 2010; Yu, et al. 1998). Here, Hox 
genes are essential for correct positioning of segmented structures (vertebrae, limbs, digestive 
and reproductive tracts), while they also play a definitive role in normal proliferation and 
differentiation of hematopoietic stem and progenitor cells (He, et al. 2011a). Heterozygous Mll 
+/- mice show retarded growth, hematopoietic abnormalities, and bidirectional homeotic 
transformation of the axial skeleton, as well as sternal malformations (Yu, et al. 1995). 
Conditional knock-out alleles leading to a Mll loss in the hematopoietic lineage revealed 
phenotypically normal fetal hematopoiesis but massive mortality at 3 weeks of age with 
surviving animals being anemic, thrombocytopenic, and showing a significant reduction of bone 
marrow hematopoietic stem / progenitor cells (Gan, et al. 2010). Consequently, Mll must be 
considered as an essential gene in embryogenesis and hematopoiesis. 
Homozygous deletion of Af9 leads to homeotic skeletal anomalies and perinatal death in mice 
but has no effect on hematopoiesis (Collins, et al. 2002). Nevertheless, AF9 is highly expressed 
in human hematopoietic stem cells and appears to be important for erythro- and 
megakaryopoiesis (Pina, et al. 2008). The effects of Af9 deletion on the axial skeleton, suggested 
an involvement of Hox gene expression. Af9 was later confirmed as a regulator of Hox genes, 
which points to an analogous role to Mll in embryogenesis (Collins, et al. 2002). 
 
Specific features of MLL and AF9 genes, transcripts and proteins are summarized in table 1 and 
compared to the average of human genes and transcripts. This comparison stresses the large size 
of the two genes and their transcripts as well as their unusual large number of encompassed 
exons and transcription variants.  
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Table 1: Comparison of MLL and AF9 genes and transcripts to the average of human 
genes and transcripts. 
 
Given gene information on MLL and AF9 refers to the consensus coding sequences from 
Ensemble data base. Features are compared to the mean of human genes as described by 
Chacko et al. (2009). nt = nucleotides, n.a. = not analyzed 
 
MLL, a histone 3 lysine 4 (H3K4) methylase and member of the trithorax / MLL gene family, is 
a large protein which is rapidly cleaved by taspase 1 (TASP1) into the subunits MLL-N (320 
kDa) and MLL-C (180 kDa). These MLL subunits interact via the FY-rich domain N-terminal 
region (FYRN) of MLL-N and the FY-rich domain C-terminal region (FYRC) and Su(var)3-9, 
Enhancer-of-zeste, Trithorax (SET) domain of MLL-C. This interaction has been shown to be 
necessary for the stability of MLL-N and the correct nuclear sublocalization of MLL-C subunits 
(Hsieh, et al. 2003; Yokoyama, et al. 2002). As depicted in figure 1, the MLL-N / MLL-C dimer 
is the core of a large protein complex, in which MLL-N together with Menin and LEDGF 
confers nuclear localization pattern and target gene selection, while the MLL-C and associated 
proteins are responsible for activating changes in the chromatin (Slany 2009). Additionally, the 
CxxC zinc finger domain of MLL-N maintains the expression of specific genes (Erfurth, et al. 
2008; Cierpicki, et al. 2010). The MLL complex is believed to be recruited by transcription 
factors to initiate RNA synthesis. H3K4 methylation is universally introduced around 
transcription start sites of all transcribed genes, and it has been estimated that each H3K4 
methyltransferase is responsible for methylation of more than 1000 gene loci. (Slany 2009) In 
leukemogenic fusions, breakpoints of MLL cluster in a 8.3 kb region of chromosome 11 
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containing MLL exons 8 to 14. They result in MLL fusion proteins which retain about 1300 N-
terminal amino acids of MLL and include the DNA binding AT-hooks and the CxxC domain 
which protects target gene CpG dinucleotides from methylation (Langer, et al. 2003; Hsieh, et al. 
2003).  
 
 
Figure 1: The MLL complex and its molecular functions. MLL-N together with Menin and 
lens epithelium-derived growth factor (LEDGF) confers subnuclear localization and target gene 
selection, while the MLL-C and associated proteins (histone acetyltransferase MYST1 (MOF), 
retinoblastoma-binding protein 5 (RBBP5), ASH2-like (ASH2L) and WD-repeat containing 
protein 5 (WDR5)) are responsible for activating changes in the chromatin (histone 4 lysine 16 
(H4K16) acetylation and H3K4 trimethylation). CxxC zinc finger domain (CxxC) of MLL-N has 
been shown to bind unmethylated CpG dinucleotides and to protect them from methylation. The 
plant (PHD) homeodomain is involved in protein-protein interactions, thus regulating the 
recruitment of repressive factors.(Slany 2009) AT, AT-hook (binding to the minor groove of 
DNA); H4K16, lysine 16 of histone 4; H3K4, lysine 4 of histone 3; Ac, acetyl group; CH3, 
methyl group. Figure modified from Slany, 2009. 
 
About 200 C-terminal amino acids of AF9 are retained in fusions to MLL and harbor a protein 
interaction domain. In contrast, the chromatin-targeting N-terminal YEATS domain (named after 
`YNK7', `ENL', `AF-9', and `TFIIF small subunit') is lost in MLL fusions. (He, et al. 2011b) 
Like other frequent fusion partners of MLL, AF9 is a component of the super elongation 
complex (SEC) and the Dot1 complex (DotCom) and interacts with the protein complex 
components via its C-terminal protein interaction domain which is retained in MLL fusions. SEC 
clears paused RNA polymerase II (Pol II) for elongation, while DotCom leads to raised histone 3 
lysine 79 (H3K79) methylation and thus both complexes lead to transcriptional activation. These 
findings led to a model, where MLL fusion proteins activate gene expression by binding to 
(MLL) target genes and – unlike MLL  – automatically recruiting SEC or DotCom, leading to 
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transcriptional activation and elongation independent of other, otherwise necessary, additional 
factors (figure 2). (Slany 2009; Mohan, et al. 2010; Margaritis, et al. 2008) Because many MLL 
fusion partners are proteins of the SEC or DotCom complexes (besides AF9, i.e. AF4, AFF4, 
ENL, ELL, AF10 and AF17), this model offers an explanation, why different MLL fusion 
proteins may lead to similar changes in gene expression and to leukemogenesis. 
 
 
Figure 2: Model of MLL complexes and their functions (A) MLL complex needs additional 
factors for transcriptional activation. (B) Complex generated by fusions of MLL with proteins of 
the super elongation complex (SEC) (e.g. AF9), is believed to automatically recruit SEC 
complex, leading to transcriptional activation. (C) Complex generated by fusions of MLL with 
proteins of DotCom (e.g. AF9), is believed to directly activate transcription via histone 3 lysine 
79 methylation. MLL-NT, N-terminal part of MLL; LEDGF, lens epithelium-derived growth 
factor; SEC, super elongation complex; DotCom, Dot1 complex; Pol II, polymerase II; K4me, 
methylated lysine 4 of histone 3; K79me, methylated lysine 79 of histone 3. RNA polymerase-
associated factor 1 complex (PAF1C) is a transcriptional elongation factor, the preinitiation 
complex (PIC) is necessary for transcription. Figure modified from Mohan et al., 2010. 
 
MLL fusions have been assigned to two functional categories dependent on the subcellular 
localization of their native fusion partner proteins. Fusions with partner proteins with nuclear 
localization (e.g. AF4, AF9, ENL, AF10 and ELL) by far represent the larger group of leukemic 
MLL-fusions, while the only common cytoplasmic fusion partner is ALL1-fused gene from 
chromosome 6 (AF6). It has been noticed that the less frequent MLL translocations to 
cytoplasmic partners occur mainly in adult patients, indicating weaker transforming activities. 
(Ayton, et al. 2001; Slany 2009) 
Altogether, MLL and AF9 proteins play essential roles in embryogenesis and hematopoiesis and 
lead to transcriptional initiation (MLL) and elongation (AF9) of their target gene transcripts. The 
fusion protein MLL-AF9 is believed to combine these properties, leading to increased activation 
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via transcriptional initiation and elongation of target gene transcripts. Resulting from this 
knowledge, new therapeutic strategies are under investigation which aim to intervene with DNA 
binding of MLLs CxxC domain or with the assembly of MLL fusion proteins with elongation 
complexes. However, a main concern with these approaches is that the physiological functions of 
the involved proteins will also be abrogated, thereby leading to toxicity. (Slany 2009) Other 
potential therapeutic targets lie downstream of MLL fusion proteins. In this context, detailed 
information on gene expression influenced by specific MLL-fusion proteins, as aimed in this 
study, is still lacking.  
6.3 The role of MLL-AF9 fusion gene in leukemia 
MLL-AF9 is either by itself sufficient to initiate acute leukemia or essential secondary mutations 
are rapidly acquired: Mll-AF9 chimeric mice (generated by knock-in of partial human AF9 
sequence into the Mll genomic region of the mouse) showed non-malignant expansion of 
myeloid precursor cells and subsequently developed acute myeloid leukemia (Corral, et al. 1996; 
Dobson, et al. 1999). Mice transplanted with bone marrow stem / progenitor cells which were 
retrovirally transduced to carry a MLL-AF9 cDNA sequence, develop AML and harbor leukemia 
stem cells (LSC). These LSC confer leukemia - even when only very few are transplanted into 
mice (Krivtsov, et al. 2006; Somervaille, et al. 2006). Krivtsov et al. (2006) additionally showed 
that the self-renewal associated mRNA expression signature of leukemic stem cells resembles 
the profile of MLL-rearranged AML patients.  
A important source of information to understand the transforming effects of a fusion gene are 
expression studies. Classic gene expression studies do not include small RNA species, so that in 
we employ the term “gene expression” for analyses of coding and non-coding transcripts 
exclusive of small RNA species. Transcript levels of miRNAs are denoted as miRNA 
expression.   
There is some prior knowledge on gene expression correlated to MLL-fusion proteins. However, 
these data are derived either from patient studies or from introduction of the cDNA sequence in 
cell lines or primary cells. Retroviral transductions of cDNA sequences may lead to 
supraphysiologic expression of the fusion protein with absence of natural occurring isoforms. 
Patient studies have to struggle with diverse genetic backgrounds and cell types of samples. Such 
problems can mask many downstream effects. Therefore, knockdown of endogenous MLL-
fusion proteins in leukemia cell lines may present an alternative tool. According to genomic 
DNA gains and losses as well as gene expression patterns, the monoblastic AML cell line THP1 
has been described to be a faithful model system for leukemia with genomic aberrations (Rucker, 
et al. 2006). The most common MLL translocation in AML (MLL-AF9) is strongly associated 
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infant AML and with the AML subclass M5 of the French-American-British (FAB) 
classification systems that describes monoblastic and monocytic phenotypes (Chowdhury, et al. 
2003; Jansen, et al. 2005). Among seven described cell lines carrying the MLL-AF9 
translocation, THP1 is the only one established from an infant AML M5 leukemia patient 
(Drexler, et al. 2004; Tsuchiya, et al. 1980) and thus may be regarded as a representative model. 
In previous studies employing RNAi, the effect of MLL-AF9 knockdown on the expression of a 
few selected genes was investigated in this cell line (Kawagoe, et al. 2001; Pession, et al. 2003). 
So far, however, no comprehensive data is available on differential transcription after specific 
knockdown of endogenous MLL-fusion genes. 
6.4 MicroRNAs and their role in hematologic malignancies 
MicroRNAs are small (~ 22 nt long), abundant and highly conserved endogenous RNAs which 
regulate gene expression by translational inhibition and mRNA destabilization (Bartel 2004). 
MicroRNAs (miRNAs)  are either transcribed from independent miRNA genes encompassing a 
single or a cluster of miRNAs or are located in introns or even exons of (protein coding) genes. 
Their biogenesis and mode of action is depicted in figure 3. At present, 1424 miRNAs are known 
in humans and their number is still rising.  
Evidence from transcription and protein studies has led to the notion that mRNA targets of 
miRNAs are plentiful in number, ranging between dozens and hundreds of mRNAs per miRNA 
(Lim, et al. 2005; Hammond 2006; Baek, et al. 2008). Embryonic lethality has been observed in 
mammals for the knock-out of miRNA pathway components (Dicer, DGCR8 and Ago2), 
highlighting the significance of this gene regulatory mechanism (Babiarz, et al. 2009). 
After two decades of research since their discovery, the regulatory role and importance of 
miRNAs in normal development and cellular homeostasis, as well as in human pathogenesis and 
basic cellular functions including proliferation, differentiation and apoptosis, is widely accepted 
(Hwang, et al. 2006; Hammond 2006).  
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Figure 3: MicroRNA biogenesis and mode of action. A primary transcript, the pri-miRNA, is 
transcribed by polymerase II and processed into the precursor miRNA (pre-miRNA, a 60 to 70 nt 
long stem loop intermediate) by drosha (a RNase III endonuclease) and the cofactor DiGeorge 
syndrome critical region gene 8 (DGCR8). The pre-miRNA is actively transported from the 
nucleus to the cytoplasm by exportin-5 and further processed by dicer (also a RNase III 
endonuclease) into the mature, about 22 nt long, miRNA double strands bearing two-nucleotide 
3’-overhangs. It is presumed that drosha, not dicer, imparts the specificity of the whole cleavage 
process. One strand of the mature miRNAs gets preferentially incorporated into the RNA 
induced silencing complex (RISC), a process which is regulated depending on the miRNA 
double strand sequence and is guided by other proteins (Hutvagner 2005). The incorporated, 
active miRNA strand identifies target molecules via sequence complementarity, allowing 
mismatches and loops and thus leading to the regulation of numerous different targets. The 
binding of RISC to a target leads to mRNA cleavage, translational inhibition and mRNA 
deadenylation and might even lead to transcriptional inhibition on DNA level. (Bartel 2004; 
Landthaler, et al. 2004; Standart, et al. 2007) Figure from Cordes et al., 2010. 
 
An important role for miRNAs in tumorigenesis has been shown (Calin, et al. 2002; Calin, et al. 
2004; Cimmino, et al. 2005) and abnormal miRNA expression is a common feature of human 
malignancies. MicroRNAs are extensively involved in cancer pathogenesis of solid tumors by 
controlling the expression of protein-coding tumor suppressors and oncogenes. (Hwang, et al. 
2006; Kasinski, et al. 2011) Lu et al. (2005) showed that miRNA profiles classify tissue origin, 
differentiation state, cancer versus non-cancer state and even leukemia subtypes. In this context, 
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a profile of 217 miRNAs proofed more informative than a profile of 16000 mRNAs, highlighting 
the highly valuable information content of miRNA profiles (Lu, et al. 2005).  
Recently, in a number of patient studies, miRNAs have been found to be differentially expressed 
among distinct cytogenetic groups of AML. However, the specific signatures differ among 
studies, a phenomenon which has been ascribed to the lack of standardization of the analytic 
methods used by different groups. Concerning MLL-aberrant AML patient samples, the fact that 
different subtypes, e.g. MLL translocations with a cytoplasmic and a nuclear translocation 
partner, are grouped together may cause additional problems in obtaining specific information on 
the miRNAs involved. (Marcucci, et al. 2011) 
Guenther et al. (2005) could show that the SET domain of wild-type MLL binds to a vast 
number of miRNA loci. This was the first published direct link between MLL and miRNAs. 
Recently, miRNAs were shown to be downregulated in MLL-AF4 infant ALL as a consequence 
of CpG hypermethylation (Stumpel, et al. 2011).  
Nakamura et al. (2007) found miRNAs differentially expressed in cell lines harboring MLL 
translocations compared to pro-B cell lines without these aberrations. Popovic  et al. (2009) 
reported that miR-196b is upregulated by MLL as well as MLL fusion proteins in mouse bone 
marrow progenitors and appeared to contribute to immortalization and block of differentiation. 
Mi et al. (2010) showed that the miR-17-92 cluster, which has been previously associated with 
solid tumors, is highly expressed in MLL-aberrant leukemia and enhances proliferation and 
colony-forming capacity of mouse bone marrow progenitor cells.  
Taken together, these reports suggest that miRNAs play an important role in MLL-aberrant 
leukemogenesis. However - as argued for gene expression analyses (4.3) - studies with patient 
samples and techniques leading to overexpression of MLL fusions have limitations.  
The necessity for further studies on the effects of specific MLL-rearrangements on miRNA 
expression – as aimed in our study - has already been acknowledged (Marcucci, et al. 2011). 
This is especially important, as miRNAs are anticipated to proof useful for targeted cancer 
therapies. In vivo proof-of-principle for application of miRNA-based cancer therapies has 
already been obtained in a number of animal studies. (Kasinski, et al. 2011)  
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6.5 Aim of this study 
The general aim of our study was to identify new potential therapeutic targets for MLL-aberrant 
acute myeloid leukemia. Specifically, we decided to focus our work on the relatively common 
MLL-AF9 translocation in view of the still poor prognosis of the associated AML.  
 
In our experimental approach we aimed to define the downstream effects of MLL-AF9 both on 
the cellular phenotype and on functional endpoints as well as on gene and miRNA expression. 
 
As a prerequisite the technical goals to be achieved were: 
» selecting an appropriate cell line as model 
» designing and evaluating specific and efficient siRNAs that target the breakpoint of MLL-
AF9 while not disturbing wildtype MLL or AF9 expression 
» confirming efficient knockdown of MLL-AF9 
» setting up an experimental design that achieves a prolonged knockdown of MLL-AF9 
» constraining the masking of MLL-AF9 specific effects by the strong mitogenic influence 
of fetal bovine serum (FBS) within the culture 
 
In the biological context we aimed at evaluating the differential expression data concerning the 
functional processes involved in MLL-AF9 translocation and in respect to their potential 
relevance in the mediation of MLL-AF9 leukemogenic effects. Finally distinct candidate genes 
and miRNAs with potential as new therapeutic targets should be sorted out.  
 
For this specific purpose we planned to devise a strategy for rating and prioritization of candidate 
targets that includes   
» gene ontology analyses to identify the functional processes involved 
» disease ontology analyses to identify genes linked to leukemic disease conditions 
» comparisons of our in vitro data to published in vivo expression data  
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7 Material and Methods 
7.1 Cell and molecular biological methods 
7.1.1 Cell culture 
THP1 cells were purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und 
Zellkulturen GmbH, Braunschweig, Germany) and aliquots were frozen in liquid nitrogen after 5 
passages. Cells were maintained in RPMI 1640 with 10% heat inactivated fetal calf serum, 100 
Units Penicillin per ml and 0.1 mg/ml Streptomycin (all PAA Laboratories, Pasching, Austria) at 
a density of 0.05-0.5×10
6
 cells/ml in a humidified 37°C / 5% CO2 incubator. Experiments were 
started one day after splitting cells, in the exponential growth phase. Every two to three months, 
fresh aliquots of the cells were thawed for experiments. MCF-7 and HELA cell lines were 
obtained from DSMZ and cultured in RPMI 1640 supplemented as for THP1. 
For serum reduced conditions, cells were gently washed in Dulbecco’s PBS and resuspended in 
DMEM / Ham’s F12 medium containing 1 g/L BSA (all PAA Laboratories, Pasching, Austria) 
and 0.5 % Fetal Bovine Serum (#10270, Lot 41G3681K, Gibco, Life Technologies, Carlsbad, 
CA, USA). These culture conditions result in THP1 cells proliferating over at least 6 days, while 
showing a clearly reduced proliferation level (doubling time was reduced from 1.08 days to 1.34 
days over four days in 0.5% FBS).  
For induction of monocyte-macrophage differentiation of THP1 cells, 20 nM phorbol 12-
myristate 13-acetate (Sigma-Aldrich, St. Louis, MO, USA) was added to the culture for 48 hours 
and effect on morphology was confirmed via microscopy.  
7.1.2 SiRNAs and miRNA mimics 
For establishing MLL-AF9 specific knockdown, six siRNAs were designed according to scores 
from sfold Sirna (Ding, et al. 2001), DISR (Vert, et al. 2006) and siDESIGN Center (Thermo 
Scientific, Waltham, MA, USA) against MLL-AF9 breakpoint in THP1 cell line. Table 2 gives 
sense and antisense sequences of MLL-AF9 specific siRNAs. SiRNAs were dissolved in 1 x 
siRNA buffer (Dharmacon, Lafayette, CO, USA). SiR_1 and siR_2 were unmodified (MWG 
Biotech, Ebersberg, Germany), while siR_5 was ON-TARGETplus™ modified (Dharmacon, 
Lafayette, CO, USA) and siR_3, siR_4 and siR_6 were Silencer Select® modified (Ambion, Life 
Technologies, Carlsbad, CA, USA). Silencer Select® and ON-TARGETplus™ are proprietary 
chemical modifications of the companies and not precisely specified.  
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Table 2: THP1-breakpoint specific siRNA sequences against MLL-AF9. 
 
Sequences of siRNAs that were designed and tested in this study are given. 
Sequences in bold correspond to AF9 part of MLL-AF9. dT = deoxythymidine 
 
For analysis of transfection efficiency, AF488 labeled AllStars Negative siRNA (Qiagen, Hilden, 
Germany) was employed. As negative controls, Silencer Select negative control #1 and #2 
siRNAs (Ambion, Life Technologies, Carlsbad, CA, USA) were used (proprietary sequences of 
Ambion). 
MiR-511 and negative control #1 mimics (Pre-miR™ miRNA Precursor Molecules, Ambion, 
Life Technologies, Carlsbad, CA, USA) were employed for miRNA upregulation studies in 
THP1 cells. These small, chemically modified double-stranded RNA molecules are designed to 
mimic endogenous mature miRNAs and do not need to be further processed by the cell. 
7.1.3 Transfections of siRNAs, miRNA-mimics and shRNA plasmids  
Six chemical transfection methods (Dreamfect (OZ Biosciences, Marseille cedex, France), 
Dmrie-C (Invitrogen, Carlsbad, CA, USA), HiPerFect (Qiagen, Hilden, Germany), FuGene HD 
(Roche, Basel, Switzerland), Lipofectamine LTX and Lipofectamine 2000 (both Invitrogen, 
Carlsbad, CA, USA)) were tested in THP1 cells. Transfections were performed according to 
suppliers’ protocols. Electroporation was carried out using an EPI 2500 device (Laborgeräte 
Fischer, Heidelberg, Germany) with 200 V for 10 msec. Finally, transfections of siRNAs in 
THP1 cell line were performed with 8.9 µl Dreamfect™ (OZ Biosciences, Marseille cedex, 
France) and a final concentration of 50 nM siRNA added to 1 ml cell culture medium containing 
5×10
4
 cells in a 12-well format (Greiner, Kremsmuenster, Germany) according to supplier’s 
protocol. To ensure a MLL-AF9 knockdown which efficiently reaches the protein level and leads 
to changes in the expression of MLL-AF9 target genes, experiments were performed over eight 
(or, as indicated, over twelve) days with repeated siRNA transfections on day 0, 3, 6 (and 10). 
Before each transfection event, cell densities were determined by Cellscreen microscopy and 
cells were reseeded at 5×10
4
 cells per ml in 12- well formats.  
Transfections for miRNA upregulation studies were performed with 8.9 µl Dreamfect™ (OZ 
Biosciences, Marseille cedex, France) and a final concentration of 30 nM miRNA mimics added 
to 1 ml cell culture medium containing 5×10
4
 cells in a 12-well format (Greiner, Kremsmuenster, 
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Germany) according to supplier’s protocol. Serum reduced conditions (see section 7.1.1) were 
employed to maintain similar conditions as in which MLL-AF9 knockdown specific miR-511 
overexpression was observed. The resulting upregulation of miR-511 resembled approximately 
the expression strength of the strongest expressed endogenous miRNA in this cell line.  
For stable transfection of THP1, two shRNA plasmids against MLL-AF9 and one containing a 
control shRNA were constructed (table 3) by utilizing pSIF1-H1-Puro shRNA vector (System 
Biosciences, Mountain View, CA, USA). ShRNAs were under the polymerase III RNA promoter 
H1 as described in the supplier’s protocol. Puromycin resistant marker was replaced by a cassette 
of cGFP under CMV promoter, and a truncated version of the surface marker LNGFR under EF1 
promoter (Magg, et al. 2009). THP1 cells were transfected with a Nucleofector
®
 II Device and 
Human Monocyte Nucleofector® Kit (both Lonza, Basel, Switzerland) and nucleofector 
program Y-001. LNGFR served for positive selection of transfected THP1 cells with 
immunomagnetic CD271 (LNGFR) microbeads and MS columns (both Miltenyi Biotec, 
Bergisch Gladbach, Germany). 
 
Table 3: Overview of THP1-breakpoint specific shRNA sequences.  
 
ShRNA sequences as employed for generation of shRNA plasmids for stable transfection of 
THP1 cells. Sequences designed for being processed into siRNAs are depicted in bold. 
 
7.1.4 Confocal fluorescence microscopy 
For detecting the localization of siRNA within the cells, confocal fluorescence microscopy was 
employed. Here, 1×10
5
 AF488 siRNA transfected THP1 cells were stained with 4,6-diamidino-
2-phenylindole (DAPI, Sigma-Aldrich, St. Louis, MO, USA). Cells were centrifuged onto object 
slides at 200×g for 3 minutes, mounted in Aqua-Poly/Mount (Polysciences, Eppelheim, 
Germany) and analyzed via an Olympus IX81 confocal microscope using the UPLanSApo 
60x/1.35 oil objective (Olympus, Hamburg, Germany).  
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7.1.5 Cell diameter and proliferation  
Proliferation and cell diameter were measured via Cellscreen System (Innovatis, Bielefeld, 
Germany) on an Olympus IX 50 microscope. This system is a non-invasive, automated analysis 
system that captures and evaluates microscopic images of cell cultures. It allows to repeatedly 
measure a multi-well plate by taking images of pre-adjusted regions of interest (ROIs) and 
analyzes cell number and cell diameter through digital image recognition (examples of images 
are shown in figure 4). 
Cellscreen Microscopy was performed in 12 well formats (Greiner, Kremsmuenster, Germany) 
with 62 ROIs equivalent to 8% of the surface area of each well. Cells were allowed to settle to 
the bottom of the well on the Cellscreen microscope for 20 minutes prior to measurement to 
ensure that all cells were within the focus of the microscope. Measurement times were kept 
below 45 minutes to reduce room temperature (RT) and CO2 concentration effects. To test if cell 
size was significantly altered between MLL-AF9 knockdown and control treatments, a Welch’s  
t test was performed over five replicate experiments after confirmation of normal distribution via 
Shapiro-Wilk normality test. For analyses, all knockdown treatments (siR_3 and siR_4) were 
compared to all non-targeting control treatments (n-tg_1 and n-tg_2).  
 
Figure 4: Example of Cellscreen image evaluation. Depicted are enlarged sections (each 
corresponding to ¼) of two regions of interest (ROIs) from MLL-AF9 knockdown (left) and 
control treatments (right). Cell number and size is evaluated via an automated analysis system, 
which generates green marks (crosses) on the cells within the images. 
 
Cell Proliferation Kit I (MTT) (Roche, Basel, Switzerland) was employed according to 
supplier’s protocol to measure metabolic activity of viable cells from which proliferation may be 
deduced. Briefly, after gentle mixing, 100 µl of transfected cell suspension was taken from 6 
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transfection replicate wells per treatment, incubated with 10 µl MTT reagent for 4.5 hours and 
solved over night with 100 µl solubilization solution. Spectrophotometric read out was 
performed on a GENios (TECAN, Maennedorf, Switzerland) microplate reader. 
7.1.6 Flow cytometric measurements 
Flow cytometric measurements were performed on a BD FACSCanto
TM
 (BD Biosciences, 
Franklin Lakes, NJ, USA) with FACS Diva Software v 5.0.3. 
Flow cytometric analyses and figures were created with Cyflogic v.1.2.1 (CyFlo Ltd., Turku, 
Finland). 
7.1.6.1 Transfection efficiency 
Transfection efficiency was measured by flow cytometry (FCM) after transfection with AF488-
labeled AllStars Negative siRNA (Qiagen, Hilden, Germany). Washing with 1 mg/ml dextran 
sulphate in PBS ensured that no siRNA was attached to the surface of the cells (Zelphati, et al. 
1996). Cell viability was measured by 7-AAD exclusion staining via FCM and by trypan blue 
exclusion staining in hemocytometer counts.  
7.1.6.2 Monitoring of stable transfected cells 
Surface LNGFR was stained with phycoerythrin (PE)–anti-LNGFR antibody (Miltenyi Biotec, 
Bergisch Gladbach, Germany) and together with GFP served to monitor percentage of stable 
transfected cells within the culture by flow cytometry. 
7.1.6.3 Cell cycle analysis 
Cells were fixed in 70% ethanol at -20°C for a minimum of 2 hours and washed in PBS prior to 
staining for 30 minutes in PI/Triton X-100 buffer (0.1% Triton X-100 (Sigma-Aldrich, St. Louis, 
MO, USA), 0.2 mg/ml RNase A (Qiagen, Hilden, Germany), 20 µg/ml propidium iodide 
(Sigma-Aldrich, St. Louis, MO, USA) in Dulbecco’s PBS (PAA Laboratories, Pasching, 
Austria)). For analysis of flow cytometry data, cell doublets and aggregates were removed and 
gates were set to quantify the amount of cells within the three cell cycle phases G0/G1, S and 
G2; apoptotic cells lie within the sub-G0 area (figure 5).  
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Figure 5: Cell cycle Analysis of THP1 cells by flow cytometry. (A) Cell doublets and 
aggregates were removed from analysis by “no doublets” gate within dot blots of propidium 
iodide (PI) width to area. (B) Area of propidium iodid signal was displayed and gates were set to 
quantify the amount of cells within the three cell cycle phases G0/G1, S and G2. Apoptotic cells 
lie within the sub-G0 area.  
 
7.1.6.4 Apoptosis detection 
For analysis of apoptosis, an intracellular staining of cleaved PARP1 was performed (Kaufmann, 
et al. 1993). Cells were fixed with 70% ethanol at -20°C for a minimum of 2 hours. Cells were 
washed in PBS (PAA Laboratories, Pasching, Austria) prior to permeabilization and staining 
with Foxp3 Staining Buffer Set (eBioScience, San Diego, CA, USA) and FITC conjugated rabbit 
polyclonal anti-PARP cleavage site (214/215) specific antibody (Invitrogen, Carlsbad, CA, 
USA) according to supplier’s protocol. Briefly, cells were incubated for 30 minutes in 
fixation/permeabilization buffer, washed once and further incubated for 30 minutes in 
permeabilization buffer and stained in 100 µl permeabilization buffer with 5 µl of fluorescently 
labeled antibody. 
We used a second technique for analysis of apoptosis: staining of cells with Annexin V-PE 
Apoptosis Detection Kit I (BD Biosciences, Franklin Lakes, NJ, USA) with 7-AAD and Annexin 
V-PE according to supplier’s protocol.  
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7.1.7 RNA extraction and determination of RNA concentration, purity and 
integrity 
Total RNA was extracted with miRNeasy Mini Kit (Qiagen, Hilden, Germany) according to 
supplier’s protocol. Samples were lysed in Qiazol and stored at -80°C until extraction. Extracted 
RNA samples were stored at -80°C. 
RNA concentration and purity (absorption 260 nm / 280 nm) was analyzed using a Nanodrop 
ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). RNA integrity 
was determined by capillary electrophoresis with RNA 6000 Nano LabChip Kit on a 2100 
Bioanalyzer (both Agilent Technologies, Santa Clara, CA, USA). Here, a RNA integrity number 
(RIN) is determined from characteristics of the electropherogram, where a high RIN (maximum 
is 10) stands for intact, non-degraded RNA (Schroeder, et al. 2006). RNA samples with a RIN 
above 7.0 or 8.0 have been described to yield reliable miRNA and gene transcript qRT-PCR 
results (Mishra, et al. 2009; Fleige, et al. 2006). For all profiling samples A260/A280 was above 
2.0 and RIN was above 9.3. 
7.1.8 Reverse transcriptase quantitative real-time PCR 
Genomic DNA elimination reaction and reverse transcription was carried out with 300 – 600 ng 
total RNA and QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany) according to 
supplier’s protocol.  
Quantitative real-time PCR was performed in triplicates with iQ
TM
-SYBR® Green Supermix 
(Biorad, Hercules, CA, USA) with 0.6 µl template cDNA, 0.3 µM forward and reverse primer 
(MWG Biotech, Ebersberg, Germany) in a total volume of 15 µl on a StepOnePlus
TM
 instrument 
(Applied Biosystems, Life Technologies, Carlsbad, CA, USA). Run method was: 95°C for 3 
min, 40 cycles of 95°C for 15 sec, 56°C for 15 sec and 72°C for 1 min, followed by 72°C for 2 
min. A subsequent melt curve was performed: 95°C for 1 min and 0.5°C steps from 55 to 95.5°C 
for 30 sec each.  
Real time primer pairs were designed with Clone Manager Suite (version 7.11) software. Primer 
sites were separated by at least one intron if possible (except for transcripts with only one exon 
and the primer MDM2-001, designed to quantify only transcript variant 1). Primer sequences are 
given in supplementary table 1 on page 137. To ensure that no DNA contamination was present, 
melting curves were analyzed on all runs and primer pairs with small separating introns were 
employed. After testing for stable intra- and interexperimental expression, UBC and RPL13A 
were used as reference transcripts for normalization. Among ten tested transcripts, these control 
genes have previously been described as most stable expressed in bone marrow (Vandesompele, 
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et al. 2002). An approximately 100 % efficiency of qRT-PCR was confirmed via cDNA dilution 
series for MLL-AF9, MLL, AF9, RPL13A and UBC. 
7.1.9 Gene expression profiling 
Human Whole Genome Microarrays 4x44K v2 (arrayID 026652, Agilent Technologies, Santa 
Clara, CA, USA) were commissioned to and performed at IMGM Laboratories (Martinsried, 
Germany) with 100 ng total RNA input per sample. 
Low Input Quick Amp Labeling Kit (Agilent Technologies, Santa Clara, CA, USA) was used to 
generate fluorescent complimentary RNA (cRNA) with a sample input of 100 ng total RNA. T7 
RNA polymerase was used, which simultaneously amplifies target material and incorporates 
cyanine 3-labeled CTP. Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, 
Wilmington, DE, USA) was used to record cRNA concentration (ng/μl), RNA absorbance ratio 
(260nm/280nm) and Cyanine-3 dye concentration (pmol/μl) for all cRNA samples. cRNA yield 
and specific activity of dye incorporated in cRNA was calculated and fulfilled the requirements 
(yield of cRNA above 1.65 μg and specific activity above 9.0 pmol Cyanine-3 per μg cRNA). 
The RNA 6000 Nano LabChip Kit was used on the 2100 Bioanalyzer (both Agilent 
Technologies, Santa Clara, CA, USA) to analyze the quality of labeled non-fragmented cRNA. 
Following cRNA clean-up and quantitation (NanoDrop ND-1000, Nanodrop Technologies, 
Wilmington, DE, USA), 1.65 μg of each Cyanine-3-labeled cRNA sample was fragmented and 
prepared for One-Color based hybridization (Gene Expression Hybridization Kit, Agilent 
Technologies, Santa Clara, CA, USA). cRNA samples were hybridized at 65 °C for 17 hours on 
separate Whole Human Genome Microarrays (4x44K format). Afterwards microarrays were 
washed with increasing stringency using Gene Expression Wash Buffers (Agilent Technologies, 
Santa Clara, CA, USA) followed by drying with acetonitrile (Sigma-Aldrich, St. Louis, MO, 
USA). Fluorescent signal intensities (FI) were detected with Scan Control 8.4.1 Software on the 
Agilent DNA Microarray Scanner and extracted from the images using Feature Extraction 
10.5.1.1 Software (both Agilent Technologies, Santa Clara, CA, USA). Analysis of the Agilent 
One-Color RNA Spike-In Plot was used to ensure equal and good performance of each single 
labeling and hybridization experiment. 
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7.1.10 MicroRNA profiling and confirmatory techniques 
7.1.10.1 Quantitative microRNA detection via TaqMan miRNA Low Density Array and 
single assay qRT-PCR 
Quantitative miRNA profiles were generated with TaqMan® Array Human MicroRNA Cards 
(Applied Biosystems, Life Technologies, Carlsbad, CA, USA), also known as TaqMan® Low 
Density Arrays (LDAs). These arrays cover 664 distinct miRNA assays which are spread over 
two low density array cards, the so-called plates A and B. MiRNA profiles were generated with 
preamplification according to supplier’s protocol. An input of 350 ng total RNA per array card 
and sample pool was used. LDA runs were performed on an ABI PRISM® 7900HT machine and 
SDS 2.3 software (Applied Biosystems, Life Technologies, Carlsbad, CA, USA). 
Quantitative real time PCR of single miRNAs was performed with TaqMan® miRNA assays 
(Applied Biosystems, Life Technologies, Carlsbad, CA, USA) according to the manufacturers’ 
instructions. RNU6B, RNU44 and RNU48 assays were tested as internal references. RNU48 
showed the least intra- and interexperimental variance and thus was used as internal reference. 
Single assay miRNA measurements from experimental pools were performed after megaplex 
reverse transcription and preamplification according to supplier’s protocol. Single assay miRNA 
measurements from individual experiments were performed with Taq Man® miRNA assays after 
2-plex reverse transcription for the specific miRNA and the internal reference (RNU48) from 
200 ng total RNA.  
7.1.10.2 Semiquantitative microRNA detection via microarrays  
Expression profiling via semiquantitative microarrays was commissioned to IMGM laboratories 
(Martinsried, Germany) and carried out with 100 ng total RNA input using Agilent Human 
miRNA Microarrays (8x15K) in combination with one-color based hybridization protocol. Prior 
to the labeling reaction, the total RNA samples were spiked with in-vitro synthesized 
oligonucleotides (MicroRNA Spike-In Kit, Agilent Technologies, Santa Clara, CA, USA) which 
served as an internal labeling control for linearity, sensitivity and accuracy. The spiked total 
RNA was treated with alkaline calf intestine phosphatase (CIP). Subsequently, the 
dephosphorylated RNA was labeled (miRNA Complete Labeling and Hyb Kit, Agilent 
Technologies, Santa Clara, CA, USA) using the T4 RNA ligase. All steps were carried out 
according to manufacturer’s instructions. 
After clean-up, Cyanine-3-labeled miRNA samples were prepared for one-color based 
hybridization (Complete miRNA Labeling and Hyb Kit, Agilent Technologies, Santa Clara, CA, 
USA). Each Cyanine-3-labeled miRNA sample was hybridized for 20 hours at 55°C on separate 
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Human miRNA Microarrays (Agilent Technologies, Santa Clara, CA, USA, AMADID 029297, 
8x15K format). Afterwards, microarrays were washed with increasing stringency using Gene 
Expression Wash Buffers (Agilent Technologies, Santa Clara, CA, USA) followed by drying in 
acetonitril (Sigma-Aldrich, St. Louis, MO, USA).  
Signals on the microarrays were detected with the Agilent Microarray scanner using Scan 
Control at IMGM. 
7.2 Biochemical methods 
7.2.1 Western blot 
Protein samples were extracted from Qiazol organic phase. Phase separation was performed 
according to supplier’s miRNeasy Mini Kit protocol (Qiagen, Hilden, Germany). To the organic 
phase of 700 µl Qiazol, 210 µl 100% ethanol was added and gently mixed. DNA was pelleted by 
centrifugation (7500×g, 5 min, 4°C). 1.05 ml isopropyl alcohol was added to the supernatant, 
mixed, incubated (10 min, RT) and centrifuged to pellet protein (12000×g, 10 min, 4°C). The 
protein pellet was washed three times with 1.4 ml guanidine-hydrochloride (0.3 M in 95% 
ethanol) and once with 1.4 ml 100% ethanol at RT for 20 min each, with subsequent 
centrifugation steps (7500×g, 5 min, 4°C). The protein pellet was dried at RT and resuspended in 
2 % SDS and 1 volume Laemmli sample buffer and heated for 5 min to 95°C.  
Alternatively, whole cell lysates were generated by either adding 2 × Laemmli sample buffer and 
incubating at 95°C for 5 min or by adding RIPA buffer (150 mM sodium chloride, 50 mM Tris, 
1% Triton, 0.5% deoxycholate, 0.1% SDS, 1 × Complete Mini protease inhibitor cocktail) on 
ice, performing sonication on ice and subsequently adding one volume 2 × Laemmli sample 
buffer before loading on gels. Sonication was performed on a Sonifier S-250D digital ultrasonic 
(Branson Ultrasonics, Danbury, CT, USA) with cycles of 0.8 seconds pulse, 0.2 seconds pause 
for 4 seconds and an pulse amplitude of 10%.  
Samples were loaded on self-casted 6% polyacrylamid gels with 4% stacking gel and run in 1 x 
Tris buffer (25 mM Tris, 0.2M glycine, 1%SDS) at 100 V and 50 mA for approximately one 
hour. PVDF membrane with 0.2 µm pore size was prewet in 100% methanol, and equilibrated 
for 15 min in transfer buffer (10 mM CAPS, pH 11, 0.05% SDS). Wet blotting was performed 
with transfer buffer in a Mini-Protean
TM
 3 Cell (Biorad, Hercules, CA, USA) at 285 mA for one 
hour. Blots were blocked for 30 min in 1 × Rotiblock solution, rinsed in TBST (20 mM Tris-
HCl, pH 7.6, 137 mM sodium chloride, 0.2% Tween20) and incubated over night at 4 °C with 
primary antibody. Primary antibodies were diluted in 1.5% milk powder in TBST containing 
0.01% sodium azide. MLL1 antibody (A300-086A, Santa Cruz Biotechnology, Santa Cruz, CA, 
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USA), recognizes a N-terminal epitope and was diluted 1:2500. MLLT3 antibody (alias AF9, 
A300-597A, Santa Cruz Biotechnology, Santa Cruz, CA, USA) recognizes a C-terminal epitope 
and was diluted 1:2000. Blots were washed three times with TBST (10 min, RT) and incubated 
for 45 minutes with goat-anti-rabbit-HRP secondary antibody (sc-2004, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA,) diluted 1:2500 in 1.5% milk powder / TBST. Blots were 
washed five times with TBST (10 min, RT) and bands were detected with Immun-Star HRP 
substrate on CL-XPosure
TM
 Film.  
 
Table 4: Western blot reagents and supplier. 
Reagents Supplier 
CAPS Roth, Karlsruhe, Germany 
CL-XPosure
TM
 Film Thermo Scientific, Waltham, MA, USA 
Complete Mini Protease Inhibitor Cocktail Roche, Basel, Switzerland 
Ethanol, absolute Merck, Darmstadt, Germany 
Glycine Roth, Karlsruhe, Germany 
Guanidine hydrochloride Sigma-Aldrich, St. Louis, MO, USA 
Immun-Star HRP substrate Biorad, Hercules, CA, USA 
Laemmli sample buffer Sigma-Aldrich, St. Louis, MO, USA 
Methanol, ≥99.9% Roth, Karlsruhe, Germany 
Milk powder Roth, Karlsruhe, Germany 
Polyacrylamid Rotiphorese Gel 30 (37.5:1) Roth, Karlsruhe, Germany 
PVDF membrane, 0.2 µm pore size Biorad, Hercules, CA, USA 
Rotiblock solution Roth, Karlsruhe, Germany 
SDS, ultra pure, 20% solution National Diagnostics, Atlanta, GA, USA 
Sodium azide Merck, Darmstadt, Germany 
Sodium chloride Roth, Karlsruhe, Germany 
Sodium deoxycholate Sigma-Aldrich, St. Louis, MO, USA 
Tris Roth, Karlsruhe, Germany 
Triton Sigma-Aldrich, St. Louis, MO, USA 
Tween20 Roth, Karlsruhe, Germany 
  
7.2.2 TaqMan Protein Assay 
TaqMan® Protein Assay (Applied Biosystems, Life Technologies, Carlsbad, CA, USA) is a new, 
alternative method to Western blotting and enables detection and relative quantitation of proteins 
in cultured mammalian cell and tissue lysates (figure 6).  
To generate assay probes, antibodies against MLL and AF9 (see 7.2.1) were dialyzed (3 times 
for 2 h and once over night in 1 l PBS (PAA Laboratories, Pasching, Austria) at 4°C)  to remove 
Tris via Slide-A-Lyzer® Mini Dialysis Unit (MWCO=7000, Thermo Scientific, Waltham, MA, 
USA). Subsequently, antibodies were biotinylated with Biotin-XX Microscale Protein Labeling 
Kit (Molecular Probes, Life Technologies, Carlsbad, CA, USA) according to supplier’s protocol 
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and free biotin was removed by dialyzing as described before. To ensure efficient biotinylation 
of antibodies and removal of free biotin, a forced proximity test was performed according to 
supplier’s protocol. This test was passed, indicating high quality biotinylation of antibodies.  
To ensure equal number of cells lysed, cell suspensions were counted with one volume trypan 
blue in disposable C-chip hemocytometers (Peqlab, Erlangen, Germany). Samples were lysed in 
RIPA buffer on ice (see 7.2.1). For evaluation of TaqMan protein assay, cell lysates of THP1 and 
HELA (the latter expressing MLL wildtype but no MLL-AF9) were used and mixed in different 
proportions. HELA was used as background negative control for MLL-AF9 protein quantitation. 
Antibody binding, ligation of oligonucleotide probes, protease digestion and quantitative real-
timer PCR were performed according to supplier’s protocol. 
 
Figure 6: TaqMan
®
 Protein Assay generated to detect MLL-AF9 protein. The TaqMan
®
 
Protein Assay is a new, alternative method to Western blotting and enables detection and relative 
quantitation of proteins in lysates. Antibodies (either two monoclonal or one polyclonal) are used 
to generate two assay probes, which consist of the antibodies linked to DNA oligonucleotides 
(shown in blue or yellow). After binding of the two antibodies in close proximity, i.e. on the 
same protein molecule, DNA oligonucleotides are ligated with the help of a DNA linker and are 
quantified by real-time PCR after protease digestion. 
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7.3 Biostatistical methods 
7.3.1 Gene expression profiling data analysis 
Green channel intensities from each data file were read for further analysis. Quality weights for 
each spot on every array were assigned based on several quality measures (e.g. saturation, 
uniformity, population outlier) as produced by Agilent Feature Extraction v10.5.1.1 (FE). 
Background correction was performed by FE and scaling was used for between array 
normalization.  
Hierarchical clustering of arrays and principal component analyses were performed in 
collaboration with Dr. Philipp Pagel (Lehrstuhl für Genomorientierte Bioinformatik, 
Wissenschaftszentrum Weihenstephan, Technische Universität München) with the statistical 
language R (R Development Core Team 2008) using packages from the Bioconductor 
framework (Gentleman, et al. 2004). Analysis of differential expression between MLL-AF9 
knockdown and control treatments was carried out in R with the limma package (Smyth 2004) 
which fits a linear model for each gene and computes a moderated t statistic and its p-value 
(Smyth 2005). Limma is part of the Bioconductor project (Gentleman, et al. 2004). Adjustment 
for multiple testing was done using the method by Benjamini and Hochberg (Benjamini, et al. 
1995). Thus, logarithmic fold-change (log2FC =  21log2 ExpressionExpression  ), p-value of 
the moderated t test and p-value after correcting for multiple testing were generated. 
The unnormalized data showed an almost perfect logarithmic (log) intensity distribution which 
was more uniform than the background-corrected or the background-corrected and normalized 
data. In hierarchical clustering of arrays based on the Euclidean distance of log intensity profiles 
the treatments (MLL-AF9 knockdown or control) clearly cluster together. In principal component 
(PC) analysis of arrays based on their expression profiles clearly the first PC is the knockdown, 
which is in good agreement with the hierarchical clustering results. No clear improvement is 
seen in PC analysis through background-correction and normalization. Additionally 
unnormalized data seem to be more consistent, e.g. more identical replicate probes are within the 
top regulated probes. Due to these findings unnormalized data were used for the differential 
expression analysis. 
Agilent gene expression microarrays encompass a subset (999) of probes with 10 identical 
replicates and, depending on the transcript analyzed, between 1 and 13 non-identical probes. 
Nevertheless, because of regularly altered microarray layouts and different microarray designs 
(depending on the supplier), these replicates are all treated as independent data points in standard 
analyses, and a probe may show up as significantly regulated even though 9 other identical 
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replicates may not show differential expression. To evaluate the reliability of the results and to 
decide on a threshold p-value, a t test was performed over identical replicate probe sets for 
differentially expressed probes up to p<0.05. Here, probe sets showing a p-value below 0.05 
were regarded as reliably differentially expressed. The percentage of significant replicates was 
plotted against the p-value threshold (figure 7). This showed a plateau of high percentage of 
significant identical replicates up to p<0.03, with an almost linear decline between p<0.03 and 
0.06. Thus, to include the highest number of differentially expressed transcripts without raising 
the false positive rate, the cutoff p-value of the moderated t test was set below 0.03. Within the 
results, probes which did not show significant alteration over all identical replicates were 
removed.  
 
 
Figure 7: Gene expression microarray analysis: Percentage of significant identical replicate 
probe sets as a function of p-value threshold. Probe sets consist of ten identical replicate 
probes. Up to a p-value of 0.03 a plateau of high percentage of significant identical replicates is 
observed, with an almost linear decline following. Thus p-value cutoff was set to < 0.03. 
 
According to experimental design strategies, probes which did not show a uniform regulation 
between MLL-AF9 knockdown and non-targeting control treatments (i.e. both knockdown 
samples yielding either higher or lower FI values than the controls) were removed from the final 
results. This concerned five of 1350 deregulated probes. 
Likewise, non-identical probes against gene transcripts were investigated with a t test if not all of 
these probes were significantly differentially expressed (p<0.03). In supplementary table 2 (on 
page 139), a sign (#) denotes that possibly only one splice variant of the gene transcripts is 
differentially expressed if probe signals were not overall significantly altered (p<0.05 in a paired 
t test).  
Depending on the sequence of probes against MLL and AF9 wildtype, these probes will also 
detect MLL-AF9 transcript. This is the case for both AF9 (alias MLLT3) probes which are 
complementary to exon 11 of AF9 and for one out of four MLL probes which detects exon 6 of 
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MLL. As expected, these three probes showed significantly reduced signals (log2FC -0.69 ±0.09 
in AF9 and -0.41 ±0.09 in MLL) in MLL-AF9 knockdown samples. The other three probes 
detecting only MLL wildtype did not turn up as deregulated. AF9 wildtype is only expressed at 
low level in THP1 whereas MLL wildtype is expressed in roughly similar amounts as MLL-AF9 
(according to qRT-PCR data). Thus it is consequential that the AF9-probes detecting both AF9 
wildtype and fusion mRNA show stronger downregulation compared to the MLL-probe detecting 
both MLL versions. These three probes influenced by the knockdown of MLL-AF9 mRNA were 
excluded from the deregulated gene list.  
Within the graphs displaying differentially expression of genes from microarray data, only the 
most significant probe per gene is shown in cases where multiple probes against one gene were 
differentially expressed. In these graphs, bars indicate standard error of the mean of 4 log2FC 
ratios between MLL-AF9 knockdown and control samples. 
Gene expression strength was categorized in high, medium and low expression according to 
microarray average expression value, which is based on log geometric mean of fluorescent signal 
intensities (FIs): 21log2 ExpressionExpression  . High expression was defined as ≥ 10.0, 
medium expression 7.0 – 9.99 and low expression < 7.0 average log2 expression.  
7.3.2 Quantitative LDA miRNA profiling data analysis 
Data analysis of miRNA LDAs was performed in collaboration with Dr. Philipp Pagel (Lehrstuhl 
für Genomorientierte Bioinformatik, Wissenschaftszentrum Weihenstephan, Technische 
Universität München). All raw data tables from sds-files were imported into R programming 
language and software environment. A and B plates, on which the miRNA and control assays are 
spread, were merged into one table.  
The canonical method in qPCR analysis is to use housekeeper genes as references before looking 
at treatment effects (∆∆CT method). As it is difficult to define reliable housekeeper in the case of 
miRNAs, it has been shown that normalizing to the overall mean instead outperforms the 
reference approach (Mestdagh, et al. 2009). Based on the observation of substantial distortion of 
log RQ values over the entire CT range, we applied a LOESS normalization, similar to what is 
commonly used in the analysis of microarrays. This method works under the assumption that the 
majority of miRNAs is not differentially expressed and thus a LOESS curve fitted to the data can 
be used as reference. Cyclic LOESS normalization was applied to the data separately for the A 
and B plates. Cases of “undetermined” (no signal measured) cannot be handled in the statistical 
test. Analysis of differential expression between MLL-AF9 knockdown and control treatments 
was carried out in the statistical language R with the limma package (Smyth 2004) (see section 
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7.3.1 for details). Adjustment for multiple testing was done using the method by Benjamini and 
Hochberg (Benjamini, et al. 1995). Log2FC, p-value of the moderated t test and p-value after 
correcting for multiple testing were generated. MiRNAs which showed low expression, i.e. high 
threshold cycle (CT values above 34.5) in both treatment groups were excluded form the 
analysis. MiRNAs with a p-value below 0.05 were regarded as differentially expressed. MiRNAs 
which were either turned “on” or “off” in both MLL-AF9 knockdown versus both non-targeting 
control samples (“undetermined” versus CTs below 34.5) were added to the miRNA candidate 
list manually. For these, no ratio can be calculated but a lower limit of differential expression is 
reported as previously described (Dorsam, et al. 2004). Of the 664 distinct miRNAs detectable 
by this LDA, 73 are measured in duplicate. MiRNAs were removed from the candidate list if 
their replicate did not show concordant regulation. 
7.3.3 Semiquantitative microarray miRNA profiling data analysis 
Fluorescent signal intensities on Agilent Human miRNA Microarrays (8x15K) were detected 
with Scan Control 8.4.1 Software on the Agilent DNA Microarray Scanner and extracted from 
images using Feature Extraction 10.7.1.1 Software (all Agilent Technologies, Santa Clara, CA, 
USA) at IMGM laboratories (Martinsried, Germany). The software tool Feature Extraction 
10.7.1.1 (FE) was used for quality control, visualization of the performance of microarray 
analysis and background correction. Data analysis was performed in collaboration with Dr. 
Philipp Pagel (Lehrstuhl für Genomorientierte Bioinformatik, Wissenschaftszentrum 
Weihenstephan, Technische Universität München). To avoid negative intensities which disrupt 
principal component analysis (PCA) and clustering after log transformation, a small constant 
(25) was added to all raw intensities before further analysis. This procedure usually helps to 
interpret data, especially of genes with low expression. Between-array normalization on the Cy3 
intensity matrix was carried out with the quantile method. Hierarchical clustering of arrays based 
on the Euclidean distance of log intensity profiles after normalization was performed. Analysis 
of differential expression between MLL-AF9 knockdown and control treatments was carried out 
in statistical language R with the limma package (see section 7.3.1 for details) (Smyth 2004). 
Adjustment for multiple testing was done using the method by Benjamini and Hochberg 
(Benjamini, et al. 1995). Log2FC, p-value of the moderated t test and p-value after correcting for 
multiple testing were generated. In graphs, bars indicate standard error of the mean of 4 log2FC 
ratios between MLL-AF9 knockdown and control samples. 
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7.3.4 Correlation analysis of array and qRT-PCR data 
To test reliability of array data (Human Whole Genome Microarray and miRNA LDAs) qRT-
PCR was performed for selected transcripts / miRNAs. In each case, a linear regression model 
was fitted to the two data sets (log2FC of array data versus log2FC of qRT-PCR data) and 
Spearman’s rank correlation was calculated as previously described (MAQC Consortium 2006). 
Linear regressions and Spearman’s rank correlation coefficients were calculated with the 
statistical language R (R Development Core Team 2008). Spearman’s rank correlation was 
employed because this limited data set could not be expected to show normal distribution. 
Regression analysis was based on the formula y = mx + b. The percent difference from the ideal 
slope was calculated as m-1. Differential expression was regarded as confirmed via qRT-PCR 
when log2FC over both experimental pools was at least ±0.3 in the concordant direction. 
7.3.5 Functional disease ontology analysis 
Functional disease ontology analysis maps gene sets to diseases by highlighting statistically 
enriched (overrepresented) disease annotations of the encompassed genes. All differentially 
expressed (p<0.03) genes after MLL-AF9 knockdown in THP1 were entered in functional disease 
ontology (FunDO) using the web version (Flatow, et al. 2009). Within FunDO, the disease 
association of each gene in the genome is annotated using the Disease Ontology and peer-
reviewed evidence from GeneRIF (Osborne, et al. 2009). A condensed version of the Disease 
Ontology, Disease Ontology Lite, is used for the statistical analysis (Du, et al. 2009). Similar to 
functional gene ontology analysis, the significance of each disease association is evaluated by 
Fisher's exact test (Falcon, et al. 2007).  
7.3.6 Functional gene ontology analysis 
Functional gene ontology analysis maps gene sets to associated functional annotations by 
highlighting statistically enriched (overrepresented) annotations terms linked to the encompassed 
genes. Functional gene ontology analysis was performed with Database for Annotation, 
Visualization and Integrated Discovery v6.7 (DAVID) with an input of all deregulated genes 
(p<0.03) after MLL-AF9 knockdown in THP1. Fold enrichment (FE) is calculated for each term 
by DAVID software. This calculation includes a biostatistical normalization procedure, so that 
ranking of terms slightly deviates as compared to the percent of differentially expressed genes 
contained in each functional term (% of total).  
As recommended by DAVID (Huang, et al. 2009b), terms with equal or more than 1.5-fold 
enrichment and a p-value below 0.1 were manually screened for biological relevance. 
Annotation terms which contained the same subset of our differentially expressed genes were 
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seen as redundant and the more specific term was kept in the results. To further structure the 
results, the enriched ontology annotation terms were manually sorted into four functional higher-
order terms within which they may play a role in this biological setting.  
For all genes of the putative relevant functional terms, further information concerning important 
biological categories was collected: genes coding for kinases, for proteins with cell surface 
location, for receptors (via DAVID), for transcription factors (via DAVID and Pubmed gene data 
base) and for cytokines (via match to the genes with the annotation cytokine of Immunology 
Database and Analysis Portal (2011)).  
7.3.7 MiRNA target prediction 
MiRNA target prediction was performed for individual miRNAs with miRWalk software 
(Dweep, et al. 2011). MiRWalk employs 9 different prediction algorithms (DIANA-mT, 
miRanda, miRDB, miRWalk, PICTAR4 / PICTAR5, PITA, RNA22, RNAhybrid and 
TargetScan / TargetScanS) to scan 3’UTRs of genes for predicted miRNA binding sites. Results 
from these predictions were matched for differentially expressed transcripts in MLL-AF9 
knockdown, whose expression negatively correlated to that of the miRNA. For that purpose, the 
p-value threshold of differentially expressed genes was relaxed to p<0.05 (instead of the 
stringent p<0.03) in order to include the highest possible number of potentially relevant miRNA 
targets.  
7.4 Prioritization of likely candidate genes 
To prioritize likely candidate genes for mediation of MLL-AF9 leukemogenic effects within the 
genes which were differentially expressed after MLL-AF9 knockdown, a step-wise approach was 
utilized.  
By applying four criteria, a subset of differentially expressed genes was selected for literature 
research: (1) Genes with strong differential expression (more than ± 1.0 log2FC) (2) Genes which 
were linked to leukemia via functional disease ontology (FunDO) analysis (3) Top regulated 
genes (log2FC>± 1 and further top 5 genes) of different functional categories (higher-order 
terms) of functional gene ontology analysis (4) Genes which showed concordant regulation 
between our data set and published leukemia patient studies. 
Information from literature research together with differential expression strength subsequently 
served to rate the potential importance of these genes in the context of the transforming activity 
of MLL-AF9 via a structured rating strategy (table 5). 
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Table 5: Strategy to rate the potential role of selected, differentially expressed genes 
after MLL-AF9 knockdown concerning mediation of MLL-AF9 leukemogenic effects.  
Rating 
category 
Rating criteria 
+++ Highly likely candidates for mediation of MLL-AF9 leukemogenic effects: 
Differentially expressed gene agrees with all of the following three terms: 
(1) Coherent regulation with described role in at least one of the following 
functions: differentiation of myeloid cells (mere association to differentiation 
is not sufficient), proliferation, growth, apoptosis, survival, senescence, self-
renewal, immunosurveillance, energy-supply, regeneration. 
(2) Coherent regulation with linked association to leukemia via FunDO and / 
or comparison to published patient studies. 
(3) Differential expression of the gene ≥ ± 0.5 log2FC. 
++ Likely candidates for mediation of MLL-AF9 leukemogenic effects: 
Differentially expressed gene agrees with two of the three above described 
criteria. 
+ Genes whose regulation is coherent with its functional role in malignancies: 
Differential expressed gene agrees with either term (1) or term (2) of the three 
above described criteria.  
○ Genes with a currently undefined role in malignancies due to a lack of 
relevant literature. 
- Genes whose regulation is incoherent with its functional role in malignancies 
or its association to leukemia. 
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8 Results 
8.1 Experimental design and siRNA selection 
Within AML, the MLL-AF9 translocation is strongly associated with infant AML (Balgobind, et 
al. 2011) and with the AML subclass M5 of the French-American-British (FAB) classification 
systems (Chowdhury, et al. 2003) that describes monoblastic and monocytic phenotypes. Among 
seven cell lines carrying the MLL-AF9 translocation, the cell line THP1 is the only one 
established from an infant AML M5 leukemia patient (Drexler, et al. 2004; Tsuchiya, et al. 1980) 
and thus this representative cell line was chosen for the study. According to genomic DNA gains 
and losses as well as gene expression, THP1 – like other leukemia cell lines – has been described 
to be a reliable model system for leukemia with genomic aberrations (Rucker, et al. 2006). 
Due to the occurrence of off-target effects of siRNAs (Jackson, et al. 2010; Nature Publishing 
Group 2003), i.e. binding and downregulation of transcripts via imperfect complementarity, 
siRNA experiments should generally be designed with two different siRNA sequences against a 
single target. Only effects which can be seen in both siRNA treatments are considered to be true 
effects of the knockdown, whereas effects only seen in one are likely off-target effects. To 
control for off-target effects, two distinct siRNAs each (against MLL-AF9 and non-targeting 
controls) were used. Both of these non-targeting control siRNAs have previously been described 
to have effects on mRNA expression (as all tested control siRNAs did), but the number of off-
targets was relatively low in comparison to the total number of analyzed transcripts. 
Additionally, they affected distinct sets of mRNAs as seen by hierarchical cluster analysis. 
(Baum, et al. 2010) Thus, these two control siRNAs are unlikely to feign a MLL-AF9 
knockdown specific result by affecting a common transcript and thus can be efficiently used as 
control treatments.  
8.1.1 Transfection method and efficiency 
To establish an efficient and gentle siRNA transfection method for THP1 cells, electroporation 
and six different transfection reagents were tested. Fluorescently (AF488) labeled control siRNA 
and 7-AAD exclusion staining was used to determine transfection efficiency and percentage of 
viable cells by flow cytometry. Dreamfect, electroporation, Dmrie-C and HiPerFect were 
relatively efficient transfection methods, while FuGene HD, Lipofectamine LTX and 
Lipofectamine 2000 had transfection efficiencies below 25% (table 6). It seems that cationic 
lipids in combination with an additional component perform best for THP1 cells. Dreamfect was 
most efficient with 92.5 ±0.8% transfection rate (figure 8), while having the least effect on cell 
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viability (93.0 ±3.7% viable cells) and was selected for further studies. By fluorescence 
microscopy, we ensured that the siRNA did enter the cytoplasm (figure 9). A 50 nM final siRNA 
concentration resulted in maximum MLL-AF9 knockdown.  
 
Table 6:  Percentage of transfected and viable THP1 cells 24 h after transfection.  
 
Transfection techniques were performed according to suppliers’ protocols. 
Electroporation was performed as described in material and methods. Percentages 
were determined by flow cytometry of AF488-labeled siRNA and 7-AAD staining as 
described in material and methods. 
 
 
Figure 8: Transfection efficiency of THP1 cells with Dreamfect. Left (black) histograms are 
control siRNA treatments (non-fluorescent), while histograms on the right (red and blue) indicate 
transfections with AF488-labeled siRNA. Bar indicates gate set to analyze percentage of 
transfected cells. 1×10
4
 cells were analyzed per sample. Measurements were performed by flow 
cytometry as indicated in material and methods.  
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Figure 9: Images of THP1 cells transfected with fluorescently labeled siRNA. To evaluate, if 
siRNA efficiently enters the cytoplasm of THP1 cells, cells were transfected with Dreamfect and 
AF488-labeled siRNA, stained with DAPI and analyzed by confocal fluorescence microscopy 24 
h after transfection.  
 
8.1.2 Design and selection of efficient siRNAs against MLL-AF9 in THP1 cells 
To specifically target MLL-AF9 without disturbing MLL and AF9 wildtype expression levels, 
siRNAs were designed to target the THP1 specific fusion point of MLL-AF9 transcript. Six 
siRNAs (siR_1 – siR_6) were designed (figure 10) according to scores from sfold Sirna (Ding, et 
al. 2001), DISR (Vert, et al. 2006) and siDESIGN Center (Thermo Scientific, Waltham, MA, 
USA) and tested in comparison to non-targeting control siRNA (table 7). While siR_5 resulted in 
a highly efficient knockdown of MLL-AF9, it was the only tested siRNA which also significantly 
reduced the mRNA level of one of the wildtype gene transcripts (in this case MLL). The other 
five siRNAs performed roughly equally well. For further studies, siR_3 and siR_4 were chosen 
due to their relatively central target position on the fusion breakpoint sequence while still having 
considerably distinct sequences (a shift of 3 nucleotides). The latter is important for minimizing 
off-target effects since for miRNA-like mRNA (off-) target recognition, the so-called seed-
region of 6 – 7 nucleotides (nts) is most important. As the chemically modified siRNAs had a 
prolonged knockdown effect on the MLL-AF9 transcript, these were used for this study. 
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Figure 10: Overview of the binding positions of all designed and tested siRNAs against 
MLL-AF9. Alignments to MLL-AF9 mRNA of THP1 cells are shown. Orange sequences 
represent the MLL and black sequences the AF9 part of the fusion sequence. Underlined 
sequences correspond to seed regions for miRNA-like off-target effects. SiR_3 and siR_4 were 
selected for this study. 
 
 
Table 7: Results of tested siRNAs against MLL-AF9 in THP1 cells.  
 
MLL-AF9, MLL and AF9 transcript levels were analyzed by qRT-PCR 24 h after 
transfection. Expression levels relative to non-targeting control siRNA treatments ± 
standard error of the mean and duration of the MLL-AF9 specific effect are given. SiRNAs 
that were selected for further experiments are shaded in grey. SiRNAs siR_3 - siR_6 were 
chemically modified as indicated in material and methods. 
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8.2 MLL-AF9 knockdown 
8.2.1 Experimental conditions 
Two main aspects had to be considered for selecting an appropriate experimental setup: First, 
nothing is known about the half-life of MLL-AF9 protein, which might be significantly different 
to MLL protein. Second, MLL-AF9 leads to changes in the expression of target genes via 
epigenetic mechanisms (Mohan, et al. 2010; Slany 2009) whose reversal might take considerably 
more time than e.g. direct interaction by transcription factors (Ehrenhofer-Murray 2004; Cheng, 
et al. 2008). Thus a prolonged knockdown of MLL-AF9 over several days was envisaged. To 
simplify the experimental procedure, we aimed at a stable transfection of THP1 cells with 
shRNA plasmids (two plasmids containing distinct shRNA sequences against MLL-AF9 and one 
with a control shRNA sequence). Surprisingly, though over 94% of cells remained positive for 
the surface selection marker LNGFR, only 1% of cells stayed positive for the GFP marker and 
no MLL-AF9 knockdown could be observed via qRT-PCR. Three main reasons could account 
for this failure to downregulate MLL-AF9: (1) the H1 promoter of the shRNA could be 
inactivated like obviously the CMV promoter of GFP was, (2) shRNA levels could have been 
too low to efficiently affect MLL-AF9 transcript levels or (3) the shRNA was not processed 
correctly. Because of the time-consuming generation of stable transfected THP1 cells, we 
decided to proceed with the study employing the tested, very efficient and gentle transient 
transfection of siRNAs into THP1 via Dreamfect. To nevertheless ensure a functionally efficient 
MLL-AF9 knockdown, experiments were performed over eight days with repeated siRNA 
transfections on day 0, 3 and 6. Prior to each transfection event, cell densities were determined 
by Cellscreen microscopy and cells were reseeded at 0.05×10
6
 cells per ml. Fetal bovine serum 
(FBS), containing growth factors, has previously been reported to affect miRNA expression, 
leading to a mitogenic miRNA profile (Paroo, et al. 2009). These effects might mask changes 
which result from the knockdown treatment. Thus fetal bovine serum levels were reduced to 
0.5% from day 6 on. This concentration was determined to correspond to culture conditions in 
which THP1 cells remain proliferating over at least 6 days, while showing a clearly reduced 
proliferation level. Analyses were usually performed on day 8 of experiments which corresponds 
to 48 hours after serum reduction and last transfection. 
8.2.2 Validation of MLL-AF9 knockdown 
Knockdown was efficient and reduced MLL-AF9 transcript levels on day 8 of experiments to 22 
±6 % residual expression (figure 11 a), while MLL and AF9 wildtype levels were not 
significantly altered at any time point (day 8 levels are shown in figure 12). 
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Figure 11: Confirmation of MLL-AF9 knockdown in THP1 cells over the experimental time 
course. Employed were two siRNA against MLL-AF9 (siR_3 and siR_4) and two non-targeting 
control siRNAs (n-tg_1 and n-tg_2). (A) Relative MLL-AF9 transcript levels measured by qRT-
PCR. (B) Relative HOXA9 transcript levels which served as surrogate marker of MLL-AF9 
protein reduction. MLL-AF9 has previously been shown to directly upregulate HOXA9 
transcription. Graphs represent data from five independent experiments. Bars indicate standard 
error of the mean.  
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Figure 12: MLL and AF9 wildtype transcript levels in presence or absence of MLL-AF9 
knockdown in THP1 cells. Relative transcript levels on day 8 of experiments are shown. 
Employed siRNA were:  siR_3 and  siR_4 against MLL-AF9 and non-targeting control 
siRNAs  n-tg_1 and  n-tg_2. Graph represents data from five independent experiments. Bars 
indicate standard error of the mean. 
 
MLL-AF9 protein is hard to detect, which is already implied by the fact that other groups 
working with knockdown strategies to reduce endogenous MLL-AF9 were not able to show 
reduction on protein level (Kawagoe, et al. 2001; Pession, et al. 2003). Here, MLL-AF9 from 
THP1 cells was detectable on Western blot by antibodies detecting MLL N-terminus or AF9  
C-terminus in protein isolated from the organic phase of Qiazol (similar to Trizol) and 
redissolved in equal volumes of 2% SDS and 2 × Laemmli sample buffer (figure 13 a) or in 
equal volumes of 9.5M Urea / 2%CHAPS and 2 × Laemmli sample buffer. Several lines of 
evidence indicate that the observed band is specific for MLL-AF9: (1) it shows the predicted size 
(approximately 170 kDa), (2) it is detected by both, MLL (N-terminal) and AF9 (C-terminal) 
antibodies and (3) it is somewhat larger in MonoMac6 (MM6) cell line than in THP1 cells which 
is expected because MM6 cells harbor a further 3’-terminal breakpoint in MLL. However, due to 
the high amount of protein needed and because complete dissolution of intermediate protein 
precipitates can hardly be achieved following this isolation procedure, these samples were not 
employed for semiquantitative assessment of MLL-AF9 in knockdown experiments. Cell lysates 
prepared with standard lysis buffers (e.g. Laemmli sample buffer or RIPA buffer) were tested but 
did not lead to the MLL-AF9 specific band (figure 13 b). To overcome insufficient dissolution of 
MLL-AF9 protein or protein bound to DNA, sonication of cell lysates was tested. Surprisingly, 
MLL and AF9 wildtype could be readily detected in control lysates of MCF-7 or HELA cells, 
while no MLL or MLL-AF9 or AF9 specific band was detectable in THP1 lysates, even on the 
same Western blots (figure 13 c). This phenomenon may point to a higher tendency of MLL-
AF9 to form protein aggregates as compared to wildtype MLL protein.  
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Figure 13: Detection of MLL-AF9 by Western blot (A) Identification of MLL-AF9 protein 
band in THP1 cells: As expected, MLL-AF9 band is larger (~11 kDa) in MonoMac6 (MM6) cell 
line as compared to THP1 cells, because of a further 3’-terminal breakpoint in MLL. MLL-AF9 
band is stained by MLL (N-terminal) as well as by AF9 (C-terminal) antibody. Protein was 
extracted from Qiazol organic phase as described in material and methods. (B) MLL-AF9 band 
is not detectable by neither MLL nor AF9 antibody in THP1 cell lysates prepared with Laemmli 
sample buffer (or RIPA buffer) but is detectable in THP1 protein extracted from Qiazol organic 
phase. (C) In lysates prepared with RIPA buffer, neither MLL nor MLL-AF9 or AF9 bands are 
detectable in THP1 lysates, but wildtype MLL and AF9 bands are detectable in HELA control 
lysates (HELA cells express MLL and AF9 but do not carry MLL-AF9 translocation). Shown is 
the image of a single blot from which two lanes were excised for clarity reasons. Similar results 
were obtained with MCF7 cell line lysates. Band above MLL wildtype band in HELA might be 
unprocessed MLL protein (430 kDa). MLL and AF9 wildtype bands were assigned due to the 
expected sizes of the proteins (320 kDa and 63 kDa respectively). 
 
An alternative, new technique for relative quantitation of protein, TaqMan® Protein Assay 
(Applied Biosystems, Life Technologies, Carlsbad, CA, USA), was additionally tested for MLL-
AF9 quantitation (figure 6 in material and methods, page 26). Unfortunately, despite promising 
quality control results for the assay probes, specific signal of MLL-AF9 was not high enough 
above background (∆CT>3) to yield reliable quantitative data. Disadvantageous binding sites for 
the antibodies (i.e. located far from each other on the large MLL-AF9 protein) or again, non-
sufficient dissolution of MLL-AF9 protein, might explain this result. 
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To nevertheless ensure that MLL-AF9 knockdown is effective on protein level, we analyzed 
HOXA9 transcript level as a surrogate marker. HOXA9 transcription is raised by MLL-AF9 
through direct interaction between MLL-AF9 protein complex and HOXA9 promoter (Erfurth, et 
al. 2008; Cierpicki, et al. 2010). A MLL-AF9 knockdown specific reduction of HOXA9 transcript 
to 57 ±8 % residual expression on day 8 was detected by qRT-PCR (figure 11 b). This finding 
clearly indicates a functionally sufficient reduction of MLL-AF9 protein.  
8.3 Cellular phenotype and functional endpoints of MLL-AF9 knockdown 
To screen for cellular phenotype and functional consequences of our prolonged knockdown of 
MLL-AF9 in THP1 cells, proliferation, apoptosis, cell cycle distribution and mean cell size was 
analyzed.  
Proliferation: No significant differences in proliferation measured via Cellscreen microscopy on 
days 6, 7 and 8 and MTT-assay on day 8 were detected between MLL-AF9 depleted and control 
treatments. Likewise, no significant difference in proliferation was observed even in a prolonged 
experiment up to day 12 (figure 14). 
 
 
Figure 14: Proliferation of THP1 cells in presence or absence of MLL-AF9 knockdown.  
 MLL-AF9 knockdown,  non-targeting control treatments. Cells were counted within culture 
wells by Cellscreen microscopy as described in material and methods. Three cell culture wells 
were analyzed per siRNA-treatment and day, each with 62 regions of interest (ROIs) equivalent 
to 8% of the surface or to ~ 5000 – 32000 cells. Graph represents one experiment with each 
siRNA-treatment performed in triplicate. Bars indicate standard error of the mean. 
 
Apoptosis: Analysis of apoptotic cells via annexin V and 7AAD staining was difficult to 
interpret, due to raised autofluorescence of transfected THP1 cells. Thus detection of apoptotic 
cells was performed via anti-PARP1 cleavage site-specific antibody in flow cytometry on day 7, 
8 and 9. No significant differences (figure 15) were detected. BAX is a proapoptotic gene 
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product and the BCL-2 to BAX transcript ratio has been proposed to indicate survival or death 
following apoptotic stimuli (Oltval, et al. 1993). The mRNA expression of BCL-2 and BAX on 
day 8 was analyzed via qRT-PCR, but did not reveal a significant alteration for MLL-AF9 
knockdown versus control samples.  
 
Figure 15: Apoptosis of THP1 cells in presence or absence of MLL-AF9 knockdown. 
Percentage of apoptotic cells in  MLL-AF9 knockdown and  non-targeting control treatments 
were detected by flow cytometry after staining of cleaved PARP1 as described in material and 
methods. Graph represents one experiment with each treatment performed in triplicate. Bars 
indicate standard error of the mean. 
 
Cell cycle distribution analysis was performed on day 7, 8 and 9 via flow cytometry. No 
significant differences in the fractions of cells within the cell cycle phases G0/G1, S and G2 were 
detected between MLL-AF9 knockdown and control treatments (figure 16). Percentage of 
apoptotic cells within the sub-G0 area was also not significantly altered between these 
treatments. 
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Figure 16: Cell cycle distribution of THP1 cells in presence or absence of MLL-AF9 
knockdown. Cell cycle analyses were performed by flow cytometry after staining with 
propidium iodide as described in material and methods. Percentage of cells within the three cell 
cycle phases are given for  MLL-AF9 knockdown (siR_3 and siR_4) and  non-targeting 
control (n-tg_1 and n-tg_2) treatments. Sub-G0 (apoptotic) cells are not displayed. Graph 
represents one experiment with treatments performed in duplicate. Bars indicate standard error of 
the mean. 
 
Cell size: A highly significant and reproducible reduction of 0.3 µm in mean cell diameter was 
observed via Cellscreen microscopy on day 7 and 8 between MLL-AF9 knockdown and control 
treatments (figure 17, p-value 0.0029 and 0.00088 respectively). In the material and methods 
section, two Cellscreen images are exemplarily shown (figure 4, page 18). Although the overall 
mean diameter of the cells varied over the experimental time course, the MLL-AF9 knockdown 
specific reduction of cell size remained constant and highly significant.  
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Figure 17: Cell size of THP1 cells in presence or absence of MLL-AF9 knockdown. Cell 
diameter was significantly reduced in  MLL-AF9 knockdown as compared to  non-targeting 
control treatments from experimental day 7 onwards. Three cell culture wells were analyzed per 
siRNA-treatment and day, each with 62 regions of interest (ROIs) equivalent to 8% of the 
surface area and corresponding to ~ 5000 – 12000 cells. Graph represents data from five 
independent experiments, each performed in triplicates. Bars indicate standard error of the mean. 
Normal distribution was confirmed by Shapiro-Wilk normality test.  ** Welch’s t test p<0.005. 
 
To test if the MLL-AF9 specific reduction in cell size is dependent on serum reduced conditions 
and prolonged MLL-AF9 knockdown, additional experiments were performed without serum 
reduction (up to day 8) or with MLL-AF9 knockdown already initiated in serum reduced 
conditions on day 0 (up to day 3). In neither experiment we could observe a MLL-AF9 specific 
reduction in mean cell diameter. These observations suggest that both, a prolonged knockdown 
as well as serum reduced conditions are necessary to reveal this MLL-AF9 knockdown 
phenotypic effect.  
We also tested if the MLL-AF9 specific reduction in cell size could be due to reduced 
proliferation rates. However, even in a prolonged experiment up to day 12 (6 days after serum 
reduction) no significant difference in cell densities between MLL-AF9 knockdown and control 
treatments was observed (figure 14), while the MLL-AF9 specific reduction in cell size remained 
present up to day 11 (figure 18). Taken together, these pieces of evidence suggest that a reduced 
proliferation rate is not likely to be the cause of cell size reduction seen in MLL-AF9 knockdown.  
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Figure 18: Cell size of THP1 cells in presence or absence of MLL-AF9 knockdown over the 
experimental time course. Dotted line: MLL-AF9 knockdown (siR_3 and siR_4), solid grey 
line: non-targeting control (n-tg_1 and n-tg_2). Three cell culture wells were analyzed per 
siRNA-treatment and day, each with 62 regions of interest (ROIs) equivalent to 8% of the 
surface area. Graph represents one experiment with each treatment performed in triplicate. Bars 
indicate standard error of the mean. 
 
Cell shrinkage is a hallmark of apoptosis (Bortner, et al. 1998) and we considered the possibility 
that the observed difference in cell size is due to a raised basal levels of apoptosis. Camptothecin 
induced apoptosis (indicated by detection of cleaved PARP1) in otherwise untreated THP1 cells 
and led to a significant reduction in cell size. However, this treatment rapidly led to a much 
higher degree in cell size reduction and finally caused the cells to degrade. 
This observation in conjunction with the fact that no raised apoptosis rate could be observed after 
MLL-AF9 knockdown, suggests that apoptosis is not the cause of cell size reduction induced by 
MLL-AF9 knockdown.  
8.4 MLL-AF9 knockdown dependent effects on gene expression 
To understand the transforming activities of MLL-AF9 and to identify potential therapeutic 
targets downstream of MLL-AF9, more detailed knowledge about gene expression influenced by 
a common MLL fusion product, the MLL-AF9 protein, might be valuable. Thus, gene expression 
profiles were generated from MLL-AF9 knockdown experiments. To this end, equal amounts of 
RNA from day 8 samples of five independent experiments were pooled for each of the four 
siRNA treatments. 
To avoid initial loss of potentially relevant hits for screening purposes, probes with a p-value of 
the moderated t test below 0.03 were regarded as differentially expressed as relaxing the 
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threshold from 0.01 to 0.03 was shown to have little influence on the false positive rate (see 7.3.1 
on page 27 for details).  
8.4.1 Quality control of gene expression profiling results 
Criteria of high quality gene lists from high-throughput biological studies have been described 
by Huang et al. (2009b) are complied by our MLL-AF9 knockdown microarray data.  
First, the gene list contained important marker genes as expected for the study, e.g. genes from 
the HOXA cluster (HOXA7, HOXA9, HOXA11) and the differentiation marker CD14.  
Secondly, the gene list featured a reasonable number of genes, i.e. not extremely low or high 
(e.g., 100 – 2000). We detected 1269 differentially expressed genes, while 1000 targets have 
previously been postulated as targets of MLL and MLL-fusion proteins (Slany 2009).  
Thirdly, most of the genes significantly pass the statistical threshold for selection. These 1269 
genes match a p-value threshold of below 0.03.  
Fourthly, a notable portion of up- or downregulated genes are involved in certain interesting 
biological processes, rather than being randomly spread throughout all possible biological 
processes. In our data set, genes were indeed found as highly enriched in biological processes 
(see section 8.4.3.3).  
Fifthly, gene lists with different p-value thresholds consistently contained more enriched biology 
(concerning functional gene ontology results) than that of random lists.  
Point six of Huang et al. (2009b), high reproducibility according to the generation of similar 
gene list under the same conditions, could not be evaluated due to high costs of gene profiling 
via microarray. 
Seventhly, however, gene list data were partially confirmed by other independent wet lab tests, 
i.e. qRT-PCR. Quantitative real-time PCR was performed for 20 arbitrarily selected transcripts, 
which showed differential expression in microarray results (p<0.01). Among these, 19 were 
considered as confirmed (log2FC was > ±0.3 in concordant direction).  
We calculated Spearman’s correlations between microarray and qRT-PCR data and - though no 
data points lay around log2FC ± 0 because only differentially expressed genes were selected for 
qRT-PCR analyses - we added a linear regressions for comparison to the ideal correlation 
(perfect fit). Linear regressions between microarray and qRT-PCR data are close to the perfect 
fit: percent difference from the ideal slope was only -7.5% and 16.4% respectively for technical 
and biological validation (figure 19). Spearman’s rank correlations were significant, both when 
identical RNA was sampled (Spearman’s Rho=0.68, p=0.0009) and when RNA of independent 
biological experiments was sampled (Spearman’s Rho=0.57, p=0.008).  
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Thus, these data support reliability of the generated microarray data as well as a high 
interexperimental reproducibility.  
 
 
Figure 19: Correlation between gene expression microarray and qRT-PCR results after 
MLL-AF9 knockdown in THP1 cells. To test reliability of microarray data, qRT-PCR was 
performed for 20 arbitrary chosen transcripts which showed differential expression (p<0.01) in 
microarray results. (These were: ARHGAP26, CALR, CEBPB, CIITA, EGR2, EMP1, FOS, 
FUCA1, IL8, KCTD12, KIF26A, MAFB, NOTCH2, SOCS2, SULF2, TGFBR1, TSPAN14, 
VASH1, VDR and ZNF521). Linear regression (black line) is shown in comparison to a perfect fit 
(= ideal slope, grey dotted line). (A) Technical validation: qRT-PCRs were performed in 
identical samples (RNA) which were measured on the microarrays (significant correlation, 
Spearman’s Rho=0.68, p=0.0009). (B) Biological validation: qRT-PCRs were performed in 
additional sample pools of 2 independent experiments (significant correlation, Spearman’s 
Rho=0.57, p=0.008). Linear regressions and Spearman’s rank correlation coefficients including 
p-values were calculated with R. No data points are seen around log2FC ± 0 because only 
differentially expressed genes were selected for qRT-PCR.  
 
8.4.2 Differentially expressed genes in MLL-AF9 knockdown 
Gene expression analysis was performed with whole human genome microarrays (Agilent), 
which detect 20194 unique genes with 31153 probes. Among these, 1345 probes representing 
transcripts of 1269 unique genes were found differentially expressed between MLL-AF9 
knockdown and control treatments on day 8 with a p-value of the moderated t test below 0.03. Of 
these, 814 gene transcripts were down- and 455 were upregulated in MLL-AF9 knockdown 
samples.  
Supplementary table 2 (page 139) shows all 1345 differentially expressed probes, including the 
information if all or only some of the probes against the transcripts of a gene were differentially 
expressed and if gene expression was validated by qRT-PCR.  
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Gene expression data were submitted to and accepted by Gene Expression Omnibus (GEO) 
database, the major public archive for high-throughput microarray- and sequence-based 
functional genomic data sets (Barrett, et al. 2011), under the accession number GSE36592.  
8.4.3 Mediation MLL-AF9 leukemogenic effects: involved processes and subset 
selection of deregulated genes for prioritization of likely candidates  
To identify biological processes potentially involved in mediation of MLL-AF9 leukemogenic 
effects, an enrichment analysis of functional gene ontology terms was performed with our data 
set of deregulated genes after MLL-AF9 knockdown in THP1 cells (8.4.3.3, page 57).  
To prioritize candidate genes for mediation of MLL-AF9 leukemogenic effects within the 1269 
differentially expressed genes after MLL-AF9 knockdown, four criteria were applied to select a 
subset of genes for further literature research: 
(1) Genes with strong differential expression (more than ± 1.0 log2FC). 
(2) Genes which were linked to leukemia via functional disease ontology (FunDO) analysis. 
(3) Top regulated genes (log2FC>± 1 and further top 5 genes) of different functional categories 
(higher-order terms) based on functional gene ontology analysis.  
(4) Genes which showed concordant regulation between our data set and published leukemia 
patient studies. 
Altogether, these criteria yielded 92 genes that were then subjected to literature research. An 
overview of their known biological roles – where applicable in relation to leukemia or 
malignancies – was generated (supplementary table 3 on page 175). 
This information, together with differential expression strength, was subsequently used to rate 
the potential importance of these genes concerning the transforming activity of MLL-AF9 via a 
structured rating strategy (table 5, page 33). Results are shown in table 8 on page 68.  
In the following sections, results from each of the four selection criteria are presented. 
8.4.3.1 Genes with strong differential expression 
27 transcripts showed a more than ± 1.0 logarithmic fold-change (log2FC). Among these, 13 
were down- and 14 were upregulated (figure 20). 16 of these were not contained in any enriched 
gene ontology annotation of DAVID bioinformatical resource.  
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Figure 20: Strongest differentially regulated transcripts from microarray data of MLL-AF9 
knockdown in THP1 cells. All transcripts with > ±1.0 log2FC and p<0.03 are displayed. 
Grayscale of columns indicates expression strength according to microarray fluorescent signal 
intensities:  high,  medium and  low expression (classified as described in material and 
methods, section 7.3.1). Bars indicate standard error of the mean as described in material and 
methods. Transcripts are sorted according to log fold change (strongest regulated on top). 
lincRNA = large intervening noncoding RNA. 
 
TAS1R3: Taste receptor type 1 member 3, a glucose sensor which may be involved in energy 
supply (Mace, et al. 2009), was the most significant (p=7.47×10
-8
) and strongest regulated 
protein coding gene transcript (log2FC -2.01) and showed medium expression strength according 
to the fluorescent signal intensity (FI). However, only one of three non-identical probes against 
TAS1R3 showed this differential expression indicating the possibility that only a certain isoform 
is regulated dependent on MLL-AF9. 
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CCL2: The second strongest regulated gene transcript was the chemokine (C-C motif) ligand 2 
(CCL2) with a log2FC of 1.61 and a p-value of 1.11×10
-6
. CCL2 binds to chemokine (C-C motif) 
receptor 2 and 4 (CCR2 and CCR4). CCR2 is also found upregulated in a MLL-AF9 knockdown 
specific manner. CCL2 displays chemotactic activity for monocytes and basophils.  
HLA class II: The next three top differential expressed transcripts were two classical and one 
non-classical HLA class II gene: HLA-DPA1, HLA-DPB1 and HLA-DMB. MHC class II proteins 
are selectively expressed in professional antigen presenting cells; besides monocytes these 
include macrophages, B-cells and dendritic cells (Ting, et al. 2002). Classical HLA class II 
proteins are expressed on the cell surface to present peptides to T-helper cells, while non-
classical HLA class II proteins are involved in the process of peptide loading to classical HLA 
class II proteins (Shiina, et al. 2009). Further eleven HLA class II gene transcripts are 
upregulated in a MLL-AF9 knockdown specific manner. These encompass genes of all types of 
classical HLA class II genes (HLA-DP, -DQ and -DR), as well as the two non-classical HLA 
class II genes HLA-DMA and HLA-DMB. These will be further described in the gene ontology 
annotation section (8.4.3.3). 
Other noteworthy gene transcripts, downregulated with more than log2FC -1.0 were:  
LHX9 of the LIM homeobox gene family, a developmentally expressed transcription factor with 
a suggested role in gonadal development;  
LOC100129722 and LOC84989, encoding two large intervening noncoding RNAs (a group of 
RNAs which are usually associated with open chromatin signatures such as histone modification 
sites);  
SP9: a transcription factor whose vertebrate homologs have a described role in embryo limb 
outgrowth (Kawakami, et al. 2004), are involved in the formation of regeneration epithelium 
(like Hoxa-9 and Hoxa-13) and were described as dedifferentiation marker of the mature skin 
epidermis in the axolotl (Satoh, et al. 2008);  
RHBDL1: the rhomboid veinlet-like 1, whose Drosophila homolog has been implicated in the 
positive modulation of epidermal growth factor receptor signaling (Pascall, et al. 1998);  
SOCS2: the suppressor of cytokine signaling 2, which is a negative regulator of cytokine 
receptor signaling via the Janus kinase pathway, suppresses the apoptotic effect of leukemia 
inhibitory factor (LIF) (Minamoto, et al. 1997), may play a regulatory role in insulin-like growth 
factor 1 (IGF1) receptor signaling (Dey, et al. 1998) and is induced by a wide number of 
cytokines and hormones (e.g. estrogen and GM-CSF) (Rico-Bautista, et al. 2006). 
Other noteworthy gene transcripts upregulated with more than log2FC +1.0 were:  
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GPNMB: glycoprotein (transmembrane) nmb, a putative transmembrane glycoprotein which has 
been described to be involved in growth delay and reduction of metastatic potential in human 
melanoma (Weterman, et al. 1995);  
CD14 molecule, a myelomonocytic differentiation antigen (Goyert, et al. 1988) and 
differentiation marker for maturating monocytes (Schwende, et al. 1996);  
FOSB: the FBJ murine osteosarcoma viral oncogene homolog B, a component of the dimeric 
transcription factor AP-1, which displays subunit and context dependent effects on proliferation, 
differentiation and apoptosis (Hess, et al. 2004). 
8.4.3.2 Functional disease ontology and gene association to leukemia 
Gene Ontology (GO) is a collection of controlled vocabularies describing the biology of a gene 
product in an organism. Functional disease ontology (FunDO) analysis takes a list of genes and 
finds relevant diseases based on statistical analysis of the Disease Ontology annotation database 
and peer-reviewed evidence from GeneRIF (Osborne, et al. 2009). Within this process, an 
enrichment analysis is performed yielding fold enrichment and p-values for each term associated 
to the set of genes. 
All 1269 differentially expressed genes (p<0.03) after MLL-AF9 knockdown in THP1 were 
entered in FunDO (Flatow, et al. 2009), which recognized and analyzed 1034 genes. Of these, 
122 of were found to be associated with diseases.  
Figure 21 shows an overview of the top 5 diseases and the genes which map to them as well as a 
table listing the corresponding statistics. The disease term leukemia mapped on upmost position, 
with the 38 contained genes being 4.7-fold enriched with a highly significant p-value (3.4×10
-15
). 
The terms cancer and breast cancer were also found to be associated with our differentially 
expressed gene list. The top-5 terms also included Atherosclerosis and Diabetes mellitus, two 
diseases in which immune cells play important roles. This fact might account for the association 
of these disease terms with our set of differentially expressed genes upon MLL-AF9 knockdown. 
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Figure 21: Functional Disease Ontology (FunDO): The top 5 diseases associated with our set 
of differentially expressed genes after MLL-AF9 knockdown in THP1 cells. Shown are the 
top 5 associated diseases and the differentially expressed genes which map to them. For 
leukemia, the contained genes are additionally depicted in figure 22. The sizes of the disease 
nodes (red dots) are proportional to the number of associated genes. The p-value is calculated 
using Fisher's exact test. 
 
Figure 22 shows the leukemia associated genes depicting their differential expression and 
expression strength. Supplementary table 3 (on page 175) includes an overview of the biological 
functions of these 38 genes according to literature research.  
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Figure 22: MLL-AF9 knockdown and “leukemia” associated genes: Differentially expressed 
genes after MLL-AF9 knockdown in THP1 cells (microarray results), which are associated with 
leukemia according to Functional Disease Ontology (FunDO) are shown. Grayscale of columns 
indicates expression strength according to microarray fluorescent signal intensities:  high,  
medium and  low expression (classified as described in material and methods, section 7.3.1). 
Bars indicate standard error of the mean as described in material and methods. Transcripts are 
sorted according to log2FC. 
 
Some of these transcripts do not reveal functional concordance with previously published roles 
in malignancies, while others do. For example, programmed cell death 5 (PDCD5) is a 
proapoptotic protein, and reduced levels of PDCD5 in AML and CML bone marrow cells 
compared to normal donor bone marrow cells were described (Ruan, et al. 2006; Ruan, et al. 
2008). In contrast, a downregulation of PDCD5 transcript after reduction of leukemogenic MLL-
AF9 protein was observed in our data set.  
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A transcript which regulation very well matches previous knowledge is zinc finger protein 521 
(ZNF521), which we found as strongly downregulated in MLL-AF9 knockdown cells. ZNF521 is 
highly expressed in the most immature hematopoietic cells and declines with differentiation. 
Enforced expression leads to proliferation and decreases granulo-monocytic and erythroid 
differentiation. High expression has been associated with MLL-rearrangements and ZNF521 
silencing in THP1 cells led to impaired growth and clonogenicity. (Bond, et al. 2008)  
The homeodomain interacting protein kinase 2 (HIPK2) is upregulated after MLL-AF9 
depletion. HIPK2 is a described tumor suppressor, which - in response to DNA damage - 
phosphorylates the tumor suppressor PML, resulting in its stabilization. This phosphorylation is 
required for the ability of PML to cooperate with HIPK2 for the induction of cell death (Gresko, 
et al. 2009). Mutations of HIPK2 have been described in AML cases (Li, et al. 2007). 
Insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2 alias IMP-2) is downregulated 
in our MLL-AF9 knockdown. It encodes a member of embryonically expressed IGF2 mRNA-
binding proteins (IMPs: IMP1–3). IMP-1 has been shown to repress IGF2 translation by binding 
to the 5' UTR of the IGF2 mRNA (Nielsen, et al. 1999). IGF2BP2 was previously found 
overexpressed in MLL-AF4 positive acute B cell lymphoblastic leukemia (Stoskus, et al. 2011). 
Calreticulin (CALR) is downregulated in a MLL-AF9 knockdown-specific manner. CALR acts as 
a major Ca
2+
-binding (storage) protein in the lumen of the endoplasmic reticulum and might be 
important for gene transcription (e.g. for glucocorticoid receptor regulated transcripts) (Burns, et 
al. 1994). It is also a chaperone and well-established effector of the unfolded protein response 
(Schardt, et al. 2011). The chaperone CALR inhibits the translation of CEBPA, which is a key 
myeloid transcription factor and a frequently disrupted in AML (Schardt, et al. 2011). 
The aryl hydrocarbon receptor (AHR) was upregulated after our MLL-AF9 depletion. 
Upregulation of AHR has been shown to promote retinoic acid–induced differentiation of 
myeloblastic leukemia cells (Bunaciu, et al. 2011). The strongly differentially expressed 
transcripts CCL2, HLA-DPB1 and SOCS2 were already described in 8.4.3.1 of this chapter.  
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8.4.3.3 Functional gene ontology analysis 
Functional gene ontology analysis systematically maps gene sets to associated functional 
annotations and statistically highlights the most overrepresented (enriched) biological 
annotations out of thousands of linked terms. This strategy increases the likelihood to identify 
the most relevant biological processes within the biological phenomena under study. (Huang, et 
al. 2009b)  
Here, gene ontology analysis was performed with Database for Annotation, Visualization and 
Integrated Discovery v6.7 (DAVID) with an input of all deregulated genes (p<0.03) after MLL-
AF9 knockdown in THP1. This tool identifies enriched functional annotation terms associated 
with a gene list and clusters functionally similar terms into groups (cluster). Clustering 
annotation terms may help to identify related and redundant terms.  
DAVID recognized 1159 of the 1270 distinct array probe IDs, which represented 1114 
differentially expressed genes. From the resulting 289 functional annotation clusters 
encompassing 2191 functional annotation terms, 480 terms had at least a 1.5-fold enrichment and 
a p-value below 0.1 and were selected for further consideration (criteria suggested by Huang et 
al., 2009). As recommended by Huang et al., these 480 terms were then manually screened 
concerning biological relevance. Among these, 43 functional terms were considered as of 
potential biological relevance. These encompassed 331 differentially expressed genes 
(supplementary figure 1 a-i on pages 166 - 175). These 43 selected and enriched functional 
annotation terms were subsequently manually sorted into five functional higher-order terms 
(figure 23). 
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Figure 23: MLL-AF9 knockdown associated enriched functional gene annotations. 
Functional annotation terms were manually assorted to 5 functional higher-order terms according 
to the major role of the biological process within this biological setting. Annotation terms which 
were assigned to two higher-order terms are depicted between these two, indicated by dotted 
division lines. Annotation terms which could not be assigned to one of the four specific higher-
order terms are collected under the term “other”. Some annotations were abbreviated as indicated 
by superscript numbers: 
1
Pertussis toxin-insensitive CCR5 Signaling in Macrophage, 
2
Antigen 
processing and presentation of peptide or polysaccharide antigen via MHC class II, 
3
Embryonic 
development ending in birth or egg hatching, 
4
Regulation of specific transcription from RNA 
polymerase II promoter and 
5
Antigen processing and presentation of peptide antigen via MHC 
class I. Bars show proportion of    down- and    upregulated genes after MLL-AF9 knockdown 
in THP1 cells. Next to the bars, p-value, fold enrichment (FE) of annotation term and percent of 
differentially expressed genes within the term are given. All differentially expressed genes 
contained in each functional annotation term are shown in supplementary figure 1 a-i on pages 
166 - 175. 
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The higher-order term “proliferation, cell growth and death” includes terms like regulation of 
apoptosis, growth and translational elongation, the higher-order term “differentiation” holds e.g. 
antigen processing and presentation, phagocytosis, endocytosis, response to bacterium and 
hemopoiesis, the higher-order term “early development” includes the two annotation terms 
pattern specification process and embryonic development ending in birth or egg hatching and the 
higher-order term “calcium associated” holds e.g. calcium binding and calcium ion homeostasis. 
The higher-order term “other” holds terms which could not be assorted to one of the other four 
higher-order terms, e.g. response to estrogen stimulus and protein folding. The strongest 
regulated genes of these higher-order terms (all genes with more than ±1.0 log2FC and further 
top 5 genes) were selected for further literature analysis. This approach provided 43 genes to be 
included in the assembly of genes for prioritization concerning mediation of MLL-AF9 
leukemogenic effects.  
 
The three most significantly enriched annotation terms were 1) antigen processing and 
presentation, 2) antigen processing and presentation of peptide or polysaccharide antigen via 
MHC class II and 3) response to wounding (p-values 1.1×10
-8
, 4.4×10
-8
 and 6.1×10
-7
 
respectively). The three most enriched ontology annotation terms according to fold enrichment 
were 1) phorbol ester binding, 2) HMG17 (non-histone components of chromatin) and 3) 
Saposin B (describing lysosomal proteins containing a Saposin B domain), which were 11.4-, 
10.8- and 8.3-fold enriched respectively. Except HMG17, all of these functional annotation terms 
were assigned to the higher-order term “differentiation”. 
 
In the following the functional annotation terms are presented in context with the higher-order 
terms to which they were assigned. 
Twelve functional annotation terms were assigned to the higher-order term “proliferation, cell 
growth and death”. Four of these were additionally assigned to “differentiation” (figure 23). The 
annotation term regulation of apoptosis included 65 genes, which can be further divided into 
positive or negative regulation of apoptosis and the term anti-apoptotic, describing direct effects 
on apoptosis. All terms encompassed up- and downregulated transcripts, and no preference in the 
direction of pro-apoptotic regulation can bee seen according to the number of associated 
transcripts. Positive regulators of apoptosis, which were upregulated in MLL-AF9 knockdown 
were genes encoding e.g. DUSP1, the transcription factors VDR, CEBPB, HIPK2, BCL6, 
INHBA, NOTCH1 and SMAD3, the kinases PRKCE, LCK, TRIO, TGFBR1, CDKN2A, PRKCA, 
ERN1, MAP3K5 and the cell surface molecule NOTCH2. Vice versa, genes encoding negative 
Results 
 
60 
regulators of apoptosis, whose expression was reduced in MLL-AF9 knockdown, were SOCS2, 
SOX4, STAMBP, HSP90B1, ANXA4, CFL1, SMO, TMBIM6 and the transcription factors MEF2C 
and GRIN1 as well as the kinase BRAF (supplementary figure 1 a, page 166).  
Within the term growth, 58% of differential expressed transcripts were downregulated in MLL-
AF9 knockdown, among these the genes encoding NINJ2, GSN, BRCA2, SMO, the kinases 
PRKCQ and FGFR3 and the transcription factors AR and HOXA11. The term regeneration is 
defined as the regrowth of a lost or destroyed body part, such as an organ or tissue. As such, it is 
related to growth and proliferation and holds some overlapping genes with the term growth. 
The term HMG17 describes a nucleosomal binding domain which facilitates binding of proteins 
to nucleosomes in chromatin. Accordingly, this term holds non-histone components of chromatin 
thought to be involved in unfolding higher-order chromatin structure, facilitating the 
transcriptional activation of genes (Porkka, et al. 2002) and affecting DNA replication, 
recombination and repair (Pogna, et al. 2010). Among the three genes within this term, HMGN2 
and HMGN3 were downregulated and strongly expressed. HMGN2 has been previously found 
overexpressed in CML and other cancer types, and an association to proliferation has been 
suggested (Kondos, et al. 1995). HOXA9 overexpression has previously been found to upregulate 
HMGN2 (Dorsam, et al. 2004), suggesting that the effect observed in our data set might be an 
indirect one via HOXA9 reduction. 
A notable finding was that all of the of genes within the term translational elongation were 
downregulated. The ten encompassed genes mainly encode ribosomal proteins. Raised 
expression rates of ribosome components were previously associated with cell growth and 
proliferation and have been found in numerous cancer types (Andersen, et al. 2005; Ruggero, et 
al. 2003; Wang, et al. 2006). 
 
The following four terms were assorted to both higher-order terms “proliferation, cell growth 
and death” and “differentiation”. Within the annotation response to wounding, 66% of the 56 
genes were found upregulated. This functional process is associated with cell proliferation 
involved in wound healing, as well as with inflammatory responses. Monocytes are known to 
migrate into wound regions where they are involved in removing tissue debris and secreting 
factors that promote growth and biosynthetic activity of fibroblasts (Grinnell 1984). As such this 
functional annotation term might reflect a more differentiated status of the MLL-AF9 knockdown 
monoblasts. It holds many immune response associated genes important for monocytic functions, 
among these the strongly upregulated CCL2 and CD14 as well as the genes encoding the 
transcription factor CIITA, the kinase SGMS1 and the calcium binding protein S100A12. 
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The annotation protein kinase C (PKC) activity encompassed five kinases. Genes encoding the 
protein kinases C eta, theta and D3 (PRKCH, PRKCQ, PRKD3) were downregulated in MLL-
AF9 knockdown, while the genes for protein kinase C alpha (PRKCA) and epsilon (PRKCE) 
were upregulated. PRKCA is a so-called “conventional” protein C kinase, which requires 
diacylglycerol (DAG), Ca
2+
 and phospholipid hydrolysis for activation, while the other four 
PKCs are novel PKCs, which do not require Ca
2+
 for activation (Mellor, et al. 1998). PKC 
comprises a family of 12 related serine/threonine kinases connected with regulation of cell 
proliferation, differentiation, and other cellular functions (Schwende, et al. 1996). Increased PKC 
activity in monocytes enhances their initial adhesion and their differentiation into macrophages 
(Ceolotto, et al. 1999). 
The functional annotation term pertussis toxin-insensitive CCR5 signaling in macrophages 
describes a pathway in which the dimeric transcription factor AP-1 is activated via calcium 
influx. AP-1 has subunit and context dependent effects on proliferation, differentiation and 
apoptosis (Hess, et al. 2004). 
A growing body of evidence documents that myeloid malignancies are caused by genetic 
mutations that constitutively activate tyrosine kinases (Scott, et al. 2010). Nevertheless, only 4 
(NIN, FGFR3, TFG and ENST00000374440) or 36% of transcripts within the annotation term 
tyrosine protein kinase were downregulated in MLL-AF9 knockdown.  
 
Under normal circumstances, the monoblast is the earliest precursor of the monocyte-
macrophage maturation. Leukemic monoblasts, however, are halted in their differentiation at this 
stage. Monocytes and macrophages have important functions like the defense against certain 
microorganisms, the removal of damaged or dying cells and cell debris, antigen processing and 
presentation and the interaction with lymphoid cells in the cell-mediated immune reaction 
(Territo, et al. 1977). To perform these functions, certain characteristics are necessary that 
include a well-developed phagocytic activity, the ability to adhere to charged surfaces, motility, 
responsiveness to chemotactic stimuli, a rich content in lysosomal enzymes and the ability to kill 
certain microorganisms and to digest a wide variety of organic particles (Territo, et al. 1977). As 
these functions are increased during monocyte-macrophage maturation, the following 17 
functional annotation terms were assorted to the higher-order term “differentiation”.  
The term antigen processing and presentation encompassed 22 genes, among these, 13 and 4 
genes were also included in the more specific terms antigen processing and presentation of 
peptide or polysaccharide antigen via MHC class II (assigned to “differentiation”), and antigen 
processing and presentation of peptide antigen via MHC class I (assigned to “other”), 
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respectively. The remaining 5 genes (not contained in these more specific terms), included the 
strongly upregulated transcription factor and master controller of MHC class II, CIITA (Ting, et 
al. 2002), the downregulated RFX5, which activates transcription of MHC class II genes in 
cooperation with CIITA (Scholl, et al. 1997) and the upregulated cathepsin B (CTSB), encoding 
a lysosmal cysteine protease which plays an essential role in antigen processing for MHC class II 
presentation in macrophages (Katunuma, et al. 1994). In concordance with the strong activation 
of CIITA, all 13 differentially expressed transcripts of antigen processing and presentation of 
peptide or polysaccharide antigen via MHC class II, among these eleven HLA class II genes, 
were upregulated.  
Other pieces of evidence from functional gene ontology analysis indicating a more differentiated 
status of the MLL-AF9 knockdown cells were: the raised expression of 84% and 71% of genes 
within the annotations immune response and defense response, significant enrichment of 
differentially expressed genes within the terms phagocytosis, endocytosis, positive regulation of 
exocytosis and Saposin B domain proteins (lysosomal proteins), leukocyte chemotaxis, response 
to bacterium, regulation of cytokine production and actin binding. Actin binding proteins have 
been previously found to show altered expression and to be important in the differentiation of 
myeloid cells (Leung, et al. 1992). 
The enrichment of genes within the annotations phorbol ester binding, response to vitamin and 
response to retinoic acid might be corresponding to differentiation, as PMA (a phorbol ester) as 
well as vitamin D (1,25-dihydroxyvitamin D3) and retinoic acid are well known differentiating 
agents for monoblasts (Matikainen, et al. 1994; Gemelli, et al. 2008; Schwende, et al. 1996).  
The annotations hemopoiesis and hematopoietic cell lineage were also significantly enriched. 
The latter included solely upregulated transcripts like the differentiation marker for maturating 
monocytes, CD14 as well as several HLA class II genes, the cell adhesion molecule CD36, 
FCER2 (CD23) which mediates macrophage mediated lymphocyte tolerance (Swingler, et al. 
2003), and colony stimulating factor 2 receptor, alpha (CSF2RA) which mediates control of the 
production, differentiation, and function of granulocytes and macrophages. 
 
The term homeobox, conserved site was assorted to both higher-order terms “differentiation” and 
“early development”, while the two terms pattern specification processes and embryonic 
development ending in birth or egg hatching were only assorted to the higher-order term “early 
development”. 
Homeobox transcription factors, in particular HOXA9, have previously been identified as 
deregulated by MLL fusion proteins (Kawagoe, et al. 2001; Cierpicki, et al. 2010). In our data, 
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the annotation homeobox, conserved site holds 18 genes. Among these, EVX1, HMBOX1, 
HOXC4 and LHX9 show an even more pronounced downregulation as the well known MLL-
AF9 target HOXA9. Many homeobox genes play a role in pattern specification processes, which 
also showed up as an enriched ontology annotation and includes regulated genes such as ROR2, 
EGR2, DLL1 and MAFB. EGR2 encodes a transcription factor and tumor suppressor whose 
deletion leads to cancer cell proliferation. It inhibits neutrophil- and activates macrophage-
specific genes and interacts with PU.1, a master transcription factor in macrophage 
differentiation (Gabet, et al. 2010).  
Another functional annotation term assigned to the higher-order term “early development” is 
embryonic development ending in birth or egg hatching, where 66% of transcripts are found 
downregulated. These include a number of transcription factors, besides HOXA9 and HOXA7 
for example the nuclear androgen receptor (AR), even-skipped homeobox 1 (EVX1) and 
retinoblastoma binding protein 8 (RBBP8).  
 
Surprisingly, a high number of calcium associated genes were found to be differentially 
expressed, suggesting an important role of calcium signaling in this setting. Thus the higher-
order term “calcium” was generated and included the functional annotations calcium binding 
(p=3.4×10
-6
, 3.67-fold enriched), where over 18% of all genes of this term were found 
differentially expressed, as well as the annotation EGF-like calcium binding, the terms calcium 
(meaning calcium dependent or calcium binding), calcium ion homeostasis and calmodulin 
binding. Among the included genes, ATP2B2 encodes a plasma membrane pump whose rat 
homolog (97.9% identical to human) maintains a low free cytosolic Ca
2+
 concentration (Elwess, 
et al. 1997). Further deregulated transcripts are the bidirectional sodium/calcium exchanger 
SLC8A1 (Mai, et al. 2010), CCL2 (with a described role in calcium mobilization in primary 
cultured neurons (Banisadr, et al. 2005)), and VDR, encoding the receptor for 1,25-
dihydroxyvitamin D3, which has been shown to cause a sustained increase of intracellular Ca
2+
 
concentration (Sergeev 2005).  
 
The higher-order term “other” contains functional annotations which could not be assorted to one 
of the other four higher-order terms. 
These include the terms response to estrogen / estradiol stimulus. The latter of the two showed a 
stronger enrichment (3.57-fold) with 60% of its transcripts being upregulated. The strongest 
regulated of the 15 genes within these terms, however, was the strongly expressed and 
profoundly downregulated SOCS2.  
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Protein kinases play a role in a wide array of biological processes and are represented by over 
500 genes. They are known to be involved in cell cycle control, embryonic development and 
cancer pathways, and thus constitute important drug targets (Manning, et al. 2002; Martin, et al. 
2010). In our data, the enriched annotation protein kinase cascade contained 31 transcripts found 
to be differentially expressed in dependence of MLL-AF9. These include, e.g. ROR2, WNK1, 
MAP4K1, TGFBR1, MAP4K12, SYK and TYK2. 
17 genes showed up within the enriched annotation term protein folding, and remarkably 15 
(88%) of these were downregulated, including e.g. DNAJC, HSCB, HSP90AA1 and HSP90B1.  
The significantly enriched term regulation of specific transcription from RNA polymerase II 
promoter included 6 up- and 5 downregulated transcripts, among them e.g. the transcription 
factors CIITA, VDR, IKZF2, DLX1 and MEF2C. 
Within the functional annotation term antigen processing and presentation of peptide antigen via 
MHC class I, HLA-F transcript was upregulated, while HLA-B, B2M and CALR were 
downregulated. Two genes contained in the more general annotation term antigen processing 
and presentation, the downregulated heat shock proteins 70 (HSP90AA1) and 90 (HSPA2), are 
as well involved in peptide antigen presentation via MHC class I (Callahan, et al. 2008). MHC 
class I deficient tumor clones may escape T-cell immune responses, but might be more 
susceptible to natural killer (NK) cell-mediated lysis (Algarra, et al. 2004). 
8.4.3.4 Comparison of in vitro gene expression data with published in vivo findings 
Agreement of our in vitro data with previously published in vivo data might support biological 
relevance of these transcripts in MLL-aberrant leukemia.  
Homeobox genes have been extensively associated with MLL and MLL aberrations in leukemia 
(Slany 2009; Ansari, et al. 2010; Afonja, et al. 2000; Kawagoe, et al. 2001; Pession, et al. 2003). 
Homeobox A9 (HOXA9), the best described and direct target of MLL and MLL-AF9 (Erfurth, et 
al. 2008; Cierpicki, et al. 2010), is downregulated in our data set as was expected. HOXA7 and 
HOXA11 were also significantly downregulated, while HOXA10 was not differentially expressed 
after MLL-AF9 knockdown (in microarray and qRT-PCR analyses). In contrast to expectations 
due to published findings (Afonja, et al. 2000), the Meis homeobox 1 gene (MEIS1) was not 
downregulated after MLL-AF9 knockdown but slightly upregulated (log2FC 0.32, p=0.03) 
although just above the employed microarray p-value cutoff of < 0.03.  
Transcripts which have been shown to be class discriminating for MLL chimeric fusion gene 
associated AML patient samples (Ross, et al. 2004) were in part also deregulated in our in vitro 
MLL-AF9 knockdown data set: expression of HOXA9, SOCS2, PBX3 and DACH1 was 
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concordantly altered, but expression of HOXA5, PRG1, MICAL, CES1 and AK2 was not 
affected.  
Overlapping with the results of Ross et al.’s (2004) top-100 probe set selected by significance 
analysis of microarray (SAM) for MLL chimeric fusion gene AML were the six differentially 
expressed gene transcripts DEXI, LGALS1, MBNL1, MEF2C, NKG7 and RNPEP.  
Armstrong et al. (2002) compared gene expression profiles of patient samples with MLL 
translocated B-precursor ALL to other ALL and AML patient samples and described 13 
upregulated transcripts. Although these MLL-rearranged cells were of a different cell type, 
LGALS1 also turns up as deregulated in our data set. In a later study, LGALS1 has been found to 
be a highly sensitive and specific biomarker of MLL-rearrangement in B-ALL and is likely 
induced by a MLL-dependent epigenetic modification (Juszczynski, et al. 2010). LGALS1 has 
been described to promote escape from T cell dependent immunity and to confer immune 
privilege to tumor cells (Juszczynski, et al. 2010). 
Kohlmann et al. (2005) identified transcripts which were commonly altered in their expression in 
MLL-rearranged samples, irrespective of their lineage (lymphoblastic or myeloid). Here, only 
HOXA9 shows concordant regulation upon MLL-AF9 knockdown in our in vitro study. They also 
describe the top-50 differentially expressed genes which classify AML with t(11q23) compared 
to other AML cases. Here, the genes DACH1, HOXA7, HOXA9, PBX3, SOCS2 and ZNF521 
were concordantly regulated in our data set. 
Further concordance compared to in vivo studies of MLL-aberrant AML as compared to other 
AML subtypes (Rozovskaia, et al. 2003; Bullinger, et al. 2004; Valk, et al. 2004) include HLA-
DRB4, HOXA9, PBX3, BMI1, MBNL1, MEF2C and SOCS2. 
Zheng et al. (2006) presented transcripts differentially expressed between CML chronic phase 
(CP) and blastic phase (BP), i.e. in the transition to an acute myeloid leukemia. Seven out of the 
34 described BP versus CP distinguishing genes were also concordantly regulated in our data set: 
SOCS2 (up in BP, down in MLL-AF9 knockdown) and FOS, FOSB, CEBPB, IL8, KLF4 and 
S100A12 (down in BP and upregulated in MLL-AF9 knockdown). This overlap might suggest 
importance of this gene set concerning aggressiveness of the leukemia. 
Altogether, 20 genes showed concordant regulation to leukemia patient studies (figure 24) and 
thus were included in the gene list for further literature research. 
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Figure 24: Differentially expressed genes after MLL-AF9 knockdown in THP1 cells with 
concordance to patient studies of acute leukemia. The number of leukemia patient studies 
describing concordant differential expression are depicted on the y-axis. References to these 
studies for each gene are listed in supplementary table 3 on page 175.  
 
8.4.4 Candidate genes with likely relevance in mediation of MLL-AF9 
leukemogenic effects 
The above described four criteria (see 8.4.3.1 - 8.4.3.4) yielded 92 genes that were subjected to 
literature research for potential biological function related to malignancies and leukemogenesis 
(figure 25).  
Via a rating strategy, the 92 genes were assorted to five categories representing (1) highly likely 
candidates, (2) likely candidates for mediation of MLL-AF9 leukemogenic effects, (3) genes 
whose regulation is coherent with its functional role in malignancies, (4) genes with a currently 
undefined role in malignancies due to a lack of relevant literature and (5) genes whose regulation 
is incoherent with its functional role in malignancies (material and methods section 7.4 on page 
32). 
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Figure 25: Strategy to prioritize candidate genes for mediation of MLL-AF9 leukemogenic 
effects. Four approaches (first line) were used to select 92 genes from the set of 1269 
differentially expressed genes after MLL-AF9 knockdown in THP1 cells. Subsequent to literature 
research, their likelihood to play a role in leukemogenesis was rated via a structured rating 
strategy (see material and methods section 7.4 on page 32 for details).  
 
This strategy led to the prioritization of 40 genes as likely candidates for mediation of MLL-AF9 
leukemogenic effects (figure 27, page 71). An overview of all 92 genes with their assorted rating 
category is given in table 8 and the distribution of these genes over the rating categories is shown 
in figure 26. Additionally, supplementary table 3 (page 175) includes the information from 
literature research which was used to assort the genes to rating categories.  
Within the candidate genes likely mediating MLL-AF9 leukemogenic effects, is e.g. the taste 
receptor and glucose sensor TAS1R3, the chemokine CCL2, the transcription factor SP9 which 
is involved in dedifferentiation, the suppressor of cytokine signaling SOCS2, the transcription 
factor and tumor suppressor EGR2, the transcription factor ZNF521, the tumor suppressor 
HIPK2 and the chaperon CALR which is involved in calcium signaling, in the unfolded protein 
response and in myeloid differentiation. 
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Table 8: Rating of selected differentially expressed genes after MLL-AF9 knockdown in 
THP1 cells concerning mediation of leukemogenic effects.  
Gene 
Rating 
category 
log2FC Official full name 
ABCA3 - 0.31 
ATP-binding cassette, subfamily A (ABC1), 
member 3 
AFF4 + -0.36 AF4/FMR2 family, member 4 
AHR ++ 0.44 aryl hydrocarbon receptor 
ALOX5 - 0.76 arachidonate 5-lipoxygenase 
ATP2B2 ++ -0.69 ATPase, Ca++ transporting, plasma membrane 2  
B2M + -0.47 beta-2-microglobulin  
BMI1 ++ -0.33 BMI1 polycomb ring finger oncogene  
CALR +++ -0.51 calreticulin  
CAMP + 0.46 cathelicidin antimicrobial peptide 
CCL2 +++ 1.61 chemokine (C-C motif) ligand 2  
CD14 ○ 1.05 CD14 molecule  
CD19 ○ 0.35 CD19 molecule 
CD209 ○ 0.73 CD209 molecule 
CD74 ○ 0.77 
CD74 molecule, major histocompatibility complex, 
class II invariant chain 
CEBPB +++ 0.53 CCAAT/enhancer binding protein (C/EBP), beta  
CIITA +++ 0.83 
class II, major histocompatibility complex, 
transactivator 
CTSG ○ -0.43 cathepsin G 
CYBB + 0.4 cytochrome b-245, beta polypeptide 
DACH1 ++ -0.54 dachshund homolog 1 (Drosophila) 
DEFA3 ○ 1.36 defensin, alpha 3, neutrophil-specific 
DEXI ++ -0.56 Dexi homolog (mouse)  
DLL1 +++ -0.54 delta-like 1 (Drosophila) 
DRD5 ○ -0.96 dopamine receptor D5 
EGR2 ++ 0.81 early growth response 2 
F13A1 ○ 0.33 coagulation factor XIII, A1 polypeptide 
FMNL1 ○ 0.36 formin-like 1  
FOS +++ 0.88 FBJ murine osteosarcoma viral oncogene homolog 
FOSB +++ 1.05 
FBJ murine osteosarcoma viral oncogene homolog 
B  
GNLY ○ 0.38 granulysin 
GPNMB ++ 1.24 glycoprotein (transmembrane) nmb 
HAPLN2 ○ -1.2 hyaluronan and proteoglycan link protein 2  
HIPK2 +++ 0.5 homeodomain interacting protein kinase 2 
HLA-B ○ -0.64 major histocompatibility complex, class I, B 
HLA-DMB ++ 1.49 
major histo-compatibility complex, class II, DM 
beta 
HLA-DPA1 ++ 1.6 
major histo-compatibility complex, class II, DP 
alpha1 
HLA-DPB1 ++ 1.54 
major histo-compatibility complex, class II, DP beta 
1  
HLA-DQA1 ++ 0.96 
major histocompatibility complex, class II, DQ 
alpha 1  
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Gene 
Rating 
category 
log2FC Official full name 
HLA-DQB1 ++ 1.19 
Major histo-compatibility complex, class II, DQ 
beta 1  
HLA-DRB4 ++ 0.45 
major histocompatibility complex, class II, DR beta 
4  
HMBOX1 ○ -0.95 homeobox containing 1 
HOXA11 ++ -0.5 homeobox A11 
HOXA7 + -0.41 homeobox A7 
HOXA9 +++ -0.57 homeobox A9 
HOXC4 ++ -0.76 homeobox C4 
HPX2 ○ 0.75 homeobox HPX-2 
IFI30 ○ 0.91 interferon, gamma-inducible protein 30 
IGF2BP2 + -0.42 
insulin-like growth factor 2 mRNA binding protein 
2 (alias IMP-2) 
IKZF2 ++ -0.6 IKAROS family zinc finger 2 (Helios)  
IL18 + -0.38 interleukin 18 
IL2RG - -0.31 interleukin 2 receptor, gamma  
IL8 ++ 0.65 interleukin 8 
ITGAL ○ 0.57 integrin, alpha L / CD11A 
ITGAX ○ 0.62 integrin, alpha X / CD11C 
KLF4 ++ 0.48 Kruppel-like factor 4 
LGALS1 ++ -0.41 lectin, galactoside-binding, soluble, 1 
LGALS2 ○ 1.02 lectin, galactoside-binding, soluble, 2  
LHX9 ○ -1.34 LIM homeobox protein 9 
LOC100129722 ○ -1.32 hypothetical LOC100129722 
LOC84989 ○ -1.06 hypothetical LOC84989 
LPL ○ 0.71 lipoprotein lipase 
LRRC2 ○ -1.43 leucine rich repeat containing 2  
MAP3K5 ○ 0.31 mitogen-activated protein kinase kinase kinase 5 
MAPRE2 + -0.37 
microtubule-associated protein, RP/EB family, 
member 2 
MBNL1 + -0.34 muscleblind-like (Drosophila) 
MEF2C +++ -0.6 myocyte enhancer factor 2C  
MERTK ○ 1.04 c-mer proto-oncogene tyrosine kinase 
NAIP - 0.6 NLR family, apoptosis inhibitory protein 
NKG7 + -0.34 natural killer cell group 7 sequence  
NPTX1 ○ -1 neuronal pentraxin I  
PBX3 +++ -0.51 pre-B-cell leukemia homeobox 3 
PDCD5 - -0.82 programmed cell death 5 
PDE4D ++ -0.34 phosphodiesterase 4D, cAMP-specific 
PRLR - 0.64 prolactin receptor  
RHBDL1 ++ -1.13 rhomboid, veinlet-like 1  
RHOH + 0.33 ras homolog gene family, member H 
RNPEP + -0.32 arginyl aminopeptidase (aminopeptidase B) 
ROR2 ++ 0.81 receptor tyrosine kinase-like orphan receptor 2 
RPL23A ○ -1.09 ribosomal protein L23a  
RPS26 ○ -0.85 ribosomal protein S26 
S100A12 ++ 0.84 S100 calcium binding protein A12 
SGK1 - 1.1 serum/glucocorticoid regulated kinase 1  
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Gene 
Rating 
category 
log2FC Official full name 
SLC8A1 ○ 1.15 solute carrier family 8, member 1 
SNRPD2P2 ○ -1.13 
small nuclear ribonucleoprotein D2 pseudogene 2 
(LOC645339)  
SOCS2 +++ -1.07 suppressor of cytokine signaling 2 
SOCS3 - 0.53 suppressor of cytokine signaling 3 
SOX4 ++ -0.84 SRY (sex determining region Y)-box 4 
SP9 ++ -1.19 Sp9 transcription factor homolog (mouse) 
TAS1R3 ++ -2.01 Taste receptor, type 1, member 3  
TSGA10 - 1.03 testis specific, 10  
VDR ++ 0.67 vitamin D (1,25- dihydroxyvitamin D3) receptor 
VWA1 ○ -1.01 von Willebrand factor A domain containing 1  
ZNF521 +++ -0.73 zinc finger protein 521  
Rating categories (based on biological role and differential expression): +++ highly likely 
candidates and ++ likely candidates for mediation of MLL-AF9 leukemogenic effects, + genes 
whose regulation is coherent with its functional role in malignancies, ○ genes with a currently 
undefined role in malignancies due to a lack of relevant literature, - genes whose regulation is 
incoherent with its functional role in malignancies. Supplementary table 3 (on page 175) 
includes information from literature research which was used to assort the genes to the 
categories. 
 
 
Figure 26: Distribution of rating categories over the assessed 92 genes. A rating strategy was 
employed to assort 92 selected, differentially expressed genes after MLL-AF9 knockdown in 
THP1 cells concerning their potential as mediators of MLL-AF9 leukemogenesis. +++ highly 
likely candidates and ++ likely candidates for mediation of MLL-AF9 leukemogenic effects, + 
genes whose regulation is coherent with its functional role in malignancies, ○ genes with a 
currently undefined role in malignancies due to a lack of relevant literature, - genes whose 
regulation is incoherent with its functional role in malignancies. 
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Figure 27: Differentially expressed genes potentially involved in mediation of MLL-AF9 
leukemogenic effects. Differential expression after MLL-AF9 knockdown in THP1 cells of 40 
genes considered as likely candidates for mediation of leukemogenic effects of MLL-AF9. Gene 
names in bold indicate genes rated as highly likely candidates. Columns show log2FC from 
microarray data of MLL-AF9 knockdown versus control treatments on day 8. Bars indicate 
standard error of the mean as described in material and methods. Grayscale of columns indicates 
expression strength according to microarrays fluorescent signal intensities:  high,  medium 
and  low expression (classified as described in material and methods). Transcripts are sorted 
according to categories of encoded proteins and alphabetically. * Indicates genes coding for 
proteins which belong to conventionally druggable protein classes (see section 9.4.3, page 104 
for details).  
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8.5 MicroRNAs in MLL-AF9 knockdown 
We hypothesized that the fusion protein MLL-AF9 is associated with differential expression of 
miRNAs. Such miRNAs might support the leukemogenic effect of MLL-AF9 and could yield a 
new category of potential therapeutic targets for the associated leukemia subtype. Therefore, a 
differential miRNA expression profile was generated after knockdown of endogenous MLL-AF9 
in THP1 cells. 
8.5.1 MLL-AF9 knockdown dependent effects on miRNA expression 
Total RNA from day 8 samples of five independent experiments was pooled for each of the four 
treatments (two MLL-AF9 knockdown and two controls). These samples were used for miRNA 
profiling via two different techniques. For quantitative TaqMan miRNA Low Density Arrays 
(LDAs), power calculations had revealed that at least eight replicates are needed to obtain over 
90% power with a type I error rate below 0.0005 to detect a log2FC of ±1, given the observed 
standard deviations for most miRNAs (Chen, et al. 2009). To circumvent this high number of 
replicates, it was decided to additionally profile miRNAs from the same samples through a 
second independent technique. Semiquantitative Agilent Human miRNA Microarrays were 
chosen for this purpose. Supplementary table 4 (on page 185) shows differentially expressed 
miRNAs from both platforms.  
Concerning data analysis of miRNA profiles, it is difficult to define reliable housekeeper. 
Normalizing the data to the overall mean instead, was shown to outperform the housekeeper 
reference approach (Mestdagh, et al. 2009). Thus, in collaboration with Dr. Philipp Pagel 
(Lehrstuhl für Genomorientierte Bioinformatik, Technische Universität München), we employed 
quantile normalization for semiquantitative microarrays (Agilent). For quantitative LDA profiles, 
we applied a novel strategy: LOESS normalization, which was based on the observation of 
substantial distortion of log RQ values over the CT range. These methods work under the 
assumption that the majority of miRNAs are not differentially expressed.  
Little is known, about how and to what extent the administration of an siRNA can disturb 
endogenous miRNA expression levels. In our study, we observed a strikingly high difference (∆ 
log2FC = 7.9) in the expression of miR-34c between the two non-targeting control siRNA 
treatments, which points to an off-target effect from one of these control siRNAs. Within the 
siRNAs designed to knockdown MLL-AF9 a similar and reproducible (in LDA and Agilent 
microarray data) expression difference was seen in miR-100 (not detectable in one MLL-AF9 
knockdown treatment but strongly expressed (CT 15.4) in the other). This finding underlines the 
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importance of using adequate controls for off-target effects in siRNA studies, like the study 
design employed here. 
In semiquantitative microarray results, 37% of all covered (1048) miRNAs were detected above 
background and only two miRNAs (miR-328 and miR-744*) were differentially expressed with 
significance level of p<0.05. These miRNAs were not differentially expressed in the data set of 
quantitative LDAs.  
Within the quantitative LDAs, 53% of all covered (664) miRNAs were detected above 
background. Among those, 15 reached significant (p<0.05) differential expression and additional 
6 miRNAs were either turned “on” or “off” in both MLL-AF9 knockdown versus both control 
samples (“undetermined” versus CTs below 34.5). For these, no exact ratio can be determined but 
- as previously described (Dorsam, et al. 2004) - a lower limit of differential expression was 
calculated. Among these 21 miRNAs considered as differentially expressed after MLL-AF9 
knockdown, 10 were down- and 11 upregulated (figure 28). The vast majority of differentially 
expressed miRNAs from quantitative LDA results, i.e. 20 miRNAs, was not detectable and the 
remaining one miRNA was not differentially expressed in the semiquantitative microarray 
measurements (supplementary table 4 on page 185).  
Low correlation between LDAs and microarrays from the same samples has previously been 
described and the LDA was evaluated to display a higher sensitivity and specificity (Chen, et al. 
2009). Because of this, the LDA was selected as the method of choice and its results applied to 
further validation.  
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Figure 28: Differentially expressed miRNAs after MLL-AF9 knockdown in THP1 cells. 
LDA analysis was utilized for quantitation of differential expression which is shown relative to 
non-targeting control siRNA treatments. Bars indicate standard error of the mean as described in 
material and methods. Transcripts are sorted from most down- to most upregulated. ● denotes 
miRNAs selected for single assay qRT-PCR confirmation, * indicates miRNAs which were 
confirmed via single assay qRT-PCR. Columns on the right show log2 fold change, mean 
threshold cycle (CT) value (indicating expression strength) and p-value of the corresponding 
miRNA. For miRNAs which were turned „on“ or „off“, i.e. not detectable in either both control 
or both MLL-AF9 knockdown samples, a lower limit of differential expression is reported as 
described in material and methods. Here no p-value can be calculated. n.a., not available. 
 
Based on LDA results, 11 miRNAs were selected for single-assay qRT-PCR confirmation. Nine 
of these were selected according to strongest regulation and lowest variance of differential 
expression (miR-219-5p, miR-432, miR-539, miR-582-3p, miR-589, miR-758, miR-760, miR-
511 and miR-214). Additional two miRNAs were selected due to predicted targets associated 
with leukemogenesis: miR-369-3p (potential targets e.g. ZNF521, SOCS2, B2M) and miR-576-
5p (potential targets e.g. B2M, PSIP1, MAPRE2). Confirmatory qRT-PCR was performed in the 
pools of 5 experiments which had already been used for miRNA profiling (technical validation) 
and in replicate pools of additional two independent experiments (biological validation). 
Comparison of miRNA data generated by LDA and single-assay qRT-PCR showed a highly 
significant correlation between both quantitation methods (technical validation) and significant 
correlation when biological replicates were analyzed (figure 29). These findings support good 
technical and interexperimental reproducibility of our LDA miRNA profiling data. However, the 
linear regression between the two techniques showed a strong deviation from the perfect fit. 
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Percent difference from the ideal slope is -79.1% and -79.0% respectively for technical and 
biological validation. This suggests that in our data sets, the magnitude of differential expression 
of LDA profiling results emerge as more pronounced than data from single assay qRT-PCR.  
 
 
Figure 29: Correlation between miRNA data from LDA and single assay qRT-PCR after 
MLL-AF9 knockdown in THP1 cells. MiRNA TaqMan low density array (LDA) data and 
single-assay qRT-PCR performed for 11 miRNAs which showed differential expression in LDA 
results (as described in the methods section) were compared. Linear regression (black line) is 
shown in comparison to a perfect fit (= ideal slope, gray dotted line). (A) Technical validation: 
single-assay qRT-PCRs were performed in identical samples (“pool 1”, same reverse 
transcription and preamplification products) that were measured on the LDA (significant 
correlation, Spearman’s Rho=0.92, p<2.2e-16). (B) Biological validation: single-assay qRT-
PCRs were performed in additional sample pools of 2 independent experiments (“pool 2”, 
significant correlation, Spearman’s Rho=0.66, p=0.03). Linear regressions and Spearman’s rank 
correlation coefficients including p-values were calculated with R.  
 
As shown in table 9, among the 11 miRNAs selected for single assay qRT-PCR, 7 were 
confirmed to be differentially expressed (with a concordant regulation of at least ±0.3 log2FC).  
This suggests less reproducibility of miRNA profiling data as compared to gene expression data: 
64% of miRNAs were confirmed via qRT-PCR as compared to 95% of genes.  
Among the confirmed miRNAs, miR-511 showed the strongest differential expression and thus 
was chosen for further investigations. MiR-511 upregulation in a MLL-AF9 knockdown-specific 
manner was additionally confirmed (log2FC 1.0, p=0.003) in three replicate experiments by qRT-
PCR utilizing single-assay reverse transcription (instead of megaplex) without preamplification.  
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Table 9: Confirmation of differential miRNA expression 
via single assay qRT-PCR.  
 
Differential expression and standard error of the mean (SE) 
of miRNAs in MLL-AF9 knockdown versus control in 
THP1 cells is given. MiRNAs concordantly regulated to 
LDA with > ± 0.3 log2FC were regarded as confirmed 
(shaded in grey). Single assay qRT-PCRs were performed 
after megaplex reverse transcription and pre-amplification of 
experimental “pool 1” and “pool 2” samples. 
 
All analyses were performed on day 8 samples which corresponds to a condition of 48 hours 
after serum reduction as described in 8.2.1. No differential expression of miR-511 on day 6 of 
experiments (i.e. before serum reduction) could be observed. To test if serum reduction was 
necessary to reveal this effect, miR-511 levels were also determined on day 8 samples of an 
experiment without serum reduction. Here, no differential expression of miR-511 was observed 
between MLL-AF9 knockdown and controls. Thus, analogous to cell size reduction, serum 
reduced conditions are necessary to reveal the MLL-AF9 knockdown specific effect on miR-511 
expression.  
8.5.2 Comparison of differential miRNA expression after MLL-AF9 knockdown 
to data from patient studies 
Recently, in a number of studies, miRNAs have been found to be differentially expressed among 
distinct cytogenetic groups of AML. However, the specific signatures differ among studies, a 
phenomenon which has been ascribed to the lack of standardization of the analytic methods used 
by different groups. (Marcucci, et al. 2011) An additional limitation for inter-study comparisons 
is the fact that novel human miRNAs are still being identified and thus studies performed just a 
few years ago may represent only a fraction of the presently known miRNAs. Nevertheless, 
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existing concordance of in vivo data to our in vitro data might point to potentially relevant 
miRNA candidates. 
Class discriminating studies compare miRNA expression in certain types of leukemia to all other 
leukemia / cancer types. For these studies one should expect that miRNAs characterizing AML 
or MLL-aberrant leukemia should be inversely regulated after MLL-AF9 knockdown. However, 
miRNAs more generally involved in the malignant state of the cells may not show up as 
differentially expressed in these patient data sets.  
 
Lu et al. (2005) described a general downregulation of miRNAs in malignancies (including 
AML) and found clustering of samples according to miRNA expression with respect to tumor 
type and differentiation state. Three of the miRNAs we found upregulated in a MLL-AF9 
dependent manner in our in vitro screen (miR-137, miR-214 and miR-301a) were shown by Lu 
et al. (2005) to have a reduced expression in AML versus all other samples.  
Jongen-Lavrencic et al. (2008) profiled 260 miRNAs in 215 AML patient samples including 6 
with MLL aberrations. They found 4 miRNAs being most discriminating for MLL-aberrant 
AML. However, none of these were differentially expressed in our MLL-AF9 knockdown data 
set. We also searched Jongen-Lavrencics data set concerning the miRNAs we had validated to be 
significantly altered in a MLL-AF9 dependent manner. Here, miR-511 is reported as being 
downregulated in AML samples with NPM1 and CEBPA abnormalities but upregulated in AML 
samples with inversion of chromosome 16 (Inv(16)) and FLT3 internal tandem duplication (Flt3-
ITD). In their study miR-214 was downregulated in AML samples with CEBPA abnormalities 
and Flt3-ITD. MiR-432 was found downregulated in AML samples with Inv(16) and NPM1 
aberrations but upregulated in AML with t(15;17). 
Concordant to our in vitro study, Garzon et al. (2008) identified miR-219 to be upregulated in 
MLL-AF6 and MLL-AF9 positive AML versus all other AML cases. 
An overview of concordant differential miRNA expression between our in vitro data and 
previous in vivo studies is given in table 10. 
 
Results 
 
78 
Table 10: Overview of concordant differential miRNA expression between in 
vitro MLL-AF9 knockdown and in vivo patient studies. 
 
Comparison of our data to class discriminating (e.g. in AML versus all other 
leukemia samples) in vivo studies is shown.  
 
8.5.3 Association of differentially expressed miRNAs to monocytic 
differentiation 
Our differential gene expression profile (chapter 8.4) argued for a more differentiated state of 
MLL-AF9 knockdown as compared to control cells. We aimed to explore if the MLL-AF9 
knockdown-specific differentially expressed miRNAs might also be related to differentiation. 
Publications concerning miRNAs in monocytic differentiation were thus examined, presuming 
that these miRNAs might be candidates for involvement in the differentiation block of leukemic 
monoblasts.  
Lutherborrow et al. (2011) described 12 miRNAs differentially expressed between AML cases of 
FAB type M1 (immature myeloblasts) and FAB type M5 (more differentiated monoblasts / 
monocytes) and thus potentially involved in the differentiation block of M1 blasts and in 
differentiation along the monocytic lineage. Wang et al. (2011) studied miRNA expression in 
monocytic differentiation using PMA treated U937 cells and detected 32 upregulated and 12 
downregulated miRNAs during differentiation. However, none of these miRNAs was found to 
be differentially expressed in our MLL-AF9 knockdown study.  
Tserel et al. (2011) detected miRNAs differentially expressed between monocytes and 
macrophages and thus potentially involved in macrophage differentiation. Among these were the 
upregulated miR-511 and miR-137, which we also detected as stronger expressed after MLL-AF9 
knockdown.  
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In our data, miR-511 was the strongest regulated of the confirmed differentially expressed 
miRNAs. To investigate if miR-511 is in deed associated to monocytic differentiation, THP1 
cells were differentiated through the addition of phorbol 12-myristate 13-acetate (PMA) as 
previously described (Martino, et al. 2009). Monocyte / macrophage differentiation of THP1 
cells was confirmed by Cellscreen microscopy: cells adhered tightly to the well surface and lost 
their round morphology (figure 30). Additionally, the transcript levels of MLL-AF9 and MLL, 
and also of AF9 and HOXA9 were analyzed via qRT-PCR. As previously reported (Martino, et 
al. 2006), MLL-AF9 and MLL mRNA levels were significantly reduced 48 hours after PMA 
addition (fold change 0.38 ±0.02 and 0.34 ±0.02), while additionally a significant reduction of 
AF9 and HOXA9 expression was detected, with fold change of 0.43 ±0.04 and 0.06 ±0.004 
respectively.  
MiR-511 expression was determined via single assay qRT-PCR in these samples. Indeed, miR-
511 showed a significant twofold upregulation in PMA-differentiated compared to control 
treated THP1 cells (figure 31). This observation is consistent with the hypothesis that miR-511 
plays a role in the differentiation process of monoblasts. 
 
 
Figure 30: Morphological changes of differentiated THP1 cells. THP1 cells were treated for 
48 h with phorbol 12-myristate 13-acetate (PMA, left image) and compared to control (right 
image). Cellscreen images of two regions of interest (ROIs) as described in material and methods 
are shown. 
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Figure 31: Expression of miR-511 in differentiated THP1 cells, 48 h after phorbol 12-
myristate 13-acetate (PMA) addition. The experiment was performed in triplicate. Bars indicate 
standard error of the mean.* p=0.05 
 
8.5.4 Potential direct targets of upregulated miR-511 
Recently, the first two direct targets of miR-511, TLR4 and CD80, have been experimentally 
validated (Tserel, et al. 2011). However, these two genes were not detected as differentially 
expressed in our data set. To further explore the functional role of miR-511, potential additional 
direct targets of this miRNA were searched via computational techniques.  
Computational target prediction remains a complex task as evidenced by the existence of a large 
number of available algorithms which lead to notable different results. Employing more than one 
algorithm is thus recommended to improve the reliability of predictions. We performed an in-
depth in silico target prediction for miR-511 using 9 different prediction algorithms via 
miRWalk (Dweep, et al. 2011). Among the predicted targets, potentially important ones within 
this biological setting were selected for further analysis. Figure 32 gives an overview of the 
selection process of predicted targets of miR-511 with potential 3’-UTR binding sites and 
includes information on their connection to leukemia. MiRWalk predicted a total of 8112 genes 
as potential targets for miR-511. Among these, according to our gene expression microarray 
results, 730 genes were differentially expressed upon MLL-AF9 knockdown (p<0.05). Of those, 
445 genes (61%) were downregulated and thus inversely correlated to miR-511 as expected for 
true miRNA-target gene pairs. These 445 potential target genes were then subjected to functional 
disease ontology (FunDO) analysis in order to identify leukemia and cancer associated genes. 
Five additional genes were added to the resulting list because of previously reported functional 
links to leukemia. As result, 19 leukemia and 22 cancer associated genes were recovered. These 
were rated by literature research to determine if the observed direction of regulation matched 
their described role in malignancy. Finally 9 genes (AFF1 (alias AF4), AFF4, FGFR1, FGFR3, 
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IGF2BP2, MAPRE2, DACH1, MDM2, MEF2C) were selected as likely candidate targets of 
miR-511 within this biological setting. 
 
Figure 32: Overview of the selection process of predicted targets of miR-511 with potential 
3’-UTR binding sites for experimental validation. Included is information on their link to 
malignancy. 
 
Results 
 
82 
For confirmatory purposes, miR-511 upregulation experiments were performed in THP1 cell line 
via transfection of miR-511 or negative control mimics (Pre-miR™ miRNA Precursor 
Molecules). MiR-511 levels were determined via qRT-PCR and proofed to be strongly 
upregulated in miR-511 mimic treatments as compared to negative control mimic treated cells 
(log2FC of 19.8 ±0.25). Levels of miR-511 after upregulation roughly resembled the expression 
strength of the strongest expressed endogenous miRNA in THP1. Expression of the selected 9 
potential target genes was subsequently analyzed 48 and 72 h after treatment. Except for 
DACH1, an expected downregulation was observed, although these reductions in expression 
strengths did not reach significance (figure 33). 
 
Figure 33: Effect of transient upregulation of miR-511 in THP1 cells on potential direct 
target genes. Expression levels were measured by qRT-PCR 48 and 72 h after transient 
transfection of miR-511 or control mimics under serum reduced conditions (0.5% FBS). 
Transcripts are sorted according to p-value. Graph represents four experimental data sets. Bars 
indicate standard error of the mean.  
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9 Discussion 
In this study we employed RNAi to functionally interfere with endogenous MLL-AF9 in the 
monoblastic cell line THP1. This technique served to deduce candidate genes and miRNAs for 
mediation of leukemogenic effects of MLL-AF9. Besides revealing downstream effects of MLL-
AF9, our study aimed to identify new potential therapeutic targets of MLL-aberrant acute 
myeloid leukemia. This is relevant, as prognosis is still poor for this type of leukemia and 
because strategies aiming to interfere directly with MLL-AF9 function might be too toxic. We 
performed a specific and efficient knockdown of MLL-AF9 in the cell line THP1 and for the first 
time describe, beside phenotypic changes, comprehensive gene and miRNA expression profiles 
in this setting. Both sources of information, gene expression and miRNA expression, may help 
with the identification of future therapeutic targets.  
 
9.1 Experimental Design 
We aimed to identify downstream effects of MLL-AF9 via RNAi. The goal of our experimental 
design was to avoid conditions that lead to unspecific effects or to masking of MLL-AF9 specific 
effects. To this end a number of measures were taken: (1) To avoid the contamination of results 
by off-target effects, the experimental design included the utilization of two distinct, highly 
specific and effective siRNAs against MLL-AF9 in THP1 cells as well as of two distinct control 
siRNAs. (2) The experimental design should allow sufficient time for reversal of potential 
epigenetic changes. This was accomplished by a prolonged duration of experiments over eight 
days. (3) We strived to constrain the masking of MLL-AF9 specific effects through the strong 
mitogenic influence of fetal bovine serum (FBS) by reduction of FBS to 0.5% from day 6 of 
experiments onwards. This FBS concentration was determined to lead to culture conditions in 
which THP1 cells remain proliferating over at least 6 days while showing a clearly reduced 
doubling rate. (4) To reduce the effects of interexperimental variation, samples were pooled from 
five independent experiments for the analysis of gene and miRNA profiles.  
Altogether, these experimental steps resulted in a high reproducibility of the phenotypic as well 
as gene and miRNA expression data we generated. In functional disease ontology (FunDO) 
analysis, of all possibly associated disease terms, the term leukemia was significantly and on 
prime position associated with our differentially expressed gene data set, a fact which confirms 
the validity of our experimental approach in this biological context. 
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9.2 Confirmation of MLL-AF9 knockdown 
Efficiency of MLL-AF9 knockdown was monitored on mRNA level over the time course of 
experiments and reached a residual expression of 22 ±6 % at the time point of gene and miRNA 
expression analyses (day 8).  
MLL-AF9 protein is hard to detect by standard techniques, as suggested by previous studies not 
being able to show MLL-AF9 reduction on protein level after knockdown (Kawagoe, et al. 2001; 
Pession, et al. 2003). In our study, MLL-AF9 from THP1 cells could only be detected on 
Western blot performed with protein isolated from the organic phase of Qiazol (similar to Trizol) 
which is a strong denaturing agent. However, this kind of protein isolate was not suitable for 
quantitative procedures, because complete dissolution of intermediate protein pellets can hardly 
be achieved. Cell lysates generated with standard lysis buffers, e.g. Laemmli sample buffer or 
RIPA buffer, did not yield any MLL, AF9 or MLL-AF9 bands in THP1 samples. Surprisingly, 
however, MLL and AF9 wildtype was readily detected in MCF-7 and HELA control lysates with 
identical procedures.  
A possible explanation is that MLL-AF9 binding to DNA is stronger as in MLL wildtype, 
leading to complexes which are not easily dissolved even after sonication. However, this would 
not explain the simultaneous non-detectability of MLL and AF9 wildtype protein in conventional 
THP1 protein lysates. Alternatively, a tendency of MLL-AF9 to form protein aggregates and co-
aggregation of MLL and AF9 wildtype protein might explain this finding. This hypothesis is 
supported by the fact that protein folding was a significantly enriched functional gene ontology 
term associated with our differential gene expression set after MLL-AF9 knockdown. Within this 
annotation term, the vast majority (88%) of transcripts was downregulated after MLL-AF9 
knockdown. Protein folding is a similar process in the test-tube and within cells and is dependent 
on certain positions in the amino acid sequence (Taubes 1996). Because MLL-AF9 is not a 
physiologically occurring protein, it might be more prone to form aggregates, a feature that – if 
confirmed – might play a role in MLL-AF9 related malignancy (chapter 9.4.1.4, page 92).  
An alternative and innovative method we employed (TaqMan Protein Assay described on page 
25) was also not sufficient to quantify MLL-AF9 protein. To overcome this problem, we utilized 
HOXA9 transcript level as surrogate marker for MLL-AF9 protein level. This indirect method is 
able to indicate efficiency of MLL-AF9 knockdown because HOXA9 transcription is known to be 
raised through direct interaction between MLL-AF9 protein complex and the HOXA9 promoter 
(Erfurth, et al. 2008; Cierpicki, et al. 2010). Thus we were able to indirectly confirm an efficient 
functional knockdown of MLL-AF9 in the cell line THP1 on protein level. 
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9.3 Cellular phenotype and functional endpoints of MLL-AF9 knockdown 
Various features such as cell cycle distribution, proliferation rate, apoptosis rate and mean cell 
size were assessed to screen for phenotypic and functional consequences of prolonged 
knockdown of MLL-AF9 in THP1 cells.  
In our study, we were not able to detect effects on proliferation, cell cycle or apoptosis with the 
techniques employed. Wiederschain et al. (2005) have previously demonstrated that MLL-AF9 
and other MLL-fusion proteins can downregulate p53-mediated induction of p21, MDM2 and 
Bax and could thus act antiapoptotic. Kawagoe et al. (2001) and Pession et al. (2003) detected 
inhibition of cell growth and a moderate increase of apoptosis after 1 - 3 days after MLL-AF9 
knockdown in THP1 cells. However, experimental conditions between our and these studies are 
not directly comparable. While we performed a prolonged MLL-AF9 knockdown via siRNAs 
over 8 days in the monoblastic leukemia cell line THP1, Kawagoe et al. (2001) and Pession et al. 
(2003) employed antisense oligodeoxyribonucleotides (ODNs) in THP1 and detected differences 
up to three days after MLL-AF9 knockdown, while Wiederschain et al. (2005) expressed MLL-
fusion constructs in epithelial and lymphoblastic leukemia cell lines. Alternatively, the lack of 
observable effects on proliferation and apoptosis in our study might be explained by the absence 
of sufficient apoptosis inducing stimuli, by residual MLL-AF9 protein level or by different 
secondary mutations within the cell line.  
MLL-AF9 knockdown in THP1 led to a highly significant cell size reduction of about 0.3 µm. In 
order to retain cell size homeostasis, cells need to coordinate cell growth and division, while 
slowly growing cells tend to be smaller (Shin, et al. 2009). However, changes in proliferation, 
cell cycle distribution or apoptosis appear unlikely to be the underlying mechanisms of the cell 
size reduction we observed. Apoptosis is expected to lead to a high magnitude of cell size 
reduction and finally to cells dissolving into small vesicles. Thus we expected that these 
phenomena would all lead to a difference in cell number within our prolonged study design. 
However, we detected no effect on cell number even up to day 12 of MLL-AF9 knockdown.  
Genomic scale gene deletion analyses in the yeast Saccharomyces cerevisiae revealed 49 genes 
involved in cell size regulation without profoundly changing cell proliferation. Among these, the 
majority (71%) have putative human homologs (Zhang, et al. 2002). We searched our data set 
for differential expression of these human homologs. Indeed, two gene homologs whose deletion 
led to abnormally small yeast phenotypes were downregulated in our data set: the gene RPL34 
encoding a ribosomal protein involved in protein synthesis as well as the gene RASGRF1 (ras 
protein-specific guanine nucleotide-releasing factor 1) encoding a signal transduction protein. 
Remarkably, repression of RASGRF1 was recently linked to quiescence in very small 
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embryonic-like stem cells in adult murine tissues including bone marrow (Shin, et al. 2009) and 
thus repression of this gene might connect cell size with quiescence.  
Deletion of the homolog of AF9 (ANC1) led to an abnormal large phenotype in yeast (Zhang, et 
al. 2002). In our MLL-AF9 knockdown within THP1 cells, AF9 wildtype was not differentially 
expressed at transcript level. However, aggregation of MLL-AF9 protein – as suspected due to 
our biochemical findings (see 9.2 on page 84 and 9.4.1.4, page 92) – might account for this 
phenomenon. Partially folded proteins may form self-aggregates, e.g. due to mutations (Taubes 
1996). If MLL-AF9 would co-aggregate AF9 due to a partial identical sequence, MLL-AF9 
could render AF9 protein non-functional and – in analogy to deletion of yeast AF9 homolog – 
could lead to a cell size increase. Knockdown of MLL-AF9 could alleviate AF9 co-aggregation 
thus returning its functional activity and reducing cell size. Supportive for this hypothesis is the 
fact that besides the MLL-AF9 band also the MLL and AF9 wildtype bands are non-detectable in 
conventional lysates of THP1 cells (8.2.2, page 42).  
Cell size has been previously described to be largely determined by ribosome biogenesis, which 
is dependent on the activity of RNA polymerase I (Sun, et al. 2006a). Our expression data indeed 
point to reduced ribosome biogenesis after MLL-AF9 knockdown as we observed reduced 
expression of TTF1 (transcription termination factor, RNA polymerase I) as well as the 
upregulation of CDKN2A mRNA. TTF1 regulates RNA polymerase I, and thus rRNA 
transcription, while CDKN2A gene product p14/p19
ARF
 (ARF) is a tumor suppressor, which 
represses ribosome biogenesis by binding and inactivating the nucleolar localization motif of 
TTF1 (Lessard, et al. 2010). Additionally, all transcripts within the enriched gene annotation 
term translational elongation - among these seven encoding ribosomal proteins - were 
downregulated (see figure 23 on page 58 and supplementary figure 1 b on page 167).  
Another contributing mechanism for the size reduction after MLL-AF9 depletion might be a 
raised intracellular (cytosolic) Ca
2+
 concentration, as previously described in many cell types 
(Tanaka, et al. 2004a; Koivusalo, et al. 2009). In this context, Ca
2+
 is believed to serve as a 
signal for activation of channels that mediate a net loss of ions, thus leading to a regulatory 
volume decrease (Koivusalo, et al. 2009). Our gene expression data support this possibility: the 
calcium transporter ATP2B2, which is responsible for maintaining low free cytosolic Ca
2+
 
levels, as well as calreticulin (CALR), a major Ca
2+
 storage protein in the lumen of the 
endoplasmic reticulum, were found downregulated after MLL-AF9 knockdown.  
The aquaporines AQP1, AQP3 and AQP7P1 were downregulated in our data after MLL-AF9 
knockdown. Though this was not previously described to influence cell size, it seems 
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conceivable that reduced expression of aquaporines may inhibit water entry into the cells with 
the consequence of cell size reduction.  
9.4 Differential gene expression profile after MLL-AF9 knockdown 
We analyzed differential gene expression profiles after MLL-AF9 knockdown with the prospect 
to better understand the transforming activities of MLL-AF9 and to find downstream genes 
encoding proteins suitable as therapeutic targets.  
We employed the term “gene expression” for analyses of coding and non-coding transcripts 
exclusive of small RNA species which are not typically included in these profiling techniques, 
while transcript levels of miRNAs are denoted as miRNA expression.   
The goal of our data analysis of differential gene expression after MLL-AF9 knockdown was to 
include the highest number of differentially expressed transcripts without rising the false positive 
rate. To this end, we rated the differential expression of identical replicate probe sets as a 
function of p-value cutoff. We detected a plateau of high percentage of significant identical 
replicate probes up to p<0.03 and a subsequent, almost linear decline with less stringent cutoffs. 
Thus, the cutoff p-value of the moderated t test was set to below 0.03.  
This analysis resulted in 1269 unique genes being differentially expressed between MLL-AF9 
knockdown and control treatments. In line with our number of observed transcripts influenced by 
MLL-AF9 knockdown, it has previously been estimated that MLL and MLL-fusion proteins target 
about 1000 genomic loci (Slany 2009). 
Among the detected 1269 differentially expressed gene transcripts, the majority (64%) were 
found downregulated after MLL-AF9 knockdown. Apparently, this data set contains both, direct 
targets of MLL-AF9 as well as an array of secondary changes in gene expression. Nevertheless, 
this regulatory imbalance confirms the hypothesis that MLL-AF9 mainly acts as a transcriptional 
activator as has been deduced from mechanistic studies of MLL aberrations (Slany 2009; Mohan, 
et al. 2010; Margaritis, et al. 2008).  
To interpret this extensive gene expression data set, 1) functional gene ontology was employed 
to describe the biological processes behind the full data set (section 9.4.1), 2) a strategy to filter 
out and rate genes presumably important for mediation of leukemogenic effects of MLL-AF9 
was created (section 9.4.2) and 3) an exploration of the latter gene set concerning their 
druggability was performed (section 9.4.3).  
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9.4.1 Biological processes potentially involved in mediation of MLL-AF9 
leukemogenic effects 
A standard procedure to track down biological meaning behind large lists of genes is enrichment 
analysis of functional gene ontology. This kind of analysis was performed for the set of 
differentially expressed genes after MLL-AF9 knockdown in THP1 cells. The results should 
finally serve to identify processes which may be involved in MLL-AF9 mediated 
leukemogenesis. To structure the results consisting of 43 functional ontology annotation terms, 
these were grouped into 5 higher-order terms.  
Based on the results (a simplified overview is given in table 11), we discuss in the following 
sections a number of biological processes and transcripts which we propose to be involved in 
mediation of MLL-AF9 leukemogenic effects.  
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Table 11: Overview of MLL-AF9 knockdown associated enriched 
functional gene annotations 
 
This table depicts a simplified version of figure 23 on page 58. Functional 
annotation terms were manually assorted to 5 higher-order terms 
according to the major role of the biological process within this biological 
setting. Annotation terms which were assigned to two higher-order terms 
are depicted between these two, indicated by dotted division lines. 
Annotation terms which could not be assigned to one of the four specific 
higher-order terms are collected under the term “other”. Some annotations 
were abbreviated as indicated by superscript numbers: 
1
Antigen 
processing and presentation of peptide or polysaccharide antigen via 
MHC class II, 
2
Embryonic development ending in birth or egg hatching, 
3
Antigen processing and presentation of peptide antigen via MHC class I.  
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9.4.1.1 Proliferation, cell growth and cell death  
We hypothesized that transcripts downstream of MLL-AF9 which are involved in proliferation, 
cell growth and cell death may contribute to the malignancy of MLL-AF9. 
We found a high number of differentially expressed genes potentially playing a role in apoptosis. 
This suggests an effect on the apoptotic functions of the cells. However, the amount of apoptotic 
cells within MLL-AF9 knockdown was not detectably altered. This might be due to the absence 
of a sufficient apoptotic stimulus in the culture or due to other conditions influencing the 
dynamic apoptosis network. 
Some differentially expressed genes coding for anti-apoptotic regulator proteins showed reduced 
expression after MLL-AF9 knockdown and thus might be involved in malignancy of MLL-AF9 
positive the cells. These were SOCS2, MEF2C, STAMBP, HSP90B1, ANXA4, CFL1 and BRAF 
(see supplementary figure 1 b on page 167). 
Two gene transcripts with HMG17-domains were strongly expressed and downregulated, while a 
third showed intermediate expression strength and was upregulated. This group of proteins 
contains non-histone components of chromatin thought to be involved in unfolding higher-order 
chromatin structure, facilitating the transcriptional activation of genes (Porkka, et al. 2002) and 
affecting DNA replication, recombination and repair (Pogna, et al. 2010). The included gene 
HMGN2 has previously been found overexpressed in CML and other cancer types and 
association to proliferation has been suggested (Kondos, et al. 1995).  
Expression rates of ribosomal proteins were previously associated with cell growth and 
proliferation and are altered in numerous cancer types (Andersen, et al. 2005; Ruggero, et al. 
2003; Wang, et al. 2006). Thus, the finding that genes encoding ribosomal proteins (within the 
annotation term translational elongation) were downregulated as well as the occurrence of the 
annotation term growth in our MLL-AF9 depleted THP1 cells would point to an influence on 
proliferation or cell growth. However, this could not be observed on functional level implicating 
that potential effects may be either too weak to be detected by our tools or may be restricted to 
more unfavorable growth conditions. 
9.4.1.2 Differentiation 
We observed a raised expression of the monocytic maturation markers CD14, BCL6, CEBPB, 
EGR2, FOS, KLF4, MAFB, MNDA (Lutherborrow, et al. 2011; Klco, et al. 2011; Kelly, et al. 
2000), MHC class II and SERPINA1 (Abrink, et al. 1994) as well as a reduced expression of 
markers of immature cells of the monocytic lineage (ELANE, CTSG and PRTN3). This finding is 
strongly suggestive for maturation of THP1 monoblasts after MLL-AF9 knockdown.  
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Gene ontology analysis of our data was also in line with a more differentiated state of the cells 
after MLL-AF9 reduction.  
Monocytes are cells of the innate immune response responsible for phagocytotic uptake and 
digestion of microbes and particles (via lysosomes), antigen presentation as well as cytokine 
production and release (via exocytosis). Monocytes may adhere to vessel walls and migrate from 
the blood stream to tissues where they further differentiate into macrophages or dendritic cells. 
Within differentiation of monocytes, it has been suggested that phagocytosis is acquired prior to 
microbicidal activity, which again develops prior to locomotion (Glasser 1981).  
 
The most significantly enriched functional annotations concerned antigen processing and 
presentation, especially via MHC class II. This is a major biological function of differentiated 
monocytes and macrophages. Upregulation of HLA class II gene transcripts has previously been 
associated with differentiation of monoblasts, while THP1 cells were observed to have reduced 
HLA class II expression levels compared to mature monocytes (Abrink, et al. 1994). We 
observed an upregulation of all differentially expressed genes within the category antigen 
processing and presentation via MHC class II. This finding might be explained by the 
transcriptional upregulation of the transcription factor and master controller of MHC class II, 
class II major histocompatibility complex transactivator CIITA (Ting, et al. 2002). Another 
transcriptional activator gene of MHC class II, regulatory factor X 5 (RFX5), was found 
downregulated, but can activate transcription only in cooperation with CIITA (Scholl, et al. 
1997). RFX5 was strongly expressed in our data set and its downregulation does not reduce 
MHC class II expression, suggesting that the residual level of RFX5 is sufficient for MHC class 
II expression.  
Further genes indirectly indicating a more differentiated cellular status fell into the following 
monocyte / macrophage-related enriched annotation terms: phagocytosis, regulation of cytokine 
production, endocytosis, defense response, response to bacterium, positive regulation of 
exocytosis, Saposin B (lysosomal proteins), and actin binding (may indicating changes in cell 
shape and motility). Additionally, phorbol ester binding, response to vitamin and response to 
retinoic acid suggested links to the differentiating effects of PMA, 1,25- dihydroxyvitamin D3 
and retinoic acid on monoblasts. All genes within the annotation hematopoietic cell lineage were 
upregulated, as was the majority of transcripts within the terms immune response and defense 
response.  
Other genes (EGR2, VDR, SP9 and ZNF521) of the differentiation associated annotations are 
discussed in section 9.4.2).  
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Taken together, these findings are consistent with the hypothesis that MLL-AF9 depletion leads 
to a partial release of the differentiation block in THP1 cells. 
9.4.1.3 Early development 
The three enriched ontology annotation terms homeobox conserved site, pattern specification 
process and embryonic development ending in birth or egg hatching were grouped to the higher-
order term “early development”. The wildtype genes involved in the MLL-AF9 translocation, 
play essential roles in embryogenesis and their disruptions lead to homeotic transformations 
indicating a role in pattern specification (section 6.2, page 5). Thus deregulation within these 
terms might mainly be related to their wildtype functions. However, some of the genes 
encompassed in these annotations (e.g. HOX genes, PBX3, HIPK2 and BMI1) have additionally 
been reported to play a role in leukemogenesis (Eklund 2007; Milech, et al. 2001; Li, et al. 2007; 
Yuan, et al. 2011a).  
9.4.1.4 Calcium associated gene functions and protein folding 
Our set of differentially expressed genes after MLL-AF9 knockdown was significantly enriched 
in calcium associated annotation terms like calcium-binding and calcium ion homeostasis. This 
finding suggests that the cellular calcium homeostasis is influenced by MLL-AF9. 
The charged calcium ion, together with the charged phosphate ion, is the primary signaling 
element of the cell. It is the most tightly regulated ion and influences every aspect of a cell’s life 
and death, including differentiation, proliferation and apoptosis. Ca
2+
 binds to thousands of 
proteins and influences their localization, association and function. (Clapham 2007) 
Decreased levels of intracellular Ca
2+
 may lead to endoplasmatic reticulum (ER) stress and thus 
activate the unfolded protein response (Schardt, et al. 2011).  
 
Protein folding was an enriched annotation term with remarkable 88% of the transcripts being 
downregulated in MLL-AF9 knockdown. In compartmentalized eukaryotic cells, integrity of the 
protein-folding environments has to be ensured in the cytosol, the endoplasmatic reticulum (ER) 
as well as in the mitochondria (Haynes, et al. 2010). To this end, cells contain compartment-
specific chaperones as well as specific mechanisms protecting them from unfolded or misfolded 
protein: the heat-shock response in the cytoplasm, the unfolded protein response (UPR) in the 
ER and the mitochondrial UPR (Haynes, et al. 2010).  
In our data set, genes encoding chaperones of all three compartments were downregulated: e.g. 
HSP90AA1 and PPIC from the cytoplasm, HSP90B1 and CALR from the ER and HSCB from 
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mitochondria (and the cytoplasm). This finding might be a consequence of the reduced 
expression of protein coding transcripts in general (64% of differentially expressed transcripts 
were downregulated) and ribosomal genes in particular. However, our biochemical findings on 
MLL-AF9 protein were suggestive of its disposition to aggregate (section 9.2, page 84). Thus 
reduced expression of protein folding genes may alternatively be caused by an attenuated heat-
shock response within the cytoplasm due to less misfolded MLL-AF9 protein after MLL-AF9 
depletion and / or an attenuated UPR, e.g. due to MLL-AF9 dependent effects on the cellular 
calcium ion homeostasis. Both mechanisms, the heat-shock response and the UPR, are 
interrelated as they share the proteasome and the eIF2alpa kinase regulatory pathway (Heldens, 
et al. 2011). 
Heat shock proteins have previously been found to be overexpressed in a wide range of human 
cancers, including hematological malignancies (Yokoyama, et al. 2002) and evidence is 
accumulating for the involvement of the unfolded protein response in the pathogenesis of many 
tumor types as well as in AML linked to fusion genes (Schardt, et al. 2011). Thus, these 
interrelated mechanisms might also play a role within MLL-AF9 dependent leukemogenesis. 
9.4.1.5 Estrogen signaling 
Estrogen signaling was also a significantly enriched functional ontology term within our MLL-
AF9 dependent gene expression data set and encompassed the terms response to estrogen 
stimulus and response to estradiol stimulus. 
Promoter methylation of estrogen receptor has been previously associated with improved 
survival in adult AML patients and is reduced in AML of the subtypes M4 and M5 according to 
FAB classification (Li, et al. 1999). As MLL-AF9 positive myeloid leukemias are mainly of the 
FAB type M5, this might point towards importance of estrogen regulated genes in MLL-AF9 
leukemias.  
A number of previous observations also point towards importance of estrogen signals in 
leukemogenesis and in particular in MLL-associated leukemogenesis: (1) high estrogen levels 
may lead to MLL gene aberrations, (2) MLL-rearrangements have a higher incidence in maternal 
ALL cases, (3) MLL-aberrant leukemia is associated with increased birth weight, which in turn is 
positively correlated with maternal estradiol levels (Aljurf, et al. 2011; Nagata, et al. 2006) and 
(4) proteins of the MLL family may bind to gene promoters in an estradiol-dependent manner 
(Ansari, et al. 2009; Ansari, et al. 2011).  
MLL-fusion proteins might also indirectly influence the cellular protein level of estrogen 
receptor: The nuclear aryl hydrocarbon receptor AHR, which emerged as transcriptionally 
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suppressed by MLL-AF9 in our data set, is known to be important for estrogen receptor alpha 
ubiquitination and degradation (Bunaciu, et al. 2011).  
A widespread crosstalk of retinoic acid and estrogen signaling to regulate gene expression in 
opposing directions was observed within a breast cancer cell line (Hua, et al. 2009). Retinoic 
acid is well known for promoting differentiation of monoblasts (Matikainen, et al. 1994). Also in 
line with these observations, stimulation of membrane-bound estrogen receptor inhibited retinoic 
acid-induced functional differentiation of HL-60 myeloblastic leukemia cells (Kauss, et al. 
2008).  
These findings support the hypothesis that hematopoietic progenitor cells, expressing high levels 
of estrogen receptor and / or being within an environment of strong estrogen signaling might be 
prone to transform into leukemic blasts. This transformation might arise via formation of MLL-
aberrations which in turn support estrogen receptor expression and inhibit retinoic acid signaling 
pathways thus leading to a block in differentiation.  
9.4.1.6 Evasion of immunosurveillance 
We found a strong downregulation of ZNF521 and reduced expression of most genes within 
functional terms related to MHC class I antigen presentation (the terms antigen processing and 
presentation as well as antigen processing and presentation of peptide antigen via MHC class I). 
This concerned downregulation of the genes HLA-B, B2M, CALR, HSP90AA1 and HSPA2 after 
MLL-AF9 knockdown.  
MHC class I deficient tumor clones have been found to be able to escape T cell immune 
responses, but might be more susceptible to NK cell-mediated lysis (Algarra, et al. 2004). The 
zinc finger transcription factor ZNF521 has previously been associated with enhanced MHC 
class I expression and reduced susceptibility to NK cell-mediated lysis (La Rocca, et al. 2009). 
Pig cells transgenic for human HLA-E/B2M are protected against human NK cell-mediated 
cytotoxicity (Weiss, et al. 2009). These facts support the importance of HLA class I and B2M 
proteins for avoiding NK cell-mediated lysis. In this context, MLL-AF9-associated, strong 
expression of B2M might suggest that MLL-AF9 positive cells are able to avoid NK cell-
mediated cytotoxicity, a capability potentially being abrogated  after knockdown.  
We detected a strong transcriptional upregulation of all differentially expressed genes involved 
in antigen processing and presentation via MHC class II (see section 9.4.1.2 on page 91). Loss of 
MHC class II gene expression has previously been shown to be strikingly correlated with poor 
patient outcome and has been linked to decreased immunosurveillance via cytotoxic T cells in 
large B cell lymphoma patients (Rimsza, et al. 2004).  
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Additionally the enriched annotation term leukocyte chemotaxis might point towards changes 
related to immunosurveillance. This term included the strong transcriptional upregulated 
chemokine CCL2. AML blasts have been described to produce different amounts of CCL2 
which influences the number of monocytes migrating towards AML blasts (Legdeur, et al. 
2001). Plasma levels of CCL2 have been shown to be decreased in patients with AML of the 
FAB subtype M4 and M5 (Mazur, et al. 2007). Thus, upregulation of CCL2 might lead to 
improved immunosurveillance of M4 and M5 blasts. In this context, CCL2 has been proposed 
for adoptive immunotherapy (Legdeur, et al. 2001).  
9.4.2 Candidate genes for mediation of MLL-AF9 leukemogenic effects 
To prioritize likely candidates for mediation of MLL-AF9 leukemogenic effects within the 1269 
differentially expressed genes after MLL-AF9 knockdown, a subset of these genes had to be 
selected for further literature research concerning their potential as mediators of MLL-AF9 
leukemogenic effects. To achieve this task, four criteria were applied as outlined in results 
section 8.4.3 (page 50).  
Magnitude of differential expression is often taken as hint for biological importance or 
relevance. This approach, however, is not necessarily predictive and may depend on the specific 
functions of the encoded proteins (Huang, et al. 2009a). Therefore, besides the magnitude of 
differential expression, we aimed to cover a broader functional spectrum by additionally 
selecting genes according to functional gene ontology terms. Because we were especially 
interested in genes in context to leukemia, we added those genes that have already been linked to 
leukemia via functional disease ontology or leukemia patient studies.  
Concerning the latter, one has to take into account that comparison of our in vitro data to in vivo 
data from patient samples remains difficult. Our data representing a homogenous cell population 
can only partly mirror events seen in heterogeneous cell populations from in vivo studies. 
Additionally, due to the quantity of resulting data from these array approaches, only selected 
differences in gene expression are be presented in most publications. These are e.g. the 
transcripts with best group-distinguishing properties or those with highest differential expression 
within these studies. These, however, do not necessarily give a comprehensive picture of the 
biological situation. For example, genes involved in the malignant state of leukemic cells in 
general are not necessarily expected to be discriminating for certain subsets of leukemias. Yet, a 
concordant regulation between our in vitro and previous in vivo data may support the hypothesis 
that these transcripts are relevant in leukemia.  
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The selecting approaches altogether yielded 92 genes that were subjected to literature research 
and a subsequent rating strategy with respect to potential relationship to leukemogenesis. Among 
these genes, a set of 40 candidates for mediation of leukemogenic effects of MLL-AF9 was 
prioritized. In the following these genes are discussed according to the protein classes they 
belong to (table 12). 
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Table 12: Overview of differentially expressed genes 
potentially involved in mediation of MLL-AF9 
leukemogenic effects. 
 
Top-40 differentially expressed genes rated as likely 
candidates for mediation of leukemogenic effects of MLL-
AF9. Gene names in bold indicate genes rated as highly likely 
candidates. Transcripts are sorted according to categories of 
encoded proteins and alphabetically. reg.: up- or 
downregulated after MLL-AF9 knockdown in THP1;  
* Indicates genes coding for proteins which belong to 
conventionally druggable protein classes (see 9.4.3 on page 
104 for details). This table depicts a simplified version of 
figure 27 which is displayed on page 71. 
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Receptors 
One MLL-AF9 dependent transcript which was not encompassed in functional gene annotation 
results and has not been previously associated with leukemia or cancer, is the taste receptor type 
1 member 3 (TAS1R3). It was strongly downregulated in MLL-AF9 depleted THP1 cells. As a 
heteromer with TAS1R2, this glucose sensor may contribute to the control of energy supply to 
the cell (Mace, et al. 2009) and(Nakajima, et al. 2006) thereby might facilitate a rapid 
reproduction of leukemic blasts. TAS1R3 could serve as a marker for leukemic MLL blasts and / 
or as a target or docking molecule for drugs. This target appears druggable as illustrated by a 
patent for the use and manufacturing of TAS1R3 receptor inhibitors to treat obesity and diabetes 
(PCT/EP2005/054760).  
The upregulated gene ROR2 encodes a receptor / coreceptor for Wnt5a and mediates 
noncanonical Wnt signaling (Minami, et al. 2010). It has been previously hypothesized that 
Wnt5a is a tumor suppressor in leukemogenesis acting through the Wnt5a/Ror2 noncanonical 
signaling pathway that inhibits Wnt canonical signaling (Yuan, et al. 2011b). 
 
Nuclear receptors 
The nuclear aryl hydrocarbon receptor (AHR) supports retinoic acid–induced differentiation of 
myeloblastic cells and might do so via downregulation of estrogen receptor signaling (see section 
9.4.1.5 on page 93). 
Transcription of vitamin D (1,25- dihydroxyvitamin D3) receptor (VDR), a ligand-inducible 
transcription factor, was upregulated in a MLL-AF9 knockdown dependent manner. Its ligand, 
(1,25-dihydroxyvitamin D3) is capable of inducing in vitro monocyte / macrophage 
differentiation of both normal bone marrow progenitor cells and leukemic myeloid cell lines 
(Gocek, et al. 2010; McCarthy, et al. 1983).  
 
Transcription factors 
Sixteen transcription factors were within the top-40 gene set for mediation of leukemogenic 
effects of MLL-AF9. Among these, six, namely CEBPB, CIITA, EGR2, FOS, FOSB, and KLF4 
were upregulated and ten (DACH1, HOXA9, HOXA11, HOXC4, IKZF2, MEF2C, PBX3, SOX4, 
SP9 and ZNF521) were downregulated after MLL-AF9 depletion. 
The transcription factor CEBPB was previously shown to activate the promoter of PU.1, a tumor 
suppressor for AML (Mueller, et al. 2006). Additionally, activation of CEBPB expression was 
described to lead to differentiation and reduced proliferation of CML cells and is reactivated 
after imatinib treatment of BCR/ABL CML cells (Guerzoni, et al. 2006). 
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The class II major histocompatibility complex transactivator CIITA is the master controller of 
MHC class II expression. As described in section 9.4.1.2 (on page 91) upregulation of CIITA 
seems to be responsible for activation of all differentially expressed MHC class II encoding 
genes in our data set and is believed to be related to a more differentiated state of MLL-AF9 
depleted monoblasts.  
DACH1 gene, encoding dachshund homolog 1 (Drosophila), was shown to be overexpressed in 
MLL-aberrant leukemia (Ross, et al. 2004). DACH1 binds to the IL8 promoter and repressed it 
through AP1(JUN/FOS)- and NFKB-binding sites (Wu, et al. 2008). In concordance to this, IL8 
is upregulated in a MLL-AF9 dependent manner in our study. 
Early growth response 2 (EGR2) encodes a transcription factor and tumor suppressor involved in 
restriction of cancer cell proliferation. EGR2 interacts with PU.1, a master transcription factor in 
macrophage differentiation and upregulates macrophage-specific genes like colony stimulating 
factor 1 receptor (CSF1R). (Gabet, et al. 2010) Expression of ten identical probes detecting 
CSF1R was significantly higher after MLL-AF9 knockdown in our data set although the 
individual probes were not within the employed microarray p-value cutoff of < 0.03.  
Binding motifs of FBJ murine osteosarcoma viral oncogene homolog (FOS) and homolog B 
(FOSB) were found activated and being within the 30 ‘core’ motifs explaining the expressional 
changes after PMA-differentiation in THP1 cells (Suzuki, et al. 2009). Both are components of 
the dimeric transcription factor AP-1, which can mediate gene regulation in response to 
cytokines, growth factors, stress signals, oncogenic stimuli, bacterial and viral infections. AP-1 
has effects on proliferation, differentiation and apoptosis (Hess, et al. 2004). 
HOX genes have been extensively linked to expression of MLL, AF9 as well as to 
embryogenesis and hematopoiesis as described in introductory section 6.2 on page 6. 
In the context of leukemia, homeobox A9 (HOXA9) is the best studied homeobox transcription 
factor and directly regulated by MLL-AF9 protein complex (Erfurth, et al. 2008; Cierpicki, et al. 
2010). Its mouse homolog is overexpressed in hematopoietic stem and progenitor cells after Mll-
AF9 knock-in (Chen, et al. 2008). HOXA9 knock-out in mice reduces the number of committed 
hematopoietic progenitor cells (Lawrence, et al. 1997). Overexpression of Hoxa9 alone does not 
lead to leukemic transformation of primary bone marrow cells in mice but does in conjunction 
with Meis1 overexpression (Kroon, et al. 1998). In our data set, however, MEIS1 was not 
downregulated. In conjunction with BMI1, HOXA9 is essential for the self-renewal capacity of 
leukemic stem cells transformed by MLL-AF9 (Smith, et al. 2011). 
Reduced HOXA11 transcription was previously detected after PMA-induced differentiation of 
monocytic cell lines (Martino, et al. 2009; Wang, et al. 2011). In myeloid malignancies, 
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HOXA11 translocations were described (Mizoguchi, et al. 2009). Thus far, specific processes of 
HOXA11 influencing the development of leukemia could not be elucidated.  
In our MLL-AF9 knockdown, the transcription factor homeobox C4 (HOXC4) was even stronger 
downregulated as the well known MLL targets HOXA9 and HOXA11. HOXC4 has been 
previously detected to induce expansion of hematopoietic progenitor cells after in vitro 
overexpression (Daga, et al. 2000). The murine HoxC4 was suggested to contribute to the stem 
cell character of mesenchymal stem cells (Phinney, et al. 2005).  
IKZF2 (IKAROS family zinc finger 2 (Helios)) encodes a hematopoietic specific transcription 
factor involved in the regulation of lymphocyte development. A short isoform is overexpressed 
in patients with adult T-cell leukemia / lymphoma (Tabayashi, et al. 2007). Up to now, no link to 
myeloid leukemia or myeloid cell differentiation has been reported.  
The transcription factor kruppel-like factor 4 (KLF4) is a marker for and inducer of monocytic 
and terminal macrophage differentiation (Klco, et al. 2011; Schuetz, et al. 2011). KLF4 
transcription was previously shown to be upregulated by CCL2 in induced-pluripotent mouse 
stem cells, along with the other key transcription factors of pluripotency, Nanog, Sox2 and Tbx3 
(Hasegawa, et al. 2011). In concordance to that, CCL2 was upregulated in our MLL-AF9 
depleted THP1 cells, so that the effect of MLL-AF9 on KLF4 might be indirect. 
MEF2C is a member of the MADS box transcription enhancer factor 2 (MEF2) family. MEF2C 
was shown to promote myeloid progenitor proliferation (Johnnidis, et al. 2008) and is 
upregulated in leukemic stem cells of MLL-associated leukemia (Krivtsov, et al. 2006; Schuler, 
et al. 2008). Its mouse homolog was detected to be overexpressed in hematopoietic stem and 
progenitor cells after Mll-AF9 knock-in (Chen, et al. 2008). Mef2c appears to act as a 
cooperating oncogene in leukaemogenesis that is unable to induce leukemia when expressed 
alone (Krivtsov, et al. 2006).  
One isoform of the transcription factor pre-B-cell leukemia homeobox 3 (PBX3) was previously 
found to be preferentially expressed in leukemic cells (Milech, et al. 2001). PBX proteins 
function as part of large complexes with other homeodomain-containing proteins to regulate 
gene expression during developmental and / or differentiation processes. Together with HOXA7, 
HOXA9 and HOXA11 (all downregulated in our MLL-AF9 depleted THP1 cells), PBX3 was 
previously negatively associated with the overall survival of cytogenetically abnormal AML 
patients (Li, et al. 2012).  
SOX4 gene, encoding a leukemogenic transcription factor in mouse leukemias, has been 
described to be overexpressed in human AML samples (Sun, et al. 2006b).  
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Expression of the transcription factor SP9 has not previously been linked to leukemia or cancer. 
It is involved in the formation of regeneration-epithelium and an early marker for 
dedifferentiation of keratinocytes in the axolotl (Satoh, et al. 2008). In this process, expression of 
HoxA9 and HoxA13 is also reduced – two transcripts, which are downregulated in our MLL-AF9 
knockdown, indicating similar regulation patterns between these two entirely different biological 
settings.  
In healthy cells, ZNF521 is highly expressed in the most immature hematopoietic cells and 
declines with differentiation. An enforced expression has been found to lead to proliferation and 
to a decrease in granulo-monocytic differentiation. Furthermore, high ZNF521 expression levels 
have previously been associated with MLL-rearrangements in leukemia, while ZNF521 silencing 
in THP1 cells was shown to lead to impaired growth and clonogenicity. (Bond, et al. 2008) 
 
Signaling proteins 
The chemokine (C-C motif) ligand 2 (CCL2) is produced by AML blasts and its levels 
influences the number of monocytes that migrate towards the blasts (Legdeur, et al. 2001). In 
this context, CCL2 seems to be involved in immunosurveillance (see section 9.4.1.6 on page 95). 
Interleukin 8 (IL8) gene encodes a multifunctional CXC chemokine and chemoattractant for 
neutrophils in inflammation. It influences basophils and T cell function and may act as an 
angiogenic, proliferative, autocrine and metastatic factor. IL8 serum levels were raised in 
leukemia patients and IL8 was preferential released by myeloid blasts showing monocytic 
differentiation. (Vinante, et al. 1996) Thus, upregulation of this transcript might be associated 
with differentiation of monoblasts. Raised expression of IL8 may be mediated by 
downregulation of DACH1, a repressor of IL8 transcription (Wu, et al. 2008).  
S100 calcium binding protein A12 (encoded by S100A12) has multiple proinflammatory 
activities including chemotaxis for monocytes and neutrophils (Kishimoto, et al. 2006) which 
implicates a potential role in immunosurveillance. S100A12 was described to be upregulated in 
PMA-differentiated U937 monocytes (Wang, et al. 2011).  
SOCS2 encodes an anti-apoptotic regulatory protein and was previously reported as upregulated 
in a number of myeloid leukemias (Ross, et al. 2004; Valk, et al. 2004; Zheng, et al. 2006). Such 
agreement with in vivo studies may argue for a role of SOCS2 upregulation in AML, potentially 
being achieved via suppressing the apoptotic effect of leukemia inhibitory factor LIF (Minamoto, 
et al. 1997). 
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Enzymes 
In response to DNA damage, the homeodomain interacting protein kinase 2 (encoded by HIPK2) 
phosphorylates and stabilizes the promyelocytic leukemia (PML) tumor suppressor protein. 
Phosphorylated PML cooperates with HIPK2 for the induction of cell death. (Gresko, et al. 
2009) Loss of Hipk2 increases susceptibility to radiation induced tumors in mice (Mao, et al. 
2012) and mutations of HIPK2 have been detected in AML cases (Li, et al. 2007).  
Phosphodiesterase 4D, cAMP-specific (PDE4D) encodes a cAMP degrading enzyme. 
Stimulating the cAMP signaling pathway with a phosphodiesterase 4 (PDE4) inhibitor was 
previously shown to induce apoptosis in primary B cell chronic lymphocytic leukemic (B-CLL) 
(Dong, et al. 2010).  
By gene annotation inferred from electronic annotation, rhomboid veinlet-like 1 drosophila 
homolog (encoded by RHBDL1) was suggested to posses serine-type endopeptidase activity and 
be involved in regulated intramembrane proteolysis and the subsequent release of functional 
polypeptides from their membrane anchors (UniProt Consortium 2012; National Center for 
Biotechnology Information 2012). RHBDL1 has been implicated in the positive modulation of 
epidermal growth factor receptor signaling (Pascall, et al. 1998) but so far has not been described 
as a component of leukemogenesis.  
 
Transporter 
The calcium ion transport ATPase ATP2B2 has previously been shown to be downregulated in 
PMA-differentiated U937 monocytes (Wang, et al. 2011). Raised expression of ATP2B2 in our 
MLL-AF9 positive cells might be linked to estrogen signaling because estradiol and estrogen 
were previously described to decrease ATP2B2 expression and activity (El Beialy, et al. 2010). 
Overexpression of ATP2B2 was detected to lower intracellular Ca
2+
 and protect from apoptosis 
in breast cancer cells (VanHouten, et al. 2010). Endoplasmatic reticulum (ER) stress may be a 
consequence of decreased intracellular Ca
2+
 levels which in turn may activate the unfolded 
protein response (Schardt, et al. 2011).  
 
Other proteins 
BMI1 polycomb ring finger oncogene (BMI1) encodes a polycomb group protein described to be 
essential for reprogramming of myeloid progenitors into leukemia stem cells (Yuan, et al. 2011a) 
and, together with HOXA9, for the self-renewal capacity of leukemic stem cells transformed by 
MLL-AF9 (Smith, et al. 2011). BMI1 was previously described to be downregulated in PMA-
differentiated U937 monocytes (Wang, et al. 2011). 
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Calreticulin (CALR) belongs to the group of calcium associated genes and is a multifunctional 
protein: 1) It can act as an important modulator of the regulation of gene transcription by nuclear 
hormone receptors. In this context, CALR was shown to inhibit retinoic acid-induced 
differentiation in neuronal cells (Dedhar, et al. 1994). 2) Calreticulin also acts as a major 
calcium-storage protein in the lumen of the endoplasmic reticulum (Burns, et al. 1994), with 
evidence for a role in reducing the cytotoxic effect of Ca
2+
 influx (Zhu, et al. 1999). 3) 
Calreticulin is a chaperone and well-established effector of the unfolded protein response 
(Schardt, et al. 2011) and inhibits the translation of CEBPA, which is a key myeloid transcription 
factor and a frequent target for disruption in AML (Schardt, et al. 2011; Foran 2010). 
Surprisingly, repression of CEBPA translation via CALR and the unfolded protein response has 
been recently linked to a number of other fusion proteins in AML (PML-RARA, BCR-ABL, 
AML1-MDS1-EVI1, CBFB-SMMHC) indicating the possibility of a common pathogenetic 
mechanisms in these cases (Schardt, et al. 2011). Inhibition of CALR via siRNA has been 
reported to restore the differentiation potential of leukemic cells (Schardt, et al. 2011). 
Dexi mouse homolog (DEXI) is a dexamethasone-induced transcript which was within the top-
100 probe set characterizing MLL chimeric fusion gene AML within the study of Ross et al. 
(2004). It is suspected to be a membrane protein that dimerizes either with itself or another 
protein. (Edgar, et al. 2001) Its function is so far unknown.  
Delta-like 1 (Drosophila) (DLL1) is a NOTCH ligand. NOTCH activation has been causally 
linked to leukemia and cancer and NOTCH has been directly targeted by a peptide antagonist to 
inhibit proliferation in leukemia models (Moellering, et al. 2009). DLL1 also influences the 
differentiation of human hematopoietic progenitors into the B cells and NK cells (Jaleco, et al. 
2001). DLL1 activated the NF-kappaB pathway via Notch in THP-1 cells (Itoh, et al. 2009), 
which in turn promotes cell survival (Breccia, et al. 2010). DLL1 also acts pro-proliferative via 
reduction of TNFalpha induced growth suppression and apoptosis in monoblastic leukemia U937 
cells (Murata-Ohsawa, et al. 2004).  
Glycoprotein (transmembrane) nmb (GPNMB) encodes a putative transmembrane (golgi) 
glycoprotein which has been described to be involved in growth delay and reduction of 
metastatic potential in human melanoma (Weterman, et al. 1995). GPNMB expression was 
upregulated during macrophage differentiation and acted as a negative regulator of macrophage 
inflammatory responses (Ripoll, et al. 2007). Thus upregulation of GPNMB might be associated 
with a more differentiated state of our MLL-AF9 depleted THP1 cells. 
MHC class II genes (HLA-DMB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-
DRB4) were upregulated likely via raised expression of the transcription factor CIITA and are 
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regarded as a sign of differentiation of MLL-AF9 depleted THP1 monoblasts because antigen 
presentation via MHC class II is a key feature of monocytes (see 9.4.1.2 on page 91).  
LGALS1 encodes lectin, galactoside-binding, soluble 1. This protein belongs to the galectines, a 
group of proteins which have been implicated in diverse biological processes including 
modulation of cell–cell and cell–matrix interactions (Wada, et al. 1997). LGALS1 promotes 
escape from T cell–dependent immunity and confers immune privilege to tumor cells. It is a 
highly sensitive and specific biomarker of MLL-rearrangement in B-ALL that is likely induced 
by a MLL-dependent epigenetic modification. (Juszczynski, et al. 2010) 
 
In addition to these genes, two other strongly downregulated transcripts might be equally 
important although they escaped by the use of our prioritization strategy due to the absence of 
specific functional information: the large intervening noncoding RNAs (lincRNA) 
LOC100129722 and LOC84989. They belong to a group of RNAs which are usually associated 
with chromatin signatures such as histone modification sites. For example, HOTAIR is a 
lincRNA strongly overexpressed in breast cancer metastasis with prognostic value (Gupta, et al. 
2010). HOTAIR was found to bind and redistributed genomic localization of a H3K27 methylase 
complex, leading to gene expression changes. (Gupta, et al. 2010) The lincRNAs found here 
might be the opening to a new field in respect to MLL-AF9 leukemogenesis, and might point to 
alternative opportunities for epigenetic-derived therapeutic strategies as compared to recent and 
challenging strategies to target methyltransferases via chemical inhibitors as described by 
Travers et al. (2011). 
9.4.3 Genes considered as likely therapeutic targets 
In the previous sections, we focused on genes and processes which are presumably important in 
mediating leukemogenic effects of MLL-AF9. However, some of these genes may not be suited 
well as therapeutic targets even though they may be involved in malignancy. Thus, we asked 
which genes of our top-40 set for mediation of leukemogenic effects of MLL-AF9 may be 
amenable for future therapies.  
Three target classes, namely receptors (including nuclear receptors), enzymes and transporters 
encompass 88% of all currently known 435 therapeutic effect-mediating human protein targets 
of US Food and Drug Administration (FDA) approved and experimental drugs. This indicates 
that these classes encompass proteins especially amenable to drug development. However, 
“innovation peaks” may arise when new protein types emerge as novel drug targets. This was 
e.g. the case when the first drugs targeting an integrin or a kinase were introduced in the years 
1997 and 2001. (Rask-Andersen, et al. 2011) Transcription factors (TFs) have traditionally been 
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considered as “non-druggable”. Recently, strategies to target TFs by blocking protein-protein or 
protein-DNA interactions are emerging (Berg 2008). However, they still do not belong to 
frequent drug targets of approved drugs. An exception builds the class of nuclear receptors, 
which comprises the second most frequent gene-family of drug targets (Overington, et al. 2006). 
These facts point out that receptors, enzymes and transporters within our top-40 set of genes 
suggested for mediation of leukemogenic effects of MLL-AF9 might be “druggable”. 
Eight of our top-40 genes encode proteins of these classes. Among these is one G-protein-
coupled receptor, the taste receptor TAS1R3. Furthermore are two nuclear receptors, the vitamin 
D receptor (VDR) and the aryl hydrocarbon receptor (AHR).  
Among the enzymes is the receptor tyrosine kinase ROR2, the putative endopeptidase RHBDL1, 
the kinase HIPK2 and the phosphodiesterase PDE4D. The only transporter within our top-40 set 
is the calcium ion transporting plasma membrane ATPase ATP2B2.  
 
Drugs targeting AHR, VDR and PDE4D already exist (Wishart, et al. 2008).  
VDR agonists e.g. reduce parathyroid hormone levels and are employed in secondary 
hyperparathyroidism associated with chronic kidney disease, in refractory rickets, hypocalcemia 
and in the management and prevention of osteoporosis.  
AHR is targeted by drugs used in rheumatoid arthritis, for the prevention of coronary heart 
disease, in ventricular tachycardia and in the management of metastatic carcinoma of the 
prostate. 
PDE4 inhibitors, which also target PDE4D, exhibit antidepressant, anti-inflammatory and 
neuroprotective properties. They are e.g. employed in respiratory disorders. 
To our knowledge, TAS1R3, RHBDL1 and PDE4D have not previously been linked to myeloid 
leukemia and thus represent entirely novel, potentially “druggable” targets for MLL-aberrant 
AML.  
9.5 MLL-AF9 associated changes in miRNA expression 
In the previous sections we analyzed MLL-AF9 dependent effects on gene expression and the 
potential involvement in leukemogenesis as well as the prospective druggability of identified 
targets. Other downstream effects involve miRNAs that might equally lead to the development 
of novel therapies. To date, miRNA-based cancer therapies have not yet reached clinical 
application. They are, however, considered as promising strategies since pre-clinical in vivo data 
support the suitability of re-expression of tumor suppressive miRNAs or the targeting of 
oncogenic miRNAs via antagomiRs in a number of cancer models. The small size of miRNAs 
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and their low antigenicity may present benefits as compared to protein-coding gene replacement 
therapies. (Kasinski, et al. 2011) 
We hypothesized that the fusion protein MLL-AF9 leads to differential expression of miRNAs 
thereby supporting the leukemogenic effects of MLL-AF9. The identified leukemogenic 
miRNAs could then serve as therapeutic targets for the associated leukemia subtype. Therefore, a 
differential miRNA expression profile was generated after knockdown of endogenous MLL-AF9 
in THP1 cells. 
9.5.1 Deregulated miRNAs 
We employed a quantitative (TaqMan Low Density Arrays, LDA) as well as a semiquantitative 
(Agilent microarrays) profiling technique to analyze differential expression of miRNAs after 
MLL-AF9 depletion in THP1 cells.  
With these array systems, 21 out of 664 (3.2%, LDA) and 2 out of 1048 (0.2%, Agilent 
microarray) analyzed miRNAs were detected as differentially expressed in MLL-AF9 
knockdown versus control treatments (p<0.05). In comparison, our gene expression data 
revealed 6 % of the analyzed (~ 20000) genes of the human genome (International Human 
Genome Sequencing Consortium 2004) as differentially expressed. Thus, the percentage of 
detected differentially expressed miRNAs is somewhat lower than that of genes.  
No overlapping results between the differentially expressed miRNAs from the two profiling 
platforms were present in our datasets. Low correlation between LDA and microarray results 
from the same samples has previously been reported. As the quantitative LDA was evaluated to 
display a higher sensitivity and specificity, we concentrated on these miRNA results for 
screening purposes. (Chen, et al. 2009) 
A subset of the 21 differentially expressed miRNAs from LDA results was additionally assessed 
via single-assay qRT-PCR to confirm our results. Here, the majority of these miRNAs (7 out of 
11) was confirmed to be differentially expressed.  
Little is known, about how and to what extent the administration of an siRNA can disturb 
endogenous miRNA expression levels. In our study, we observed strikingly high differences in 
the expression of single miRNAs between the two non-targeting control siRNA treatments or 
between the two siRNAs designed to knockdown MLL-AF9. These observations suggest that 
siRNAs may have off-target effects not only on mRNA expression but also on miRNAs and 
corroborates the importance of using adequate controls for off-target effects in siRNA studies.  
As example, the miRNA 196b has been previously described to be upregulated by MLL-AF9 
(Popovic, et al. 2009; Cierpicki, et al. 2010). In this study however, we observed a clear 
discrepancy of miR-196b levels when we compared the two non-targeting control siRNA 
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treatments. Thus miR-196b did not fulfill our criteria for technical validation and was excluded 
from our results.  
The high stringency of our experimental design might thus explain the relatively low number of 
differentially expressed miRNAs we detected.  
Seven out of eleven miRNAs (miR-214, miR-219-5p, miR-432, miR-511, miR-539, miR-589 
and miR-758) were confirmed by single assay qRT-PCR to be differentially expressed in MLL-
AF9 depleted THP1 cells. 
Some of the differentially expressed miRNAs have a genomic location within introns of protein-
coding or non-coding genes. These host-genes, however, were not detected as differentially 
expressed in our data set. This is not surprising, as miRNAs are not necessarily coregulated with 
their host genes because miRNA processing is a specifically regulated process.  
 
Recently, in a number of in vivo studies, miRNAs have been found to be differentially expressed 
among distinct cytogenetic groups of AML. However, the specific signatures differed among 
studies, most likely due to the lack of standardized methods used by different groups. (Marcucci, 
et al. 2011)  
Nevertheless, some concordance was detected between our in vitro data set and previously 
published in vivo data. This concerned four of our confirmed differentially expressed miRNAs, 
namely miR-214, miR-219-5p, miR-432 and miR-511 which were reported in various myeloid 
leukemia subtypes (table 10, page 78). These concordant in vivo observations are mostly not 
specifically derived from AML with MLL-aberrations or with MLL-AF9 translocation, so that 
they may only weakly support the hypothesis that these miRNAs play a role in MLL-AF9 
positive leukemia. 
 
So far, no link for either miR-432, miR-539, miR-589 or miR-758 to leukemia has been 
described. 
MiR-432 is derived from chromosome 14 and lies within exon 1 of retrotransposon-like 1 
(RTL1) gene. RTL1 showed low expression in microarray data and was not coregulated. This 
gene contains more miRNAs (miR-136, miR-127, miR-433 and miR-431) but these were also 
not detected as differentially expressed in MLL-AF9 knockdown. So far, no direct targets of 
miR-432 have been validated.  
Mir-539 is located within intron 1 of the lincRNA RP11 on human chromosome 14. It has been 
suggested that its reduced expression might increase proliferation of mast cells in mastocytosis, a 
disease which is characterized by abnormal accumulation of mast cells (Lee, et al. 2011). Mir-
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539 was downregulated in gastric extranodal marginal zone lymphomas compared to gastritis 
(Thorns, et al. 2012). However, in our data set, miR-539 expression is reduced after MLL-AF9 
knockdown.  
MiR-589 lies within an intron of human gene F-box and leucine-rich repeat protein 18 (FBXL18) 
on chromosome 7. No biological role or direct target for human miR-589 has been described up 
to date.  
MiR-758 is located intergenic on human chromosome 14. ATP-binding cassette transporter A1 
(ABCA1), a major regulator of macrophage cholesterol efflux, is a described target of miR-758 
(Ramirez, et al. 2011). However, ABCA1 was not detected as deregulated after MLL-AF9 
knockdown in THP1 cells.  
 
Two intergenic copies of miR-219-5p exist in the human genome: one on chromosome 6 and one 
on chromosome 9. MiR-219-5p was upregulated in a childhood myeloid leukemia cell line upon 
stimulation with either IL3, GM-CSF or G-CSF, supporting a role during leukemic and normal 
hematopoiesis (Favreau, et al. 2012). 
MiR-214 is derived from chromosome 1 and lies in an intron of dynamin 3 gene (DNM3), which 
showed low expression and was not regulated in microarray data of MLL-AF9 knockdown. MiR-
214 has been described to have pro-metastatic functions in melanoma (Bar-Eli 2011) but on the 
other hand inhibits the proliferation capacity, migration and invasion ability in cervical tumor 
(Qiang, et al. 2011). Thus no clear role as onco-miR or tumor-suppressor-miR can be assigned. 
MiR-214 has been described to target PTEN in monocytes and THP1 cells thus leading to 
delayed apoptosis (Li, et al. 2011). MiR-214 has also been described to be part of a negative 
feedback loop by targeting the EZH2 encoding a polycomb-group protein and thus promoting 
skeletal muscle cell differentiation (Juan, et al. 2009). EZH2 has been shown to be responsible 
for long-term repopulating potential of hematopoietic stem cells (Kamminga, et al. 2006) 
suggesting a potential role for miR-214 in leukemogenesis. However EZH2 was not detected as 
differentially expressed after MLL-AF9 knockdown in our study.  
MiR-511 is located on chromosome 10 within intron 5 of the gene coding for macrophage 
mannose receptor 1 (MRC1). In our gene expression microarray analysis, MRC1 gene transcript 
showed low expression and was not found coregulated with miR-511. 
Both, miR-214 and miR-511, were reported to be significantly lower expressed in adrenocortical 
and hepatocellular carcinomas (Tombol, et al. 2009; Wang, et al. 2012). Estep et al. (2010) found 
miR-511 significantly lower expressed in the visceral adipose tissue of non-alcoholic 
steatohepatitis (NASH) patients, a condition in which inflammation plays an important role. 
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MiR-511 has also been described to be a novel potent modulator of human immune response 
being upregulated during dendritic cell and macrophage differentiation. Additionally, the first 
known direct targets of miR-511, TLR4 and CD80 were described. (Tserel, et al. 2011)  
However, no differential expression of TRL4 and CD80 was observed after MLL-AF9 
knockdown, suggesting that other targets might be more prominently regulated in our setting. 
9.5.2 MiR-511 in monocytic differentiation and potential target genes 
The strongest regulated of our confirmed differentially expressed miRNAs after MLL-AF9 
knockdown, miR-511, was selected for further investigation. 
The target prediction algorithms we used identified a wide range of predicted targets for miR-
511. Among those, we experimentally assessed nine via expression analysis after miR-511 
upregulation in THP1. Though we observed a trend towards the expected downregulation in 
eight of these transcripts, none of these alterations reached statistical significance.  
Because most direct miRNA targets are reduced on mRNA level (Baek, et al. 2008), it might be 
more straight forward, to analyze a gene expression profile after miR-511 upregulation in THP1 
and subsequently search for its direct targets within this set of differentially expressed mRNAs.  
Except for miR-511 and miR-137 which seem to be involved in macrophage differentiation 
(Tserel, et al. 2011), we did not observe overlapping results between our differentially expressed 
miRNA data set and published information on miRNAs in monocytic differentiation.  
We were, however, able to detect a significant upregulation of miR-511 in THP1 cells stimulated 
to differentiate into monocytes / macrophages by the addition of PMA. This finding further 
supports the hypothesis that miR-511 is involved in the differentiation processes of monoblasts.  
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10 Conclusions 
This study aimed to identify new potential therapeutic targets for acute myeloid leukemia (AML) 
with the MLL-AF9 translocation, a subtype with still poor clinical prognosis. Specifically the 
identification of leukemogenic downstream effects of the MLL-AF9 aberration both on the 
cellular phenotype as well as on gene and miRNA expression pattern should generate 
information on candidate targets. 
For this purpose we optimized an experimental approach that utilized a cell line carrying this 
specific translocation (THP1) in conjunction with RNA interference capable to downregulate  
MLL-AF9 protein and function. The technical achievements included: 
» The successful design of efficient siRNAs that specifically target the breakpoint of MLL-
AF9 while not disturbing wildtype MLL or AF9 expression or producing off-target effects. 
» Confirmation of MLL-AF9 knockdown efficiency at transcript level (down to 20%) as well 
as at functional protein level by analyzing HOXA9 transcript as a surrogate marker, because 
MLL-AF9 protein showed very low solubility and appeared to be prone to aggregate. 
» Elaboration of experimental conditions that ensured a prolonged knockdown of MLL-AF9 in 
cell culture and minimized the masking of MLL-AF9-specific effects by the strong 
mitogenic influence of fetal bovine serum. 
MLL-AF9 knockdown changed the phenotype of THP1 cells characterized by a highly 
significant reduction of cell diameter of about 0.3 µm. This effect was highly reproducible and 
persisted over time in culture. Indirect evidence pointed to reduced ribosomal biogenesis and / or 
to AF9 protein co-aggregation with MLL-AF9 as potential causative mechanisms. No effects of 
the knockdown on cell proliferation rate, cell cycle or on apoptosis was observed. 
After MLL-AF9 knockdown differential gene and miRNA array expression data were evaluated 
in the biological context; specifically to sort out candidate genes and functions with a high 
likelihood to be involved in the mediation of MLL-AF9 leukemogenic effects. 
1269 genes were detected to be differentially expressed. The data set was technically validated, 
complied to standard quality criteria and submitted to and accepted by Gene Expression 
Omnibus (GEO) database under the accession number GSE36592.  
Functional gene ontology analysis (GO) revealed several key biological functions and annotation 
terms as significantly enriched: In particular, functional terms related to differentiation of 
monoblasts were highly overrepresented. Others include transcripts involved in apoptosis, in 
calcium and estrogen signaling, in immunosurveillance and in the functional processes of protein 
folding. Taken together, the analysis provided evidence that depletion of MLL-AF9 leads to a 
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partial release of the differentiation block in THP1 cells. Other effects might include those on 
regulation of apoptosis though we observed no induction of apoptosis at phenotypic level, 
presumably due to missing apoptotic stimuli within our experimental setting. The influence of 
MLL-AF9 on estrogen signaling is consistent with a known role for estrogen signals in leukemia 
development and may point to potential efficiency of anti-estrogen treatments in AML. As the 
evasion of immunosurveillance is a critical feature in sustaining cancer cells, some of the MLL-
AF9 regulated genes identified within this functional category might equally be worthwhile 
targets to be addressed. The influence of MLL-AF9 knockdown on several functional processes 
of protein folding suggested mechanistic links between the heat-shock / unfolded protein 
response and myeloid leukemogenesis. This might be caused by low solubility of MLL-AF9 
protein which appears to be prone to aggregate.  
The functional disease ontology database (FunDO) contains curated preexisting evidence on 
genes associated with disease entities and was queried with our data set of 1269 differentially 
expressed genes. The term leukemia turned out both as highly significant and highly enriched 
being top ranked among all associations covered. Besides the identification of leukemia 
associated candidate targets, this analysis also validated our experimental approach in that an 
expected information content related to leukemia was indeed disclosed in our data.   
Subsequently, 40 genes were prioritized by a multistep selection approach as likely candidate 
targets for mediation of MLL-AF9 leukemogenic effects. Eight of these were rated as likely 
“druggable” and included e.g. the G-protein-coupled receptor TAS1R3, the putative 
endopeptidase RHBDL1 and the phosphodiesterase PDE4D. These three gene products have not 
previously been linked to myeloid leukemia.  
After MLL-AF9 knockdown, miRNA profiles revealed 23 miRNAs as significantly differentially 
expressed. Seven out of eleven prioritized and selected miRNA candidates were confirmed by 
qRT-PCR, the strongest deregulated miRNA being hsa-miR-511. In THP1 cells differentiated 
via phorbol 12-myristate 13-acetate (PMA) treatment, miR-511 was significantly upregulated 
suggesting a potential role of this miRNA in differentiation.  
This study yielded the first comprehensive data set for differential miRNA and gene expression 
after an efficient and prolonged MLL-AF9 knockdown in THP1 cells. It further identified key 
biological processes as well as new gene and miRNA candidates highly likely to be involved in 
mediation of MLL-AF9 leukemogenic effects. Eight of the involved gene products and miR-511 
were evaluated as potentially “druggable”. Subsequent studies of these candidate targets shall 
assess their suitability for therapeutic intervention in MLL-AF9 positive acute myeloid leukemia. 
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12 Abbreviations 
Abbreviation Full name 
adj. p-value adjusted p-value (adjusted for multiple testing) 
AF9 ALL1-fused gene from chromosome 9. Alias: myeloid/lymphoid or mixed-
lineage leukemia (trithorax homolog, Drosophila); translocated to, 3 
(MLLT3) 
ALL acute lymphoblastic leukemia 
AML acute myeloid leukemia 
B-ALL acute B lymphoblastic leukemia 
BP blastic (acute) phase (of CML) 
CLL chronic lymphoblastic leukemia 
CML chronic myeloid leukemia 
CP chronic phase (of CML) 
CT threshold cycle (represents expression strength of qRT-PCR data) 
DAPI 4,6-diamidino-2-phenylindole 
DotCom Dot1 complex 
FAB type leukemia subtypes according to French-American-British classification 
system 
FCM flow cytometry 
FI fluorescent signal intensity 
G-CSF granulocyte colony-stimulating factor 
GM-CSF granulocyte-macrophage colony-stimulating factor 
GMP granulocyte macrophage progenitors 
GOA gene ontology annotation 
HLA human leukocyte antigen  
HSC hematopoietic stem cell 
in vitro here: studies in cells (cell culture) 
in vivo here: studies in whole organisms 
in silico computational 
kb kilo base 
LDA TaqMan low density array (a high throughput qRT-PCR technique, which 
was employed here to screen miRNA expression) 
lincRNA large intervening non-coding RNA  
LNGFR low-affinity nerve growth factor receptor (NGFR), a truncated version is 
employed as a surface selection marker 
log2FC logarithmic (to the base 2) fold change 
LSC leukemia stem cells 
MHC major histocompatibility complex  
miR microRNA (employed when a certain miRNA is described (e.g. miR-511) 
miRNA microRNA 
MLL mixed-lineage leukemia gene 
n.a. not available 
ncRNA non-coding RNA 
nt nucleotide 
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n-tg non-targeting (control siRNAs, which are designed not to target any mRNA) 
nts nucleotides 
OMIM Online Mendelian Inheritance in Man® (An Online Catalog of Human 
Genes and Genetic Disorders) 
PMA phorbol 12-myristate 13-acetate 
ROI region of interest (regions selected for image analysis by Cellscreen 
microscopy) 
“pool 1” Pooled RNA samples of five independent MLL-AF9 knockdown 
experiments performed in THP1 cells which were employed for array 
profiling methods (gene and miRNA expression). 
“pool 2” Pooled RNA samples of further two independent MLL-AF9 knockdown 
experiments performed in THP1 cells which were employed for data 
validation. 
rRNA ribosomal RNA 
RT room temperature 
SAM significance analysis of microarray 
SEC super elongation complex 
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13 Supplementary data 
Supplementary table 1: Primer sequences used for qRT-PCR 
Gene name Primer 
type 
Sequence 5'-3' Design 
AF9 forward CAACGTTACCGCCATTTG own 
AF9 reverse GTCTGGGATGGTGTGAAG own 
AFF1 forward CGTAGGGTCCCAGTCAAGTG own 
AFF1 reverse ACTGCTGTTGAGGGCCAAGG own 
AFF4 forward GACCAAGCTGAACAGCTTTCC own 
AFF4 reverse AAGGGCCAACTGACATGATCG own 
ARHGAP26 forward CGAACTGGCCAAGGATTTCG own 
ARHGAP26 reverse GACGTTTCTCCTGCACGTAG own 
BAX forward ATGGACGGGTCCGGGGAGCAGCCC  (Aggarwal, et al. 1998) 
BAX reverse GGTGAGCACTCCCGCCACAAAGAT  (Aggarwal, et al. 1998) 
BCL-2 forward CGACGACTTCTCCCGCCGCTACCGC  (Aggarwal, et al. 1998) 
BCL-2 reverse CCGCATGCTGGGGCCGTACAGTTCC  (Aggarwal, et al. 1998) 
CALR forward GCCGAGCCTGCCGTCTACTTCA own 
CALR reverse AGGCTCGAAACTGGCCGACAG own 
CEBPB forward CAAACCAACCGCACATGCAG own 
CEBPB reverse AACAGCAACAAGCCCGTAGG own 
CIITA forward GTGGGAGCCGAGAGCTTGGC own 
CIITA reverse ATGGTGGGCGTCCACATCGC own 
DACH1 forward GACGAAACGGCGTGAACAAG own 
DACH1 reverse CACTGCGGTCAGCCTCTATC own 
EGR2 forward ACATCTACCCGGTGGAGGAC own 
EGR2 reverse CAGAGGTGACGCTGGATGAG own 
EMP1 forward CCAACATTAGCTGCAGTGAC own 
EMP1 reverse AAGAGCTGGAACACGAAGAC own 
FGFR1 forward TGGCCTTGACCTCCAACCAG own 
FGFR1 reverse TGAGTCCGCCATTGGCAAGC own 
FGFR3 forward ACCTGGACCGTGTCCTTACC own 
FGFR3 reverse CTGCACCTGGAGGCAAGATG own 
FOS forward CGTACTCCAACCGCATCTGCA own 
FOS reverse CTCCGGTTGCGGCATTTGGC own 
FUCA1 forward GCTACGCCGACTTCGGACCG own 
FUCA1 reverse CCCGATGAGGCCCCACGTCT own 
HOXA10 forward GCAAAGCCTCGCCGGAGAAGG own 
HOXA10 reverse CTGTCCGTGAGGTGGACGCTG own 
HOXA9 forward CACCAGACGAACAGTGAGGA  (Faber, et al. 2009) 
HOXA9 reverse TGGTCAGTAGGCCTTGAGGT  (Faber, et al. 2009) 
IGF2BP2 forward CTCGTGACCAAACGCCAGATG own 
IGF2BP2 reverse GCGACTCCCTGAGGGTATTTC own 
IL8 forward ACCACACTGCGCCAACACAG own 
IL8 reverse TCTCTTGGCCCTTGGCCTCAA own 
KCTD12 forward CCGACATCGTGGAGCTGAAC own 
KCTD12 reverse CGTCCCGGTCCAGAAAGAAG own 
KIF26A forward GCAGACACGGTCCGAGAATG own 
KIF26A reverse TGCTGCCAGGGTTGTCCTTG own 
MAFB forward GAAGCACCACCTGGAGAATG own 
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Gene name Primer 
type 
Sequence 5'-3' Design 
MAFB reverse GCGAGTTTCTCGCACTTGAC own 
MAPRE2 forward ACCTCGTGCAGAGACTAATGG own 
MAPRE2 reverse TGATGGTAACGGCAGATTGGG own 
MDM2 forward GAATCTACAGGGACGCCATCG own 
MDM2 reverse CCCTGCCTGATACACAGTAAC own 
MDM2-001 forward GCTGGGAACCTCTTGATTGTG own 
MDM2-001 reverse GTGGTGACAGGGTGCTCTAAC own 
MEF2C forward ATAACTCCCAGTCGGCTCAG own 
MEF2C reverse GCGGTGTTAAACCCAGACAG own 
MLL1 forward GTCCAGAGCAGAGCAAAC own 
MLL1 reverse CAAAGTGCCTGCATTCTCC own 
MLL-AF9 forward GCTCCCCGCCCAAGTATC own 
MLL-AF9 reverse GGGATGGTGTGAAGCTGGAG own 
NOTCH2 forward ATATGCTCAGCCGGGATACC own 
NOTCH2 reverse TGGCAGTGTCCTGGAATGTC own 
RPL13A forward CCTGGAGGAGAAGAGGAAAGAGA  (Vandesompele, et al. 2002) 
RPL13A reverse TTGAGGACCTCTGTGTATTTGTCAA  (Vandesompele, et al. 2002) 
SOCS2 forward GCTCGGTCAGACAGGATGG  (Zheng, et al. 2006) 
SOCS2 reverse TCGATTCGAAGATTAGTTGGTCC  (Zheng, et al. 2006) 
SULF2 forward GTACAAGGCCAGCTATGTCC own 
SULF2 reverse GGACTGTGTCGTTCTCTAGG own 
TGFBR1 forward AAGCCAGCCATTGCTCATAG own 
TGFBR1 reverse GATGTCAGCACGTTTGAAGG own 
TSAPAN14 forward GGCTGGAGTTGTCTTCCTTG own 
TSAPAN14 reverse CAGCACCACAGGGTCGATTC own 
UBC forward ATTTGGGTCGCGGTTCTTG  (Vandesompele, et al. 2002) 
UBC reverse TGCCTTGACATTCTCGATGGT  (Vandesompele, et al. 2002) 
VASH1 forward ATGACTTCCGCAAGGAGCTG own 
VASH1 reverse TTTCACTGCGGCTGTTCCTG own 
VDR forward GCCGCATCACCAAGGACAAC own 
VDR reverse ATCTCCCGCTTCCTCTGCAC own 
ZNF521 forward GGTGAAACTTGATATCAATGGCC  (La Rocca, et al. 2009) 
ZNF521 reverse GGAGTTTGGCAGGAGAGTCA  (La Rocca, et al. 2009) 
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Supplementary table 2: All 1345 probes, which were differentially expressed after MLL-
AF9 knockdown in THP1 cells. Besides expression changes between MLL-AF9 knockdown 
and control samples in THP1 cells from microarray data, supplementary table 2 includes the 
information if gene expression was validated by qRT-PCR (validated if qRT-PCR data 
showed log2FC>±0.3 in corresponding direction) and if all or only some of the probes against 
the transcripts of a gene were differentially expressed (all or only single transcription variants 
may be affected). adj. p-value, p-value corrected for multiple testing as described in material 
and methods section 7.3.1. Ave Expr, average expression strength (due to signal intensity). 
Column “1)”: * all probes against the transcripts of this gene were differentially expressed, # 
not all probes against the transcripts of this gene were differentially expressed. 
Probe name 
Systematic 
name 
Gene name p-value 
adj.  
p-value 
Ave Expr log2FC 1) 
confirmed 
via         
qRT-PCR 
A_23_P140876 NM_001089 ABCA3 0.02 0.45 8.15 3.12E-01   
A_23_P100539 NM_001171 ABCC6 0.00 0.26 8.87 -4.02E-01   
A_33_P3399598 AK125109 ABCD4 0.01 0.38 5.57 4.59E-01 #  
A_33_P3283713 NM_015407 ABHD14A 0.01 0.32 13.05 -3.77E-01 *  
A_23_P202520 NM_001003408 ABLIM1 0.00 0.18 6.2 4.61E-01 #  
A_23_P356616 NM_145804 ABTB2 0.01 0.38 9.64 -3.68E-01   
A_23_P89799 NM_006111 ACAA2 0.00 0.17 10.86 6.10E-01   
A_32_P215318 NM_198839 ACACA 0.00 0.22 8.21 -4.36E-01 #  
A_23_P10182 NM_003500 ACOX2 0.00 0.23 6.66 4.27E-01   
A_33_P3395008 NM_001142807 ACOXL 0.00 0.17 7.81 -4.97E-01   
A_23_P54488 NM_015162 ACSBG1 0.01 0.30 7.73 4.28E-01 #  
A_33_P3217983 NM_203380 ACSL5 0.02 0.47 11.65 -3.01E-01   
A_23_P66328 NM_182617 ACSM2B 0.02 0.45 5.73 -3.13E-01   
A_23_P148829 NM_080431 ACTRT2 0.00 0.24 5.94 4.85E-01   
A_23_P360754 NM_005099 ADAMTS4 0.02 0.41 6.34 -4.08E-01 #  
A_23_P49816 NM_018404 ADAP2 0.01 0.31 9.23 4.44E-01   
A_33_P3337161 NM_139247 ADCY4 0.01 0.41 6.83 3.60E-01 #  
A_24_P100742 NM_014189 ADD1 0.02 0.48 7.47 -3.45E-01   
A_23_P55477 NM_000676 ADORA2B 0.01 0.40 10.14 3.74E-01   
A_23_P137931 NM_000677 ADORA3 0.01 0.39 6.89 4.70E-01 #  
A_24_P221092 AF289615 AF289615 0.00 0.10 8.26 5.31E-01   
A_24_P286079 NM_014423 AFF4 0.02 0.46 9.51 -3.58E-01 #  
A_23_P7099 NM_000027 AGA 0.01 0.32 10.53 -3.80E-01   
A_23_P103720 NM_024758 AGMAT 0.02 0.46 9.25 -3.80E-01   
A_23_P69810 NM_032717 AGPAT9 0.00 0.06 8.21 6.34E-01   
A_33_P3279470 NM_001138 AGRP 0.01 0.36 6.2 3.77E-01   
A_33_P3316800 NM_001621 AHR 0.00 0.23 8.21 4.44E-01 *  
A_23_P215566 NM_001621 AHR 0.01 0.32 9.1 3.81E-01 *  
A_33_P3367077 AI669688 AI669688 0.00 0.17 6.75 4.67E-01   
A_33_P3258712 AK056005 AK056005 0.00 0.18 8.64 -4.58E-01   
A_33_P3326812 AK056267 AK056267 0.02 0.46 8.84 -3.19E-01   
A_33_P3244991 AK091251 AK091251 0.01 0.30 7.66 3.97E-01   
A_32_P30831 AK125393 AK125393 0.01 0.41 7.19 -3.56E-01   
A_33_P3422471 AK126796 AK126796 0.01 0.34 5.42 -3.88E-01   
A_33_P3307980 AK131345 AK131345 0.02 0.41 9.06 -3.34E-01   
A_23_P303978 AK311383 AK311383 0.01 0.32 5.6 -4.22E-01   
A_32_P49668 AK311627 AK311627 0.00 0.22 6.41 5.80E-01 *  
A_24_P349207 AK311627 AK311627 0.01 0.40 7.78 3.91E-01 *  
A_33_P3238433 NM_001135168 ALDH3A1 0.02 0.48 6.75 -3.13E-01 #  
A_23_P104464 NM_000698 ALOX5 0.00 0.07 8.03 7.55E-01   
A_23_P85941 NM_006492 ALX3 0.00 0.25 5.8 4.94E-01   
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Probe name 
Systematic 
name 
Gene name p-value 
adj.  
p-value 
Ave Expr log2FC 1) 
confirmed 
via         
qRT-PCR 
A_33_P3262138 NM_022662 ANAPC1 0.02 0.44 9.05 -3.21E-01 #  
A_23_P27147 NM_001002244 ANAPC11 0.00 0.12 16.22 -6.98E-01   
A_33_P3291279 NM_001029870 ANKRD56 0.00 0.24 5.54 4.32E-01   
A_23_P94501 NM_000700 ANXA1 0.01 0.39 11.49 4.30E-01   
A_32_P148345 NM_001002857 ANXA2 0.00 0.13 8.18 -5.38E-01 #  
A_23_P16976 NM_001153 ANXA4 0.01 0.40 13.03 -3.31E-01   
A_23_P145718 NM_001637 AOAH 0.02 0.43 9.1 3.96E-01   
A_33_P3258782 NM_003916 AP1S2 0.01 0.35 10.56 3.80E-01 #  
A_23_P217384 NM_003916 AP1S2 0.01 0.38 11.3 4.39E-01 #  
A_24_P287691 NM_005829 AP3S2 0.02 0.43 10.23 -3.21E-01   
A_33_P3295655 NM_001163 APBA1 0.00 0.17 5.9 4.68E-01 *  
A_23_P101905 NM_005883 APC2 0.00 0.24 7.45 -5.64E-01   
A_23_P54770 NM_018690 APOB48R 0.01 0.39 11.22 3.44E-01   
A_33_P3360097 NM_000485 APRT 0.02 0.43 14.21 -6.90E-01   
A_23_P372834 NM_198098 AQP1 0.00 0.19 6.16 -5.21E-01 #  
A_23_P112482 NM_004925 AQP3 0.00 0.27 8.29 -5.25E-01   
A_33_P3217786 NR_002817 AQP7P1 0.01 0.40 5.73 -3.45E-01 *  
A_23_P113111 NM_000044 AR 0.00 0.09 10.42 -5.41E-01   
A_33_P3228305 NM_015071 ARHGAP26 0.00 0.18 10.43 5.02E-01  yes 
A_33_P3323722 NM_005737 ARL4C 0.00 0.13 8.23 4.94E-01   
A_24_P943997 NM_178815 ARL5B 0.02 0.46 7.5 -3.02E-01   
A_24_P167473 NM_005719 ARPC3 0.01 0.30 16.01 -3.94E-01   
A_33_P3775007 NM_018482 ASAP1 0.01 0.41 8.59 3.33E-01   
A_33_P3414883 AK302556 ATMIN 0.01 0.36 6.2 -5.15E-01 #  
A_23_P148879 NM_000702 ATP1A2 0.00 0.15 7.65 -6.14E-01 *  
A_33_P3359771 NM_000702 ATP1A2 0.00 0.24 5.52 -4.23E-01 *  
A_33_P3393851 U15688 ATP2B2 0.00 0.08 5.72 -6.92E-01 #  
A_23_P87616 NM_001002031 ATP5G2 0.00 0.04 16.04 -6.69E-01   
A_23_P11353 NM_005765 ATP6AP2 0.02 0.45 12.61 -3.42E-01   
A_24_P276932 NM_001039362 ATP6V1C2 0.02 0.42 7.86 -3.29E-01   
A_24_P391368 NM_013236 ATXN10 0.00 0.12 11.78 -5.48E-01 *  
A_33_P3231367 NM_013236 ATXN10 0.01 0.35 10.36 -3.72E-01 *  
A_33_P3679768 AW303581 AW303581 0.02 0.48 10.09 -3.05E-01   
A_33_P3422701 AX746590 AX746590 0.02 0.44 6.16 3.49E-01   
A_33_P3346806 AX747590 AX747590 0.01 0.38 5.51 -3.68E-01 #  
A_33_P3244784 AX747898 AX747898 0.02 0.45 9.53 -3.10E-01   
A_33_P3708763 AX748036 AX748036 0.02 0.44 5.37 -3.15E-01   
A_23_P37441 NM_004048 B2M 0.00 0.15 17.63 -4.72E-01   
A_24_P913716 NM_145236 B3GNT7 0.01 0.39 10.34 3.53E-01 #  
A_23_P101380 NM_198540 B3GNT8 0.02 0.45 9.38 3.17E-01   
A_23_P152678 NM_015681 B9D1 0.01 0.35 7.65 -3.73E-01 #  
A_23_P49539 NM_001080519 BAHCC1 0.02 0.46 11.02 -3.20E-01   
A_33_P3262575 NM_018842 BAIAP2L1 0.01 0.35 5.6 -4.13E-01 #  
A_24_P182122 BC061915 BC061915 0.01 0.39 14.02 -3.36E-01   
A_33_P3328990 BC067767 BC067767 0.00 0.18 5.77 -5.67E-01   
A_23_P34930 NM_005872 BCAS2 0.02 0.43 12.39 -3.32E-01   
A_24_P935986 NM_005504 BCAT1 0.01 0.32 10.94 -3.97E-01 #  
A_24_P411186 NM_022893 BCL11A 0.01 0.37 8.29 3.64E-01 *  
A_33_P3249595 NM_138559 BCL11A 0.01 0.40 6.55 3.49E-01 *  
A_23_P57856 NM_001130845 BCL6 0.01 0.35 9.26 4.60E-01   
A_23_P109171 NM_001195 BFSP1 0.00 0.22 8.31 -5.01E-01   
A_33_P3269976 BG675116 BG675116 0.02 0.44 5.8 -5.28E-01   
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Probe name 
Systematic 
name 
Gene name p-value 
adj.  
p-value 
Ave Expr log2FC 1) 
confirmed 
via         
qRT-PCR 
A_32_P75581 NM_152414 BHLHE22 0.00 0.10 13.31 -6.19E-01   
A_24_P303989 NM_005180 BMI1 0.02 0.45 9.88 -3.28E-01 #  
A_33_P3219651 NM_133468 BMPER 0.01 0.30 6.11 -4.02E-01 #  
A_33_P3368301 NM_212552 BOLA3 0.01 0.31 10.6 -5.77E-01 #  
A_23_P42935 NM_004333 BRAF 0.02 0.47 8.49 -3.02E-01   
A_23_P99452 NM_000059 BRCA2 0.02 0.44 8.6 -5.64E-01   
A_24_P183264 NM_001037637 BTF3 0.02 0.45 14.04 -3.19E-01   
A_23_P105900 NR_026983 BTF3L1 0.00 0.26 14.25 -4.26E-01   
A_33_P3228427 BX103560 BX103560 0.00 0.04 5.56 6.66E-01   
A_32_P221748 BX350880 BX350880 0.02 0.45 8.4 -3.58E-01   
A_32_P86739 NM_001010911 C10orf114 0.00 0.08 9.15 -7.76E-01   
A_24_P372553 NM_015608 C10orf137 0.00 0.22 8.39 -4.54E-01 *  
A_32_P152767 NM_207371 C10orf140 0.00 0.02 8.17 -9.26E-01 #  
A_33_P3280784 NM_025125 C10orf57 0.01 0.33 7.31 -3.81E-01   
A_33_P3291454 NM_198515 C10orf96 0.02 0.46 7.88 -5.34E-01   
A_23_P202773 NM_001039496 C11orf20 0.02 0.48 6.7 -3.68E-01   
A_33_P3306898 NM_012194 C11orf41 0.02 0.42 5.79 3.41E-01 #  
A_24_P252846 NM_138787 C11orf74 0.02 0.42 9 -3.67E-01   
A_23_P345928 NM_032230 C12orf26 0.01 0.31 9.4 -4.63E-01   
A_23_P128375 NM_032829 C12orf34 0.02 0.45 9.02 -3.37E-01   
A_23_P151179 NM_022895 C12orf43 0.02 0.45 8.35 -3.43E-01   
A_23_P53763 NM_025113 C13orf18 0.00 0.13 11.48 -5.03E-01   
A_23_P15285 NM_024109 C16orf68 0.01 0.28 10.61 -4.10E-01   
A_24_P364954 NM_024648 C17orf101 0.02 0.46 10.17 -3.13E-01   
A_23_P392126 NM_001076680 C17orf108 0.02 0.41 7.29 -3.45E-01   
A_23_P164100 NM_181707 C17orf64 0.01 0.38 6.54 -3.45E-01   
A_33_P3379268 NM_207103 C17orf87 0.02 0.46 5.63 3.44E-01   
A_33_P3411945 NM_001136482 C19orf38 0.00 0.25 7.03 4.65E-01   
A_23_P153360 NM_024104 C19orf42 0.01 0.33 11.91 -3.74E-01 #  
A_23_P330561 NM_174918 C19orf59 0.01 0.40 12.65 3.57E-01   
A_23_P74668 NM_152290 C1orf158 0.00 0.21 8.31 -7.77E-01   
A_24_P190877 NM_030934 C1orf25 0.00 0.12 7.32 -5.70E-01   
A_23_P1014 NR_026761 C1orf97 0.00 0.17 9.54 -5.32E-01   
A_33_P3400843 NM_001008223 C1QL4 0.01 0.30 6.28 3.95E-01   
A_33_P3404601 NM_000063 C2 0.00 0.25 6.83 6.17E-01 #  
A_23_P68486 NM_080821 C20orf108 0.02 0.47 10.1 3.35E-01   
A_23_P372096 AK097804 C20orf112 0.00 0.23 8.69 4.92E-01 *  
A_33_P3271284 NM_080616 C20orf112 0.00 0.26 5.87 3.99E-01 *  
A_33_P3364989 NM_001024675 C20orf134 0.01 0.38 6.93 3.91E-01   
A_23_P17490 NM_001009924 C20orf30 0.01 0.40 12.04 -3.59E-01 #  
A_23_P166431 NM_015372 C22orf24 0.01 0.33 5.93 -6.13E-01   
A_33_P3250887 NM_001123225 C22orf41 0.02 0.44 6.3 -6.52E-01 #  
A_24_P28811 NR_023391 C2orf14 0.01 0.35 9.02 -6.12E-01 #  
A_23_P28652 NM_016085 C2orf28 0.00 0.19 10.89 -4.61E-01   
A_23_P108761 NM_017546 C2orf29 0.01 0.39 10.61 -3.40E-01   
A_23_P39542 NM_001017927 C2orf76 0.00 0.20 9.88 -4.55E-01   
A_33_P3242174 NM_206895 C2orf82 0.01 0.39 7.68 -3.55E-01   
A_33_P3237507 NM_207405 C4orf50 0.02 0.46 5.68 3.29E-01   
A_24_P110558 NM_001007189 C5orf53 0.01 0.34 8.79 3.80E-01   
A_24_P388940 NM_001042493 C6orf162 0.01 0.40 8.53 -3.38E-01   
A_33_P3372674 NR_026784 C6orf164 0.01 0.31 5.69 -4.05E-01 *  
A_23_P122532 NM_021184 C6orf47 0.01 0.35 9.82 4.03E-01   
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Probe name 
Systematic 
name 
Gene name p-value 
adj.  
p-value 
Ave Expr log2FC 1) 
confirmed 
via         
qRT-PCR 
A_33_P3247644 NM_152793 C7orf41 0.01 0.31 7.6 3.94E-01 #  
A_33_P3431595 NM_173687 C8orf31 0.02 0.46 8.18 -3.59E-01   
A_23_P422115 NM_001048265 C9orf116 0.01 0.36 7.79 -3.70E-01 *  
A_33_P3217649 NM_001048265 C9orf116 0.02 0.48 6.38 -2.95E-01 *  
A_33_P3375145 NM_203403 C9orf150 0.00 0.06 6.46 6.13E-01   
A_23_P312837 NR_026663 C9orf70 0.01 0.35 5.37 3.77E-01   
A_24_P915196 NM_153045 C9orf91 0.02 0.45 8.89 3.21E-01   
A_24_P943922 NM_020925 CACHD1 0.02 0.44 5.73 3.36E-01   
A_33_P3218960 NM_021098 CACNA1H 0.02 0.43 5.86 -3.39E-01   
A_33_P3292854 NM_004343 CALR 0.00 0.11 17.05 -5.13E-01  yes 
A_23_P253791 NM_004345 CAMP 0.01 0.30 8.04 4.61E-01   
A_23_P341349 NM_023083 CAPN10 0.01 0.39 9.9 -7.73E-01 #  
A_24_P902728 NM_203364 CAPRIN1 0.02 0.47 9.1 -3.13E-01 #  
A_23_P380379 AF251056 CAPS2 0.02 0.45 5.46 3.39E-01 #  
A_33_P3322353 NM_006136 CAPZA2 0.01 0.38 10.27 -3.49E-01 *  
A_32_P224666 NM_006136 CAPZA2 0.02 0.41 8.82 -3.34E-01 *  
A_23_P434890 NM_014550 CARD10 0.02 0.43 8.96 -3.32E-01   
A_23_P166306 NM_000071 CBS 0.00 0.10 11.1 -5.73E-01   
A_33_P3333975 NM_001024916 CBWD5 0.02 0.42 13.8 -3.94E-01 *  
A_33_P3222018 NM_016587 CBX3 0.01 0.34 7.35 -3.63E-01 #  
A_23_P65983 NM_033212 CCDC102A 0.01 0.38 6.91 -4.29E-01   
A_23_P73540 NM_033626 CCDC120 0.01 0.35 8.25 -3.66E-01   
A_33_P3356230 NM_001004306 CCDC144NL 0.01 0.39 7.02 -3.85E-01   
A_33_P3324854 NM_024768 CCDC48 0.00 0.07 5.68 7.04E-01 #  
A_33_P3246613 NM_001031737 CCDC78 0.02 0.41 11.05 -8.04E-01   
A_24_P289170 NM_001080414 CCDC88C 0.01 0.30 7.5 4.15E-01 #  
A_23_P89431 NM_002982 CCL2 0.00 0.00 6.89 1.61E+00   
A_23_P215491 NM_002991 CCL24 0.01 0.37 11.44 -4.59E-01   
A_33_P3305780 NM_001039780 CCNI2 0.01 0.40 5.48 -4.24E-01   
A_23_P212354 NM_001123041 CCR2 0.00 0.26 14.15 4.01E-01 #  
A_24_P131066 NM_004258 CD101 0.00 0.23 5.85 4.38E-01   
A_33_P3284508 NM_000591 CD14 0.00 0.01 8.02 1.05E+00   
A_23_P61466 NM_174941 CD163L1 0.01 0.41 11.02 -3.56E-01   
A_24_P380536 NM_006016 CD164 0.02 0.48 11.06 -3.48E-01 #  
A_23_P257815 NM_005582 CD180 0.01 0.37 6.03 4.16E-01   
A_23_P113572 NM_001770 CD19 0.01 0.37 8.5 3.52E-01   
A_24_P305345 NM_021155 CD209 0.00 0.09 8.15 7.31E-01 *  
A_33_P3272493 NM_001144897 CD209 0.01 0.27 6.15 4.40E-01 *  
A_24_P186539 NM_021155 CD209 0.01 0.38 6.43 3.98E-01 *  
A_23_P85453 NM_016382 CD244 0.01 0.41 10.08 3.88E-01 #  
A_24_P159434 NM_007261 CD300A 0.01 0.30 7.22 3.88E-01 *  
A_23_P55020 NM_139018 CD300LF 0.01 0.31 9.31 4.19E-01   
A_23_P111583 NM_001001547 CD36 0.00 0.15 10.88 5.96E-01   
A_23_P57036 NM_001250 CD40 0.00 0.24 7.45 -4.16E-01   
A_23_P70095 NM_001025158 CD74 0.00 0.03 9.93 7.65E-01   
A_24_P274795 NM_018719 CDCA7L 0.02 0.44 12.4 -3.51E-01 #  
A_23_P38732 NM_001792 CDH2 0.02 0.47 5.47 -3.28E-01 #  
A_23_P110643 NM_016508 CDKL3 0.02 0.48 8.2 -3.27E-01   
A_33_P3411628 NM_058197 CDKN2A 0.01 0.34 6.16 6.48E-01 #  
A_23_P78526 NM_020219 CEACAM19 0.02 0.45 9.57 -3.33E-01   
A_23_P411296 NM_005194 CEBPB 0.00 0.14 12.34 5.27E-01  yes 
A_33_P3262635 NM_177405 CECR1 0.02 0.41 11.21 3.62E-01   
Supplementary data 
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A_32_P148710 NM_005507 CFL1 0.01 0.41 13.22 -3.54E-01 #  
A_23_P22444 NM_002621 CFP 0.01 0.31 7.69 -4.23E-01   
A_23_P163306 NM_032866 CGNL1 0.00 0.08 7.79 -7.38E-01   
A_33_P3376971 NM_024111 CHAC1 0.01 0.30 8.39 -4.19E-01 #  
A_24_P379727 NM_032309 CHCHD5 0.01 0.32 9.94 -4.14E-01   
A_24_P85317 NM_001042572 CHD2 0.02 0.47 7.19 -3.08E-01 #  
A_23_P34888 NM_021797 CHIA 0.01 0.41 5.92 -4.60E-01   
A_23_P105571 NM_020244 CHPT1 0.02 0.46 9.76 -3.37E-01   
A_23_P40847 NM_004267 CHST2 0.01 0.34 6.92 3.75E-01   
A_24_P44514 NM_006384 CIB1 0.01 0.32 12.12 -3.89E-01   
A_33_P3308914 NM_006383 CIB2 0.01 0.35 8.48 -3.66E-01   
A_32_P209960 NM_000246 CIITA 0.00 0.02 7.96 8.28E-01 # yes 
A_23_P88134 NM_032630 CINP 0.02 0.43 8.79 -5.31E-01   
A_23_P48056 NM_006825 CKAP4 0.00 0.14 9.2 -6.03E-01   
A_24_P215804 NM_016951 CKLF 0.01 0.40 7.85 -3.47E-01 #  
A_32_P206698 NM_001826 CKS1B 0.02 0.47 12.03 -3.08E-01 #  
A_23_P311232 NM_015282 CLASP1 0.01 0.39 9.28 -3.34E-01 #  
A_33_P3415097 NM_001830 CLCN4 0.00 0.13 8.15 5.00E-01 *  
A_33_P3367596 NM_001830 CLCN4 0.01 0.32 5.92 3.85E-01 *  
A_33_P3229032 NM_002975 CLEC11A 0.01 0.39 17.03 -3.33E-01   
A_33_P3410659 NM_001129998 CLEC12B 0.00 0.27 6.21 4.74E-01 #  
A_33_P3410654 NM_205852 CLEC12B 0.01 0.38 7.25 5.52E-01 #  
A_33_P3260572 NM_024692 CLIP4 0.02 0.42 7.03 -3.25E-01 #  
A_23_P376591 NM_206808 CLYBL 0.02 0.48 8.61 -3.77E-01   
A_23_P371239 NM_198390 CMIP 0.01 0.36 9.17 4.00E-01   
A_23_P106661 NM_052999 CMTM1 0.02 0.48 6.3 -2.97E-01   
A_33_P3372682 NR_024009 CN5H6.4 0.02 0.45 7.19 -4.24E-01   
A_23_P153183 NM_001168648 CNKSR2 0.01 0.39 5.65 3.43E-01 #  
A_23_P53288 NM_014255 CNPY2 0.01 0.27 15.12 -5.72E-01   
A_33_P3296240 NM_017738 CNTLN 0.01 0.38 8.5 -3.43E-01 *  
A_23_P9135 NM_033655 CNTNAP3 0.02 0.47 7.29 -3.33E-01 *  
A_32_P80850 NM_021110 COL14A1 0.00 0.13 6.75 -5.33E-01 #  
A_23_P31124 NM_030820 COL21A1 0.02 0.43 5.44 -3.37E-01   
A_24_P365975 NM_005202 COL8A2 0.01 0.27 7.38 4.84E-01 #  
A_23_P389525 NM_152516 COMMD1 0.00 0.18 11.13 -4.54E-01   
A_23_P105625 NM_032314 COQ5 0.01 0.38 11.34 -3.57E-01   
A_23_P106761 NM_007074 CORO1A 0.00 0.22 12.74 4.40E-01   
A_32_P98502 NM_004255 COX5A 0.02 0.48 14.56 -4.02E-01   
A_33_P3397066 CR736467 CR736467 0.01 0.39 5.72 -3.40E-01   
A_32_P29806 NM_003805 CRADD 0.00 0.25 10.62 -4.30E-01   
A_23_P33465 NM_024324 CRELD2 0.00 0.10 13.42 -5.51E-01   
A_33_P3232688 ENST00000381524 CSF2RA 0.01 0.32 9.97 3.77E-01 #  
A_23_P149892 NM_018590 CSGALNACT2 0.01 0.39 9.84 4.17E-01 #  
A_33_P3246017 AK091252 CTAGE5 0.01 0.38 5.39 -3.61E-01 #  
A_23_P81880 NM_005730 CTDSP2 0.02 0.45 14.07 3.36E-01 #  
A_33_P3287631 NM_147780 CTSB 0.01 0.35 8.31 4.24E-01   
A_23_P140384 NM_001911 CTSG 0.00 0.27 18.38 -4.28E-01   
A_33_P3354291 CU013345 CU013345 0.02 0.46 5.61 -3.10E-01   
A_33_P3210303 CU688821 CU688821 0.01 0.30 5.52 3.91E-01   
A_33_P3313528 CU693037 CU693037 0.02 0.46 6.03 3.54E-01   
A_33_P3375859 NR_002712 CXCR2P 0.02 0.45 7.29 3.28E-01   
A_23_P114299 NM_001504 CXCR3 0.00 0.27 7.91 -5.28E-01   
Supplementary data 
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A_23_P102000 NM_001008540 CXCR4 0.00 0.15 14.4 5.10E-01   
A_24_P365767 NM_000397 CYBB 0.02 0.43 11.14 3.98E-01   
A_33_P3285868 NM_134268 CYGB 0.02 0.47 13.02 -3.73E-01   
A_23_P90626 NM_004288 CYTIP 0.02 0.47 7.17 3.73E-01   
A_33_P3209200 DA858408 DA858408 0.00 0.12 6.85 -5.17E-01   
A_33_P3316786 NM_080759 DACH1 0.00 0.15 13.03 -5.42E-01 *  
A_23_P32577 NM_080759 DACH1 0.00 0.18 11.41 -5.95E-01 *  
A_23_P106056 NM_001344 DAD1 0.02 0.45 14.05 -4.01E-01   
A_33_P3262742 NM_001017920 DAPL1 0.01 0.33 5.59 -4.09E-01 *  
A_23_P165598 NM_001017920 DAPL1 0.02 0.42 6.69 -3.87E-01 *  
A_23_P26439 NM_001042610 DBNDD1 0.01 0.41 6.65 -3.84E-01   
A_23_P75038 NM_014881 DCLRE1A 0.02 0.45 10.65 -3.51E-01   
A_23_P76622 NM_001922 DCT 0.01 0.30 6.25 -3.98E-01   
A_23_P44166 NM_016286 DCXR 0.02 0.48 12.71 -3.03E-01   
A_33_P3372910 NM_014314 DDX58 0.01 0.39 7.8 -4.72E-01 #  
A_23_P31816 NM_005217 DEFA3 0.00 0.01 8.5 1.36E+00   
A_23_P326080 NM_001925 DEFA4 0.00 0.25 10.17 -4.14E-01   
A_33_P3290174 NM_206918 DEGS2 0.02 0.45 8.73 -3.78E-01   
A_23_P78608 NM_024898 DENND1C 0.02 0.45 10.48 3.38E-01   
A_24_P541919 NM_144973 DENND5B 0.00 0.14 7.38 -4.90E-01 #  
A_24_P144377 NM_014015 DEXI 0.00 0.08 14.11 -5.60E-01   
A_32_P211045 NM_000791 DHFR 0.00 0.09 11.02 -6.08E-01 #  
A_33_P3359368 NM_001082488 DHRS4L1 0.01 0.33 8.66 -3.91E-01 #  
A_23_P80778 NM_032839 DIRC2 0.00 0.26 9.55 4.51E-01 #  
A_33_P3349252 AL512723 DKFZP547L112 0.02 0.48 9.83 -4.85E-01   
A_33_P3254460 NM_206539 DLK2 0.01 0.32 7.16 -4.33E-01   
A_23_P167920 NM_005618 DLL1 0.02 0.45 9.45 -5.44E-01   
A_32_P142818 NM_178120 DLX1 0.00 0.11 9.92 6.23E-01 #  
A_23_P28598 NM_004405 DLX2 0.01 0.38 7.33 5.11E-01   
A_23_P157895 NM_021240 DMRT3 0.02 0.43 5.9 -3.39E-01   
A_23_P33583 NM_018897 DNAH7 0.01 0.41 5.46 3.64E-01   
A_33_P3290687 NM_022365 DNAJC1 0.00 0.06 10.18 -6.32E-01 *  
A_24_P225604 NM_018981 DNAJC10 0.01 0.36 11.44 -3.61E-01 *  
A_23_P25913 NM_031427 DNAL1 0.01 0.38 8.46 -3.98E-01   
A_23_P119266 NM_001375 DNASE2 0.02 0.46 8.93 4.06E-01   
A_23_P16722 NM_014689 DOCK10 0.00 0.10 11.57 5.81E-01   
A_33_P3228564 NM_001144875 DOK3 0.02 0.46 8.54 -3.42E-01 #  
A_33_P3286046 NM_015448 DPCD 0.01 0.41 9.19 -3.99E-01 #  
A_33_P3423185 AK024141 DPF3 0.02 0.46 5.57 -4.16E-01 #  
A_33_P3402963 NM_001012728 DPRX 0.01 0.37 5.58 -3.89E-01   
A_24_P149036 NM_001387 DPYSL3 0.00 0.23 8.77 5.09E-01   
A_23_P427299 DQ786249 DQ786249 0.01 0.34 7.44 3.85E-01 *  
A_32_P145051 DQ786249 DQ786249 0.02 0.43 6.58 3.42E-01 *  
A_32_P54274 NM_000798 DRD5 0.00 0.02 7.62 -9.56E-01 *  
A_24_P862886 NM_000798 DRD5 0.00 0.05 6.49 -7.95E-01 *  
A_23_P4494 NM_024422 DSC2 0.00 0.17 8.13 -4.67E-01   
A_23_P19226 NM_013352 DSE 0.01 0.37 7.34 -3.92E-01   
A_23_P110712 NM_004417 DUSP1 0.00 0.13 6.36 6.07E-01   
A_33_P3359012 NM_004420 DUSP8 0.02 0.48 10.79 -3.87E-01 #  
A_23_P158257 NM_012148 DUX3 0.00 0.15 5.59 4.74E-01   
A_23_P211126 NM_130436 DYRK1A 0.00 0.19 10.45 -5.06E-01 #  
A_33_P3366082 NM_032565 EBPL 0.02 0.43 11.86 -3.26E-01 #  
Supplementary data 
 
145 
Probe name 
Systematic 
name 
Gene name p-value 
adj.  
p-value 
Ave Expr log2FC 1) 
confirmed 
via         
qRT-PCR 
A_32_P47701 NM_001402 EEF1A1 0.00 0.25 16.05 -4.07E-01 #  
A_33_P3387272 NM_001402 EEF1A1 0.02 0.42 15.59 -3.24E-01 #  
A_33_P3411744 NR_004428 EGOT 0.01 0.41 6.14 -3.36E-01   
A_23_P46936 NM_000399 EGR2 0.00 0.08 8.45 8.13E-01  yes 
A_23_P130961 NM_001972 ELANE 0.00 0.16 16.61 -4.70E-01   
A_23_P58506 NM_012081 ELL2 0.01 0.41 10.86 3.45E-01   
A_33_P3359900 NM_198449 EMB 0.00 0.08 12.88 -6.24E-01 *  
A_24_P684186 NM_198449 EMB 0.00 0.11 14.34 -6.18E-01 *  
A_23_P76488 NM_001423 EMP1 0.00 0.08 6.55 7.35E-01  yes 
A_23_P106682 NM_001424 EMP2 0.01 0.38 8.4 3.78E-01   
A_23_P502336 NM_013447 EMR2 0.02 0.47 8.44 -3.38E-01   
A_24_P69095 NM_003633 ENC1 0.00 0.24 6.26 4.92E-01   
A_32_P120604 ENST00000219090 ENST00000219090 0.02 0.45 8.6 3.22E-01   
A_24_P288993 ENST00000244249 ENST00000244249 0.00 0.07 11.61 -6.56E-01   
A_33_P3257050 ENST00000314232 ENST00000314232 0.01 0.35 6.83 -5.11E-01   
A_23_P140614 ENST00000314246 ENST00000314246 0.00 0.10 10.17 -5.37E-01   
A_33_P3377090 ENST00000314747 ENST00000314747 0.02 0.48 5.36 -2.99E-01   
A_33_P3312217 ENST00000330110 ENST00000330110 0.00 0.23 5.36 -4.74E-01 #  
A_33_P3216568 ENST00000356191 ENST00000356191 0.02 0.46 5.9 3.42E-01   
A_33_P3418611 ENST00000357491 ENST00000357491 0.02 0.43 11.25 -4.06E-01   
A_33_P3391521 ENST00000366589 ENST00000366589 0.02 0.47 6.02 -3.80E-01   
A_33_P3418576 ENST00000367101 ENST00000367101 0.02 0.48 6.16 2.96E-01   
A_33_P3220813 ENST00000367652 ENST00000367652 0.01 0.38 5.96 3.76E-01   
A_33_P3332487 ENST00000368689 ENST00000368689 0.02 0.46 5.53 -3.12E-01   
A_33_P3228402 ENST00000373495 ENST00000373495 0.01 0.41 6.15 -3.43E-01   
A_33_P3230788 ENST00000374440 ENST00000374440 0.01 0.40 8.88 -5.88E-01   
A_33_P3378680 ENST00000378013 ENST00000378013 0.01 0.30 5.54 4.10E-01   
A_33_P3216192 ENST00000381654 ENST00000381654 0.00 0.17 10.81 -4.64E-01   
A_33_P3312194 ENST00000392178 ENST00000392178 0.02 0.44 6.13 3.56E-01   
A_33_P3224265 ENST00000394333 ENST00000394333 0.02 0.43 8.65 -4.02E-01   
A_33_P3272352 ENST00000397064 ENST00000397064 0.02 0.46 12.04 -3.04E-01   
A_33_P3374684 ENST00000398617 ENST00000398617 0.02 0.43 7.86 -8.76E-01   
A_33_P3291329 ENST00000398917 ENST00000398917 0.00 0.01 7.82 -9.77E-01   
A_33_P3392213 ENST00000399125 ENST00000399125 0.01 0.34 11.7 -3.67E-01   
A_23_P331908 ENST00000399269 ENST00000399269 0.00 0.19 7.58 -4.73E-01   
A_33_P3278159 ENST00000399539 ENST00000399539 0.01 0.31 9.5 -6.37E-01   
A_33_P3424217 ENST00000399670 ENST00000399670 0.00 0.00 7.93 1.19E+00   
A_33_P3243230 ENST00000401931 ENST00000401931 0.00 0.09 6.89 5.51E-01   
A_23_P255827 ENST00000402782 ENST00000402782 0.00 0.05 9.43 -7.02E-01   
A_33_P3220302 ENST00000416014 ENST00000416014 0.01 0.38 5.23 -3.67E-01   
A_24_P280897 ENST00000418275 ENST00000418275 0.00 0.23 13.79 -4.64E-01   
A_24_P306469 ENST00000420126 ENST00000420126 0.00 0.14 11.29 -4.86E-01   
A_24_P15388 ENST00000424969 ENST00000424969 0.00 0.18 5.35 -5.64E-01   
A_24_P238570 ENST00000430873 ENST00000430873 0.02 0.45 5.93 3.27E-01   
A_33_P3244640 ENST00000432765 ENST00000432765 0.01 0.38 6.56 -3.47E-01   
A_24_P58242 ENST00000435613 ENST00000435613 0.00 0.09 10.93 -7.06E-01   
A_33_P3271711 ENST00000449914 ENST00000449914 0.01 0.38 7.26 -3.92E-01   
A_32_P76853 ENST00000450802 ENST00000450802 0.00 0.24 12.12 -4.25E-01   
A_33_P3302662 ENST00000461758 ENST00000461758 0.01 0.30 7.45 4.15E-01   
A_33_P3218975 NM_001776 ENTPD1 0.00 0.08 7.02 6.43E-01 *  
A_33_P3218980 NM_001776 ENTPD1 0.00 0.09 7.56 7.43E-01 *  
A_23_P4536 NM_012307 EPB41L3 0.02 0.45 8.45 4.53E-01   
Supplementary data 
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A_24_P257579 NM_022140 EPB41L4A 0.00 0.17 5.39 4.90E-01 #  
A_33_P3248325 AK290895 EPB41L5 0.02 0.44 7.09 -3.22E-01 #  
A_23_P34537 NM_000120 EPHX1 0.01 0.33 9.69 -3.70E-01   
A_33_P3325018 NM_015701 ERLEC1 0.02 0.46 12.13 -3.13E-01 #  
A_23_P164042 NM_001433 ERN1 0.02 0.43 6.24 3.28E-01   
A_33_P3226425 NM_001034025 ERP29 0.02 0.44 10.12 -3.21E-01 #  
A_33_P3226678 NM_001145127 EVPLL 0.01 0.27 6.34 -4.09E-01 #  
A_24_P368943 NM_001989 EVX1 0.00 0.26 10.14 -6.25E-01   
A_23_P205177 NM_000504 F10 0.02 0.44 5.79 -4.20E-01 #  
A_32_P140139 NM_000129 F13A1 0.02 0.46 5.67 3.25E-01 #  
A_23_P94879 NM_000506 F2 0.01 0.34 5.74 -3.96E-01   
A_23_P117298 NM_000131 F7 0.01 0.34 5.86 4.03E-01   
A_23_P133438 NM_019018 FAM105A 0.00 0.15 10.98 4.74E-01 *  
A_32_P51848 NM_019018 FAM105A 0.01 0.35 7.11 3.94E-01 *  
A_23_P120973 NM_017911 FAM118A 0.02 0.43 7.63 -3.22E-01   
A_23_P142688 NM_024293 FAM134A 0.02 0.46 9.78 3.03E-01 *  
A_23_P398172 NM_020819 FAM135A 0.02 0.45 7.98 3.46E-01 #  
A_23_P100001 NM_207446 FAM174B 0.02 0.48 8.74 -2.96E-01   
A_33_P3290573 NM_017633 FAM46A 0.00 0.05 12.96 -7.42E-01 *  
A_33_P3410599 NM_017633 FAM46A 0.00 0.08 13.72 -6.96E-01 *  
A_23_P379327 NM_001040450 FAM63B 0.02 0.46 8.95 -4.18E-01   
A_33_P3316410 NR_026789 FAM66A 0.02 0.46 6.74 -3.04E-01 #  
A_33_P3217364 NM_001083124 FAM75A3 0.02 0.48 7.3 3.01E-01 #  
A_33_P3222045 NM_201400 FAM86A 0.01 0.30 8.6 -4.07E-01 #  
A_33_P3374878 NM_024582 FAT4 0.02 0.46 5.45 3.21E-01 #  
A_32_P220463 NR_024356 FBLL1 0.01 0.38 7.43 -3.82E-01 *  
A_23_P211631 NM_006486 FBLN1 0.00 0.08 7.83 -5.85E-01 #  
A_23_P406385 NM_153350 FBXL16 0.02 0.46 5.68 3.11E-01   
A_33_P3259507 NM_012166 FBXO10 0.02 0.44 9.28 -3.32E-01   
A_23_P168847 NM_172366 FBXO16 0.01 0.38 8.1 -3.91E-01   
A_23_P395566 NM_024735 FBXO31 0.02 0.46 7.93 -3.34E-01 #  
A_23_P164773 NM_002002 FCER2 0.00 0.04 6.36 8.75E-01   
A_23_P85716 NM_021642 FCGR2A 0.00 0.23 9.97 -4.87E-01 #  
A_33_P3327617 NM_201563 FCGR2C 0.02 0.44 9.02 -3.80E-01   
A_33_P3255509 NM_001161357 FCHO1 0.01 0.30 10.96 3.78E-01   
A_23_P500501 NM_000142 FGFR3 0.01 0.36 8.55 -4.97E-01 #  
A_33_P3332018 NM_006682 FGL2 0.00 0.04 7.01 9.40E-01   
A_23_P103932 NM_001042747 FGR 0.00 0.06 10.69 6.31E-01   
A_33_P3278330 AK131224 FLJ16124 0.01 0.33 5.95 -6.64E-01   
A_33_P3711933 NM_152432 FLJ32810 0.01 0.41 6.54 3.47E-01 #  
A_32_P473302 NR_015375 FLJ35024 0.01 0.33 7.18 -4.21E-01   
A_33_P3259890 BC042169 FLJ35946 0.01 0.30 5.46 -6.21E-01   
A_33_P3331426 AK095105 FLJ37786 0.01 0.37 7.42 -3.66E-01 #  
A_24_P194661 AK095698 FLJ38379 0.00 0.16 6.51 -5.79E-01   
A_33_P3543288 AK124832 FLJ42842 0.02 0.44 5.58 -5.44E-01   
A_23_P256059 NR_029406 FLJ43681 0.02 0.42 14.55 -3.37E-01   
A_33_P3227482 AK125932 FLJ43944 0.01 0.41 5.67 -3.33E-01   
A_33_P3248900 NR_028324 FLJ45445 0.01 0.34 12.83 -4.21E-01 #  
A_23_P47168 NM_013280 FLRT1 0.02 0.46 6.98 3.79E-01   
A_24_P390668 NM_005892 FMNL1 0.01 0.38 9.58 3.55E-01 *  
A_23_P417942 NM_001024948 FNBP1L 0.02 0.43 7.72 -3.82E-01   
A_23_P53176 NM_016725 FOLR1 0.01 0.32 7.16 -3.71E-01   
Supplementary data 
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A_23_P47709 NM_000803 FOLR2 0.01 0.30 6.2 -4.80E-01 #  
A_23_P106194 NM_005252 FOS 0.00 0.06 11.15 8.78E-01  yes 
A_23_P429998 NM_006732 FOSB 0.00 0.01 7.24 1.05E+00   
A_32_P34920 NM_004472 FOXD1 0.00 0.10 9.33 -6.32E-01   
A_32_P119248 NM_207305 FOXD4 0.02 0.42 9.17 -3.38E-01   
A_24_P15391 NM_001135649 FOXI3 0.02 0.45 6.19 -3.93E-01   
A_33_P3261173 NM_005479 FRAT1 0.02 0.44 6.12 3.21E-01 #  
A_33_P3364112 NM_006654 FRS2 0.00 0.27 9.08 -4.32E-01   
A_33_P3411075 NM_003088 FSCN1 0.00 0.12 12.22 -6.32E-01   
A_33_P3225022 NM_206965 FTCD 0.02 0.41 5.79 -3.25E-01 *  
A_23_P11543 NM_000147 FUCA1 0.00 0.04 10.19 6.82E-01  yes 
A_33_P3406493 NM_005458 GABBR2 0.02 0.43 5.87 3.19E-01   
A_32_P25514 NM_198904 GABRG2 0.00 0.19 7.24 -6.04E-01   
A_24_P910667 AF220235 GAFA3 0.02 0.47 6.54 7.18E-01   
A_23_P374844 NM_015973 GAL 0.00 0.07 12.66 -6.11E-01   
A_33_P3402350 CR598865 GAPDHP32 0.02 0.48 5.79 -3.00E-01   
A_24_P85942 NM_181453 GCC2 0.00 0.18 9.96 -4.99E-01 *  
A_23_P122662 NM_018988 GFOD1 0.02 0.46 10.59 3.08E-01   
A_33_P3408953 NM_199127 GGTLC2 0.01 0.40 9.66 -3.34E-01 #  
A_23_P214411 NM_006708 GLO1 0.01 0.38 12.39 -3.65E-01   
A_32_P19294 NM_144669 GLT1D1 0.00 0.13 7.6 5.70E-01   
A_24_P392925 NM_001014985 GLTPD2 0.01 0.30 6.51 3.86E-01   
A_33_P3285580 NM_145262 GLYCTK 0.01 0.34 7.19 3.97E-01 #  
A_23_P209954 NM_006433 GNLY 0.01 0.30 5.4 3.83E-01 *  
A_24_P323072 NM_178332 GNRH2 0.00 0.24 7.88 -4.14E-01 #  
A_33_P3332474 NM_001001413 GOLGA6L1 0.00 0.23 7.58 -5.90E-01   
A_33_P3239101 NM_001164465 GOLGA6L10 0.02 0.45 6.9 -3.26E-01 #  
A_33_P3220025 NM_001145004 GOLGA6L6 0.00 0.16 9.73 -5.72E-01 #  
A_24_P50972 NM_001145004 GOLGA6L6 0.00 0.26 11.22 -5.41E-01 #  
A_32_P231086 NM_198181 GOLGA6L9 0.02 0.48 11.15 -3.01E-01 #  
A_24_P98277 NM_001002296 GOLGA7 0.02 0.45 9.81 -3.30E-01 #  
A_32_P2392 NM_181077 GOLGA8A 0.01 0.28 10.53 -3.92E-01 #  
A_32_P119569 NR_033350 GOLGA8E 0.00 0.07 9.94 -6.01E-01 *  
A_33_P3262833 NR_033350 GOLGA8E 0.00 0.13 11.19 -4.91E-01 *  
A_24_P229669 NR_024074 GOLGA9P 0.00 0.08 10.16 -6.91E-01   
A_33_P3210671 NM_207328 GPAT2 0.00 0.25 5.69 4.24E-01 #  
A_23_P209904 NM_002081 GPC1 0.02 0.46 9.24 -3.85E-01   
A_23_P112874 NM_004466 GPC5 0.00 0.11 5.92 -5.21E-01   
A_33_P3375467 NM_177483 GPLD1 0.02 0.46 5.42 -3.48E-01 #  
A_23_P378416 NM_001001996 GPM6B 0.01 0.35 7.62 -3.71E-01 *  
A_23_P134426 NM_001005340 GPNMB 0.00 0.00 8.48 1.24E+00   
A_24_P334718 NM_181791 GPR141 0.01 0.36 6.9 3.49E-01   
A_23_P14165 NM_005292 GPR18 0.02 0.46 9.96 3.40E-01   
A_33_P3375368 NM_005301 GPR35 0.01 0.38 7.44 4.07E-01   
A_23_P37892 NM_133443 GPT2 0.01 0.30 9.28 -3.99E-01   
A_24_P418816 NM_015696 GPX7 0.02 0.45 9.78 -3.23E-01   
A_23_P257962 NM_007327 GRIN1 0.01 0.33 5.43 -4.07E-01 #  
A_33_P3423365 NM_001127663 GSN 0.00 0.19 12.31 -4.84E-01 #  
A_23_P115407 NM_146421 GSTM1 0.01 0.40 10.27 -3.55E-01   
A_23_P12343 NM_000849 GSTM3 0.00 0.23 14.35 -4.82E-01   
A_23_P153945 NM_001006636 GTDC1 0.01 0.29 9.53 -3.99E-01   
A_24_P274640 NM_001042490 GTF2H2D 0.01 0.37 12.42 -3.55E-01   
Supplementary data 
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A_33_P3375646 AK296003 GTPBP6 0.02 0.45 6.53 -3.58E-01 #  
A_33_P3388192 NM_144594 GTSF1 0.02 0.47 14.04 -3.21E-01   
A_33_P3362933 NM_002099 GYPA 0.01 0.40 7.9 3.31E-01 #  
A_23_P117602 NM_004131 GZMB 0.00 0.24 6.3 4.25E-01   
A_23_P128993 NM_033423 GZMH 0.01 0.35 6.22 -3.98E-01   
A_23_P121182 NM_012260 HACL1 0.02 0.47 12.1 -3.07E-01   
A_33_P3318946 NM_021817 HAPLN2 0.00 0.02 11.35 -1.20E+00   
A_33_P3382887 ENST00000426779 hCG_1659830 0.00 0.01 7.16 -2.19E+00   
A_24_P290013 NR_024363 hCG_1990547 0.02 0.47 7.95 -3.04E-01 #  
A_33_P3281036 NR_026790 HCG11 0.01 0.40 12.12 -3.64E-01   
A_24_P17870 NM_006674 HCP5 0.00 0.10 8.19 8.01E-01   
A_24_P55250 NM_016063 HDDC2 0.00 0.26 11.8 -9.88E-01 *  
A_33_P3212650 BC001671 HDDC2 0.02 0.45 12.63 -3.09E-01 *  
A_23_P122796 NM_016063 HDDC2 0.01 0.37 8.45 -3.54E-01   
A_23_P258689 NM_017802 HEATR2 0.01 0.27 11.35 -4.08E-01 #  
A_23_P59349 NM_016217 HECA 0.02 0.46 12.92 3.17E-01   
A_32_P166693 NM_020733 HEG1 0.00 0.06 10.29 6.24E-01   
A_23_P368805 NM_007072 HHLA2 0.00 0.08 5.67 5.83E-01 #  
A_24_P363548 NM_005338 HIP1 0.01 0.40 7.64 4.18E-01   
A_24_P681011 NM_022740 HIPK2 0.00 0.15 7.21 5.02E-01 *  
A_23_P7976 NM_005321 HIST1H1E 0.00 0.01 11.74 -9.68E-01   
A_23_P30813 NM_003541 HIST1H4K 0.02 0.48 11.01 -3.33E-01 #  
A_23_P137909 NM_003493 HIST3H3 0.01 0.27 16.01 -3.96E-01   
A_23_P217958 NM_033500 HK1 0.00 0.13 9.35 5.44E-01   
A_32_P175739 NM_000189 HK2 0.01 0.30 10.76 4.22E-01 #  
A_33_P3424800 NM_005514 HLA-B 0.00 0.06 14.75 -6.40E-01 #  
A_24_P50245 NM_006120 HLA-DMA 0.00 0.08 9.43 6.40E-01 *  
A_23_P42306 NM_006120 HLA-DMA 0.00 0.08 9.82 7.00E-01 *  
A_32_P351968 NM_002118 HLA-DMB 0.00 0.00 8.74 1.49E+00   
A_23_P30913 NM_033554 HLA-DPA1 0.00 0.00 10.41 1.60E+00 *  
A_33_P3234277 NM_033554 HLA-DPA1 0.00 0.01 9.81 1.33E+00 *  
A_24_P166443 NM_002121 HLA-DPB1 0.00 0.00 10.22 1.54E+00 *  
A_23_P258769 NM_002121 HLA-DPB1 0.00 0.00 11.09 1.63E+00 *  
A_33_P3271651 NM_002121 HLA-DPB1 0.00 0.00 9.37 1.65E+00 *  
A_33_P3271635 NM_002121 HLA-DPB1 0.00 0.00 8.48 1.45E+00 *  
A_24_P288836 NR_001435 HLA-DPB2 0.00 0.01 7.7 9.36E-01 #  
A_33_P3293049 NM_002122 HLA-DQA1 0.00 0.01 6.29 9.62E-01 *  
A_33_P3273884 NM_002122 HLA-DQA1 0.00 0.09 5.8 5.93E-01 *  
A_24_P852756 NM_020056 HLA-DQA2 0.00 0.07 5.57 5.94E-01   
A_23_P136683 NM_002123 HLA-DQB1 0.00 0.02 9.08 9.42E-01 *  
A_33_P3424222 NM_002123 HLA-DQB1 0.00 0.06 10.51 8.09E-01 *  
A_23_P8108 AK304543 HLA-DQB1 0.00 0.11 10.95 5.98E-01 *  
A_23_P19510 NR_003937 HLA-DQB2 0.00 0.06 7.67 6.68E-01   
A_32_P87697 NM_019111 HLA-DRA 0.00 0.04 11.64 8.73E-01   
A_24_P343233 NM_002124 HLA-DRB1 0.00 0.06 13.17 7.35E-01   
A_33_P3383912 NM_022555 HLA-DRB3 0.00 0.13 11.32 5.59E-01   
A_24_P370472 NM_021983 HLA-DRB4 0.00 0.22 10.37 4.53E-01   
A_23_P45099 NM_002125 HLA-DRB5 0.00 0.12 13.09 5.98E-01   
A_33_P3379967 NM_001098478 HLA-F 0.00 0.24 8.76 5.27E-01 #  
A_33_P3323448 NM_178582 HM13 0.02 0.46 6.76 6.11E-01 #  
A_24_P932736 ENST00000397358 HMBOX1 0.00 0.01 6.48 -9.46E-01 #  
A_23_P148990 NM_031935 HMCN1 0.01 0.40 5.53 3.74E-01   
Supplementary data 
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A_32_P41487 NM_005517 HMGN2 0.02 0.44 18.01 -3.15E-01 #  
A_24_P132099 NM_138730 HMGN3 0.01 0.30 13.61 -4.02E-01   
A_24_P397515 NM_006353 HMGN4 0.02 0.43 9.89 3.65E-01   
A_24_P136161 NM_001013631 HNRNPCL1 0.01 0.38 9.25 -3.69E-01   
A_33_P3264528 NM_005523 HOXA11 0.00 0.13 9.78 -4.95E-01   
A_24_P280983 NR_002795 HOXA11AS 0.01 0.38 11.5 -3.53E-01   
A_23_P70968 NM_006896 HOXA7 0.00 0.26 6.69 -4.07E-01   
A_23_P500998 NM_152739 HOXA9 0.00 0.14 11.59 -5.65E-01 #  
A_33_P3300975 NM_014620 HOXC4 0.00 0.04 7.38 -7.64E-01   
A_23_P139527 NM_002150 HPD 0.00 0.11 6.18 -5.93E-01   
A_33_P3320241 XM_001722088 HPX-2 0.00 0.05 5.35 7.51E-01 #  
A_23_P142125 NM_002152 HRC 0.00 0.26 8.26 -5.38E-01   
A_33_P3309231 NM_172002 HSCB 0.00 0.10 15.71 -5.76E-01 #  
A_23_P63209 NM_181755 HSD11B1 0.00 0.22 12.59 -4.73E-01   
A_33_P3335042 NM_016142 HSD17B12 0.02 0.42 10.34 -3.20E-01 #  
A_23_P11859 NM_016371 HSD17B7 0.01 0.40 10.22 -3.81E-01   
A_33_P3510335 NM_213655 HSN2 0.01 0.28 8.11 -4.06E-01   
A_23_P162874 NM_005348 HSP90AA1 0.01 0.38 14.17 -3.74E-01   
A_33_P3408212 NM_003299 HSP90B1 0.01 0.31 12.62 -4.01E-01 #  
A_33_P3401252 NR_003130 HSP90B3P 0.01 0.39 13.84 -3.39E-01   
A_23_P88303 NM_021979 HSPA2 0.02 0.42 7.54 -3.54E-01   
A_33_P3418511 NR_027756 HTA 0.02 0.42 5.84 3.27E-01   
A_24_P153820 BC028351 HYDIN 0.02 0.48 5.67 2.97E-01 #  
A_33_P3209351 NM_013417 IARS 0.01 0.41 10.14 -3.31E-01 #  
A_33_P3209346 NM_013417 IARS 0.02 0.47 7.85 -3.30E-01 #  
A_23_P152655 NM_000873 ICAM2 0.02 0.48 9.1 -3.05E-01   
A_23_P119143 NM_003259 ICAM5 0.00 0.15 6.28 6.29E-01   
A_23_P153745 NM_006332 IFI30 0.00 0.06 10 9.14E-01   
A_33_P3337540 NM_000874 IFNAR2 0.00 0.17 12.33 -4.91E-01 #  
A_23_P406135 NM_015662 IFT172 0.02 0.44 11.79 -3.26E-01   
A_33_P3242973 NM_006548 IGF2BP2 0.01 0.27 7.47 -4.15E-01 *  
A_23_P250156 NM_006548 IGF2BP2 0.02 0.48 10.33 -3.36E-01 *  
A_23_P119943 NM_000597 IGFBP2 0.01 0.32 7.73 -3.68E-01   
A_33_P3372004 NM_005849 IGSF6 0.00 0.06 6.43 6.44E-01   
A_32_P114284 NM_001079526 IKZF2 0.00 0.10 8.09 -5.96E-01 #  
A_23_P203173 NM_001558 IL10RA 0.00 0.13 9.55 5.27E-01   
A_23_P72077 NM_001559 IL12RB2 0.00 0.26 8.21 -4.39E-01   
A_24_P73599 NM_172217 IL16 0.00 0.20 6.44 4.94E-01 *  
A_23_P61057 NM_004513 IL16 0.01 0.30 7.88 4.39E-01 *  
A_23_P104798 NM_001562 IL18 0.01 0.38 8.35 -3.79E-01   
A_33_P3228322 NM_173042 IL18BP 0.01 0.41 6.62 -3.30E-01   
A_23_P91850 NM_144717 IL20RB 0.02 0.43 9.48 -3.73E-01   
A_33_P3290394 NM_000206 IL2RG 0.02 0.47 7.37 -3.09E-01 #  
A_32_P87013 NM_000584 IL8 0.00 0.06 7.75 6.47E-01  yes 
A_23_P109907 NM_175924 ILDR1 0.00 0.11 15.02 -5.11E-01   
A_33_P3290403 NM_014214 IMPA2 0.02 0.42 9.8 3.34E-01 *  
A_23_P50081 NM_014214 IMPA2 0.02 0.47 13.56 3.04E-01 *  
A_23_P122924 NM_002192 INHBA 0.01 0.38 6.43 4.10E-01   
A_33_P3397995 NM_001130699 IPCEF1 0.02 0.45 9.28 3.70E-01 #  
A_32_P21474 NM_001010844 IRAK1BP1 0.02 0.45 7.57 -3.82E-01   
A_33_P3352970 NM_001570 IRAK2 0.01 0.38 8.2 3.73E-01   
A_23_P206022 NM_001004439 ITGA11 0.02 0.48 6.8 -3.04E-01   
Supplementary data 
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A_23_P128084 NM_002206 ITGA7 0.02 0.47 12.78 3.50E-01   
A_23_P206806 NM_002209 ITGAL 0.00 0.22 10.63 5.68E-01   
A_23_P50907 NM_002210 ITGAV 0.02 0.42 11.25 -3.35E-01   
A_23_P312132 NM_000887 ITGAX 0.00 0.24 10.43 6.17E-01 #  
A_23_P104199 NM_133376 ITGB1 0.02 0.45 9.99 -3.21E-01   
A_23_P76529 NM_000889 ITGB7 0.01 0.34 9.44 3.69E-01   
A_23_P171074 NM_004867 ITM2A 0.00 0.06 7.46 -7.55E-01   
A_24_P379820 NM_030926 ITM2C 0.01 0.41 10.37 -3.33E-01 #  
A_24_P835500 NM_001034841 ITPRIPL2 0.00 0.13 8.95 4.91E-01   
A_23_P106024 NM_002226 JAG2 0.02 0.42 6.73 -4.83E-01   
A_23_P427217 NM_032776 JMJD1C 0.01 0.36 9.26 -3.95E-01   
A_23_P429950 NM_000216 KAL1 0.02 0.42 7.13 3.69E-01   
A_33_P3209866 NM_153186 KANK1 0.01 0.30 8.83 -4.00E-01 #  
A_33_P3260530 NM_181712 KANK4 0.02 0.47 5.68 -3.10E-01 *  
A_23_P101516 NM_004977 KCNC3 0.01 0.38 7.73 3.42E-01 #  
A_23_P3177 NM_022054 KCNK13 0.00 0.18 6.45 4.76E-01   
A_23_P119573 NM_002248 KCNN1 0.00 0.26 5.59 4.27E-01   
A_23_P150648 NR_024627 KCNQ1DN 0.01 0.41 5.61 3.54E-01   
A_33_P3395823 NM_172109 KCNQ2 0.00 0.17 8.04 -8.12E-01 #  
A_33_P3240512 NM_138444 KCTD12 0.00 0.16 11.66 5.39E-01 # yes 
A_23_P211504 NM_016657 KDELR3 0.01 0.36 5.67 -3.69E-01   
A_33_P3297621 NM_015047 KIAA0090 0.02 0.43 9.95 -3.43E-01 #  
A_23_P324490 NM_014686 KIAA0355 0.01 0.38 9.08 -3.69E-01   
A_23_P206310 NM_014732 KIAA0513 0.02 0.42 7.33 3.75E-01   
A_24_P295601 NM_014741 KIAA0652 0.02 0.47 10.41 -3.10E-01 #  
A_23_P116168 NM_032424 KIAA1826 0.02 0.47 9.01 3.14E-01   
A_23_P126888 NM_017596 KIF21B 0.01 0.32 9.62 3.76E-01 #  
A_32_P27917 NM_015656 KIF26A 0.00 0.03 5.98 8.37E-01  no 
A_33_P3414683 NM_145754 KIFC2 0.01 0.38 6.3 3.41E-01 #  
A_23_P315451 NM_199180 KIRREL2 0.02 0.47 8.33 -3.15E-01 #  
A_23_P32233 NM_004235 KLF4 0.01 0.30 7.8 4.82E-01   
A_23_P64898 NM_005810 KLRG1 0.02 0.46 7.07 -3.35E-01 #  
A_33_P3306207 NM_198508 KLRG2 0.00 0.13 11.51 -4.91E-01 #  
A_24_P11791 NM_002268 KPNA4 0.01 0.40 13.01 -3.62E-01   
A_33_P3364520 NM_181602 KRTAP6-1 0.02 0.45 6.34 3.12E-01   
A_23_P89780 NM_198129 LAMA3 0.01 0.31 7.12 -3.81E-01 #  
A_33_P3223780 NM_002292 LAMB2 0.00 0.24 5.51 4.51E-01 #  
A_33_P3413815 NR_004405 LAMB2L 0.01 0.28 8.87 4.59E-01   
A_33_P3338121 NM_001017402 LAMB3 0.01 0.29 10.05 -4.72E-01   
A_33_P3238007 NM_178043 LARP1B 0.01 0.38 9.25 -3.52E-01 #  
A_23_P89187 NM_006148 LASP1 0.00 0.23 12.13 -5.94E-01   
A_32_P48466 NM_152505 LCA5L 0.02 0.47 5.56 3.16E-01   
A_33_P3382746 NM_005356 LCK 0.00 0.13 6.35 5.20E-01 #  
A_23_P215931 NM_015344 LEPROTL1 0.02 0.42 11.44 -3.60E-01 #  
A_23_P166459 NM_002305 LGALS1 0.01 0.33 15.05 -4.05E-01   
A_23_P120902 NM_006498 LGALS2 0.00 0.02 7.38 1.02E+00   
A_33_P3365437 NM_020204 LHX9 0.00 0.00 7.64 -1.34E+00 *  
A_23_P327562 NM_020204 LHX9 0.00 0.04 6.04 -7.22E-01 *  
A_32_P70158 NM_006864 LILRB3 0.00 0.08 5.79 6.64E-01 #  
A_33_P3408762 NM_005572 LMNA 0.01 0.34 13.19 3.95E-01 #  
A_32_P33561 NR_024407 LOC100009676 0.02 0.47 7.33 -3.04E-01 #  
A_33_P3301297 XR_039256 LOC100128086 0.00 0.20 6.28 -6.35E-01   
Supplementary data 
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Ave Expr log2FC 1) 
confirmed 
via         
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A_32_P100641 XM_001719779 LOC100128139 0.01 0.40 6.63 3.66E-01   
A_33_P3326447 AK125272 LOC100128276 0.00 0.17 7.42 6.01E-01   
A_33_P3339990 AK123323 LOC100128429 0.02 0.46 5.9 3.66E-01   
A_33_P3383071 AK126077 LOC100128437 0.02 0.46 5.99 -3.37E-01 #  
A_32_P834166 AF128541 LOC100128843 0.02 0.46 6.69 4.78E-01   
A_33_P3318763 BM457408 LOC100128994 0.00 0.02 7.75 -9.53E-01 *  
A_33_P3265872 XM_001717144 LOC100128994 0.00 0.03 8.74 -1.01E+00 *  
A_32_P91042 NR_027406 LOC100129034 0.01 0.37 8.59 3.67E-01   
A_33_P3333560 XM_001715999 LOC100129101 0.02 0.42 6.44 -3.52E-01   
A_33_P3261953 XR_037125 LOC100129536 0.00 0.26 6.27 4.01E-01   
A_33_P3409580 AK097764 LOC100129722 0.00 0.00 10.26 -1.32E+00   
A_33_P3263284 NR_024563 LOC100130238 0.02 0.46 10.06 -7.55E-01 #  
A_33_P3400334 AK127532 LOC100130372 0.01 0.28 5.53 4.11E-01   
A_33_P3404671 NR_024567 LOC100130557 0.02 0.44 10.65 -3.17E-01 #  
A_24_P76078 ENST00000437256 LOC100130794 0.01 0.37 12.91 -3.78E-01   
A_33_P3239579 AK296298 LOC100131060 0.00 0.10 5.87 5.33E-01   
A_33_P3373573 XM_001717835 LOC100131316 0.02 0.42 5.58 3.23E-01   
A_33_P3315704 XM_001721221 LOC100131778 0.02 0.48 6.42 3.26E-01   
A_33_P3258127 AY203946 LOC100132188 0.02 0.47 5.61 3.33E-01   
A_33_P3308101 AK128836 LOC100132217 0.01 0.40 8.81 -5.54E-01 #  
A_33_P3223631 AK128836 LOC100132217 0.02 0.44 7.9 -3.48E-01 #  
A_24_P167877 NM_001135865 LOC100132247 0.01 0.32 15.98 3.69E-01 #  
A_33_P3244369 XR_037592 LOC100132541 0.02 0.46 7.53 -4.26E-01 #  
A_24_P367421 XM_001718703 LOC100132816 0.00 0.07 9.3 -6.24E-01 *  
A_33_P3334738 XM_001718703 LOC100132816 0.01 0.41 6.54 -3.59E-01 *  
A_33_P3413795 AV727532 LOC100133008 0.00 0.10 9.07 -7.89E-01 #  
A_33_P3388909 AK128414 LOC100133077 0.02 0.45 5.99 3.11E-01   
A_33_P3405864 XM_001716939 LOC100133165 0.00 0.17 5.98 -4.56E-01   
A_33_P3256480 XR_038016 LOC100133478 0.00 0.26 8.1 -5.91E-01   
A_33_P3292602 XM_001722336 LOC100133737 0.02 0.45 12.1 -3.27E-01 #  
A_33_P3366493 XR_037443 LOC100133990 0.00 0.14 7.97 -6.66E-01   
A_33_P3337742 XM_001714782 LOC100134002 0.02 0.47 8.88 -4.58E-01   
A_33_P3281905 NR_021493 LOC100144604 0.01 0.36 9.52 -3.64E-01   
A_33_P3419003 XM_002342467 LOC100289258 0.00 0.17 17.53 -4.66E-01   
A_33_P3395237 XM_001724470 LOC134505 0.02 0.43 10.8 -4.03E-01   
A_33_P3387656 XM_002343801 LOC139431 0.00 0.17 5.81 1.66E+00   
A_33_P3406572 AK091704 LOC149773 0.02 0.46 6.01 -7.48E-01   
A_33_P3404641 NR_027034 LOC150381 0.00 0.23 7.3 -5.11E-01   
A_32_P81676 NR_024281 LOC157627 0.00 0.19 5.79 4.84E-01   
A_33_P3348011 NR_002936 LOC222699 0.01 0.37 7.26 -4.59E-01   
A_33_P3711318 AK001439 LOC257152 0.02 0.48 9.39 -6.73E-01   
A_33_P3394140 NR_024431 LOC283050 0.01 0.29 6 3.97E-01   
A_33_P3235761 NR_024349 LOC284023 0.02 0.43 5.89 -3.33E-01   
A_32_P13151 NR_027995 LOC284232 0.02 0.47 7 -7.03E-01 #  
A_33_P3387766 NR_015417 LOC284276 0.01 0.30 6.36 -3.80E-01 #  
A_32_P232808 NR_029390 LOC284412 0.01 0.39 5.45 3.64E-01   
A_33_P3362148 NR_026963 LOC284900 0.02 0.41 6.19 4.81E-01 #  
A_33_P3802966 BM559483 LOC285740 0.02 0.45 6.06 4.18E-01 #  
A_33_P3548190 BC043259 LOC338864 0.00 0.19 6.01 8.79E-01   
A_33_P3414880 XM_001726300 LOC339192 0.01 0.39 6.97 4.54E-01   
A_33_P3398618 NR_001443 LOC339240 0.02 0.45 5.57 3.10E-01 *  
A_33_P3472460 BC041488 LOC339260 0.00 0.13 7.35 -5.40E-01   
Supplementary data 
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A_33_P3793307 AK023856 LOC339803 0.00 0.10 8.74 -5.89E-01   
A_33_P3429242 BC041468 LOC339988 0.01 0.38 8.11 3.45E-01   
A_24_P135579 XM_293026 LOC344382 0.01 0.30 9.75 -3.83E-01   
A_33_P3282641 AK309325 LOC344887 0.01 0.34 7.17 -3.86E-01 #  
A_33_P3422740 NR_027002 LOC388692 0.01 0.32 8.94 -6.35E-01 #  
A_33_P3364293 NR_027420 LOC389834 0.00 0.24 8.68 -7.11E-01 #  
A_33_P3357626 XM_001716257 LOC390998 0.00 0.24 10.71 -6.15E-01   
A_33_P3366396 XM_001720500 LOC392435 0.00 0.08 5.5 5.52E-01   
A_33_P3546363 BQ950045 LOC400128 0.00 0.18 13.49 -4.86E-01   
A_33_P3388588 ENST00000378340 LOC400558 0.01 0.40 13.22 -7.90E-01   
A_33_P3328360 NR_027033 LOC400931 0.00 0.18 11.57 -4.63E-01 #  
A_33_P3257910 NM_001168214 LOC401097 0.00 0.10 6.85 -5.74E-01 *  
A_23_P305245 NM_001168214 LOC401097 0.00 0.18 7.88 -5.18E-01 *  
A_33_P3358601 ENST00000382123 LOC402778 0.01 0.38 5.65 3.59E-01   
A_33_P3227899 NR_015361 LOC440896 0.00 0.22 9.93 -4.24E-01   
A_33_P3212375 BC063653 LOC441239 0.02 0.47 6.71 -3.22E-01   
A_33_P3403053 BC066990 LOC441242 0.00 0.00 7.21 -1.11E+00   
A_24_P161813 NR_024380 LOC441666 0.00 0.25 8.17 -4.74E-01 #  
A_33_P3273266 NR_024380 LOC441666 0.01 0.27 10.14 -4.46E-01 #  
A_24_P84008 ENST00000454093 LOC441722 0.00 0.21 10.06 -5.12E-01   
A_33_P3620246 AK302879 LOC441728 0.00 0.24 8.4 -4.11E-01 #  
A_33_P3391316 AK125677 LOC441956 0.01 0.37 6.58 -3.49E-01   
A_33_P3250273 XR_040018 LOC442132 0.02 0.45 6.81 -3.45E-01 #  
A_24_P647682 NR_003598 LOC442308 0.00 0.23 9.59 -5.17E-01   
A_33_P3860067 BC009388 LOC554174 0.01 0.28 6.37 -4.31E-01   
A_32_P57702 NR_033245 LOC641746 0.01 0.41 12.44 -3.47E-01   
A_33_P3328973 AK129565 LOC642384 0.02 0.43 6.26 3.48E-01   
A_33_P3401307 AK123703 LOC643441 0.00 0.05 5.25 7.26E-01   
A_24_P366415 XM_001721772 LOC643997 0.01 0.37 15.38 -3.95E-01   
A_33_P3596355 BG033631 LOC644242 0.00 0.23 5.64 4.69E-01   
A_33_P3332175 XM_001714131 LOC644310 0.02 0.41 11.81 -3.25E-01   
A_33_P3576034 BX248273 LOC644919 0.02 0.48 5.77 -2.97E-01   
A_33_P3329352 XM_001717733 LOC644992 0.01 0.29 8.33 -4.43E-01   
A_33_P3384900 BC014600 LOC645339 0.00 0.01 7.09 -1.13E+00   
A_33_P3259447 NR_027024 LOC645752 0.00 0.07 5.65 -6.54E-01 *  
A_33_P3276153 NR_027024 LOC645752 0.00 0.21 9.59 -4.66E-01 *  
A_33_P3260511 XR_036884 LOC646070 0.01 0.35 5.77 4.87E-01 #  
A_33_P3259861 XM_001726976 LOC646396 0.01 0.38 8.57 3.83E-01 #  
A_24_P332651 XM_001726994 LOC650157 0.00 0.07 7.4 -6.16E-01   
A_33_P3240340 XR_015456 LOC727796 0.01 0.35 10 -8.62E-01   
A_33_P3384312 XM_001720692 LOC727872 0.02 0.47 5.88 -5.73E-01   
A_33_P3292814 CR747917 LOC727878 0.00 0.07 7.48 -6.19E-01   
A_33_P3327687 AK090681 LOC727993 0.02 0.45 6.1 3.36E-01   
A_33_P3248580 XR_039169 LOC728217 0.01 0.28 9.76 -4.29E-01   
A_24_P213354 XR_015710 LOC729046 0.01 0.38 14.74 -3.43E-01   
A_24_P66932 NR_033244 LOC729080 0.02 0.47 8.88 -3.15E-01   
A_32_P36143 CR602569 LOC729088 0.02 0.46 7.67 -3.37E-01   
A_24_P267686 XR_037423 LOC729314 0.01 0.31 7.53 3.99E-01   
A_33_P3222341 BC037261 LOC729822 0.01 0.34 7.63 3.65E-01   
A_33_P3240972 XR_037628 LOC729900 0.01 0.35 8.33 -3.83E-01   
A_33_P3407618 NR_026811 LOC80154 0.01 0.37 5.57 -4.31E-01 *  
A_33_P3789382 NR_027182 LOC84989 0.00 0.02 9.34 -1.06E+00   
Supplementary data 
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A_24_P781615 NR_002773 LOC90586 0.02 0.46 5.77 3.04E-01   
A_23_P39799 NM_032603 LOXL3 0.02 0.46 6.82 3.06E-01 #  
A_23_P146233 NM_000237 LPL 0.00 0.06 9.33 7.06E-01   
A_23_P87150 NM_004811 LPXN 0.00 0.22 8.79 4.32E-01   
A_23_P124837 NM_002332 LRP1 0.00 0.18 5.76 4.50E-01   
A_23_P155463 NM_024512 LRRC2 0.00 0.01 6.48 -1.43E+00 #  
A_23_P61487 NM_018205 LRRC20 0.01 0.40 9.61 -3.43E-01   
A_23_P143857 NM_052953 LRRC3B 0.01 0.28 6.18 -4.32E-01   
A_33_P3263217 NM_022143 LRRC4 0.00 0.26 6.47 -4.01E-01   
A_32_P190049 NM_001099678 LRRC58 0.01 0.40 9.22 3.69E-01   
A_23_P157527 NM_033402 LRRCC1 0.00 0.08 9.17 -6.44E-01   
A_23_P13382 NM_001013254 LSP1 0.00 0.25 5.46 4.25E-01 #  
A_23_P211252 NM_001001438 LSS 0.02 0.44 8.37 -3.31E-01 #  
A_33_P3221064 NM_001042544 LTBP4 0.02 0.45 12.33 -3.31E-01 #  
A_24_P7584 NM_025262 LY6G5C 0.01 0.40 7.13 3.33E-01   
A_33_P3281028 NM_080676 MACROD2 0.02 0.46 6.17 7.46E-01 #  
A_23_P17345 NM_005461 MAFB 0.00 0.23 9.1 6.65E-01 * yes 
A_33_P3220837 NM_005461 MAFB 0.01 0.29 11.28 5.65E-01 * yes 
A_23_P103110 NM_012323 MAFF 0.02 0.45 6.57 3.92E-01   
A_33_P3564409 AK094541 MAGED4B 0.02 0.47 5.8 3.14E-01 #  
A_33_P3329444 NM_182574 MAMSTR 0.00 0.05 6.54 7.06E-01 #  
A_23_P103601 NM_020379 MAN1C1 0.02 0.43 10.42 3.50E-01 #  
A_23_P105409 NM_006301 MAP3K12 0.00 0.24 6.81 4.47E-01   
A_23_P207319 NM_003954 MAP3K14 0.01 0.41 8.19 3.66E-01   
A_23_P134125 NM_005923 MAP3K5 0.02 0.46 10.71 3.12E-01 #  
A_23_P5002 NM_001042600 MAP4K1 0.00 0.21 9.27 4.46E-01   
A_33_P3409513 NM_002751 MAPK11 0.02 0.48 8.15 -4.42E-01 #  
A_24_P89835 NM_139021 MAPK15 0.00 0.08 5.44 5.79E-01 #  
A_23_P418015 NM_014268 MAPRE2 0.02 0.46 10.54 -3.68E-01   
A_23_P102242 NM_022826 MARCH7 0.01 0.39 10.09 -3.38E-01   
A_23_P214222 NM_002356 MARCKS 0.01 0.29 9.69 4.27E-01   
A_23_P310 NM_023009 MARCKSL1 0.01 0.30 8.48 -5.11E-01   
A_23_P101992 NM_006770 MARCO 0.00 0.04 10.32 7.40E-01   
A_23_P97677 NM_002379 MATN1 0.02 0.45 5.74 3.21E-01 #  
A_33_P3854030 NM_018328 MBD5 0.02 0.47 6.53 3.63E-01   
A_23_P357811 NM_021038 MBNL1 0.02 0.47 14.74 -3.42E-01   
A_24_P808100 NM_014060 MCTS1 0.01 0.36 8.36 3.54E-01 *  
A_23_P105730 NM_020128 MDM1 0.00 0.26 7.16 -4.17E-01   
A_24_P233915 NM_201542 MED8 0.02 0.45 10.69 -3.29E-01 #  
A_23_P320739 NM_002397 MEF2C 0.00 0.23 10.5 -6.01E-01   
A_32_P129894 NM_001080497 MEGF9 0.01 0.30 8.99 3.86E-01   
A_33_P3402091 NM_006343 MERTK 0.00 0.01 6.21 1.04E+00   
A_23_P164057 NM_002404 MFAP4 0.00 0.13 11.18 -6.41E-01   
A_33_P3270315 NR_026666 MGC16384 0.01 0.33 8.61 3.80E-01 *  
A_23_P110167 NM_002413 MGST2 0.02 0.42 13.19 -3.66E-01   
A_23_P2041 NM_032867 MICALCL 0.01 0.40 6.22 3.46E-01   
A_24_P230916 NM_001077702 MIER1 0.02 0.42 11.19 -3.52E-01 #  
A_32_P108156 NR_001458 MIR155HG 0.01 0.29 6.96 4.17E-01   
A_23_P211680 NM_015166 MLC1 0.01 0.36 15.99 -3.54E-01   
A_33_P3301306 NM_170606 MLL3 0.02 0.43 11.25 -3.65E-01 #  
A_24_P116535 NM_002428 MMP15 0.01 0.30 9.49 -3.82E-01   
A_23_P137935 NM_002432 MNDA 0.00 0.25 13.44 4.42E-01   
Supplementary data 
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A_23_P31064 NM_015529 MOXD1 0.00 0.20 11.28 -4.52E-01   
A_24_P153568 NM_001039396 MPEG1 0.02 0.43 6.16 4.58E-01 #  
A_23_P60579 NM_002435 MPI 0.01 0.37 9.66 -3.65E-01   
A_33_P3215953 NM_024569 MPZL1 0.02 0.42 8.26 -5.46E-01 #  
A_23_P357207 NM_138409 MRAP2 0.02 0.42 6.88 -4.66E-01   
A_24_P279797 NM_001031727 MRI1 0.02 0.47 9.2 -3.11E-01   
A_23_P3979 NM_015971 MRPS7 0.01 0.40 11.7 -3.52E-01   
A_23_P36120 NM_022349 MS4A6A 0.01 0.38 11.09 3.40E-01 #  
A_33_P3379326 NM_138715 MSR1 0.00 0.09 5.7 6.61E-01 #  
A_24_P148796 NM_020998 MST1 0.02 0.48 10.46 3.07E-01   
A_33_P3368313 NM_005951 MT1H 0.01 0.29 7.96 -4.97E-01 #  
A_23_P423695 NM_006454 MXD4 0.01 0.34 10.11 -3.95E-01 #  
A_23_P128362 NM_206819 MYBPC1 0.00 0.27 5.63 -4.08E-01 #  
A_23_P127385 NM_000256 MYBPC3 0.02 0.44 7.5 -3.14E-01   
A_23_P201655 NM_012333 MYCBP 0.02 0.46 12.37 -3.01E-01   
A_23_P377212 NM_138336 MYEOV2 0.00 0.12 5.62 7.31E-01 #  
A_33_P3235004 NM_005964 MYH10 0.00 0.17 5.64 -5.91E-01   
A_23_P59738 NM_021223 MYL7 0.01 0.35 5.96 3.68E-01   
A_33_P3539345 NM_004999 MYO6 0.00 0.22 9.85 -5.07E-01   
A_23_P422350 NM_000260 MYO7A 0.01 0.32 6.9 -4.90E-01 #  
A_23_P1320 NM_021245 MYOZ1 0.00 0.10 6.83 -5.61E-01   
A_23_P251785 NM_024561 NAA16 0.01 0.30 10.14 -5.10E-01 #  
A_24_P66679 NM_001011713 NAA30 0.02 0.46 6.41 -3.22E-01 #  
A_23_P59888 NR_002182 NACAP1 0.01 0.36 12.5 -4.42E-01   
A_33_P3346461 AK311046 NAIP 0.00 0.25 7 4.37E-01 *  
A_23_P110473 NM_004536 NAIP 0.00 0.07 9.84 6.03E-01   
A_24_P703830 NM_001098622 NANOS3 0.02 0.42 6.76 -3.81E-01   
A_33_P3405068 NM_020443 NAV1 0.00 0.08 6.46 6.85E-01 *  
A_24_P102880 NM_020443 NAV1 0.02 0.46 5.54 3.41E-01 *  
A_32_P199429 ENST00000400546 NCAM2 0.02 0.41 8.62 -4.53E-01 #  
A_33_P3299854 NM_002486 NCBP1 0.01 0.35 10.2 -3.60E-01 #  
A_33_P3369393 NM_000265 NCF1 0.01 0.38 11.3 5.03E-01 #  
A_23_P138194 NM_000433 NCF2 0.00 0.13 9.67 6.19E-01   
A_23_P120442 NM_181659 NCOA3 0.01 0.28 9.29 4.23E-01   
A_33_P3344423 NM_001145467 NCR3 0.01 0.40 5.84 -3.33E-01 *  
A_33_P3413188 NR_024493 NCRNA00087 0.02 0.46 9.21 -3.09E-01 #  
A_33_P3279362 NR_027021 NCRNA00110 0.00 0.24 5.66 4.30E-01 #  
A_24_P273143 NR_024204 NCRNA00152 0.01 0.38 10.36 -3.38E-01   
A_33_P3275350 NM_014286 NCS1 0.00 0.23 6.32 -4.24E-01   
A_33_P3404508 NM_001144027 NDOR1 0.00 0.18 8.99 -4.83E-01 #  
A_33_P3403666 NM_001144026 NDOR1 0.02 0.45 6.51 3.11E-01 #  
A_23_P145777 NM_002489 NDUFA4 0.00 0.03 16.02 -7.16E-01   
A_23_P77440 NM_173164 NFATC3 0.01 0.38 10.08 3.47E-01   
A_24_P412512 NM_016350 NIN 0.00 0.23 9.32 -4.86E-01 #  
A_23_P48109 NM_016533 NINJ2 0.00 0.08 10.29 -6.36E-01   
A_33_P3250840 NM_144599 NIPA1 0.00 0.13 11.26 -5.04E-01   
A_23_P120860 NM_003634 NIPSNAP1 0.02 0.45 9.52 -3.16E-01   
A_23_P51376 NM_024522 NKAIN1 0.02 0.48 6.51 -3.23E-01   
A_23_P119042 NM_005601 NKG7 0.01 0.39 11.94 -3.44E-01   
A_23_P207125 NM_020795 NLGN2 0.01 0.30 7.31 3.88E-01   
A_23_P101434 NM_033297 NLRP12 0.00 0.23 5.93 4.26E-01   
A_23_P60387 NM_017617 NOTCH1 0.02 0.44 8.44 3.50E-01   
Supplementary data 
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A_23_P200792 NM_024408 NOTCH2 0.00 0.08 11.78 5.62E-01 # yes 
A_24_P83544 NP239768 NP239768 0.00 0.22 10.51 -4.79E-01   
A_33_P3209497 NP511207 NP511207 0.02 0.46 8.31 4.46E-01   
A_33_P3261869 NM_182795 NPM2 0.00 0.25 8.74 -4.10E-01 #  
A_23_P124905 NM_002522 NPTX1 0.00 0.01 8.39 -1.00E+00   
A_33_P3237775 NM_005693 NR1H3 0.00 0.25 9.63 -4.43E-01   
A_33_P3403117 NM_005654 NR2F1 0.01 0.30 8.01 -3.92E-01   
A_24_P238333 NM_014886 NSA2 0.02 0.47 12.78 -3.18E-01 #  
A_23_P1199 NM_014142 NUDT5 0.01 0.36 11.77 -3.60E-01   
A_33_P3402489 NM_006187 OAS3 0.02 0.46 7.26 -4.40E-01 #  
A_23_P121702 NM_001014446 OCIAD2 0.01 0.34 12.36 -4.05E-01   
A_33_P3376090 NM_001004452 OR1J4 0.00 0.25 6.8 -4.15E-01   
A_33_P3243118 NM_001004704 OR4C6 0.02 0.47 5.74 4.01E-01   
A_24_P302574 NM_022353 OSGEPL1 0.00 0.13 9.46 -5.51E-01   
A_23_P254852 NM_194248 OTOF 0.00 0.11 10.98 5.14E-01   
A_33_P3326647 AK128214 OTOG 0.00 0.18 5.28 -4.77E-01 #  
A_23_P403284 NM_014562 OTX1 0.00 0.19 12.44 -4.51E-01 #  
A_33_P3214481 NM_001142595 P4HA1 0.02 0.44 9.79 -4.13E-01   
A_23_P30363 NM_004199 P4HA2 0.01 0.38 8.62 -4.06E-01 #  
A_33_P3252043 NM_000918 P4HB 0.01 0.35 17.62 -3.58E-01 #  
A_23_P82693 NM_002568 PABPC1 0.01 0.41 16.46 -3.28E-01   
A_33_P3271105 NM_001135654 PABPC4 0.01 0.37 8.45 -3.52E-01 #  
A_32_P123514 NM_001114734 PABPC4L 0.02 0.46 8.77 -3.11E-01   
A_23_P258088 NM_020804 PACSIN1 0.00 0.20 6.54 -4.59E-01   
A_24_P77681 NM_006451 PAIP1 0.01 0.38 10.87 -4.17E-01 #  
A_33_P3384287 NM_002579 PALM 0.00 0.17 10.54 -4.69E-01   
A_32_P133244 NM_002582 PARN 0.02 0.44 10.71 -3.50E-01   
A_32_P144342 NM_006437 PARP4 0.02 0.42 8.68 -3.25E-01 #  
A_23_P121898 NM_024615 PARP8 0.00 0.07 11.73 -6.27E-01   
A_23_P71821 NM_006195 PBX3 0.00 0.14 11.51 -5.13E-01 *  
A_33_P3348887 NM_006195 PBX3 0.00 0.18 10.87 -4.83E-01 *  
A_32_P137980 NM_032973 PCDH11Y 0.01 0.33 5.41 -3.72E-01 *  
A_23_P57709 NM_013363 PCOLCE2 0.02 0.44 11.3 3.26E-01   
A_24_P14731 NM_013271 PCSK1N 0.01 0.34 10.87 -4.80E-01   
A_33_P3394809 NM_002861 PCYT2 0.01 0.39 10.99 -3.46E-01 #  
A_24_P339611 NM_004708 PDCD5 0.00 0.07 12.56 -8.18E-01 *  
A_32_P22338 NM_013374 PDCD6IP 0.00 0.16 11.33 -4.63E-01 #  
A_33_P3389653 NM_001165899 PDE4D 0.01 0.38 9.25 -3.44E-01 #  
A_33_P3326992 NM_014644 PDE4DIP 0.00 0.10 6.96 7.20E-01 *  
A_23_P200801 NM_001002811 PDE4DIP 0.00 0.15 7.53 6.25E-01 *  
A_33_P3323803 NM_014644 PDE4DIP 0.00 0.24 7.49 6.68E-01 *  
A_33_P3272090 NM_014644 PDE4DIP 0.01 0.29 6.43 5.71E-01 *  
A_33_P3286774 AK024906 PDE4DIP 0.02 0.43 6.03 4.23E-01 *  
A_33_P3308223 NM_014644 PDE4DIP 0.02 0.45 5.74 3.35E-01 *  
A_23_P64913 NM_006205 PDE6H 0.01 0.32 6.19 4.24E-01   
A_24_P243749 NM_002612 PDK4 0.00 0.25 6.8 4.82E-01   
A_24_P279870 NM_024411 PDYN 0.02 0.44 6.18 -3.75E-01   
A_33_P3424057 NM_006210 PEG3 0.01 0.29 5.98 -3.92E-01 #  
A_23_P65532 NM_021255 PELI2 0.01 0.40 10.06 3.62E-01   
A_23_P213908 NM_032177 PHAX 0.00 0.22 11.22 -4.91E-01   
A_24_P915692 NM_007350 PHLDA1 0.01 0.35 6.22 3.95E-01   
A_33_P3311083 BC070094 PHLDB3 0.02 0.47 6.27 7.55E-01 #  
Supplementary data 
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A_23_P34307 NM_005482 PIGK 0.01 0.41 10.49 -3.74E-01 #  
A_23_P143484 NM_153681 PIGP 0.01 0.41 10.83 -3.88E-01   
A_23_P66543 NM_014308 PIK3R5 0.02 0.48 6.85 3.02E-01   
A_33_P3235987 NM_006223 PIN4 0.01 0.38 10.39 -3.95E-01 #  
A_33_P3235262 NM_001135219 PIP5KL1 0.01 0.36 9.31 -3.56E-01   
A_23_P84189 NM_181671 PITPNC1 0.01 0.39 7.63 3.57E-01   
A_33_P3240328 NM_002653 PITX1 0.01 0.32 8.69 -3.79E-01 #  
A_33_P3317628 NM_007183 PKP3 0.02 0.46 5.71 3.09E-01   
A_33_P3241316 NM_213600 PLA2G4F 0.02 0.46 5.49 3.44E-01 #  
A_33_P3306146 NM_001145031 PLAU 0.02 0.45 9.29 3.17E-01 *  
A_23_P24104 NM_002658 PLAU 0.01 0.34 12.63 4.05E-01   
A_23_P254801 NM_002660 PLCG1 0.01 0.41 7.95 -3.38E-01   
A_33_P3254946 NM_024927 PLEKHH3 0.01 0.40 11.27 -3.77E-01   
A_23_P30254 NM_006622 PLK2 0.02 0.45 9.29 3.59E-01   
A_33_P3413048 NM_017514 PLXNA3 0.00 0.27 9.68 -4.12E-01   
A_33_P3339103 NM_203290 POLR1C 0.00 0.23 11.71 -4.82E-01 #  
A_33_P3237784 NM_203473 PORCN 0.02 0.44 9.03 3.19E-01   
A_33_P3882624 NM_015450 POT1 0.00 0.01 8.6 -9.39E-01   
A_23_P373724 NM_003622 PPFIBP1 0.01 0.34 8.81 -4.30E-01 #  
A_24_P203226 NM_178230 PPIAL4A 0.02 0.46 15.82 -3.76E-01 *  
A_24_P304723 NM_000942 PPIB 0.00 0.26 13.55 -4.00E-01   
A_23_P422724 NM_000943 PPIC 0.01 0.37 10.36 -4.02E-01   
A_23_P213661 NM_015216 PPIP5K2 0.02 0.43 11.02 -3.24E-01   
A_32_P150030 NM_003620 PPM1D 0.02 0.43 10.16 -3.22E-01 #  
A_23_P35414 NM_005398 PPP1R3C 0.01 0.32 7.47 -4.59E-01   
A_33_P3397399 AK301582 PPP3CB 0.01 0.34 8.38 -3.84E-01 #  
A_33_P3214293 NM_000945 PPP3R1 0.02 0.45 8.31 -6.27E-01 #  
A_23_P356330 NM_015704 PPPDE2 0.02 0.42 8.44 -4.64E-01   
A_33_P3388491 NM_001040125 PQLC2 0.01 0.32 18.36 -6.14E-01   
A_23_P114232 NM_006406 PRDX4 0.00 0.20 14.77 -4.82E-01   
A_23_P413641 NM_020820 PREX1 0.02 0.46 12.9 3.15E-01   
A_23_P44139 NM_000947 PRIM2 0.02 0.46 11.38 -5.05E-01 #  
A_24_P916496 NM_002737 PRKCA 0.01 0.39 12.34 4.48E-01   
A_23_P250564 NM_005400 PRKCE 0.00 0.08 8 5.87E-01   
A_23_P205567 NM_006255 PRKCH 0.00 0.27 6.66 -4.35E-01   
A_23_P1374 NM_006257 PRKCQ 0.00 0.21 7.07 -4.42E-01   
A_24_P165656 NM_005813 PRKD3 0.00 0.19 9.26 -4.64E-01   
A_24_P671164 NM_000949 PRLR 0.00 0.07 7.39 6.41E-01 *  
A_23_P167468 NM_000949 PRLR 0.00 0.10 6.96 6.16E-01 *  
A_33_P3416757 NM_000949 PRLR 0.01 0.32 6.23 5.01E-01 *  
A_33_P3379922 NM_000312 PROC 0.01 0.28 6.3 3.91E-01 #  
A_33_P3403102 NM_175922 PRR18 0.01 0.29 6.38 -3.89E-01 #  
A_23_P121637 NM_003619 PRSS12 0.00 0.05 11.42 -7.21E-01   
A_23_P102864 NM_002772 PRSS7 0.00 0.08 5.67 6.12E-01   
A_33_P3298775 NM_214710 PRSSL1 0.00 0.25 14.38 -8.20E-01   
A_23_P142345 NM_002777 PRTN3 0.02 0.43 15.61 -3.37E-01   
A_23_P259692 NM_058179 PSAT1 0.01 0.41 11.13 -7.66E-01   
A_24_P48587 NM_172341 PSENEN 0.01 0.34 11.82 -3.60E-01   
A_32_P435367 NM_002810 PSMD4 0.02 0.47 15.05 -3.11E-01   
A_23_P48997 NM_003978 PSTPIP1 0.01 0.39 10.63 3.74E-01   
A_24_P102821 NM_000952 PTAFR 0.00 0.04 8.1 6.98E-01 #  
A_33_P3229918 NM_138296 PTCRA 0.00 0.21 8.51 4.31E-01   
Supplementary data 
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A_33_P3298159 NM_000954 PTGDS 0.02 0.46 12.58 -3.51E-01 #  
A_23_P148047 NM_000958 PTGER4 0.02 0.43 13.3 4.59E-01   
A_33_P3346403 NM_001099285 PTMA 0.01 0.31 16.62 -3.76E-01 #  
A_23_P161352 NM_014241 PTPLA 0.00 0.16 10.31 -4.86E-01 *  
A_33_P3235410 BC027709 PTPLA 0.01 0.30 7.37 -3.80E-01 *  
A_23_P210015 NM_014369 PTPN18 0.01 0.33 10.83 4.11E-01 *  
A_33_P3309468 NM_002850 PTPRS 0.01 0.30 10.51 -4.02E-01 #  
A_23_P121064 NM_002852 PTX3 0.01 0.34 6.6 -3.67E-01   
A_23_P130194 NM_006907 PYCR1 0.01 0.37 13.63 -3.47E-01 *  
A_33_P3271930 NM_153824 PYCR1 0.02 0.45 7.55 -3.27E-01 *  
A_23_P34233 NM_014298 QPRT 0.02 0.43 13.41 -3.91E-01   
A_23_P75800 NM_013401 RAB3IL1 0.01 0.41 5.85 -3.25E-01   
A_23_P121222 NM_020165 RAD18 0.02 0.48 8.68 -4.80E-01   
A_33_P3272390 NM_006267 RANBP2 0.00 0.25 9.84 -4.47E-01 #  
A_23_P3371 NM_002891 RASGRF1 0.02 0.45 6.3 -3.27E-01 #  
A_23_P166400 NM_001007279 RASL10A 0.00 0.14 8.61 -5.72E-01   
A_33_P3232562 NM_005610 RBBP4 0.02 0.45 10.44 -3.64E-01 #  
A_33_P3240702 NM_002894 RBBP8 0.02 0.43 10.65 -4.53E-01   
A_23_P132910 NM_019027 RBM47 0.01 0.40 9.15 4.26E-01 #  
A_33_P3382648 NM_001006121 RBMY1B 0.00 0.15 5.59 5.49E-01 #  
A_23_P75283 NM_006744 RBP4 0.02 0.46 5.96 -3.16E-01   
A_23_P67339 NM_020650 RCN3 0.02 0.46 8.55 3.43E-01   
A_23_P203023 NM_002906 RDX 0.02 0.44 9.84 -3.30E-01 #  
A_23_P83028 NM_021111 RECK 0.01 0.38 10.32 3.76E-01 #  
A_23_P19182 NM_016606 REEP2 0.02 0.47 7.57 -3.54E-01   
A_33_P3262789 NM_138393 REEP6 0.01 0.40 9.23 -3.68E-01 #  
A_33_P3312682 NM_020695 REXO1 0.02 0.47 13.78 3.19E-01   
A_24_P20032 NM_000449 RFX5 0.00 0.26 12.48 -4.04E-01 #  
A_23_P320578 NM_002928 RGS16 0.00 0.21 10.08 -5.35E-01 *  
A_23_P217845 NM_002928 RGS16 0.01 0.35 7.77 -3.93E-01 *  
A_23_P302550 NM_130782 RGS18 0.02 0.48 10.99 3.54E-01   
A_23_P46045 NM_003617 RGS5 0.00 0.14 6.25 -5.20E-01 #  
A_23_P26468 NM_003961 RHBDL1 0.01 0.30 11.19 -1.13E+00   
A_23_P58132 NM_004310 RHOH 0.02 0.45 5.43 3.29E-01   
A_23_P73667 NM_001031745 RIBC1 0.02 0.45 6.75 -3.09E-01 #  
A_24_P305570 NM_018993 RIN2 0.02 0.46 6.79 3.97E-01   
A_23_P151820 NM_024832 RIN3 0.01 0.36 7.98 4.12E-01   
A_24_P8088 NM_153005 RIOK1 0.02 0.48 10.45 -3.29E-01   
A_23_P385500 NM_178841 RNF166 0.02 0.48 7.48 -3.79E-01   
A_24_P333019 NM_007219 RNF24 0.00 0.19 9.86 4.51E-01   
A_24_P415601 NM_002939 RNH1 0.01 0.40 13 3.44E-01   
A_24_P48408 NM_003799 RNMT 0.02 0.46 8.69 -3.48E-01 *  
A_33_P3258091 NM_020216 RNPEP 0.02 0.46 13.53 -3.15E-01   
A_23_P100499 NM_024589 ROGDI 0.01 0.28 8.94 4.11E-01   
A_33_P3298535 NM_080748 ROMO1 0.01 0.30 15.14 -3.83E-01 *  
A_23_P143414 NM_080748 ROMO1 0.02 0.46 14.41 -3.41E-01 *  
A_23_P121885 NM_031916 ROPN1L 0.00 0.23 7.18 -4.50E-01   
A_23_P158318 NM_004560 ROR2 0.00 0.06 5.98 8.05E-01 #  
A_32_P42725 XR_040330 RP11-403I13.9 0.00 0.25 7.3 -4.99E-01 #  
A_23_P90143 NM_012423 RPL13A 0.01 0.39 17.99 -3.43E-01 *  
A_32_P118258 NM_000982 RPL21 0.01 0.30 17.96 -3.83E-01 *  
A_23_P26713 NM_000978 RPL23 0.01 0.39 18 -3.33E-01 #  
Supplementary data 
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A_33_P3382560 NM_000984 RPL23A 0.01 0.35 15.62 -1.09E+00 #  
A_33_P3295066 NR_026673 RPL23P8 0.01 0.38 16.9 -3.54E-01   
A_33_P3299319 NM_001136137 RPL28 0.02 0.45 7.31 3.11E-01 #  
A_24_P7085 NR_002778 RPL29P2 0.01 0.41 14.07 -4.45E-01   
A_23_P7221 NM_033625 RPL34 0.00 0.17 17.01 -4.61E-01 #  
A_23_P44956 NM_000996 RPL35A 0.02 0.46 18 -3.10E-01   
A_23_P142724 NM_000998 RPL37A 0.02 0.46 17.99 -3.29E-01 #  
A_32_P225604 NM_000969 RPL5 0.00 0.22 17.58 -4.36E-01 *  
A_33_P3246163 NM_000969 RPL5 0.01 0.41 17.92 -3.35E-01 *  
A_24_P63262 NM_002950 RPN1 0.01 0.39 11.9 -3.68E-01   
A_32_P3476 NM_203400 RPRML 0.01 0.32 5.69 -3.75E-01 #  
A_32_P14894 NM_001014 RPS10 0.02 0.45 17.19 -3.41E-01 #  
A_32_P14744 NM_001019 RPS15A 0.01 0.29 16.99 -3.84E-01 #  
A_23_P47357 NM_001028 RPS25 0.02 0.45 17.56 -3.32E-01   
A_23_P116694 NM_001029 RPS26 0.00 0.05 16.8 -8.48E-01 #  
A_23_P157196 NR_026676 RPS2P32 0.00 0.27 16.13 -7.42E-01 #  
A_23_P35791 NM_003942 RPS6KA4 0.02 0.46 10.48 3.10E-01   
A_24_P465772 NR_026825 RPSAP52 0.02 0.43 14.77 -3.26E-01   
A_23_P133691 NM_021244 RRAGD 0.01 0.28 10.51 4.15E-01   
A_23_P54605 NM_015659 RSL1D1 0.02 0.46 12.13 -3.16E-01 #  
A_24_P203502 XM_001714653 RSL24D1P11 0.01 0.29 9.34 -3.90E-01   
A_23_P102950 NM_080860 RSPH1 0.01 0.41 6.06 -4.01E-01   
A_33_P3390335 NM_012425 RSU1 0.01 0.39 10.83 -3.78E-01 #  
A_33_P3362371 NM_201430 RTN3 0.02 0.47 8.36 -3.67E-01 #  
A_33_P3341841 NM_001004312 RTP2 0.01 0.30 5.78 4.67E-01   
A_32_P161762 NM_004348 RUNX2 0.02 0.43 6.27 4.63E-01 #  
A_23_P74001 NM_005621 S100A12 0.00 0.25 7.05 8.38E-01 *  
A_33_P3385785 NM_005621 S100A12 0.01 0.36 6.44 5.36E-01 *  
A_23_P115467 NM_002962 S100A5 0.00 0.27 7.43 5.84E-01   
A_23_P119448 NM_014931 SAPS1 0.02 0.43 8.96 -3.41E-01   
A_24_P158421 NM_020150 SAR1A 0.02 0.47 11.49 -3.79E-01 #  
A_23_P90484 NM_017827 SARS2 0.00 0.06 9.91 -7.39E-01   
A_24_P237443 NM_018990 SASH3 0.00 0.12 9.85 5.88E-01   
A_23_P259741 NM_002971 SATB1 0.02 0.45 12.63 -3.56E-01   
A_33_P3352019 NM_182826 SCARA3 0.01 0.31 5.53 4.00E-01 #  
A_33_P3417459 NR_023358 SCARNA9L 0.00 0.19 8.35 -4.71E-01   
A_33_P3228023 NM_021626 SCPEP1 0.01 0.41 8.6 3.40E-01 *  
A_23_P366366 NM_014766 SCRN1 0.02 0.47 9.38 -3.46E-01 #  
A_23_P17012 NM_024583 SCRN3 0.02 0.45 6.75 -3.32E-01 #  
A_23_P109034 NM_002999 SDC4 0.01 0.35 7.85 3.70E-01   
A_23_P208009 NM_033280 SEC11C 0.01 0.34 13.78 -4.07E-01   
A_23_P23438 NM_022367 SEMA4A 0.01 0.30 9.35 3.80E-01   
A_24_P261169 NM_006378 SEMA4D 0.01 0.37 8.03 3.86E-01 #  
A_33_P3372727 NM_003966 SEMA5A 0.00 0.10 5.99 5.69E-01   
A_33_P3284919 NM_030913 SEMA6C 0.01 0.34 8.17 -3.81E-01 #  
A_33_P3376644 NM_015571 SENP6 0.00 0.25 8.84 4.93E-01 *  
A_33_P3386429 NM_015571 SENP6 0.01 0.33 7.24 4.84E-01 *  
A_23_P121926 NM_005410 SEPP1 0.02 0.43 5.59 -3.30E-01   
A_33_P3329686 NM_002688 SEPT5 0.02 0.41 8.2 -3.50E-01 #  
A_23_P218111 NM_001002236 SERPINA1 0.02 0.42 7.29 3.41E-01 #  
A_23_P313981 NM_005024 SERPINB10 0.00 0.12 7.36 5.05E-01   
A_24_P245379 NM_002575 SERPINB2 0.00 0.01 9.14 8.16E-01   
Supplementary data 
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A_24_P147461 NM_001031848 SERPINB8 0.00 0.07 10.15 6.67E-01   
A_23_P35082 NM_031459 SESN2 0.02 0.47 7.96 3.11E-01   
A_32_P456318 NM_080743 SFRS13B 0.01 0.39 7.96 -3.95E-01   
A_33_P3305840 NM_001031684 SFRS7 0.02 0.45 13.99 -3.28E-01 #  
A_24_P333857 NM_032291 SGIP1 0.01 0.39 6.25 -3.62E-01 *  
A_23_P19673 NM_005627 SGK1 0.00 0.01 8.39 1.10E+00   
A_32_P163125 NM_147156 SGMS1 0.00 0.08 8.11 7.54E-01   
A_33_P3333033 AK125203 SGSM2 0.02 0.44 11.41 -3.20E-01 #  
A_24_P686965 NM_001103161 SH2D5 0.00 0.10 7.27 6.23E-01   
A_32_P205624 NM_012435 SHC2 0.00 0.24 6.29 -4.13E-01 #  
A_33_P3417339 NM_020859 SHROOM3 0.02 0.48 5.54 -3.47E-01 #  
A_33_P3382498 NM_001098612 SIGLEC14 0.02 0.48 9.15 3.54E-01 #  
A_33_P3211734 NM_001102396 SIKE1 0.00 0.24 12.45 -4.34E-01 *  
A_33_P3383261 NM_001102396 SIKE1 0.01 0.35 12.68 -3.62E-01 *  
A_24_P937855 NM_001102396 SIKE1 0.01 0.39 9.01 -3.53E-01 *  
A_23_P216340 NM_001045556 SLA 0.00 0.16 11.34 4.67E-01   
A_24_P13311 NM_145648 SLC15A4 0.01 0.39 9.89 3.51E-01 *  
A_33_P3481987 NM_213606 SLC16A12 0.00 0.14 17.67 -4.82E-01   
A_23_P118741 NM_201566 SLC16A13 0.02 0.47 5.64 3.20E-01   
A_23_P137097 NM_006517 SLC16A2 0.00 0.13 7.63 -6.48E-01   
A_23_P93213 NM_153320 SLC22A7 0.02 0.42 5.63 3.45E-01 #  
A_23_P25204 NM_213611 SLC25A3 0.01 0.32 17.02 -4.17E-01   
A_23_P408455 NM_001104647 SLC25A36 0.02 0.45 11.12 -3.21E-01 #  
A_24_P64100 AF495725 SLC25A37 0.02 0.43 11.1 3.17E-01 #  
A_33_P3281537 ENST00000271857 SLC27A3 0.01 0.32 5.59 5.17E-01 #  
A_33_P3251108 NM_004733 SLC33A1 0.02 0.46 8.47 -5.17E-01   
A_33_P3261737 NM_005660 SLC35A2 0.00 0.17 7.98 -5.13E-01 *  
A_23_P69840 NM_080670 SLC35A4 0.02 0.45 10.17 3.23E-01 #  
A_33_P3369799 NM_001008783 SLC35D3 0.02 0.47 7.28 -3.42E-01   
A_23_P413888 NM_001029858 SLC35F1 0.01 0.32 7.99 -4.08E-01 #  
A_33_P3474319 NM_198277 SLC37A2 0.00 0.22 6.56 5.82E-01 #  
A_24_P382467 NM_144564 SLC39A3 0.01 0.38 10.51 -3.56E-01   
A_24_P46093 NM_003043 SLC6A6 0.01 0.41 11.31 3.50E-01 #  
A_32_P147078 NM_021097 SLC8A1 0.00 0.01 6.79 1.15E+00 #  
A_24_P136866 NM_021097 SLC8A1 0.01 0.30 5.7 4.27E-01 #  
A_33_P3319542 NM_015063 SLC8A2 0.02 0.46 5.27 -3.07E-01   
A_23_P389141 NM_144990 SLFNL1 0.02 0.45 6.72 -3.30E-01   
A_23_P48936 NM_005902 SMAD3 0.02 0.46 10.8 3.16E-01   
A_23_P70818 NM_005631 SMO 0.02 0.48 8.36 -3.41E-01   
A_23_P163567 NM_018667 SMPD3 0.02 0.43 8.61 -3.79E-01   
A_23_P72117 NM_006714 SMPDL3A 0.00 0.12 6 5.05E-01   
A_24_P83922 NM_003093 SNRPC 0.00 0.25 8.78 -4.76E-01 #  
A_33_P3320152 NM_003094 SNRPE 0.00 0.24 12.04 -4.53E-01 *  
A_33_P3265355 NM_003094 SNRPE 0.01 0.38 13.74 -3.56E-01 *  
A_24_P347624 NM_022804 SNURF 0.01 0.33 12.82 -3.77E-01   
A_23_P154585 NM_001042633 SNX21 0.01 0.41 7.3 3.48E-01 #  
A_23_P128215 NM_003877 SOCS2 0.00 0.03 12.73 -1.07E+00  yes 
A_23_P207058 NM_003955 SOCS3 0.00 0.14 7.32 5.27E-01   
A_23_P77103 NM_003104 SORD 0.02 0.46 10.74 -3.30E-01 #  
A_23_P87049 NM_003105 SORL1 0.00 0.07 12.21 5.93E-01   
A_23_P85703 NM_005686 SOX13 0.02 0.45 6.37 3.43E-01 #  
A_24_P911676 NM_003107 SOX4 0.00 0.04 8.25 -8.40E-01   
Supplementary data 
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Probe name 
Systematic 
name 
Gene name p-value 
adj.  
p-value 
Ave Expr log2FC 1) 
confirmed 
via         
qRT-PCR 
A_33_P3383184 ENST00000394967 SP9 0.00 0.00 6.67 -1.19E+00 #  
A_33_P3382924 NM_003118 SPARC 0.01 0.39 9.23 -3.68E-01   
A_33_P3299000 NM_031952 SPATA9 0.01 0.29 6.28 -4.65E-01 #  
A_33_P3332666 NM_020126 SPHK2 0.01 0.36 7 3.67E-01 #  
A_23_P49060 NM_181642 SPINT1 0.02 0.43 8.35 3.32E-01   
A_23_P27795 NM_021102 SPINT2 0.00 0.13 11.11 -5.09E-01   
A_24_P551028 NM_001001664 SPOPL 0.02 0.46 9.73 3.20E-01   
A_23_P7313 NM_001040058 SPP1 0.01 0.32 5.37 3.81E-01   
A_24_P388810 NM_003135 SRP19 0.01 0.35 10.83 -3.59E-01   
A_23_P136978 NM_014467 SRPX2 0.02 0.47 5.67 -3.91E-01   
A_23_P102060 NM_006751 SSFA2 0.01 0.41 11.95 4.32E-01   
A_23_P250800 NM_006100 ST3GAL6 0.01 0.35 10.89 3.69E-01   
A_33_P3380751 NM_003034 ST8SIA1 0.00 0.15 6.96 -6.10E-01 #  
A_33_P3291484 NM_005668 ST8SIA4 0.01 0.32 9.26 4.04E-01 #  
A_33_P3364696 NM_213622 STAMBP 0.01 0.29 9.87 -4.92E-01   
A_33_P3382147 AY082592 STARD13 0.02 0.42 10.26 3.52E-01 #  
A_23_P344481 NM_152709 STOX1 0.02 0.47 7.05 -3.12E-01 #  
A_24_P163237 NM_020225 STOX2 0.01 0.38 9.43 3.52E-01   
A_24_P203308 NM_182489 STRA8 0.00 0.19 6.55 -5.45E-01   
A_23_P104734 NM_152713 STT3A 0.02 0.45 10.99 -4.14E-01   
A_23_P156788 NM_003764 STX11 0.01 0.34 8.16 3.66E-01   
A_23_P154605 NM_018837 SULF2 0.00 0.11 8.32 6.60E-01  yes 
A_23_P106773 NM_177528 SULT1A2 0.00 0.10 9.84 -6.73E-01   
A_32_P223189 NR_002190 SUMO1P3 0.01 0.37 9.49 -3.67E-01   
A_24_P89971 NM_033161 SURF4 0.01 0.38 12.1 -3.44E-01 #  
A_33_P3370461 NR_024187 SUZ12P 0.00 0.08 16.4 -7.61E-01 #  
A_23_P722 NM_003176 SYCP1 0.00 0.01 10.41 -9.74E-01   
A_23_P210675 NM_014258 SYCP2 0.00 0.25 6.92 5.48E-01   
A_23_P9255 NM_003177 SYK 0.01 0.39 12.53 3.34E-01   
A_33_P3324839 NM_006772 SYNGAP1 0.01 0.33 5.89 4.52E-01 #  
A_33_P3284404 NM_145731 SYNGR1 0.01 0.40 11.55 -3.41E-01 *  
A_33_P3397658 ENST00000394243 SYNPO 0.00 0.07 6.7 -6.15E-01 *  
A_23_P344531 NM_007286 SYNPO 0.00 0.14 7.23 -4.89E-01 *  
A_33_P3390868 NM_133477 SYNPO2 0.00 0.08 10.15 -8.07E-01 #  
A_33_P3237201 NM_001135805 SYT1 0.01 0.41 5.42 4.16E-01 #  
A_33_P3214899 NM_001136504 SYT2 0.01 0.41 5.59 3.39E-01 *  
A_33_P3286973 ENST00000339381 TAS1R3 0.00 0.00 9.8 -2.01E+00 #  
A_24_P330633 NM_000353 TAT 0.01 0.38 6.42 4.57E-01   
A_33_P3216292 NM_018421 TBC1D2 0.01 0.41 11.2 3.91E-01   
A_24_P168994 NM_178571 TBC1D26 0.01 0.39 6.63 -3.50E-01   
A_33_P3327539 NM_015130 TBC1D9 0.01 0.34 7.03 3.81E-01 #  
A_23_P90357 NM_001060 TBXA2R 0.01 0.38 9.24 -3.74E-01 #  
A_33_P3325808 XM_001723171 tcag7.1058 0.02 0.44 7.46 -3.47E-01   
A_23_P147641 NM_003195 TCEA2 0.02 0.43 8.57 3.20E-01 #  
A_23_P34375 NM_003196 TCEA3 0.00 0.23 5.53 4.55E-01   
A_32_P18470 NM_001012979 TCEAL5 0.01 0.40 9.59 -3.57E-01   
A_32_P192545 NM_001006938 TCEAL6 0.01 0.39 10.4 -3.47E-01 #  
A_23_P254816 NM_004609 TCF15 0.01 0.38 10.99 3.81E-01   
A_33_P3381684 NM_007113 TCHH 0.01 0.27 5.73 -4.08E-01 *  
A_32_P98072 NM_007113 TCHH 0.02 0.43 8.17 -4.92E-01 *  
A_23_P40611 NM_000355 TCN2 0.02 0.44 5.6 -3.63E-01   
A_32_P38283 NM_174910 TCTE3 0.01 0.39 6.78 -4.44E-01   
Supplementary data 
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Probe name 
Systematic 
name 
Gene name p-value 
adj.  
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Ave Expr log2FC 1) 
confirmed 
via         
qRT-PCR 
A_33_P3404779 NM_001013632 TCTEX1D4 0.00 0.19 6.15 4.49E-01 *  
A_23_P82000 NM_003214 TEAD3 0.01 0.34 8.38 -5.00E-01   
A_23_P112412 NM_017746 TEX10 0.01 0.38 11.33 -3.43E-01   
A_23_P10518 NM_016521 TFDP3 0.00 0.08 7.74 -7.50E-01   
A_33_P3398634 NM_007162 TFEB 0.01 0.32 11.48 -4.09E-01 #  
A_24_P345822 NM_006070 TFG 0.02 0.44 11.96 -3.46E-01   
A_33_P3331451 NM_004612 TGFBR1 0.00 0.23 9.38 4.52E-01  yes 
A_33_P3320112 THC2471881 THC2471881 0.00 0.05 5.47 6.50E-01   
A_33_P3337931 THC2502236 THC2502236 0.00 0.17 8.9 4.66E-01   
A_33_P3371305 THC2507457 THC2507457 0.02 0.42 5.52 3.31E-01   
A_33_P3372161 THC2507627 THC2507627 0.01 0.29 15.99 -3.94E-01   
A_33_P3273424 THC2516883 THC2516883 0.01 0.41 5.48 3.56E-01   
A_33_P3375002 THC2518870 THC2518870 0.00 0.02 8.6 -9.00E-01   
A_33_P3235454 THC2542270 THC2542270 0.00 0.00 8.04 -1.68E+00   
A_24_P127312 THC2554858 THC2554858 0.01 0.37 12.87 -4.00E-01   
A_33_P3292130 THC2566648 THC2566648 0.02 0.43 12.08 6.11E-01   
A_33_P3322046 THC2596076 THC2596076 0.00 0.22 6.91 -7.67E-01   
A_33_P3255782 THC2600290 THC2600290 0.02 0.43 16.96 -3.32E-01   
A_33_P3230493 THC2727687 THC2727687 0.00 0.23 5.43 5.17E-01   
A_33_P3325384 THC2752493 THC2752493 0.00 0.14 7.33 -5.18E-01   
A_23_P149375 NM_053055 THEM4 0.00 0.18 9.41 -5.05E-01 #  
A_24_P400324 NM_015204 THSD7A 0.01 0.33 10.28 -4.62E-01   
A_23_P208937 NM_024760 TLE6 0.02 0.46 6.1 3.27E-01 *  
A_24_P193498 NM_078474 TM2D3 0.01 0.41 8.91 -3.38E-01   
A_23_P116037 NM_003273 TM7SF2 0.01 0.38 9.36 -3.45E-01   
A_23_P204702 NM_003217 TMBIM6 0.02 0.48 13.97 -2.96E-01 #  
A_23_P346093 NM_152468 TMC8 0.02 0.45 9.09 3.19E-01 #  
A_23_P355067 NM_019026 TMCO1 0.02 0.48 12.2 -3.85E-01   
A_32_P87649 NM_001008740 TMCO2 0.00 0.18 6.74 -4.84E-01   
A_23_P26173 NM_007364 TMED3 0.01 0.33 13 -3.74E-01   
A_32_P123088 NM_001164468 TMED7-TICAM2 0.02 0.45 8.4 -3.10E-01 #  
A_33_P3282566 NM_017728 TMEM104 0.00 0.23 10.75 -4.32E-01 #  
A_24_P119131 NM_001080825 TMEM120B 0.01 0.34 7.42 -4.03E-01 #  
A_23_P13524 NM_032273 TMEM126A 0.02 0.45 12.71 -3.14E-01   
A_24_P161959 NM_199337 TMEM179B 0.00 0.20 10.17 -4.83E-01   
A_23_P255601 NM_032508 TMEM185A 0.02 0.46 9.14 -3.09E-01   
A_32_P40288 NM_052913 TMEM200A 0.01 0.37 5.37 -4.08E-01   
A_24_P371281 NM_025246 TMEM22 0.01 0.38 6.25 -4.95E-01   
A_33_P3230219 NM_033504 TMEM54 0.00 0.12 9.93 -5.23E-01   
A_24_P100673 NM_016454 TMEM85 0.01 0.30 13.31 -4.10E-01 *  
A_23_P114952 NM_016456 TMEM9 0.02 0.48 9.67 -3.19E-01   
A_24_P307289 NM_198154 TMEM95 0.01 0.31 9.14 -4.19E-01   
A_23_P68106 NM_021103 TMSB10 0.02 0.47 13.81 -3.26E-01   
A_24_P374516 NM_021109 TMSB4X 0.02 0.46 15.25 3.26E-01   
A_32_P2452 NM_175861 TMTC1 0.01 0.36 8.67 3.62E-01 #  
A_23_P104942 NM_015959 TMX2 0.01 0.39 11.69 -4.41E-01   
A_23_P139722 NM_001065 TNFRSF1A 0.00 0.27 11.12 -4.64E-01   
A_23_P30666 NM_014452 TNFRSF21 0.01 0.35 10.7 3.93E-01   
A_33_P3397865 NM_003283 TNNT1 0.01 0.28 11.2 3.97E-01   
A_33_P3321711 NM_006809 TOMM34 0.00 0.09 9.98 -5.78E-01 #  
A_24_P15754 NM_006114 TOMM40 0.02 0.45 10.42 -3.23E-01 #  
A_23_P336644 NM_145034 TOR1AIP2 0.01 0.36 8.84 -3.48E-01 #  
Supplementary data 
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confirmed 
via         
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A_24_P327050 NM_016209 TRAPPC2L 0.02 0.44 12.55 -3.19E-01   
A_33_P3319905 AK292162 TREM1 0.02 0.46 6.08 3.04E-01 #  
A_33_P3424367 NM_033219 TRIM14 0.02 0.46 8.41 3.07E-01 #  
A_23_P402778 NM_138700 TRIM40 0.00 0.24 5.56 4.37E-01   
A_23_P425880 NM_007118 TRIO 0.00 0.13 6.61 5.30E-01 *  
A_33_P3415500 ENST00000344204 TRIO 0.00 0.25 7.17 5.06E-01 *  
A_23_P71170 NM_018646 TRPV6 0.01 0.31 5.67 3.92E-01 #  
A_23_P17103 NM_025244 TSGA10 0.01 0.39 7.02 1.03E+00 #  
A_23_P215070 NM_018718 TSGA14 0.01 0.38 8.75 -3.94E-01   
A_23_P361014 NM_020856 TSHZ3 0.00 0.05 7.7 7.27E-01   
A_23_P160167 NM_005727 TSPAN1 0.02 0.46 6.85 -3.18E-01   
A_24_P135483 NM_030927 TSPAN14 0.00 0.24 8.57 4.16E-01 * yes 
A_23_P171143 NM_003270 TSPAN6 0.01 0.34 8.06 -3.76E-01   
A_23_P254031 NM_007344 TTF1 0.01 0.33 9.61 -3.98E-01 #  
A_33_P3385993 NM_001008409 TTLL9 0.01 0.41 6.18 3.99E-01 #  
A_23_P11397 NR_001537 TTTY13 0.00 0.24 6.41 -4.24E-01   
A_23_P113656 NM_006087 TUBB4 0.00 0.18 6.06 4.87E-01   
A_23_P127150 NM_006659 TUBGCP2 0.02 0.47 11.43 -3.17E-01   
A_23_P3450 NM_014444 TUBGCP4 0.02 0.42 9.59 -3.36E-01   
A_23_P434398 NM_153235 TXLNB 0.00 0.23 6.36 -5.42E-01   
A_23_P200199 NM_015913 TXNDC12 0.01 0.29 12.22 -4.78E-01   
A_33_P3209386 NM_032731 TXNDC17 0.02 0.46 8.41 -3.61E-01   
A_23_P259611 NM_016616 TXNDC3 0.02 0.47 10.13 5.38E-01   
A_23_P97700 NM_006472 TXNIP 0.02 0.45 13.39 3.53E-01   
A_23_P141917 NM_003331 TYK2 0.02 0.45 8.66 3.11E-01   
A_23_P123866 NM_016525 UBAP1 0.02 0.47 9.87 -3.21E-01   
A_33_P3310989 NM_014847 UBAP2L 0.01 0.39 9.22 -3.35E-01 *  
A_24_P13032 NM_003338 UBE2D1 0.01 0.39 10.02 -3.97E-01   
A_23_P78563 NM_024292 UBL5 0.00 0.08 14.98 -6.13E-01   
A_23_P166333 NM_005659 UFD1L 0.01 0.30 12.2 -4.55E-01 #  
A_24_P313109 NM_016617 UFM1 0.02 0.48 8.13 -4.32E-01 #  
A_23_P204980 NM_020121 UGGT2 0.00 0.14 11.8 -5.01E-01 #  
A_23_P69617 NM_003728 UNC5C 0.01 0.35 6.99 -3.78E-01 #  
A_23_P171366 NM_004651 USP11 0.02 0.46 11.36 -3.10E-01 #  
A_24_P322908 NM_001145073 USP27X 0.01 0.41 6.38 3.77E-01 *  
A_23_P67829 NM_025076 UXS1 0.02 0.48 11.43 -3.05E-01   
A_23_P77000 NM_014909 VASH1 0.00 0.14 10.95 4.88E-01  yes 
A_23_P115492 NM_024749 VASH2 0.01 0.32 7.24 -3.75E-01   
A_23_P400449 NM_020927 VAT1L 0.01 0.39 6.01 -3.46E-01   
A_23_P144959 NM_004385 VCAN 0.00 0.24 6.06 4.72E-01   
A_32_P33083 NM_016378 VCX2 0.02 0.44 12.13 3.28E-01 #  
A_23_P162589 NM_001017535 VDR 0.00 0.06 10.66 6.70E-01  yes 
A_24_P294982 NM_016485 VTA1 0.01 0.41 10.45 -3.66E-01 *  
A_23_P42368 NM_016485 VTA1 0.02 0.48 10.08 -3.04E-01 *  
A_23_P10785 NM_145206 VTI1A 0.01 0.34 8.41 -3.70E-01   
A_33_P3395743 NM_022834 VWA1 0.00 0.01 7.92 -1.01E+00 #  
A_33_P3416668 NM_022834 VWA1 0.01 0.30 5.96 3.81E-01 #  
A_23_P52986 NM_152718 VWCE 0.01 0.36 7.67 -6.18E-01 *  
A_33_P3414487 NM_017528 WBSCR22 0.02 0.47 12.75 -3.07E-01   
A_24_P83379 NM_178583 WDFY3 0.01 0.30 10.56 -3.92E-01 #  
A_24_P389038 NM_005452 WDR46 0.02 0.46 9.58 3.14E-01   
A_23_P49021 NM_025234 WDR61 0.01 0.37 12.41 -3.61E-01   
Supplementary data 
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confirmed 
via         
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A_23_P106617 NM_021197 WFDC1 0.00 0.05 7.11 -6.40E-01   
A_24_P769359 NM_018979 WNK1 0.00 0.08 11.74 -5.48E-01   
A_23_P102117 NM_025216 WNT10A 0.01 0.31 5.72 4.88E-01   
A_23_P34176 NM_015691 WWC3 0.01 0.38 7.72 3.85E-01   
A_23_P120845 NM_005080 XBP1 0.00 0.25 12.54 -4.05E-01   
A_23_P218793 NM_022098 XPNPEP3 0.02 0.45 7.6 -3.16E-01   
A_33_P3363515 CR610241 XRCC3 0.01 0.32 16.96 -4.72E-01 #  
A_23_P166135 NM_012255 XRN2 0.02 0.43 11.12 -3.45E-01   
A_23_P47226 NM_020470 YIF1A 0.02 0.45 13.18 -3.12E-01 #  
A_33_P3613000 NM_001105539 ZBTB10 0.02 0.47 6.93 8.13E-01   
A_23_P218807 NM_017590 ZC3H7B 0.01 0.37 9.22 -3.72E-01   
A_23_P51853 NM_032283 ZDHHC18 0.01 0.39 8.25 3.40E-01   
A_24_P374427 NM_178566 ZDHHC21 0.02 0.46 7.33 -3.04E-01 #  
A_23_P355447 NM_174976 ZDHHC22 0.00 0.26 6.21 4.71E-01 #  
A_23_P161183 NM_022494 ZDHHC6 0.01 0.34 9.44 -4.08E-01   
A_23_P99540 NM_004926 ZFP36L1 0.01 0.38 7.08 4.51E-01 *  
A_33_P3417865 NM_004926 ZFP36L1 0.02 0.43 7.14 3.45E-01 *  
A_23_P101960 NM_006887 ZFP36L2 0.00 0.12 12.73 5.53E-01   
A_33_P3222744 NM_015852 ZNF117 0.01 0.30 10.55 -4.15E-01   
A_23_P84910 NM_003446 ZNF157 0.02 0.45 8.25 -3.65E-01   
A_24_P22981 NM_021047 ZNF253 0.02 0.48 7.27 -3.49E-01   
A_32_P144908 NM_203282 ZNF254 0.02 0.46 14.25 -3.21E-01 #  
A_23_P209032 NM_018443 ZNF302 0.00 0.26 8.68 -4.22E-01   
A_33_P3343442 XR_079205 ZNF316 0.01 0.36 11.6 -3.64E-01   
A_33_P3302736 NM_001166012 ZNF397OS 0.01 0.33 6.8 -4.19E-01 #  
A_33_P3736691 NM_025189 ZNF430 0.01 0.34 8.85 -4.11E-01 #  
A_23_P101476 NM_030824 ZNF442 0.01 0.38 6.92 -3.56E-01   
A_23_P67278 NM_005815 ZNF443 0.02 0.46 7.27 -3.38E-01   
A_23_P115861 NM_145312 ZNF485 0.01 0.36 7.04 -3.60E-01   
A_24_P332862 NM_001076678 ZNF493 0.01 0.37 10.44 -5.70E-01 #  
A_23_P159027 NM_015461 ZNF521 0.00 0.03 11.22 -7.29E-01 * yes 
A_33_P3219398 NM_015461 ZNF521 0.00 0.08 9.34 -7.08E-01 * yes 
A_32_P139229 NM_213598 ZNF543 0.02 0.46 8.11 3.22E-01   
A_23_P416751 NM_173530 ZNF610 0.01 0.39 6.22 -3.73E-01   
A_24_P205036 NM_001001411 ZNF676 0.01 0.34 7.1 -3.67E-01 #  
A_32_P68148 NR_027130 ZNF738 0.01 0.40 11.24 -8.41E-01 #  
A_33_P3344816 NM_001004301 ZNF813 0.02 0.43 7.66 -3.53E-01 #  
A_24_P323967 NM_001145434 ZNF880 0.02 0.46 7.25 -3.39E-01 #  
A_24_P358619 NM_001080409 ZNF99 0.00 0.22 8.6 -4.56E-01 #  
A_24_P162373 NM_032173 ZNRF3 0.02 0.48 10.46 3.20E-01 #  
A_33_P3229276 NM_001007072 ZSCAN2 0.02 0.47 6.97 -2.99E-01 #  
A_24_P153324 A_24_P153324 A_24_P153324 0.00 0.08 13.6 -5.75E-01   
A_24_P161914 A_24_P161914 A_24_P161914 0.01 0.28 11.62 -3.94E-01   
A_24_P170395 A_24_P170395 A_24_P170395 0.01 0.39 6.19 -3.52E-01   
A_24_P187023 A_24_P187023 A_24_P187023 0.01 0.33 15.07 -4.02E-01   
A_24_P221485 A_24_P221485 A_24_P221485 0.01 0.33 6.14 -4.85E-01   
A_24_P24724 A_24_P24724 A_24_P24724 0.02 0.47 12.21 -1.10E+00   
A_24_P306964 A_24_P306964 A_24_P306964 0.02 0.42 13.23 -3.29E-01   
A_24_P307306 A_24_P307306 A_24_P307306 0.01 0.36 8.33 -3.70E-01   
A_24_P307384 A_24_P307384 A_24_P307384 0.00 0.22 8.44 -5.98E-01   
A_24_P349387 A_24_P349387 A_24_P349387 0.00 0.17 15.68 -7.06E-01   
A_24_P358305 A_24_P358305 A_24_P358305 0.01 0.30 7.54 -3.92E-01   
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Probe name 
Systematic 
name 
Gene name p-value 
adj.  
p-value 
Ave Expr log2FC 1) 
confirmed 
via         
qRT-PCR 
A_24_P374973 A_24_P374973 A_24_P374973 0.01 0.37 8.17 -5.37E-01   
A_24_P384200 A_24_P384200 A_24_P384200 0.00 0.23 8.67 -4.78E-01   
A_24_P401100 A_24_P401100 A_24_P401100 0.02 0.43 17 -3.18E-01   
A_24_P409824 A_24_P409824 A_24_P409824 0.01 0.38 7.28 -7.36E-01   
A_24_P418536 A_24_P418536 A_24_P418536 0.00 0.19 10.44 -5.49E-01   
A_24_P42014 A_24_P42014 A_24_P42014 0.00 0.13 17.02 -4.84E-01   
A_24_P662366 A_24_P662366 A_24_P662366 0.00 0.18 8.61 -4.68E-01   
A_24_P739582 A_24_P739582 A_24_P739582 0.01 0.35 6.45 -4.95E-01   
A_24_P878388 A_24_P878388 A_24_P878388 0.01 0.34 15.53 -3.62E-01   
A_24_P92267 A_24_P92267 A_24_P92267 0.02 0.42 7.15 -3.54E-01   
A_32_P212373 A_32_P212373 A_32_P212373 0.01 0.41 10.77 -3.92E-01   
A_33_P3213561 A_33_P3213561 A_33_P3213561 0.00 0.08 9.42 -7.15E-01   
A_33_P3227556 A_33_P3227556 A_33_P3227556 0.02 0.42 8.74 -3.36E-01   
A_33_P3230676 A_33_P3230676 A_33_P3230676 0.00 0.11 5.47 5.54E-01   
A_33_P3235184 A_33_P3235184 A_33_P3235184 0.00 0.15 10.81 -5.20E-01   
A_33_P3235831 A_33_P3235831 A_33_P3235831 0.01 0.32 7.7 -3.91E-01   
A_33_P3238461 A_33_P3238461 A_33_P3238461 0.02 0.45 16.01 -1.07E+00   
A_33_P3249002 A_33_P3249002 A_33_P3249002 0.00 0.27 14.05 -4.41E-01   
A_33_P3249066 A_33_P3249066 A_33_P3249066 0.01 0.38 7.69 -4.42E-01   
A_33_P3259239 A_33_P3259239 A_33_P3259239 0.01 0.30 5.46 3.99E-01   
A_33_P3263157 A_33_P3263157 A_33_P3263157 0.01 0.38 11.09 8.13E-01   
A_33_P3263629 A_33_P3263629 A_33_P3263629 0.02 0.45 5.59 3.52E-01   
A_33_P3265260 A_33_P3265260 A_33_P3265260 0.00 0.27 5.41 -4.65E-01   
A_33_P3279456 A_33_P3279456 A_33_P3279456 0.01 0.34 15.62 -1.03E+00   
A_33_P3279526 A_33_P3279526 A_33_P3279526 0.01 0.37 7.94 -3.91E-01   
A_33_P3284584 A_33_P3284584 A_33_P3284584 0.00 0.13 9.58 -6.49E-01   
A_33_P3285097 A_33_P3285097 A_33_P3285097 0.01 0.38 6.05 3.48E-01   
A_33_P3288079 A_33_P3288079 A_33_P3288079 0.02 0.41 5.69 4.36E-01   
A_33_P3298612 A_33_P3298612 A_33_P3298612 0.01 0.34 5.59 3.79E-01   
A_33_P3299436 A_33_P3299436 A_33_P3299436 0.01 0.34 17.6 -3.68E-01   
A_33_P3302657 A_33_P3302657 A_33_P3302657 0.01 0.31 6.35 3.95E-01   
A_33_P3304081 A_33_P3304081 A_33_P3304081 0.00 0.26 9.32 -4.14E-01   
A_33_P3304097 A_33_P3304097 A_33_P3304097 0.01 0.38 6.34 3.38E-01   
A_33_P3305325 A_33_P3305325 A_33_P3305325 0.01 0.38 5.83 3.86E-01   
A_33_P3309684 A_33_P3309684 A_33_P3309684 0.02 0.48 15.42 -3.10E-01   
A_33_P3312564 A_33_P3312564 A_33_P3312564 0.02 0.44 13.28 -3.41E-01   
A_33_P3315027 A_33_P3315027 A_33_P3315027 0.02 0.45 18.01 -3.14E-01   
A_33_P3331791 A_33_P3331791 A_33_P3331791 0.00 0.12 9.26 -5.00E-01   
A_33_P3334428 A_33_P3334428 A_33_P3334428 0.01 0.38 5.49 3.43E-01   
A_33_P3344765 A_33_P3344765 A_33_P3344765 0.02 0.45 9.21 -3.48E-01   
A_33_P3346526 A_33_P3346526 A_33_P3346526 0.00 0.08 6.03 -7.63E-01   
A_33_P3351529 A_33_P3351529 A_33_P3351529 0.01 0.41 17.62 -3.30E-01   
A_33_P3354479 A_33_P3354479 A_33_P3354479 0.01 0.32 17.62 -3.70E-01   
A_33_P3359846 A_33_P3359846 A_33_P3359846 0.00 0.15 7.1 -6.92E-01   
A_33_P3360204 A_33_P3360204 A_33_P3360204 0.02 0.47 9.47 -3.17E-01   
A_33_P3365963 A_33_P3365963 A_33_P3365963 0.01 0.30 11.29 -4.05E-01   
A_33_P3389558 A_33_P3389558 A_33_P3389558 0.01 0.33 5.46 3.99E-01   
A_33_P3393986 A_33_P3393986 A_33_P3393986 0.02 0.48 5.63 -4.46E-01   
A_33_P3395403 A_33_P3395403 A_33_P3395403 0.00 0.24 6.96 5.39E-01   
A_33_P3396434 A_33_P3396434 A_33_P3396434 0.01 0.39 18.04 -3.60E-01   
A_33_P3407230 A_33_P3407230 A_33_P3407230 0.02 0.42 7.34 -3.25E-01   
A_33_P3408665 A_33_P3408665 A_33_P3408665 0.00 0.25 12.4 -4.69E-01   
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Probe name 
Systematic 
name 
Gene name p-value 
adj.  
p-value 
Ave Expr log2FC 1) 
confirmed 
via         
qRT-PCR 
A_33_P3410019 A_33_P3410019 A_33_P3410019 0.00 0.27 9.57 -4.13E-01   
A_33_P3416414 A_33_P3416414 A_33_P3416414 0.01 0.38 6.94 -6.94E-01   
A_33_P3416787 A_33_P3416787 A_33_P3416787 0.01 0.29 5.56 -4.75E-01   
A_33_P3423845 A_33_P3423845 A_33_P3423845 0.00 0.23 8.75 -4.35E-01   
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Supplementary figure 1 a-i: Expression of all MLL-AF9 knockdown-associated genes which 
mapped to functional annotation terms considered to be of biological relevance. On the left 
the functional annotation term is given, followed by the encompassed genes and a sign for 
additional important categories to which they belong (  cytokine,  kinase, ○ cell surface 
protein, ● transcription factor, ∆ cytokine receptor, ▲ other receptor). Their logarithmic fold-
change in MLL-AF9 knockdown versus control treatments in THP1 cells are given on the x-axis. 
The color of bars indicates expression strength according to microarrays fluorescent signal 
intensities:  high,  medium and  low expression (classified as described in material and 
methods). On the right side of the graph the p-value and the fold enrichment (FE) of the 
annotation term are given. Within each term the genes are sorted according to their p-value of 
differential expression. 
 
Supplementary table 3: Biological roles and rating concerning mediation of MLL-AF9 
leukemogenic effects of selected differentially expressed genes after MLL-AF9 
knockdown. Rating categories (based on biological role and differential expression, see 
material and methods 7.4, page 32): +++ highly likely candidates and ++ likely candidates 
for mediation of MLL-AF9 leukemogenic effects, + genes whose regulation is coherent with 
its functional role in malignancies, ○ genes with a currently undefined role in malignancies 
due to a lack of relevant literature, - genes whose regulation is incoherent with its functional 
role in malignancies. The column on the right gives the basis of selection of this gene for 
further literature research. GOA, higher-order term of gene ontology annotation. 
Gene 
Rating 
category 
log2 
FC 
Official full name 
Biological role 
Selection 
criteria  
ABCA3 
- 
0.31 
ATP-binding cassette, subfamily A (ABC1), member 3 
A ATP-binding cassette (ABC) transporter which is overexpressed in AML and 
might be involved in drug resistance of leukemic primitive progenitor cells 
(Norwood, et al. 2004; Steinbach, et al. 2006). 
FunDO 
AFF4 
+ 
-0.36 
AF4/FMR2 family, member 4 
A rare translocation partner of MLL in leukemia and a component of the super 
elongation complex (SEC). SEC is believed to be recruited by many MLL-fusion 
proteins to activate translational elongation of target genes (Mohan, et al. 2010). 
AFF4 is required for SEC stability and proper transcriptional elongation (Lin, et 
al. 2010). 
FunDO 
AHR 
++ 
0.44 
aryl hydrocarbon receptor 
AHR is a nuclear receptor. Upregulation of AHR has been shown to promote 
retinoic acid–induced differentiation of myeloblastic leukemia cells. Additionally, 
AHR acts as a E3 ubiquitin ligase and is important for estrogen receptor alpha and 
androgen receptor degradation. (Bunaciu, et al. 2011) 
FunDO 
ALOX5 
- 
0.76 
Arachidonate 5-lipoxygenase 
Enzyme in the synthesis of leukotrienes (mediators of inflammatory and allergic 
conditions) from arachidonic acid. ALOX5 has functions in oxidative stress, 
inflammation and cancer and supports CML stem cell maintenance. (Naka, et al. 
2010) 
GOA: calcium 
associated 
ATP2B2 
++ 
-0.69 
ATPase, Ca++ transporting, plasma membrane 2 
A plasma membrane pump which is activated by calmodulin and whose rat 
homolog (97.9% identical to human) maintains low free cytosolic Ca2+ 
concentration (Elwess, et al. 1997). ATP2B2 is downregulated in PMA 
differentiated U937 monocytes (Wang, et al. 2011). Overexpression of ATP2B2 in 
breast cancer cells lowers intracellular calcium and protects from apoptosis 
(VanHouten, et al. 2010). Estradiol and estrogen decreases ATP2B2 expression 
and activity (El Beialy, et al. 2010).  
GOA: calcium 
associated 
B2M 
+ 
-0.47 
Beta-2-microglobulin 
A serum protein found in association with the major histocompatibility complex 
(MHC) class I heavy chain. Elevated B2M serum levels are of prognostic value in 
CLL and multiple myeloma (Melillo, et al. 1988) and predictive of the risk of a 
myelodysplastic syndrome evolving into an AML (Neumann, et al. 2009).  
FunDO 
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Gene 
Rating 
category 
log2 
FC 
Official full name 
Biological role 
Selection 
criteria  
BMI1 
++ 
-0.33 
BMI1 polycomb ring finger oncogene  
BMI1 is a polycomb group protein described to be essential for reprogramming of 
myeloid progenitors into leukemia stem cells (Yuan, et al. 2011a) and, together 
with HOXA9, for the self-renewal capacity of LSC transformed by MLL-AF9 
(Smith, et al. 2011). BMI1 is downregulated in PMA differentiated U937 
monocytes (Wang, et al. 2011). 
in concordance with 
patient study (Valk, 
et al. 2004) 
CALR 
+++ 
-0.51 
Calreticulin  
CALR acts as a major Ca(2+)-binding (storage) protein in the lumen of the 
endoplasmic reticulum (Burns, et al. 1994). It can also act as an important 
modulator of the regulation of gene transcription by nuclear hormone receptors 
(Dedhar, et al. 1994). In this context, CALR can inhibit the transcriptional 
activities of retinoic acid receptor and was shown to inhibit retinoic acid-induced 
differentiation in neuronal cells (Dedhar, et al. 1994). It is a chaperone and well-
established effector of the unfolded protein response (Schardt, et al. 2011). The 
chaperone CALR inhibits the translation of CEBPA, which is a key myeloid 
transcription factor and a frequent target for disruption in AML (Schardt, et al. 
2011). 
FunDO 
CAMP 
+ 
0.46 
Cathelicidin antimicrobial peptide 
An antimicrobial protein found in monocytes and other leukocytes. A direct target 
of the vitamin D receptor, which is strongly upregulated in myeloid cells by 1,25-
dihydroxyvitamin D3. (Gombart, et al. 2005) Lower CAMP protein expression 
was detected in neutrophils of AML patients (An, et al. 2005). 
FunDO 
CCL2 
+++ 
1.61 
Chemokine (C-C motif) ligand 2  
The second strongest regulated gene transcript was chemokine (C-C motif) ligand 
2 (CCL2) with a p-value of 1.11E-6. CCL2 binds to chemokine (C-C motif) 
receptor 2  and 4 (CCR2 and CCR4), the former of which is also upregulated in a 
MLL-AF9 knockdown specific manner in our data set. CCL2 displays chemotactic 
activity for monocytes and basophils. It is upregulated in PMA differentiated 
U937 monocytes (Wang, et al. 2011). AML blasts have been described to produce 
different amounts of CCL2 which influences the number of monocytes migrating 
towards AML blasts (Legdeur, et al. 2001). Plasma levels of CCL2 are decreased 
in patients with AML of the subtype M4 and M5 (Mazur, et al. 2007). Thus, low 
levels of CCL2 might lead to reduced immunosurveillance of M4 and M5 blasts. 
In this context, CCL2 has been proposed for adoptive immunotherapy (Legdeur, et 
al. 2001). In induced pluripotent mouse stem cells, Ccl2 induces the key 
transcription factor genes for pluripotency, Klf4, Nanog, Sox2 and Tbx3 
(Hasegawa, et al. 2011). KLF4, which is also a marker for and inducer of 
monocytic and terminal macrophage differentiation (Klco, et al. 2011; Schuetz, et 
al. 2011), is also upregulated in a MLL-AF9 knockdown specific manner in our 
data set. 
FunDO, 
log2FC>±1, GOA: 
differentiation, 
calcium associated, 
other 
CD14 
○ 
1.05 
CD14 molecule 
A pattern recognition receptor (Kitchens 2000) and myelomonocytic 
differentiation antigen (Goyert, et al. 1988) and differentiation marker for 
maturating monocytes (Schwende, et al. 1996; Abrink, et al. 1994).  
log2FC>±1, GOA: 
proliferation, cell 
growth and death; 
differentiation  
CD19 
○ 
0.35 
CD19 molecule 
While normally expressed on B cells, CD19 is also expressed in mixed lineage 
leukemia cells (Schubert, et al. 2011). 
 FunDO 
CD209 
○ 
0.73 
CD209 molecule 
A transmembrane receptor expressed in dendritic cells and macrophages, 
recognizing numerous pathogens and playing a role in cell adhesion. (Geijtenbeek, 
et al. 2000; Dominguez-Soto, et al. 2011; Tassaneetrithep, et al. 2003) 
GOA: calcium 
associated 
CD74 
○ 
0.77 
CD74 molecule, major histocompatibility complex, class II invariant chain 
CD74 ensures stabilization, proper folding as well as transport of newly 
synthesized HLA class II heterodimers to the MHC class II containing 
compartments (Pieters, et al. 1993; Anderson, et al. 1992). 
GOA: other 
CEBPB 
+++ 
0.53 
CCAAT/enhancer binding protein (C/EBP), beta 
CEBPB activates the promoter of PU.1, a tumor suppressor for AML (Mueller, et 
al. 2006). Activation of CEBPB expression leads to differentiation and reduced 
proliferation of CML cells. CEBPB is reactivated after imatinib treatment of 
BCR/ABL CML cells. (Guerzoni, et al. 2006)  
in concordance with 
patient study 
(Zheng, et al. 2006) 
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Gene 
Rating 
category 
log2 
FC 
Official full name 
Biological role 
Selection 
criteria  
CIITA 
+++ 
0.83 
Class II, major histocompatibility complex, transactivator 
Transcriptional coactivator and master controller of MHC class II expression 
(Ting, et al. 2002). MHC-II is not expressed on leukemia cells of most patients 
with acute promyelocytic leukemia and some with acute myeloblastic leukemia. It 
is considered that these leukemia cells are unable to present the antigens to helper 
T cells which enhances the function of cytotoxic T cells (CTL) against leukemia 
cells and may therefore escape the immunological surveillance of the body. 
Although the regulatory mechanism of individual MHC-II expression has still to 
be elucidated, these findings reveal a possible new strategy using the CIITA gene 
in immuno-gene therapy for patients with MHC-II negative hematological 
malignancies. (Liu, et al. 1999) Phosphorylation of CIITA directs its 
oligomerization, accumulation and increased activity on MHCII promoters (Tosi, 
et al. 2002). 
 FunDO, GOA: 
other 
CTSG 
○ 
-0.43 
Cathepsin G 
A hematopoietic serine protease with microbicidal and proinflammatory activity 
which is strongly expressed in neutrophils. CTSG proteolytically degrades 
engulfed cell debris and displays a variety of pathophysiological effects, among 
these enhancing hematopoietic progenitor cell mobilization by cleaving CD106 
(Sun, et al. 2004) and is putatively regulated by PU.1, c-myb and C/EBP 
(Lennartsson, et al. 2005). 
FunDO 
CYBB 
+ 
0.40 
Cytochrome b-245, beta polypeptide 
An essential component of phagocytic NADPH-oxidase which is responsible for 
generating microbicidal superoxide and other oxidants (OMIM).  
CYBB is downregulated in MLL-ENL/MLL-ELL positive myeloid leukemia 
progenitor cells (Li, et al. 2009). CYBB is a common target gene repressed by 
HoxA10 and activated by HoxA9 (Bei, et al. 2005). 
FunDO 
DACH1 
++ 
-0.54 
Dachshund homolog 1 (Drosophila) 
Was shown to be overexpressed in MLL-aberrant leukemia (Ross, et al. 2004). 
DACH1 binds to the IL8 promoter and repressed it through AP1(JUN/FOS)- and 
NFKB-binding sites. (Wu, et al. 2008) In concordance to this, IL8 is upregulated 
in a MLL-AF9 dependent manner in this study. 
in concordance with 
patient studies 
(Ross, et al. 2004; 
Kohlmann, et al. 
2005) 
DEFA3 
○ 
1.36 
Defensin, alpha 3, neutrophil-specific 
An antimicrobial gene. In this setting possibly an indicator for differentiation. 
log2FC>±1, GOA: 
differentiation 
DEXI 
++ 
-0.56 
Dexi homolog (mouse) 
DEXI is suspected to be a membrane protein that dimerizes either with itself or 
another protein. DEXI is a dexamethasone-induced transcript and is overexpressed 
in emphysematous lung tissue. (Edgar, et al. 2001) Its function is unknown.  
in concordance with 
patient study (Ross, 
et al. 2004) 
DLL1 
+++ 
-0.54 
Delta-like 1 (Drosophila) 
DLL1, a Notch ligand, completely inhibited the differentiation of human 
hematopoietic progenitors into the B cells, while keeping the potency to develop 
into NK cells (Jaleco, et al. 2001). DLL1 activated the NF-kappaB pathway via 
Notch in THP-1 cells (Itoh, et al. 2009). DLL1 reduces TNF-alpha induced growth 
suppression and apoptosis in monoblastic leukemia cell line U937 cells (Murata-
Ohsawa, et al. 2004). 
FunDO 
DRD5 
○ 
-0.96 
Dopamine receptor D5 
A G-protein coupled receptor which stimulates cAMP (Grandy, et al. 1991). 
GOA: proliferation, 
cell growth and 
death; calcium 
associated 
EGR2 
++ 
0.81 
Early growth response 2 
A transcription factor and tumor suppressor, whose deletion leads to cancer cell 
proliferation. EGR2 inhibits neutrophil- and activates macrophage-specific genes. 
It interacts with PU.1, a master transcription factor in macrophage differentiation. 
(Gabet, et al. 2010) EGR2 is upregulated in PMA differentiated U937 monocytes 
(Wang, et al. 2011) and EGR2 binding motifs were found activated and being 
within the 30 ‘core’ motifs explaining the expressional changes after PMA 
differentiation in THP1 cells (Suzuki, et al. 2009). Its mouse homolog is 
underexpressed in hematopoietic stem and progenitor cells after Mll-AF9 knock-in 
(Chen, et al. 2008). 
GOA: early 
development 
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Rating 
category 
log2 
FC 
Official full name 
Biological role 
Selection 
criteria  
F13A1 
○ 
0.33 
Coagulation factor XIII, A1 polypeptide 
The intracellular form of this coagulation factor is expressed in monocytes and 
macrophages and has been shown to be a marker for AML FAB M4 and M5 blasts 
(Kiss, et al. 2008). 
FunDO 
FMNL1 
○ 
0.36 
Formin-like 1  
A formin, which is overexpressed in lymphoid malignancies and has been shown 
to associate with Akt (a survival regulator in different cell types) (Favaro, et al. 
2003). It is upregulated in PMA differentiated U937 monocytes (Wang, et al. 
2011). 
FunDO 
FOS 
+++ 
0.88 
FBJ murine osteosarcoma viral oncogene homolog 
FOS and FOSB binding motifs were found activated and being within the 30 
‘core’ motifs explaining the expressional changes after PMA differentiation in 
THP1 cells (Suzuki, et al. 2009). They are components of the dimeric transcription 
factor AP-1, which mediates subunit and context dependent gene regulation in 
response to cytokines, growth factors, stress signals, oncogenic stimuli, bacterial 
and viral infections. AP-1 has effects on proliferation, differentiation and 
apoptosis (Hess, et al. 2004). 
GOA: proliferation, 
cell growth and 
death; in 
concordance with 
patient study 
(Zheng, et al. 2006) 
FOSB 
+++ 
1.05 
FBJ murine osteosarcoma viral oncogene homolog B  
see FOS. 
log2FC>±1, in 
concordance with 
patient study 
(Zheng, et al. 2006) 
GNLY 
○ 
0.38 
Granulysin 
A antimicrobial and proinflammatory protein, whose transcription has been shown 
to be induced by AP-1 (Kida, et al. 2002). One isoform induces immune response, 
chemotaxis and cell adhesion genes in monocytes (Castiello, et al. 2011). 
 FunDO 
GPNMB 
++ 
1.24 
Glycoprotein (transmembrane) nmb  
Encodes a putative transmembrane glycoprotein and has been described to be 
involved in growth delay and reduction of metastatic potential in human 
melanoma (Weterman, et al. 1995). 
log2FC>±1 
HAPLN2 
○ 
-1.20 
Hyaluronan and proteoglycan link protein 2  
Previously has been assessed as brain specific, although leukocytes were not 
analyzed in the study (Spicer, et al. 2003). Cell adhesion molecule. 
log2FC>±1 
HIPK2 
+++ 
0.50 
Homeodomain interacting protein kinase 2 
A tumor suppressor. In response to DNA damage, HIPK2 phosphorylates the 
tumor suppressor PML, thus leading to PML stabilization. This phosphorylation is 
required for the ability of PML to cooperate with HIPK2 for the induction of cell 
death (Gresko, et al. 2009). Mutations have been found in AML cases (Li, et al. 
2007). 
 FunDO 
HLA-B 
○ 
-0.64 
Major histocompatibility complex, class I, B 
MHC class I deficient tumor clones may escape T-cell immune responses, but 
might be more susceptible to NK cell-mediated lysis (Algarra, et al. 2004). 
 FunDO 
HLA-
DMB 
++ 
1.49 
Major histo-compatibility complex, class II, DM beta 
see HLA-DPA1 
log2FC>±1, GOA: 
differentiation 
HLA-
DPA1 
++ 
1.60 
Major histo-compatibility complex, class II, DP alpha1 
The following three top differential expressed transcripts were two classical and 
one nonclassical HLA class II gene: HLA-DPA1, HLA-DPB1 and HLA-DMB. 
HLA class II histocompatibility antigen, DQ beta 1 (ENST00000399670) is also 
strongly upregulated. MHC class II proteins are selectively expressed in 
professional antigen presenting cells, besides monocytes these are macrophages, 
B-cells and dendritic cells (Ting, et al. 2002). Upregulation of these transcripts has 
been associated with differentiation of monoblasts and THP1 cells were observed 
to have reduced HLA class II expression levels compared to mature monocytes 
(Abrink, et al. 1994). In addition, loss of MHC class II gene expression has been 
shown to be strikingly correlated with poor patient outcome and decreased 
immunosurveillance in large B-cell lymphoma patients (Rimsza, et al. 2004). 
log2FC>±1, GOA: 
differentiation 
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log2 
FC 
Official full name 
Biological role 
Selection 
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HLA-
DPB1 
++ 
1.54 
Major histo-compatibility complex, class II, DP beta 1 
Classical HLA class II gene. See HLA-DPA1  
FunDO, 
log2FC>±1, GOA: 
differentiation 
HLA-
DQA1 
++ 
0.96 
Major histocompatibility complex, class II, DQ alpha 1 
Classical HLA class II gene. See HLA-DPA1  
GOA: 
differentiation 
HLA-
DQB1 
++ 
1.19 
Major histo-compatibility complex, class II, DQ beta 1 
Classical HLA class II gene. See HLA-DPA1  
log2FC>±1, GOA: 
differentiation 
HLA-
DRB4 
++ 
0.45 
Major histocompatibility complex, class II, DR beta 4 
Classical HLA class II gene. See HLA-DPA1  
in concordance with 
patient study 
(Rozovskaia, et al. 
2003) 
HMBOX1 
○ 
-0.95 
Homeobox containing 1 
Transcription factor, transcriptional repressor (Zhang, et al. 2010). Key factor in 
differentiation of bone marrow stromal cells into vascular endothelial cells (Su, et 
al. 2010). 
GOA: 
differentiation, 
early development 
HOXA11 
++ 
-0.50 
Homeobox A11 
HOXA11 (together with HOXA4, A7, A10 and MEIS1) is downregulated after 
PMA induced differentiation in THP1 cells (Martino, et al. 2009). It is also 
downregulated in PMA differentiated U937 monocytes (Wang, et al. 2011). 
HOXA11 has been found to be translocated in hematologic malignancies 
(Panagopoulos, et al. 2003). 
FunDO 
HOXA7 
+ 
-0.41 
Homeobox A7 
A leukemogenic factor which is, like other homeobox genes, frequently 
upregulated in MLL aberrations and leukemia (Kawagoe, et al. 2001; Afonja, et al. 
2000). Its mouse homolog is overexpressed in hematopoietic stem and progenitor 
cells after Mll-AF9 knock-in (Chen, et al. 2008). 
FunDO, in 
concordance with 
patient study 
(Kohlmann, et al. 
2005) 
HOXA9 
+++ 
-0.57 
Homeobox A9 
A well studied homeobox transcription factor whose transcription level is raised 
by MLL-AF9 through direct interaction between MLL-AF9 protein complex and 
HOXA9 promoter (Erfurth, et al. 2008; Cierpicki, et al. 2010). It’s mouse 
homolog is overexpressed in hematopoietic stem and progenitor cells after Mll-
AF9 knock-in (Chen, et al. 2008). Concerning hematopoiesis, HOXA9 knock-out 
in mice has little or no effect on earlier progenitors but decreases the number of 
committed progenitor cell (Lawrence, et al. 1997). Overexpression of Hoxa9 alone 
does not lead to leukemic transformation of primary bone marrow cells in mice 
but does in conjunction with Meis1 overexpression (Kroon, et al. 1998). In 
conjunction with BMI1, HOXA9 is essential for the self-renewal capacity of LSC 
transformed by MLL-AF9 (Smith, et al. 2011). HOXA9 is downregulated in 
differentiating THP1 cells after PMA addition (Martino, et al. 2006). 
in concordance with 
patient studies 
(Ross, et al. 2004; 
Erfurth, et al. 2008; 
Kohlmann, et al. 
2005; Bullinger, et 
al. 2004) 
HOXC4 
++ 
-0.76 
Homeobox C4 
Estrogen-estrogen receptor (ER) complexes upregulate HOXC4 expression in B 
cells, thereby inducing activation-induced cytosine deaminase (AID) and thus 
leading to antibody class switch DNA recombination (CSR) and somatic 
hypermutation (Mai, et al. 2010). Murine HoxC4 may contribute to stem cell 
character of mesenchymal stem cells (Phinney, et al. 2005). In vitro 
overexpression induces expansion of committed as well as very early 
hematopoietic progenitors (Daga, et al. 2000). 
GOA: early 
development 
HPX-2 
○ 
0.75 
Homeobox HPX-2 
Homeobox containing gene, cloned from human CD34+ hematopoietic cells 
(Moretti, et al. 1994). Biological role unknown. 
GOA: early 
development 
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IFI30 
○ 
0.91 
Interferon, gamma-inducible protein 30 
A lysosomal thiol reductase constitutively expressed in antigen-presenting cells. 
This enzyme has an important role in MHC class II-restricted antigen processing. 
(Arunachalam, et al. 2000) 
GOA: 
differentiation 
IGF2BP2 
+ 
-0.42 
Insulin-like growth factor 2 mRNA binding protein 2 (alias IMP-2) 
A member of embryonically expressed IGF-II mRNA-binding proteins (IMPs: 
IMP1 – 3).  IMP-1 has been shown to repress IGF2 translation  by binding to the 
5' UTR of the (IGF2) mRNA (Nielsen, et al. 1999). Overexpressed in MLL-AF4 
positive acute lymphoblastic leukemia (B-ALL) (Stoskus, et al. 2011). One 
isoform was expressed at high levels in several cancer cell lines and was suspected 
to be involved in transformation leading to hepatocellular carcinoma because 
novel autoantibody responses against this isoform have been detected in patients 
and may be a immune system reaction involved in transformation-associated 
cellular events (Zhang, et al. 1999). 
FunDO 
IKZF2 
++ 
-0.60 
IKAROS family zinc finger 2 (Helios)  
A hematopoietic specific transcription factor involved in the regulation of 
lymphocyte development. A short isoform is overexpressed in patients with adult 
T-cell leukemia / lymphoma (Tabayashi, et al. 2007). 
FunDO 
IL18 
+ 
-0.38 
Interleukin 18 
A proinflammatory cytokine; has been shown to induce maturation in the acute 
myeloid leukemia cell line KG-1 (dendritic cell progenitors) (Bachmann, et al. 
2007). On the other hand, IL18 has been shown to be overexpressed in AML and 
to upregulate transmigration of HL-60 cells (human promyelocytic leukemia) 
(Zhang, et al. 2004). 
FunDO 
IL2RG 
- 
-0.31 
Interleukin 2 receptor, gamma  
Heterodimerizes to form a number of interleukin receptors (IL2, IL4, IL7, IL9, 
IL15, IL21) (OMIM). IL2RG is upregulated by 1,25-dihydroxyvitamin D3 in HL-
60 (human promyelocytic leukemia) cells (Savli, et al. 2002). 
FunDO 
IL8 
++ 
0.65 
Interleukin 8 
A multifunctional CXC chemokine, chemoattractant for neutrophils in 
inflammation, influences basophils and T cell function, may act as an angiogenic, 
proliferative, autocrine and metastatic factor. Relevant amounts of IL8 are 
produced by the great majority of AML with monocytic components (M4 and 
M5). IL8 is preferential released by myeloid blasts showing monocytic 
differentiation (Vinante, et al. 1996) Thus, upregulation of these transcripts might 
be associated with differentiation of monoblasts.  
DACH1 binds to the IL8 promoter and repressed it through AP1(JUN/FOS)- and 
NFKB-binding sites. (Wu, et al. 2008) 
FunDO, in 
concordance with 
patient study 
(Zheng, et al. 2006) 
ITGAL 
○ 
0.57 
Integrin, alpha L / CD11A 
Adhesion molecule, upregulated upon differentiation with all-trans retinoic acid in 
AML patients (Wu, et al. 2007). 
FunDO 
ITGAX 
○ 
0.62 
Integrin, alpha X / CD11C 
Adhesion molecule. Expression strongly correlated with increased white blood cell 
count in AML, independent of FAB subtype and was upregulated in AML patients 
upon differentiation with all-trans retinoic acid (Wu, et al. 2007). 
FunDO 
KLF4 
++ 
0.48 
Kruppel-like factor 4 
A transcription factor and a marker for monocytic and terminal macrophage 
differentiation (Klco, et al. 2011; Schuetz, et al. 2011). While a Klf4 zincfinger 
domain mutant induces self-renewal and block of maturation, wild-type 
KLF4 induces terminal macrophage differentiation (Schuetz, et al. 2011). KLF4 is 
induced by CCL2 in induced-pluripotent mouse stem cells, along with the other 
key transcription factor genes for pluripotency, Nanog, Sox2 and Tbx3 
(Hasegawa, et al. 2011) 
in concordance with 
patient study 
(Zheng, et al. 2006) 
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LGALS1 
++ 
-0.41 
Lectin, galactoside-binding, soluble, 1 
A galectin. These are a group of proteins which have been implicated in diverse 
biological processes, including modulation of cell–cell and cell–matrix 
interactions (Wada, et al. 1997). LGALS1 promotes escape from T-cell–dependent 
immunity and confers immune privilege to tumor cells. It is a highly sensitive and 
specific biomarker of MLL-rearrangement in B-ALL which is likely induced by a 
MLL-dependent epigenetic modification. (Juszczynski, et al. 2010) 
in concordance with 
patient studies 
(Armstrong, et al. 
2002; Ross, et al. 
2004) 
LGALS2 
○ 
1.02 
Lectin, galactoside-binding, soluble, 2  
A galectin. These are a group of proteins which have been implicated in diverse 
biological processes, including modulation of cell–cell and cell–matrix 
interactions (Wada, et al. 1997). Surprisingly, LGALS2 was previously neither 
reasonably detected in untreated nor in differentiated HL-60 cells (Abedin, et al. 
2003). However, it is upregulated in PMA differentiated U937 monocytes (Wang, 
et al. 2011). 
log2FC>±1, 
LHX9 
○ 
-1.34 
LIM homeobox protein 9 
Gene of the LIM homeobox gene family, a developmentally expressed 
transcription factor with a suggested role in gonadal development. 
log2FC>±1,, GOA: 
differentiation, 
early development 
LOC 
100129 
722 
○ 
-1.32 
Hypothetical LOC100129722 
A long non-coding RNA (lncRNA). LncRNAs are a group of RNAs whose 
primary role includes to act as epigenetic regulators of protein-coding gene 
expression. Many associate with chromatin-modifying complexes and there is 
evidence for two lncRNAs to be associated with MLL. LncRNAs may also play a 
role in organelle biogenesis and subcellular trafficking (e.g. cytoplasmic-to-
nuclear shuttling of transcription factors). (Taft, et al. 2010; Dinger, et al. 2008) 
log2FC>±1 
LOC 
84989 
○ 
-1.06 
Hypothetical LOC84989 
A long non-coding RNA. See LOC 100129722. 
log2FC>±1 
LPL 
○ 
0.71 
Lipoprotein lipase 
LPL plays a major role in the metabolism and transport of lipids, facilitates 
lipoprotein particle uptake (e.g. in macrophages) and can mediate the selective 
uptake of lipoprotein-associated lipids and lipophilic vitamins without the 
concomitant uptake of the lipoprotein particles (Wang, et al. 2009). LPL mRNA 
level is controlled by activation of protein kinase C (PKC) and by mobilization of 
intracellular Ca2+ and is induced by PMA in the THP-1 (Auwerx, et al. 1989). 
LPL is a prognostic marker in CLL with high expression predicting shorter overall 
survival (Kaderi, et al. 2011). 
FunDO 
LRRC2 
○ 
-1.43 
Leucine rich repeat containing 2 
Unknown function.  
log2FC>±1 
MAP3K5 
○ 
0.31 
Mitogen-activated protein kinase kinase kinase 5 
A component of a protein kinase signal transduction cascade, whose 
overexpression induces apoptosis (Ichijo, et al. 1997). On the other hand, in 
leukemic cells treated with arsenic trioxide, MAP3K5 has been shown to be 
activated by reactive oxygen species resulting in negative regulation of apoptosis 
without activating p38 and JNK (Yan, et al. 2007). 
FunDO 
MAPRE2 
+ 
-0.37 
Microtubule-associated protein, RP/EB family, member 2 
A tubulin binding protein which is activated by the AML associated fusion gene 
Nup98-HOXA9. Nup98-HOXA9 is a transcription factor whose activity depends 
on the HOXA9 DNA binding domain. (Ghannam, et al. 2004) Thus 
downregulation of MAPRE2 might be a secondary effect of reduced expression of 
HOXA9. 
FunDO 
MBNL1 
+ 
-0.34 
Muscleblind-like (Drosophila) 
A regulator of developmentally programmed alternative splicing and possibly 
cellular RNA metabolism. MBNL1 is involved in the molecular mechanism of 
myotonic dystrophy (Teplova, et al. 2008; Onishi, et al. 2008). Its mouse homolog 
is overexpressed in hematopoietic stem and progenitor cells after Mll-AF9 knock-
in (Chen, et al. 2008). 
in concordance with 
patient studies 
(Ross, et al. 2004; 
Valk, et al. 2004) 
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MEF2C 
+++ 
-0.60 
Myocyte enhancer factor 2C  
A member of the MADS box transcription enhancer factor 2 (MEF2) family 
involved in myogenesis. MEF2C promotes myeloid progenitor proliferation 
(Johnnidis, et al. 2008). Mef2c is upregulated in leukemic stem cells of MLL-
associated leukemia (Krivtsov, et al. 2006; Schuler, et al. 2008) and its mouse 
homolog is overexpressed in hematopoietic stem and progenitor cells after Mll-
AF9 knock-in (Chen, et al. 2008). Expression of Mef2c in granulocyte 
macrophage progenitors increases the number of differentiated myelomonocytic 
cells, but does not induce serial replating activity. Mef2c is a cooperating 
oncogene in leukaemogenesis that is unable to induce leukemia when expressed 
alone. (Krivtsov, et al. 2006) 
in concordance with 
patient studies 
 (Ross, et al. 2004; 
Valk, et al. 2004) 
MERTK 
○ 
1.04 
C-mer proto-oncogene tyrosine kinase 
Regulates cytokine secretion and clearance of apoptotic cells by macrophages and 
promotes macrophage survival in response to oxidative stress (Anwar, et al. 2009). 
log2FC>±1, GOA: 
proliferation, cell 
growth and death; 
differentiation 
NAIP 
- 
0.60 
NLR family, apoptosis inhibitory protein 
Antiapoptotic protein, overexpressed in acute mixed lineage leukemia and might 
be involved in drug resistance (Nakagawa, et al. 2005). 
FunDO 
NKG7 
+ 
-0.34 
Natural killer cell group 7 sequence  
NGK7 expression is upregulated by G-CSF and NGK7 protein accumulates during 
the differentiation of myeloid cells towards mature neutrophils (Shimane, et al. 
1999). 
in concordance with 
patient study (Ross, 
et al. 2004) 
NPTX1 
○ 
-1.00 
Neuronal pentraxin I  
NPTX1 rat homolog has been described to be downregulated upon antiestrogen 
treatment (Yasuhara, et al. 2008). 
log2FC>±1, GOA: 
calcium associated 
PBX3 
+++ 
-0.51 
Pre-B-cell leukemia homeobox 3 
One isoform of PBX3 is preferentially expressed in leukemic cells (Milech, et al. 
2001). PBX proteins function as part of large complexes with other homeodomain-
containing proteins to regulate gene expression during developmental and/or 
differentiation processes. Overexpression of PBX3 might play a role in 
BCR/ABL-mediated myeloid differentiation and transformation. (Salesse, et al. 
2003) 
in concordance with 
patient studies 
(Ross, et al. 2004; 
Bullinger, et al. 
2004; Kohlmann, et 
al. 2005) 
PDCD5 
- 
-0.82 
Programmed cell death 5 
A proapoptotic protein, whose translocation to the nucleus has been described as 
an universal early event in apoptosis. Reduced levels of PDCD5 in AML and 
CML marrow cells compared to normal donor marrow cells was detected. (Ruan, 
et al. 2006; Ruan, et al. 2008) 
FunDO 
PDE4D 
++ 
-0.34 
Phosphodiesterase 4D, cAMP-specific 
A protein that degrades cAMP. In primary B cell chronic lymphocytic leukemic 
(B-CLL) apoptosis could be induced by stimulating the cAMP signaling pathway 
with a phosphodiesterase4 (PDE4) inhibitor (Dong, et al. 2010). 
FunDO 
PRLR 
- 
0.64 
Prolactin receptor 
A survival factor that supports tumor growth and confers chemoresistance in 
breast and prostate cancers (Jacobson, et al. 2010). A rise in intracellular Ca2+ 
elicited by activation of PRLR has been described to be JAK2-dependent (Zhang, 
et al. 2009).  
GOA: other 
RHBDL1 
++ 
-1.13 
Rhomboid, veinlet-like 1  
As suggested by gene annotation inferred from electronic annotation, RHBDL1 
may posses serine-type endopeptidase activity and be involved in regulated 
intramembrane proteolysis and the subsequent release of functional polypeptides 
from their membrane anchors (UniProt Consortium 2012; National Center for 
Biotechnology Information 2012). RHBDL1 drosophila homolog has been 
implicated in the positive modulation of epidermal growth factor receptor 
signaling (Pascall, et al. 1998). 
log2FC>±1 
RHOH 
+ 
0.33 
Ras homolog gene family, member H 
A member of the Rho family of small GTPases. Low expression of RHOH 
transcript implied negative prognosis in AML patients concerning overall and 
disease-free survival (Iwasaki, et al. 2008) 
FunDO 
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RNPEP 
+ 
-0.32 
Arginyl aminopeptidase (aminopeptidase B) 
RNPEP is an exopeptidase which is proposed to play a role in the final stages of 
protein precursor processing (Aurich-Costa, et al. 1997). 
in concordance with 
patient study (Ross, 
et al. 2004) 
ROR2 
++ 
0.81 
Receptor tyrosine kinase-like orphan receptor 2 
A receptor / coreceptor for Wnt5a which mediates noncanonical Wnt signaling. 
Mutations within the human Ror2 gene are responsible for genetic skeletal 
disorders. Oncogenic and anti-oncogenic roles have been described in a wide array 
of malignancies. (Minami, et al. 2010) It has been previously hypothesized that 
Wnt5a is a tumor suppressor in myeloid leukemogenesis acting through the 
Wnt5a/Ror2 noncanonical signaling pathway that inhibits Wnt canonical signaling 
(Yuan, et al. 2011b). Wnt-5A is able to trigger calcium release in several cell types 
(Kestler, et al. 2008). 
GOA: early 
development, other 
RPL23A 
○ 
-1.09 
Ribosomal protein L23a  
A ribosomal protein. Production of ribosomes is a major metabolic activity, tightly 
linked to cell growth, proliferation, cell-cycle regulation, senescence and stress 
response (Andersen, et al. 2005). 
log2FC>±1, 
RPS26 
○ 
-0.85 
Ribosomal protein S26 
A ribosomal protein. See RPL23A. 
GOA: proliferation, 
cell growth and 
death 
S100A12 
++ 
0.84 
S100 calcium binding protein A12 
A calcium-binding protein, with multiple proinflammatory activities including 
chemotaxis for monocytes and neutrophils (Kishimoto, et al. 2006), which 
implicates a potential role in immunosurveillance. S100A12 is upregulated in 
PMA-differentiated U937 monocytes (Wang, et al. 2011). 
GOA: proliferation, 
cell growth and 
death; calcium 
associated; in 
concordance with 
patient study 
(Zheng, et al. 2006) 
SGK1 
- 
1.10 
Serum/glucocorticoid regulated kinase 1  
A downstream target of phosphoinositide 3-kinase (PI 3-kinase)-stimulated growth 
factor signaling (Park, et al. 1999), activated by IGF1 and oxidative stress 
(Kobayashi, et al. 1999), whose transcription is induced upon cell shrinkage in 
hepatocytes (Waldegger, et al. 1997) and which activates ion channels (Gamper, et 
al. 2002) and can promote survival (Lyo, et al. 2010). 
log2FC>±1 
SLC8A1 
○ 
1.15 
Solute carrier family 8, member 1 
A bidirectional sodium/calcium exchanger that contributes to the electrical activity 
of the heart (Mai, et al. 2010). 
log2FC>±1, GOA: 
calcium associated 
SNRP 
D2P2 
○ 
-1.13 
Small nuclear ribonucleoprotein D2 pseudogene 2 (LOC645339) 
A processed pseudogene with no evidence for protein coding function, although a 
55 amino acid sequence is predicted. Unknown function.  
log2FC>±1 
SOCS2 
+++ 
-1.07 
Suppressor of cytokine signaling 2 
A negative regulator of cytokine receptor signaling via the Janus kinase pathway, 
suppresses the apoptotic effect of LIF (Minamoto, et al. 1997), may play a 
regulatory role in IGF1 receptor signaling (Dey, et al. 1998) and is induced by a 
wide number of cytokines and hormones (e.g. estrogen and GM-CSF) (Rico-
Bautista, et al. 2006) 
FunDO, 
log2FC>±1, GOA: 
proliferation, cell 
growth and death; 
other; in 
concordance with 
patient studies 
(Ross, et al. 2004; 
Kohlmann, et al. 
2005; Zheng, et al. 
2006; Valk, et al. 
2004) 
SOCS3 
- 
0.53 
Suppressor of cytokine signaling 3 
SOCS3 inhibits the therapeutic, CD33-induced, block on proliferation in AML. A 
trend towards a higher reaction response and longer overall survival in patients 
with SOCS3 CpG hypermethylation (Middeldorf, et al. 2010). 
FunDO 
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SOX4 
++ 
-0.84 
SRY (sex determining region Y)-box 4 
A leukemogenic transcription factor in mouse leukemias. SOX4 is overexpressed 
in human AML samples. (Sun, et al. 2006b) Transcriptional upregulation of SOX4 
together with proviral insertions and Evi1 activation or  p15INK4b inactivation 
has been associated with leukemia (Boyd, et al. 2006; Bies, et al. 2010). 
GOA: proliferation, 
cell growth and 
death 
SP9 
++ 
-1.19 
Sp9 transcription factor homolog (mouse) 
SP9 vertebrate homologs have a described role in embryo limb outgrowth 
(Kawakami, et al. 2004), are involved in the formation of the regeneration 
epithelium (like Hoxa-9 and Hoxa-13) and were describes as marker for the 
dedifferentiation of keratinocytes of the mature skin epidermis in the axolotl 
(Satoh, et al. 2008). 
log2FC>±1 
TAS1R3 
++ 
-2.01 
Taste receptor, type 1, member 3  
A sweet taste receptor and glucose sensor which may be involved in energy supply 
(Mace, et al. 2009), was the most significant (p = 7.47E-08) and strongest 
regulated protein coding gene transcript and showed medium expression strength 
according to FI signal. 
log2FC>±1 
TSGA10 
- 
1.03 
Testis specific, 10  
Influences the function of antigen presenting cells via its interaction with 
cytoskeletal proteins such as vimentin (Roghanian, et al. 2010) and has been found 
overexpressed in cancers (Tanaka, et al. 2004b). TSGA10 is potentially involved 
in cell proliferation and has been found expressed in the bone marrow and 
peripheral blood of ALL patients (Mobasheri, et al. 2006). 
FunDO, log2FC>±1 
VDR 
++ 
0.67 
Vitamin D (1,25- dihydroxyvitamin D3) receptor 
A ligand-inducible transcription factor affecting cellular metabolism, bone 
formation, cellular growth, differentiation, control of inflammation and calcium 
homeostasis (Carlberg, et al. 2009; Dusso, et al. 2005). 1,25-dihydroxyvitamin D3 
is capable of inducing in vitro monocyte/macrophage differentiation of both 
normal and leukemic myeloid cell lines (Gocek, et al. 2010) and to inhibit growth 
and promote differentiation of a variety of cell types and thus has suggested to 
function in preventing cancers (Dusso, et al. 2005). VDR null mice show an 
increased susceptibility to tumor formation (Carlberg, et al. 2009). 1,25-
dihydroxyvitamin D3 induces a sustained increase of intracellular Ca2+ 
concentration and thus induced apoptosis in breast cancer cell lines (Sergeev 
2005). 
GOA: other 
VWA1 
○ 
-1.01 
Von Willebrand factor A domain containing 1  
Encodes an extracellular matrix protein, which is also expressed in the apical 
ectodermal ridge of developing limb buds (like SP9) (Allen, et al. 2008). 
log2FC>±1 
ZNF521 
+++ 
-0.73 
Zinc finger protein 521 
Highly expressed in the most immature hematopoietic cells and declines with 
differentiation. Enforced expression leads to proliferation and differentiation 
block. Overexpression decreases granulo-monocytic and erythroid differentiation. 
High expression has been associated with MLL-rearrangements and silencing in 
THP1 cells led to impaired growth and clonogenicity (Bond, et al. 2008) ZNF521 
modulates erythroid cell differentiation through direct binding with GATA-1 
(Matsubara, et al. 2009). Enhances resistance to NK cell-mediated cytotoxicity in 
tumor cells involving HLA class I upregulation (La Rocca, et al. 2009).  
FunDO, in 
concordance with 
patient study 
(Kohlmann, et al. 
2005) 
 
 
Supplementary data 
 
185 
Supplementary table 4: Overview of all differentially expressed miRNAs from both 
profiling platforms in MLL-AF9 knockdown as compared to control THP1 cells. 
 
All miRNAs with p<0.05 from either platform are included. LDA, quantitative TaqMan low 
density array; microarray, semiquantitative Agilent miRNA microarray; CT and AveExpr 
values are given as an indicator of expression strength. CT, threshold cycle of LDA; 
AveExpr, average expression from microarray data (based on fluorescence signal 
intensities); n.p., not present on array; n.a. not available (p-value can not be calculated for 
miRNAs which were turned “on” or “off”); n.d., not detectable; n.det., not determined. 
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